study_id,cluster,x_tsne,y_tsne,text,top_terms
FOCUS_protocole_V1.0_20230703_NM_NRD_JL_20230725_NM_DS_NRD,2,-26.838696,26.153736,full title randomized controlled multicenter comparing efficacy safety adalimumab mycophenolate mofetil steroid dependent non infectious uveitis acronym reference focus aphp211032 eu 2023 505112 38 00 coordinating investigator pr bahram bodaghi centre national de reference des uveites department ophtalmology hospital pitie salpetriere tel 01 42 16 37 28 email bahram bodaghi assistance publique hôpitaux de paris shortening fraction scientific director applicable pr david saadoun centre national de reference maladies autoinflammatoires et amylose departement de medecine interne et immunologie clinique pitie salpetriere hospital tel 0142178042 email david saadoun assistance publique hôpitaux de paris shortening fraction sponsor assistance publique hopitaux de paris scientific justification focus first prospective randomized comparing standard care mycophenolate mofetil adalimumab recently active non infectiuous uveitis niu steroid dependency firm evidence randomized trials compared classical immunosuppressive compounds biological agents identified best condition burden niu reduced use immunosuppressive agents biologics raising question compounds preferentially used recently active niu steroid dependency main objective primary endpoint primary objective objective compare efficacy adalimumab 80mg day 0 40mg 14 days week 1 week 35 subcutaneously standard care mycophenolate mofetil 2g day orally 36 weeks recently active non infectious intermediate posterior uveitis pan uveitis steroid dependency primary endpoint primary efficacy endpoint failure rate 36 weeks failure defined following least one eye new active inflammatory chorioretinal retinal vascular lesions worsening best corrected visual acuity best corrected visual acuity 3 lines 2 step increase anterior chamber cell grade vitreous haze relative baseline secondary objectives endpoints secondary objectives comparing adalimumab 80mg day 0 40mg 14 days week 1 week 35 subcutaneously standard care mycophenolate mofetil 2g day orally 36 weeks evaluate cumulative incidence failure week 55 inclusion evaluate change best corrected visual acuity best corrected visual acuity logmar baseline week week 55 evaluate change ocular inflammation anterior chamber vitreous baseline week week 55 evaluate change signs including vessel leakage baseline week week 55 evaluate presence macular edema baseline week week 55 evaluate quality life related uveitis inclusion week 55 evaluate steroid sparing effect baseline week 55 evaluate number time relapse uveitis characteristics uveitis worsening baseline week 55 evaluate effect underlying systemic disease appropriate baseline week 55 evaluate safety adalimumab mycophenolate mofetil week 55 secondary endpoints time failure week 55 logmar best corrected visual acuity eye week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 anterior chamber cell grade week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 vitreous haze grade standardization of uveitis nomenclature criteria eye week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 central retinal thickness eye baseline week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 proportion central macular thickness 300 microns week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 time optical coherence tomographic optical coherence tomography evidence macular edema least one eye week 55 national eye institute visual functioning questionaire 25 vfq 25 composite score week 12 week 24 week 36 measures corticosteroid sparing e g percent meeting targets 0 1 milligrams kilograms day prednisone mean change mean dose week 55 cumulative dose cumulative incidence relapse number relapses week 55 manifestations underlying disease depending underlying disease evaluated week 55 safety tolerability treatments assessed frequency severity adverse events discontinuation baseline week 55 design prospective phase iii multicenter open label two arm randomized 1 1 comparing efficacy safety adalimumab standard care mycophenolate mofetil subjects recently active intermediate posterior uveitis pan uveitis despite steroid use e oral prednisone 7 milligrams day equivalent oral corticosteroids stable dose least 2 weeks prior first drug administration day 0 category cat 2 population participants adult recently active non infectious uveitis niu despite oral prednisone 7 milligrams day recently active disease defined presence least 1 following parameters either eye within 3 months prior inclusion visit active chorioretinal retinal vascular lesion presence macular edema optical coherence 2 anterior chamber cells standardization uveitis nomenclature standardization of uveitis nomenclature criteria 2 vitreous haze national eye institute national eye institute standardization of uveitis nomenclature criteria inclusion criteria eligibility criteria checked screening visit takes place four weeks maximum prior inclusion visit inclusion randomization visit adult meeting following criteria may included provide written informed consent prior performance specific procedures 18 years age diagnosis non infectious intermediate posterior pan uveitis least one eye fulfilling international group classification criteria standardization uveitis nomenclature standardization of uveitis nomenclature criteria posterior pan uveitis confirmed documented medical history recent activity niu defined presence least 1 following parameters either eye within 3 months prior inclusion visit despite 7mg day oral prednisone active chorioretinal retinal vascular lesion presence macular edema optical coherence 2 anterior chamber cells standardization uveitis nomenclature standardization of uveitis nomenclature criteria 2 vitreous haze national eye institute national eye institute standardization of uveitis nomenclature criteria chest x ray postero anterior lateral ct scanner results within 12 weeks prior inclusion evidence active tuberculosis active infection malignancy potential subject positive interferon gamma release assay igra e g quantiferon tuberculosis gold spot tuberculosis test inclusion eligible chest x ray show evidence suggestive active tuberculosis disease signs symptoms pulmonary extra pulmonary tuberculosis disease subjects latent tuberculosis infection already received prophylactic tuberculosis must agree advance complete course female subjects child bearing potential negative pregnancy test inclusion subjects reproductive potential willingness use contraceptive measures adequate prevent subject subjects partner becoming pregnant 3 months 5 months stopping therapy mycophenolate mofetil adalimumab respectively unless sterility confirmed simultaneous use two complementary methods contraception preferable methods may considered highly effective methods achieve failure rate less 1 per year used consistently correctly considered highly effective birth control methods according ctfg recommendations methods include female subjects combined estrogen progestogen containing hormonal contraceptionassociated inhibition ovulation 1 oral intravaginal transdermal progestogen hormonal contraception associated inhibition ovulation oral injectable implantable intrauterine device intrauterine device intrauterine hormone releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence context guidance sexual abstinence considered highly effective method defined refraining heterosexual intercourse entire period risk associated treatments reliability sexual abstinence needs evaluated relation duration preferred usual lifestyle subject male subjects use condoms vasectomy documentation azoospermia sexual abstinence affiliated social security system exclusion criteria subjects included meet following criteria 1 infectious uveitis masquerade syndromes idiopathic uveitis permitted 2 isolated anterior uveitis 3 monocular 4 active tuberculosis 5 positive human immunodeficiency virus serology hcv hbs ag test 6 history malignancy within 5 years prior inclusion carcinoma situ cervix non metastatic squamous basal cell carcinoma skin 7 history severe allergic anaphylactic reactions monoclonal antibodies mycophenolate mofetil rifampicin isoniazid fluorescein 8 infection requiring intravenous antibiotics within 3 weeks prior inclusion 9 history multiple sclerosis demyelinating disorder 10 laboratory values assessed inclusion hemoglobin 8g deciliter white blood cell count 2 0 x 103 cubic millimeter platelet count 80 x 103 cubic millimeter glomerular filtration rates gfr 30ml min transaminases 3 times upper normal value 11 use following systemic treatments specified periods systemic alkylating agents within 12 months prior inclusion e g cyclophosphamide chlorambucil live attenuated vaccine within 4 weeks prior inclusion 12 stage iii intravenous infusion new york heart association “new york heart association” cardiac insufficiency 13 pregnancy breastfeeding 14 legal protection 15 participation another interventional involving human participants exclusion period end previous involving human participants applicable investigational medicinal product eligible recently active niu randomized 1 1 ratio arm 1 adalimumab 80mg day 0 40mg 14 days week 1 week 35 subcutaneously arm 2 standard care defined mycophenolate mofetil 2 g day orally 36 weeks 2 groups receive corticosteroid regimen niu receive oral prednisone 10 milligrams day oral corticosteroid equivalent maximum 35 milligrams day prednisone common prednisone tapering programme applied groups decrease discontinuation week 13 week 19 long disease inactive comparator arm 2 standard care defined mycophenolate mofetil 2 g day orally 36 weeks interventions added adalimumab 80mg day 0 40mg 14 days week 1 week 35 subcutaneously visit week 4 8 16 20 30 weeks hcg plasmatic urine pregnancy test inclusion urine pregnancy test 4 8 12 16 20 24 30 36 55 weeks monthly 6 weeks stopping mycophenolate mofetil therapy 5 months stopping adalimumab therapy unless menopause sterility confirmed fundoscopy optical coherence tomography optical coherence tomography 4 8 16 20 30 weeks retinal angiography 36 weeks quality of life questionnaires day 0 week 12 week 24 36 weeks expected benefits participants society refractory non infectious uveitis serious ocular pathology accounting 10 15 total blindness cases reliable data required uveitis particularly use biotherapies corticosteroids immunosuppressants shown sustained remission rate 70 severe refractory relapsing uveitis incidence blindness uni reduced recent years use biotherapies raising question whether therapies prescribed earlier management severe non infectious uveitis compared conventional immunosuppressants biotherapies fast acting highly effective corticosteroids sparing thus limiting risk cataract cortico induced glaucoma focus first randomized comparing efficacy safety adalimumab standard care mycophenolate mofetil maintenance corticosteroid dependent uni validate optimize hard treat uveitis may also confirm whether adalimumab superior mycophenolate mofetil terms efficacy allow direct comparison safety profiles treatments could significantly improve management corticosteroid dependent uni finally help selection best prevent onset blindness side effects difficult treat cases expected benefit individual reducing morbidity non infectious uveitis collective reducing costs unemployment disability hospitalization caused uni risks burdens added risks associated toxicities investigational drugs risks associated use concomitant medication risk level risk c practical implementation collection free informed consent eligible randomized one 2 groups randomization visit day 0 arm 1 adalimumab 80mg day 0 40mg 14 days week 1 week 35 subcutaneously arm 2 mycophenolate mofetil 2 g day orally 36 weeks receive corticosteroid regimen inclusion receive corticosteroids 10 35 milligrams day inclusion following schedule reduction prednisone apply groups decrease discontinuation week 13 week 19 long disease inactive number participants included 120 60 arms number centres multicenter national including 27 centers 26 recruitment centres duration duration inclusions 30 months duration participation 13 months 3 weeks 55 weeks total duration 44 months number enrolments expected per site per month 0 15 month center statistical analysis prospective two arm randomized open label phase iii comparing adalimumab standard care mycophenolate mofetil based binary primary endpoint failure week 36 randomization stratified macular oedema steroid dose inclusion conducted using group sequential design one interim analysis 50 primary observations completed efficacy futility early stopping rules specifically assuming probability failure primary endpoint 50 soc control population versus 20 alternative hypothesis adalimumab total number 106 53 per randomization arm required ensure 90 power 2 5 one sided type error risk accounting one interim analysis 50 primary observations completed using lan demets obrien fleming type risk spending functions define efficacy futility non binding early stopping rules moreover plan include total 120 60 per randomization arm account potential 10 lost follow funding sources programme hospitalier de recherche clinique 2020 data safety monitoring board yes refractory non infectious uveitis serious ocular pathology accounting 10 15 total blindness cases3 reliable data required uveitis particularly management biotherapies corticosteroids immunosuppressants shown sustained remission rate 70 severe refractory relapsing uveitis10 incidence blindness niu reduced recent years use biotherapies raising question whether therapies prescribed earlier management severe non infectious uveitis compared conventional immunosuppressants biotherapies fast acting highly effective cortisone sparing thus limiting risk cataract cortico induced glaucoma10 despite scientific justification strong rationale treatments yet approved management uveitis focus first randomized comparing efficacy safety adalimumab standard care mycophenolate mofetil maintenance corticosteroid dependent niu validate optimize hard treat uveitis may also confirm whether adalimumab superior mycophenolate mofetil terms efficacy allow direct comparison safety profiles could significantly improve management corticosteroid dependent niu finally help selection best prevent onset blindness side effects difficult treat cases expected benefit individual reducing morbidity non infectious uveitis collective reducing costs unemployment disability hospitalization main side effects mycophenolate mofetil diarrhea leukopenia sepsis vomiting also evidence higher frequency certain types infections frequently candida mucocutaneous cmv viraemia syndrome herpes simplex 24 common side effects adalimumab include injection site reactions pain redness rash swelling itching bruising upper respiratory infections sinus infections headaches rash nausea rare severe side effects include tuberculosis reactivation neoplasia demyelinating disorder25 according article 37 4 european regulation n536 2014 irrespective outcome within one year end member states concerned sponsor shall submit ctis summary results summary shall accompanied summary written manner understandable laypersons specific documents medicinal product human use archived investigator sponsor 25 years end research indexed archiving includes particular sealed envelope investigator containing copy information notes consent forms signed individuals centre participated sealed envelope sponsor containing copy information notes consent forms signed individuals centre participated binders investigator sponsor including non exhaustive list successive versions protocol identified version number date appendices competent authority authorisations research ethics committee decisions correspondence enrolment list register appendices specific research final report data collection documents programme hospitalier de recherche clinique 2020 hospital funding research duration sponsor take insurance policy covering sponsors public liability well public liability physicians involved sponsor also provide full compensation damages caused participant enrolled beneficiaries unless sponsor prove harm fault sponsor collaborator compensation cannot refused grounds third party act voluntary withdrawal person initially consented participate assistance publique hopitaux de paris ap hp taken insurance hdi global se insurance broker biomedic insure full period covers public liability collaborator physician research staff accordance article 76 1 regulation eu 536 2014 european parliament council 16 april 2014 article l 1121 10 code de la sante publique french public health code author publication relating must include ap hp among affiliations must name sponsor ap hp délégation à la recherche clinique et à l’innovation source funding funded call tenders e g national regional programme hospitalier de recherche clinique copy publication must sent sponsor see rules governing affiliation naming sponsor funders author several affiliations order institutions mentioned ap hp university inserm etc unimportant however funded context internal ap hp call tender first affiliation must ap hp affiliations must identified address separated semicolon ap hp institution must feature acronym ap hp first address specifically followed ap hp hospital department city postcode france sponsor assistance publique hopitaux de paris direction de la recherche clinique et de linnovation research funded grant programme hospitalier de recherche clinique programme hospitalier de recherche clinique 2020 ministere de la sante registered website http clinicaltrials gov number add registration number registered 1 jabs da nussenblatt rb rosenbaum jt standardization uveitis nomenclature standardization of uveitis nomenclature working group standardization uveitis nomenclature reporting data results first international workshop j ophthalmol 2005 140 3 509 516 2 deschenes j murray principal investigator rao na nussenblatt rb international uveitis group international uveitis group international uveitis study group classification uveitis ocul immunol inflamm 2008 16 1 1 2 doi 10 1080 09273940801899822 3 durrani om meads ca murray principal investigator uveitis potentially blinding disease ophthalmologica 2004 218 4 223 236 doi 10 1159 000078612 4 joltikov ka lobo chan epidemiology risk factors non infectious uveitis systematic review front med 2021 8 695904 doi 10 3389 fmed 2021 695904 5 schiffman rm jacobsen g whitcup sm visual functioning general health status uveitis arch ophthalmol 2001 119 6 841 849 6 mello pra de ap roma de c moraes junior hv analysis life quality infectious non infectious uveitis using national eye institute vfq 25 questionnaire arq bras oftalmol 2008 71 6 847 854 7 gritz dc wong ig incidence prevalence uveitis northern california northern california epidemiology uveitis ophthalmology 2004 111 3 491 500 discussion 500 doi 10 1016 j ophtha 2003 06 014 8 suhler eb lloyd mj choi rosenbaum jt austin df incidence prevalence uveitis veterans affairs medical centers pacific northwest j ophthalmol 2008 146 6 890 896 e8 doi 10 1016 j ajo 2008 09 014 9 infectious uveitis rule prime suspects american academy ophthalmology accessed june 30 2019 https www aao org eyenet article infectious uveitis rule prime suspects 10 quartier dit maire p saadoun belot others protocole national de diagnostic et de soins sur les uveites chroniques non infectieuses de lenfant et de ladulte published online 2020 85 11 nguyen qd merrill pt jaffe gj others adalimumab prevention uveitic flare inactive non infectious uveitis controlled corticosteroids visual ii multicentre double masked randomised placebo controlled phase 3 lancet 2016 388 10050 1183 1192 doi 10 1016 s0140 6736 16 31339 3 12 jaffe gj dick autoimmune disease brezin ap others adalimumab active noninfectious uveitis n engl j med 2016 375 10 932 943 doi 10 1056 nejmoa1509852 13 doycheva deuter c stuebiger n biester zierhut mycophenolate mofetil uveitis children br j ophthalmol 2007 91 2 180 184 doi 10 1136 bjo 2006 094698 14 thorne je jabs da qazi fa nguyen qd kempen jh dunn jp mycophenolate mofetil therapy inflammatory eye disease ophthalmology 2005 112 8 1472 1477 doi 10 1016 j ophtha 2005 02 020 15 teoh subcutaneous hogan ac dick autoimmune disease lee rwj mycophenolate mofetil uveitis j ophthalmol 2008 146 5 752 760 760 e1 3 doi 10 1016 j ajo 2008 03 004 16 doycheva zierhut blumenstock g stuebiger n deuter c long term results therapy mycophenolate mofetil chronic non infectious uveitis graefes arch clin exp ophthalmol 2011 249 8 1235 1243 doi 10 1007 s00417 011 1731 8 17 petropoulos ik vaudaux jd guex crosier anti tnf alpha therapy chronic non infectious uveitis experience jules gonin eye hospital klin monbl augenheilkd 2008 225 5 457 461 doi 10 1055 2008 1027361 18 diaz llopis garcia delpech salom others adalimumab therapy refractory uveitis pilot j ocul pharmacol ther 2008 24 3 351 361 doi 10 1089 jop 2007 0104 19 diaz llopis salom garcia de vicuna c others refractory uveitis adalimumab prospective multicenter 131 ophthalmology 2012 119 8 1575 1581 doi 10 1016 j ophtha 2012 02 018 20 suhler eb lowder cy goldstein da others adalimumab therapy refractory uveitis results multicentre open label prospective br j ophthalmol 2013 97 4 481 486 doi 10 1136 bjophthalmol 2012 302292 21 zannin birolo c gerloni vm others safety efficacy infliximab adalimumab refractory uveitis juvenile idiopathic arthritis 1 year followup data italian registry j rheumatol 2013 40 1 74 79 doi 10 3899 jrheum 120583 22 simonini g taddio cattalini others prevention flare recurrences childhood refractory chronic uveitis open label comparative adalimumab versus infliximab arthritis care res hoboken 2011 63 4 612 618 doi 10 1002 american college of rheumatology 20404 23 artornsombudh p gevorgyan payal siddique ss foster cs infliximab birdshot retinochoroidopathy ophthalmology 2013 120 3 588 592 doi 10 1016 j ophtha 2012 05 048 24 rathinam standard risk gonzales ja thundikandy r others effect corticosteroid sparing mycophenolate mofetil vs methotrexate inflammation uveitis randomized jama 2019 322 10 936 doi 10 1001 jama 2019 12618 25 diaz llopis salom garcia de vicuna c others refractory uveitis adalimumab prospective multicenter 131 ophthalmology 2012 119 8 1575 1581 doi 10 1016 j ophtha 2012 02 018 26 lan kkg demets deciliter discrete sequential boundaries trials biometrika 1983 70 3 659 doi 10 2307 2336502 27 obrien pc fleming tr multiple testing procedure trials biometrics 1979 35 3 549 doi 10 2307 2530245 evaluate efficacy safety adalimumab immunosuppressant mycophenolate mofetil subjects non infectious uveitis steroid dependency uveitis term referring inflammation affecting structures eye including iris ciliary body choroid inflammation may affect one eye structure multiple structures many cases eyes involved symptoms may include decreased vision eye pain ocular redness tearing photophobia pain sensitivity light elevated intraocular pressure intraocular scarring macular edema even vascular occlusion international uveitis group international uveitis study group classified uveitis four major categories based anatomic location inflammation anterior iris ciliary body intermediate peripheral retina pars plana ciliary body posterior choroid retina panuveitis international uveitis study group anatomic classification scheme endorsed first international workshop standardization uveitis nomenclature standardization of uveitis nomenclature held 2004 us1 2008 international uveitis study group updated classification system include etiological criteria2 updated classification includes three main categories uveitis infectious non infectious including idiopathic unknown etiology well systemic autoimmune disorders masquerade syndromes neoplastic drug induced focus first prospective randomized head head comparing adalimumab immunosuppressant mycophenolate mofetil non infectious uveitis niu steroids dependency firm evidence randomized controlled trials directly addressing best biologic immunosuppressive agent niu steroids dependency maintain remission niu cause devastating visual loss 20 legal blindness 3 incidence blindness niu dramatically reduced recent years use efficient immunosuppressive treatments biologics raising question treatments immunosuppressants mycophenolate mofetil biologics adalimumab efficient steroid dependent active niu despite strong rationale place compound yet well defined strategy maintain remission uveitis guarantees innovative nature able evaluate compare efficacy safety different drugs immunosuppressants biologic agents non infectious intermediate posterior pan uveitis steroid dependency objective compare efficacy adalimumab 80mg day 0 40mg 14 days week 1 week 35 subcutaneously standard care mycophenolate mofetil 2g day orally 36 weeks recently active non infectious intermediate posterior uveitis pan uveitis steroid dependency comparing adalimumab 80mg day 0 40mg 14 days week 1 week 35 subcutaneously standard care mycophenolate mofetil 2g day orally evaluate cumulative incidence failure week 55 inclusion evaluate change best corrected visual acuity best corrected visual acuity logmar baseline week week 55 evaluate change ocular inflammation anterior chamber vitreous baseline week week 55 evaluate change signs including vessel leakage baseline week week 55 evaluate presence macular edema baseline week week 55 evaluate quality life related uveitis inclusion week 55 evaluate steroid sparing baseline week week 55 evaluate number time relapse uveitis characteristics uveitis worsening week baseline week week 55 evaluate effect underlying systemic disease appropriate baseline week week 55 evaluate safety adalimumab standard care mycophenolate mofetil week 55 primary efficacy endpoint failure rate 36 weeks failure defined following least one eye new active inflammatory chorioretinal retinal vascular lesions worsening best corrected visual acuity best corrected visual acuity 3 lines 2 step increase anterior chamber cell grade vitreous haze relative baseline time failure week 55 logmar best corrected visual acuity eye week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 anterior chamber cell grade week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 vitreous haze grade standardization of uveitis nomenclature criteria eye week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 central retinal thickness eye baseline week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 proportion central macular thickness 300 microns week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 time optical coherence tomographic optical coherence tomography evidence macular edema least one eye week 55 national eye institute visual functioning questionaire 25 vfq 25 composite score week 12 week 24 week 36 measures corticosteroid sparing e g percent meeting targets 0 1 milligrams kilograms day prednisone mean change mean dose week 55 cumulative dose cumulative incidence relapse number relapses week 55 manifestations underlying disease depending underlying disease evaluated week 55 safety tolerability treatments assessed frequency severity adverse events discontinuation baseline week 55 eligible active refractory niu randomized 1 1 ratio given free informed consent arm 1 adalimumab 80mg day 0 40mg 14 days week 1 week 35 subcutaneously arm 2 standard care mycophenolate mofetil 2 g day orally 36 weeks arms receive corticosteroid regimen inclusion randomization day 0 receive allocated randomization schedule reduction prednisone presented table 1 apply groups long disease inactive followed week week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 uncontrolled worsening flare uveitis time considered non responders treated according best standard care physician prospective phase iii multicenter bayesian multi arm multi stage randomized 1 1 comparing efficacy safety adalimumab standard care mycophenolate mofetil subjects recently active non infectious intermediate posterior pan uveitis despite steroids use oral prednisone 7 milligrams day purposes recently active non infectious uveitis niu defined presence least 1 following parameters either eye within 3 months prior inclusion visit active chorioretinal retinal vascular lesion presence macular edema optical coherence 2 anterior chamber cells standardization uveitis nomenclature standardization of uveitis nomenclature criteria 2 vitreous haze national eye institute national eye institute standardization of uveitis nomenclature criteria activity status recently active disease confirmed randomization ophtalmologic assessments followed week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 uncontrolled worsening flare uveitis time considered non responders treated discretion physician according best standard care final visit week 55 design open label two arm randomized owing different frequency administration 2 compared treatments use group sequential design one interim analysis 50 primary observations completed efficacy futility non binding stopping rules lan demets risk spending functions used define stopping boundaries obrien fleming like boundaries randomization stratified macular oedema steroid dose time inclusion 20mg vs 20mg randomization may prednisone single therapy 10 35 milligrams day systemic immunosuppressants must discontinued prior first drug administration day 0 day 30 day 0 eligibility enrollment determined day 0 inclusion randomization 1 1 ratio stratified macular oedema steroid dose inclusion 2 arms arm 1 adalimumab 80mg day 0 40mg 14 days week 1 week 35 subcutaneously arm 2 standard care mycophenolate mofetil 2 g day orally 36 weeks oral corticosteroids stable dose least 2 weeks prior first drug administration day 0 receive corticosteroid regimen inclusion 10 35 milligrams day inclusion following schedule reduction prednisone apply groups discontinuation week 13 week 19 long disease inactive table 1 schedule prednisone reduction week 4 8 12 16 20 24 30 evaluation secondary assessment criteria week 36 evaluation primary secondary assessment criteria uncontrolled worsening flare uveitis time considered non responders treated discretion physician according best standard care final visit week 55 additional visits take place case laboratory findings suggestive flare disease point time primary analysis week 36 given expected recurrence rate disease different groups 36 weeks considered sufficient period time statistically adequate comparison three medications usually required relative uveitis figure 2 scheme national multicenters involving least 27 centers participating centers internal medicine rheumatology cic crc opthalmology departments public hospitals located france visits selection follow conducted investigators internal medicine rheumatology ophtalomology centers inclusion randomization day 0 performed investigator internal medicine center rheumatology recruitment centres internal medicine rheumatology departments public hospitals located france non recruitment centres cic crc opthalmology departments public hospitals located france dynamism french national reference center inflammatory ocular diseases french uveitis network sharing strong experience investigation centers regarding inflammatory ocular conditions together expected level recruitment centers ensure feasibility french uveitis network gmio groupe francais detude des maladies inflammatoires de lil conducted recent evaluated efficiency anti tnf therapy niu recruited 250 1 year enrolled 100 controlled randomized niu programme hospitalier de recherche clinique rubi several situations possible temporary suspension investigator must document reason suspending resuming participants source file case report form case report form premature discontinuation participant remains enrolled end participation premature discontinuation withdrawal investigator must document reason collect assessment criteria time ending participation participant agrees schedule follow participant particularly case serious adverse event case severe adverse events investigator must notify sponsor follow participant premature discontinuation duration participation according research schedule notification serious adverse event must sent email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction sponsor serious adverse event monitored resolved since data safety monitoring board created committee specify validate follow methods course participation participant presents one following exclusion criteria product must discontinued participant continue monitored subject must permanently discontinue following criteria pregnancy active tuberculosis tuberculosis positive igra results indicating latent tuberculosis absence compliance prophylactic tuberculosis serious allergic grade 3 reaction drug including anaphylactic reactions stevens johnson syndrome increase alanine amino transferase aspartate amino transferase grade 3 disease flare worsening ocular inflammation requiring another immunosuppressant immunomodulator interruption 30 days serious infections grade 3 anemia grade 3 neutropenia grade 3 thrombocytopenia grade 3 malignancy situ cervix carcinoma adequately treated non metastatic squamous cell basal cell skin carcinoma multiple sclerosis demyelinating disorder human immunodeficiency virus aids viral hepatitis b c diagnosed period consent withdrawal condition would place subject risk case continuation participants may exit time reason investigator temporarily permanently withdraw participant safety reason participants best interests participant lost follow participant cannot located investigator must make every effort reconnect participant document attempts source file least determine whether participant alive dead participant exits prematurely withdraws consent data collected prior date premature exit may still used participant exits prematurely participant agrees state procedure schedule collecting data required protocol primary endpoint secondary endpoints safety assessment nb must stated information consent form state premature exit affect participant ongoing care state exactly participant offered case serious adverse events see corresponding section vigilance case report form must list various reasons participant discontinued lack efficacy adverse reaction another medical issue personal reasons participant explicit withdrawal consent lost follow consent withdrawn data collected prior withdrawal used except allow investigators use already collected data still inclusion period withdrawn implies primary outcome could analysed new included otherwise included analysed replaced intention treat analysis initial notification severe adverse event must provided written report signed investigator using severe adverse event notification form specific intended purpose case report form item form must completed investigator sponsor carry appropriate analysis initial notification sponsor serious adverse event must quickly followed additional detailed written report reports case outcome may monitored safety department provide information whenever possible investigator provide sponsor documents may useful medical reports laboratory test results results additional examinations etc documents must non identifying addition documents must include following acronym number participants initials adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even participant left initial notification severe adverse event follow reports documents must sent sponsor safety department email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction noted possible send severe adverse event reports safety department fax 33 0 1 44 84 17 99 event failed attempt send severe adverse event report email order avoid duplication use e crfs investigator completes severe adverse event notification form e case report form validates prints signs form sending email possible connect e case report form investigator complete sign send severe adverse event notification form safety department soon connection restored severe adverse event notification form e case report form must duly completed investigator must respond requests sponsor additional information questions relating notification adverse event safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction cases utero exposure investigator complete notification follow form pregnancy occurring participation investigator must monitor pregnant woman throughout pregnancy pregnancy terminated must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage pregnancy termination foetal death congenital abnormality etc investigator must follow procedure reporting saes initial pregnancy notification severe adverse event follow reports documents sent sponsor according procedures specified herein father exposed investigator must obtain pregnant woman permission collecting information pregnancy computer file used research implemented accordance french amended informatique et libertes law governing data protection european general data protection regulation gdpr regulations commitment comply reference methodology medium risk 001 research governed commission nationale informatique et libertés french data protection agency reference methodology processing personal data used within scope health research amended medium risk 001 ap hp sponsor research signed declaration compliance reference methodology eligibility criteria checked selection visit takes place four weeks maximum prior inclusion visit inclusion randomization visit adult meeting following criteria may included provide written informed consent prior performance specific procedures 18 years age diagnosis non infectious intermediate posterior pan uveitis least one eye fulfilling international group classification criteria standardization uveitis nomenclature standardization of uveitis nomenclature criteria posterior pan uveitis confirmed documented medical history recent activity niu defined presence least 1 following parameters either eye within 3 months prior inclusion visit despite 7mg day oral prednisone active chorioretinal retinal vascular lesion presence macular edema optical coherence 2 anterior chamber cells standardization uveitis nomenclature standardization of uveitis nomenclature criteria 2 vitreous haze national eye institute national eye institute standardization of uveitis nomenclature criteria chest x ray postero anterior lateral ct scanner results within 12 weeks prior inclusion evidence active tuberculosis active infection malignancy potential subject positive interferon gamma release assay igra e g quantiferon tuberculosis gold spot tuberculosis test inclusion eligible chest x ray show evidence suggestive active tuberculosis disease signs symptoms pulmonary extra pulmonary tuberculosis disease subjects latent tuberculosis infection already received prophylactic tuberculosis must agree advance complete course female subjects child bearing potential negative serum pregnancy test inclusion subjects reproductive potential willingness use contraceptive measures adequate prevent subject subjects partner becoming pregnant 3 months 5 months stopping therapy mycophenolate mofetil adalimumab respectively unless sterility confirmed simultaneous use two complementary methods contraception preferable methods may considered highly effective methods achieve failure rate less 1 per year used consistently correctly considered highly effective birth control methods according ctfg recommendations methods include female subjects combined estrogen progestogen containing hormonal contraceptionassociated inhibition ovulation 1 oral intravaginal transdermal progestogen hormonal contraception associated inhibition ovulation 1 oral injectable implantable intrauterine device intrauterine device intrauterine hormone releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence context guidance sexual abstinence considered highly effective method defined refraining heterosexual intercourse entire period risk associated treatments reliability sexual abstinence needs evaluated relation duration preferred usual lifestyle subject male subjects use condoms vasectomy documentation azoospermia sexual abstinence affiliated social security system subjects included meet following criteria infectious uveitis masquerade syndromes idiopathic uveitis permitted isolated anterior uveitis monocular active tuberculosis positive human immunodeficiency virus serology hcv hbs ag test history malignancy within 5 years prior inclusion carcinoma situ cervix non metastatic squamous basal cell carcinoma skin history severe allergic anaphylactic reactions monoclonal antibodies mycophenolate mofetil rifampicin isoniazid fluorescein infection requiring intravenous antibiotics within 3 weeks prior inclusion history multiple sclerosis demyelinating disorder laboratory values assessed inclusion hemoglobin 8g deciliter white blood cell count 2 0 103 cubic millimeter platelet count 80 103 cubic millimeter glomerular filtration rates gfr 30ml min transaminases 3 times upper normal value use following systemic treatments specified periods systemic alkylating agents within 12 months prior inclusion e g cyclophosphamide chlorambucil live attenuated vaccine within 4 weeks prior inclusion stage iii intravenous infusion new york heart association “new york heart association” cardiac insufficiency pregnancy breastfeeding legal protection participation another interventional involving human participants exclusion period end previous involving human participants applicable persons responsible quality control article l 1121 3 code de la sante publique french public health code take necessary precautions ensure confidentiality information relating investigational medicinal products participants particular identity results obtained persons well investigators bound professional secrecy accordance conditions set articles 226 13 226 14 code penal french criminal code research involving human participants data collected concerning participants sent sponsor investigators specialised collaborators rendered non identifying circumstances shall names addresses participants involved shown participants initials recorded accompanied encoded number specific indicating order enrolment sponsor ensure participant given written permission personal information strictly necessary quality control accessed data entered electronically via web browser non identifying data entered electronically via web browser use group sequential two arm randomized comparative design one interim analysis 50 completed primary observations efficacy futility non binding early stopping rules obrien fleming spending functions following analysis sets considered intent treat includes randomized subjects refer primary analyses per protocol set includes subjects intent treat set without major violations could affect evaluation primary efficacy endpoint used secondary exploratory sensitivity analyses safety set includes subjects take amount drug general strategy continuous efficacy safety endpoints summarized using summary measures median interquartile range frequency distributions counts percentages used summarize categorical endpoints similarly characteristics presented using summary measures median interquartile range quantitative characteristics counts percentages categorial characteristics analyses group presented according subjects randomized interim analysis planned half inclusions e 60 primary endpoint primary endpoint compared based intent treat set using fisher exact test critical values conclude efficacy futility given 12 2 secondary endpoint time failure week 55 estimated using kaplan meier estimator compare arms using logrank test intent treat set used logmar best corrected visual acuity eye week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 compare arms using linear random effect model wald test intent treat set used anterior chamber cell grade week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 compare arms using linear random effect model wald test intent treat set used vitreous haze grade standardization of uveitis nomenclature criteria eye week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 compare arms using linear random effect model wald test intent treat set used central retinal thickness eye baseline week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 compare arms using linear random effect model wald test intent treat set used proportion central macular thickness 300 microns week 4 week 8 week 12 week 16 week 20 week 24 week 30 week 36 week 55 compare arms using logistic random effect model wald test intent treat set used time optical coherence tomographic optical coherence tomography evidence macular edema least one eye week 55 estimated using gray cumulative incidence estimator compared arms gray test compare cumulative incidence national eye institute visual functioning questionaire 25 vfq 25 composite score week 12 week 24 week 36 compare arms using linear random effect model wald test intent treat set used measures corticosteroid sparing e g percent meeting targets 0 1 milligrams kilograms day prednisone mean change mean dose week 55 cumulative dose compare arms using fisher exact test tests respectively intent treat set used cumulative incidence relapse number relapses week 55 estimated using gray cumulative incidence estimator compared arms gray test compare cumulative incidence intent treat set used manifestations underlying disease depending underlying disease evaluated week 55 described arms safety tolerability treatments assessed frequency severity adverse events discontinuation baseline week 55 compared arms using either fisher exact test wilcoxon test according variables safetset used anticipated level statistical significance primary endpoint analysis 0 025 one sided test tests performed 0 05 level statistical significance two sided formulation interim analysis planned half inclusions e 60 critical values stop either efficacy futility given,"week, uveitis, bd, vasculitis, cd, adalimumab, disease, 16, remission, tocilizumab"
2015-001139-19_protocole-v10_20220104_MARVEL_signe,5,46.165028,13.254171,full title exploring venlafaxine pharmacokinetic variability phenotyping approach acronym marvel coordinating investigator frank bellivier department psychiatry fernand widal hospital 200 rue du faubourg saint denis 75475 paris cedex 10 inserm umr 1144 variabilite de reponse aux psychotropes universites paris descartes paris diderot tel 01 40 05 42 01 sponsor assistance publique hopitaux de paris scientific justification regarding direct costs social value depression decision antidepressant prescription must optimized much possible development personalized medicine psychiatry may reduce failure intolerance resistance hence burden costs affective disorders hope biomarkers found guide selection might decisive interest able assess individuals metabolism activity propose explore relationship activity drug metabolizing enzymes dme transporters assessed phenotypic approach efficacy antidepressants focus venlafaxine v provides reasonable second step choice depression used extensively psychiatric practice metabolism involves several cytochromes cyp p450 enzymes transporter p general practitioner primary objective correlation concentration v metabolite odesmethylv v odv drug metabolism variability assessed phenotypic approach secondary objectives compare responders non responders well without side effects cyp2c19 activity prevalence profile metabolism cyp2d6 activity prevalence profile metabolism cyp3a4 activity prevalence profile metabolism p general practitioner activity prevalance profile transport correlation v odv concentration dose v odv concentration antidepressant efficacy tolerance correlation ratio odv v cyp2d6 activity correlation concentration 2 hours area under the curve 2 3 6 hours metabolic ratio hydroxyomeprazole omeprazole conduct exploratory association analyses blood biomarkers candidate mrna mirna tolerance efficacy v analyse role genetic variations dna determination cyp2c19 2d6 phenotypes picomolar profile criteria assessment v odv concentration cyp2c19 activity 5 hydroxyomeprazole omeprazole 2 hours auc2 3 6 metabolic ratio 2 3 6 hours omeprazole oral administration cyp2d6 activity dextrorphan dextromethorphan ratio two hours dextromethorphan oral administration cyp3a4 activity 1 hydroxymidazolam midazolam ratio two hours midazolam oral administration p general practitioner activity fexofenadine auc2 3 6 based fexofenadine concentrations 2 3 6 hours fexofenadine oral administration antidepressant efficacy madrs hamd qids antidepressant tolerance prise fisber antidepressant observance mars circulating mrna mirna transcripts allelic variations cyp2c19 2 cyp2d6 4 5 experimental design interventional recherche bio medicale population involved major depressive disorder madrs 20 despite 4 weeks v regardless dose inclusion criteria hospitalized outpatient major depressive disorder madrs 20 visit selection non responders v 4 weeks v regardless dose decision psychiatrist increase dose v visit selection male female age 18 years understanding french language able give written inform consent informed consent signed participate individuals covered social security regimen non inclusion criteria treated one antidepressant mirtazapine mianserine currently treated one drug substrate cocktail esomeprazole sensitivity contra indication substrate drugs used current pregnancy desire get pregnant breastfeeding bipolar disorder schizophrenia background therapy oral extended release venlafaxine regardless dose selection increased 375mg according psychiatric follow necessary challenge agents assessment drug metabolizing enzyme activity given cocktail probe drugs oral route one time capsule omeprazole 10mg 6 8 ml oral liquid formulation dextromethorphane bromhydrate tussidane 1 5mg ml syrup 1 milligrams injectable solution midazolam oral administration midazolam 1mg ml injectable solution tablet fexofenadine 120mg procedures added research dosage venlafaxine v odemethylv odv collect dna circulating mrna mirna transcripts assessment drug efficacy tolerance adherence using standardized questionnaires risks added research administration cocktail drugs current authorization two blood samples 5ml one blood sample 2 5ml one blood sample 7ml three blood spots risque b practical procedure selection visit takes place usual medical follow include measurement madrs hamd score visits carried part traditional hospitalization needed regarding psychiatric condition conversely done day hospitalization v0 v1 consultation v2 v3 systematically supervised practitionner inclusion v0 takes place 0 20 days increase v dosage include verification inclusion non inclusion criteria signature consent screen tobacco use fagerstrom test characteristics mood disorder anxiety scale tyrer qids sr16 criteria rating medication trials antidepressant failure level resistance mars score prise score fisber score visit v1 take place 7 21 days visit v0 include sampling dosage venlafaxine v odemethylv odv collect dna circulating mrna mirna transcripts phenotypic administration cocktail probe drugs capsule omeprazole 10mg 6 8 ml oral liquid formulation dextromethorphane bromhydrate tussidane 1 5mg ml syrup 1 milligrams injectable solution midazolam oral administration midazolam 1mg ml injectable solution tablet fexofenadine 120mg pill liquid formulations taken orally successively glass water followed capillary blood samples 2 3 6 hours cocktail administration 1 drops hour small finger prick dbs device measurement cocktail drug concentrations drug parent metabolites visits v2 v3 take place 25 40 days 4 weeks 50 70 days 8 weeks visit v0 psychologist doctor included assessment drug efficacy tolerance adherence mars score prise score fisber score madrs hamd qids sr16 number subjects chosen 205 number centers 12 centers france 7 centers investigations france 4 centers involved biological analysis 3 france 1 switzerland research period included subjects length participation 7 70 days inclusion period 78 months total maximal research period 78 months 70 days 2442 days number inclusions expected per center per month 0 9 center month statistical analysis statistical analysis performed sample size reached end point measures available hypothesis prevalence cyp2c19 um profile twice high non responders comparison responders cyp2c19 metabolic profile comparable caucasians 20 demonstrate prevalence two fold observed non responders type error 0 05 statistical power 80 sample size tabulated according prevalence response thus anticipate potential large disproportion responders non responders defined inclusion decided include 205 allow control type type ii error rates comparison prevalence cyp2c19 um profile among groups addition sample size allow sufficient numbers cyp2d6 picomolar intramuscular um determine effects cyp2d6 variations v odv plasma levels efficacy risk adverse events type error rate fixed 0 05 tests two sided compared thus 0 05 multiple imputations popular approach handling pervasive problem missing data biostatistics used usually performed missing random mar assumption multiple imputations chained equation knowledge flexible approach handle complex patterns missing data including categorical data quantitative data survival data primary analyses performed intent treat basis secondary exploratory analyses consider population compliers completed according scheduled protocol funding source programme hospitalier de recherche clinique aom 14562 dosages determination phenotypes department pharmacology toxicology geneva data safety monitoring board anticipated non twenty 45 major depressive disorder episode mde psychiatric setting fail achieve goal antidepressant agents1 2 consequence consecutive failures concept pseudoresistance resistant depression trd emerged last years regarding direct costs social value depression decision antidepressant prescription must optimized much possible development personalized medicine psychiatry may reduce failure intolerance resistance hence burden costs affective disorders hope biomarkers found guide selection might decisive interest able assess individuals metabolism activity propose explore relationship activity drug metabolizing enzymes dme transporters assessed phenotypic approach concentration efficacy tolerance antidepressants focus venlafaxine v provides reasonable second step choice depression used extensively psychiatric practice metabolism involves several cytochromes p450 cyp enzymes transporter p gp3 5 naturalistic able give critical information reliability results phenotypic approach drug metabolism pharmacokinetics pharmacodynamics antidepressant pharmacodynamic e efficacy adverse events investigating interest phenotypic guided prescription approach correlation concentration v odv drug metabolism variability assessed phenotypic approach compare responders non responders well without side effects cyp2c19 activity prevalence profile metabolism cyp2d6 activity prevalence profile metabolism cyp3a4 activity prevalence profile metabolism p general practitioner activity prevalance profile transport correlation v odv concentration dose v odv concentration antidepressant efficacy tolerance correlation ratio odv v cyp2d6 activity correlation concentration 2 hours area under the curve 2 3 6 hours metabolic ratio hydroxyomeprazole omeprazole conduct exploratory association analyses blood biomarkers candidate mrna mirna tolerance efficacy v analyse role genetic variations dna determination cyp2c19 2d6 phenotypes picomolar profile procedure research represented figure 5 figure 6 visits carried part traditional hospitalization needed regarding psychiatric condition conversely done day hospitalization v0 v1 consultation v2 v3 systematically supervised practitioner notification severe adverse event must initially provided written report using special form reporting severe adverse event report must signed investigator item form must completed investigator sponsor carry appropriate analysis initial notification must followed one detailed follow report writing signed within maximum 8 days case fatal life threatening event within 15 days cases whenever possible investigator provide sponsor documents may useful medical reports laboratory test results results additional exams etc documents must made anonymous addition documents must include following research acronym number initials subject nature date serious adverse event adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even subject left initial notification severe adverse event follow reports documents must sent sponsor via fax vigilance division drcd fax 01 44 84 17 99 investigator must comply requests sponsor additional information questions relating notification adverse event vigilance division drcd contacted via email vigilance drcd drc assistance publique hôpitaux de paris shortening fraction hospitalized outpatient major depressive disorder madrs 20 visit selection non responders v 4 weeks v regardless dose decision psychiatrist increase dose v visit selection male female age 18 years understanding french language able give written inform consent informed consent signed participate individuals covered social security regimen treated one antidepressant mirtazapine mianserine currently treated one drug substrate cocktail esomeprazole sensitivity contra indication substrate drugs used current pregnancy desire get pregnant breastfeeding bipolar disorder schizophrenia responsible biomedical research quality control article l 1121 3 french public health code take necessary precautions ensure confidentiality information medications research research subjects particular identity subjects results obtained individuals well investigators subject professional secrecy accordance conditions set articles 226 13 226 14 penal code biomedical research data collected research subjects sent sponsor investigators specialised parties made non identifying circumstances names addresses subjects involved shown sponsor ensure research subject given permission writing access personal information strictly necessary quality control research data entered staff dedicated task via duplicate data entry forms collecting anonymised data statistical team saint louis hospital paris france statistical analysis performed sample size reached end point measures available type error rate fixed 0 05 tests two sided compared thus 0 05,"prevalence, graall, concentration, treated, leukemia, activity, survival, nervous, central, responders"
OPTISAGE_protocol_v2.0_20240617_FMA-MC_CGC-MC_soumis _clean,1,11.428052,-38.876873,full title phase iii comparing graft versus host disease prophylaxis anti thymoglobulin thymoglobulin atlg grafalon elderly acute myeloid leukemia myelodysplatic syndrome receiving allogeneic hematopoietic stem cell transplantation 10 10 human leukocyte antigen matched unrelated donor following reduced intensity conditioning regimen fludarabine treosulfan acronym reference optisage aphp230276 eu ct n2023 504555 27 00 coordinating investigator pr regis peffault de latour bmt department hopital saint louis avenue vellefaux 75010 paris email regis peffaultdelatour assistance publique hôpitaux de paris shortening fraction scientific director pr marie therese rubio hematology department chru nancy hopital brabois allee du morvan 54500 vandoeuvre les nancy france email rubio chru nancy shortening fraction sponsor assistance publique hopitaux de paris scientific justification allogeneic hematopoietic stem cell transplantation allo hematopoietic stem cell transplantation remains curative therapy acute myeloid leukemia aml myelodysplastic syndrome mds requiring allo hematopoietic stem cell transplantation 50 years age transplanted reduced intensity conditioning ric regimen optimal ric graft versus host disease prophylaxis regimen allowing good control disease preventing graft versus host disease remains determined elderly phase iii comparing conventional ric fludarabine busulfan 2 days fludarabine treosulfan demonstrated advantage flu treosulfan arm terms event free survival event-free survival therefore considered new standard ric regimen aml mds graft versus host disease prevention crucial role post transplant outcomes potentially interfering graft versus leukemia gvl effect immune reconstitution anti thymocyte globulins anti thymoglobulin recommended reduce risk acute chronic graft versus host disease transplants performed matched unrelated donors however optimal type anti thymoglobulin 2 approved brands anti thymoglobulin thymoglobulin atlg grafalon displaying distinct characteristics optimal dose anti thymoglobulin still unknown retrospective transplanted mainly ric matched related unrelated donors haematological malignancies observed atlg associated reduction grade ii intravenous infusion acute graft versus host disease comparison anti thymoglobulin without increasing incidence relapse phase iii randomized propose compare graft versus host disease prevention anti thymoglobulin versus atlg aml mds 50 years age transplanted matched unrelated donor following fludarabine treosulfan ric hypothesis atlg would better control graft versus host disease population thus limiting risk morbidity mortality procedure main objective primary endpoint main objective compare incidence grade ii intravenous infusion acute graft versus host disease day 100 post transplantation mds aml transplanted 10 10 matched unrelated donor mud following reduced intensity conditioning fludarabine treosulfan receiving graft versus host disease prophylaxis anti thymoglobulin thymoglobulin versus atlg grafalon primary endpoint incidence grade ii intravenous infusion acute graft versus host disease according magic classification appendix 19 9 section 1 day 100 post transplantation secondary objectives endpoints secondary objectives evaluate effect 2 graft versus host disease prophylaxis engraftment graft failure evaluate effect 2 graft versus host disease prophylaxis incidence grade acute graft versus host disease chronic graft versus host disease evaluate effect 2 graft versus host disease prophylaxis incidence infections evaluate effect 2 graft versus host disease prophylaxis progression free survival evaluate effect 2 graft versus host disease prophylaxis relapse incidence evaluate effect 2 graft versus host disease prophylaxis non relapse mortality evaluate effect 2 graft versus host disease prophylaxis overall survival evaluate effect 2 graft versus host disease prophylaxis graft versus host disease relapse free survival grfs evaluate effect 2 graft versus host disease prophylaxis health related quality life fact bmt evaluate effect 2 graft versus host disease prophylaxis chimerism evaluate effect 2 graft versus host disease prophylaxis immune reconstitution b nk regulatory cell levels peripheral blood evaluate effect 2 graft versus host disease prophylaxis days hospitalisation first 12 months post transplantation evaluate effect 2 graft versus host disease prophylaxis incidence severity vod identify prognostic factors associated primary endpoint prophylaxis arm search covariate interactions primary endpoint evaluate effect 2 graft versus host disease prophylaxis incidence late acute graft versus host disease day 100 overlap syndromes chronic graft versus host disease secondary endpoints hematopoietic recoveries least 7consecutive days neutrophils 0 5 g l platelets 20 g l immune reconstitution analyzing b nk regulatory cell gammaglobulin levels peripheral blood month 1 100 month 6 month 12 month 24 post transplantation chimerism month 1 100 month 6 month 12 grade acute graft versus host disease incidence appendix 19 9 section 1 acute graft versus host disease treatments first line response steroids courses refractory acute graft versus host disease chronic graft versus host disease incidence date grading month 12 month 24 nih classification 48 appendix 19 9 section 4 relapse incidence month 12 month 24 relapse defined reappearance leukemic cells mds features allo hematopoietic stem cell transplantation bonne marrow cytology cytogenetic analysis bone marrow aspiration extra medullary sites proven biopsy progression free survival month 12 month 24 severe infections ctae grade 3 4 100 month 12 fully described incidences cmv ebv reactivations 100 month 6 month 12 non relapse mortality month 6 month 12 month 24 overall survival month 12 month 24 graft versus host disease relapse free survival grfs defined alive without disease relapse without developed acute grade iii intravenous infusion severe chronic graft versus host disease health related quality life assessed using fact bmt v4 questionnaire inclusion 100 month 6 month 12 post transplantation number days hospitalization transplant hospitalization transplantation related complications month 12 incidence severity vod 100 lymphocyte counts standard blood counts conditioning 7 late acute graft versus host disease overlap syndromes chronic graft versus host disease 100 120 design phase iii multicenter randomized controlled open label comparing gvdh prophylaxis anti thymoglobulin versus atlg aml mds transplanted mud following fludarabine treosulfan ric category cat 3 low intervention population participants 50 years age presenting aml mds indication allogeneic stem cell transplantation inclusion criteria age 50 70 years 50 55 years unfit myeloblative conditioning aml requiring allogeneic stem cell transplantation intermediate high risk aml complete cytologic response cr1 mds requiring allogeneic stem cell transplantation ipss 1 5 ipss r 4 5 ipss r 3 4 5 risk features rapide blast increase life threatening neutropenia 0 3 g l thrombopenia 30g l high transfusion needs 2 month 6 months without human leukocyte antigen matched related donor identified matched human leukocyte antigen 10 10 unrelated donor usual criteria hematopoietic stem cell transplantation eastern cooperative oncology group (= performans status (= ecog)) performans status 2 severe uncontrolled infection cardiac left ventricular ejection fraction 50 lung diffusing capacity of lung for carbon monoxide 40 adequate organ function aspartate amino transferase alanine-aminotransferase 3n total bilirubin 2n creatinine clearance 50 ml min except abnormalities linked hematological disease health insurance coverage signed written informed consent contraception methods must prescribed duration research nb authorized contraceptive methods women childbearing age absence permanent sterilization oral intravaginal transdermal combined hormonal contraception oral injectable implantable progestogen hormonal contraception intrauterine device intrauterine device intrauterine hormonal releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence preferred usual lifestyle participants man absence permanent sterilization sexual abstinence condoms exclusion criteria carcinomas last 5 years except basal cell carcinoma skin situ carcinoma cervix uncontrolled infection seropositivity human immunodeficiency virus htlv 1 active hepatitis b c yellow fever vaccine others live virus vaccines within 2 months transplantation heart failure according “new york heart association” ii left ventricular ejection fraction 50 lung diffusing capacity of lung for carbon monoxide 40 preexisting acute hemorrhagic cystitis renal failure creatinine clearance 50ml min pregnancy hcg positive breast feeding debilitating medical psychiatric illness would preclude realization sct understanding protocol state medical aid legal protection protection court curatorship guardianship grafalon contraindication mentioned smpc grafalon thymoglobulin hypersensitivity rabbit proteins excipients participation trials medicinal products human use exclusion period end previous contraindication mentioned smpc auxiliary medicinal products planned used cyclosporine mycophenolate mofetil fludarabine treosulfan investigational medicinal product phase iii grafalon 10 milligrams kilograms day intravenous infusion 3 consecutive days day 3 1 transplantation thymoglobuline 5 milligrams kilograms intravenous infusion 2 3 days transplantation transplantation modalities 1 conditionning regimen receive conditioning regimen fludarabine 30 milligrams month 2 day intravenous infusion 5 days day 6 day 2 treosulfan 10 g month 2 day intravenous infusion 3 days day 4 day 2 2 donor stem cell source human leukocyte antigen 10 10 matched unrelated donor gcsf mobilized peripheral blood stem cells accepted cd34 target dose 4 10 6 kilograms body weight 3 graft versus host disease prophylaxis prophylaxis graft versus host disease depend randomization arm atlg grafalon 10 milligrams kilograms day intravenous infusion 3 consecutive days day 3 1 atlg grafalon anti thymoglobulin thymoglobuline anti thymoglobulin thymo two schedules administration anti thymocyte globulin anti thymoglobulin accepted 2 5 milligrams kilograms day intravenous infusion 2 consecutive days day 3 2 0 5 milligrams kilograms intravenous infusion day 4 followed 2 milligrams kilograms intravenous infusion day 3 2 5 milligrams kilograms day 2 addition receive cyclosporine cyclosporine a 3 milligrams kilograms day mycophenolate mofetil mycophenolate mofetil 30 milligrams kilograms day follows cyclosporine a day 1 month 4 6 progressive withdrawal starting 3 months post sct agvhd according practice center mycophenolate mofetil day 1 day 45 arms interventions added randomisation ratio 1 1 anti thymoglobulin atlg graft versus host disease prophylaxis health related quality fact bmt v4 life 100 month 6 month 12 biological biocollection pharmacokinetic atlg frozen plasma 5 ml 1 tube 5ml edta days 3 2 1 day 0 day 14 day 28 day 60 100 accordance decree february 17 2021 biocollection blood pbmcs plasma dry pellets 28 ml 4 tubes 7 ml edta point 9 base line 100 month 6 month 12 via cryostem day 14 day 21 day 28 month 2 40 ml 5 tubes 8 ml edta accordance decree february 17 2021 ancillary bio collection peripheral blood mononuclear cell plasma dry pellets total blood cells performed 9 base line day 14 21 28 56 100 month 6 month 12 60 per arm future biological would performed finding complementary funding collections organized via cryostem order better understand modulation immune response two anti thymoglobulin brands plasma collection anti thymoglobulin pharmacokinetic analysis atlg arm samples collected administration atlg days 3 1 day 0 14 month 1 month 2 100 frozen center data analyzed according pre conditioning lymphocyte counts correlated post transplant outcomes graft versus host disease relapse non relapse related mortality able determine formula optimize atlg dose lymphocyte counts future plasma collection start including finding complementary funding expected benefits participants society expect demonstrate benefice terms reduction acute graft versus host disease atlg arm improve outcome elderly aml mds number participants included 324 number centres 26 france duration inclusion period 36 months participation period 24 months total duration 60 months number enrolments expected per site per month 0 35 month centre statistical analysis hypotheses based reduction incidence day 100 post hematopoietic stem cell transplantation grade ii intravenous infusion acute graft versus host disease 40 anti thymoglobulin arm 23 atlg arm assuming 10 risk randomised would reach transplant incidence 5 competing risk death without graft versus host disease arm accounting competing risks two sided logrank test overall sample size 324 subjects 162 control group 162 group achieves 91 power 0 05 significance level detect hazard ratio 0 50 follow time 100 days total 162 162 324 included interim analysis scheduled performed funding sources funded industrial support neovii medac data safety monitoring board yes justification use fludarabine treosulfan ric conditioning treosulfan approved conditioning allo hematopoietic stem cell transplantation retrospective suggest treosulfan might lower toxicity profile compared busulfan higher anti leukemic effect 19 20 receiving treosulfan developed less mucositis graft versus host disease compared receiving myeloablative doses busulfan without increase relapse 20 relapse risk reduced treosulfan comparison busulfan based reduced intensity conditioning ric 19 20 prospective phase iii european multicentric randomized performed aml mds compared fludarabine busulfan fludarabine treosulfan ric arms received anti thymoglobulin atlg case matched unrelated donor 3 primary endpoint 2 year event-free survival hypothesis non inferiority possibility demonstrate superiority enrolled 240 220 busulfan treosulfan groups respectively two year event free survival 640 95 ci 560709 treosulfan group 504 428575 busulfan group high risk 065 95 ci 047090 p 0 0001 non inferiority p 0 0051 superiority 3 figure 1 event free survival event-free survival fludarabine treosulfan versus fludarabine busulfan ric randomized 3 advantage event-free survival treosulfan group particularly significant transplanted matched unrelated donor high risk 0 61 95 ci 0 42 0 9 p 0 012 older 50 years high risk 0 65 95 ci 0 47 0 91 p 0 013 3 overall survival 2 years 71 3 56 4 treosulfan busulfan groups respectively high risk 0 61 95 ci 0 42 0 88 differences explained reduced 2 year toxicity related mortality treosulfan group 12 1 versus 28 2 high risk 0 54 95 ci 0 32 0 91 relapse incidence 2 years similar groups 23 3 versus 24 6 high risk 0 87 95 ci 0 59 1 30 3 thus results unique randomized type reduced intensity conditioning suggest fludarabine treosulfan might considered new standard reduced intensity conditioning ric aml mds currently referenced ric european countries impact graft versus host disease prophylaxis post transplant outcomes justification choice randomization graft versus host disease prophylaxis distinct graft versus host disease prevention strategies progressively developed according type stem cell source level human leukocyte antigen compatibility donor recipient addition standard post transplantation immunosuppression calcineurin inhibitor cell cycle inhibitor methotrexate mycophenolate mofetil several prospective randomized demonstrated interest adding anti thymocyte globulin anti thymoglobulin prevent acute chronic graft versus host disease without impairing graft versus leukemia gvl effect context myeloablative conditioning regimens 21 24 reduction severe chronic graft versus host disease also associated improvement quality life grfs 4 23 25 randomized performed reduced intensity conditionings similar observations made retrospective 10 11 two brands anti thymoglobulin approved graft versus host disease prophylaxis anti thymoglobulin thymoglobulin atlg grafalon correspond polyclonal igg obtained sera rabbits immunized either human thymocytes anti thymoglobulin thymoglobulin human jurkatt leukemic cell line atlg grafalon 26 deplete recipient cells avoid donor stem cell rejection partially deplete potential alloreactive donor cells contained hematopoietic stem cell graft distinct origin 2 brands distinct affinities immune cells vitro 26 27 explains differences doses required deplete cells vivo whether distinct characteristics impact efficacy deplete alloreactive cells immune cells vivo prevent graft versus host disease never explored prospective comparative furthermore dose anti thymoglobulin impact transplant outcomes higher doses increase viral infections ebv cmv reactivations might also increase risk relapse particular ric 4 lower doses associated increased incidence graft versus host disease 28 recommended dose anti thymoglobulin thymoglobulin 4 5 6 milligrams kilograms 2 3 days 10 optimal dose atlg grafalon determined yet many groups adopted dose 30 milligrams kilograms ric matched unrelated donors 29 30 post transplant cyclophosphamide pt cy represents another graft versus host disease prophylaxis strategy allo hematopoietic stem cell transplantation administration cyclophosphamide days 3 4 transplantation induces depletion early activated alloreactive donor preserves regulatory cells 31 post transplant cyclophosphamide initially shown efficiently prevent acute chronic graft versus host disease haplo identical stem cell transplantation 32 33 matched related unrelated donor transplants pt cy superior standard post transplant graft versus host disease prophylaxis without anti thymoglobulin preventing acute chronic graft versus host disease de jong ash 2019 however comparisons pt cy anti thymoglobulin showed comparable results retrospective prospective 34 35 retrospective including 64 received atlg 50 receiving anti thymoglobulin allo hematopoietic stem cell transplantation matched related donors mud distinct haematological malignancies diverse conditioning regimen observed use atlg associated reduction incidence ii intravenous infusion acute graft versus host disease uni multivariate analyses cumulative incidence day 100 grade ii intravenous infusion agvhd 49 anti thymoglobulin vs 21 5 atlg high risk high risk 0 36 0 180 75 p 0 006 5 biologically comparison anti thymoglobulin atlg associated reduced il 15 production first month post hematopoietic stem cell transplantation compensated higher production il 21 reduced proportions tscm cd8 cells first 2 months transplantation significant reduction expression pd1 cd4 cd8 memory cells suggesting reduced activation cells manuscript preparation thus atlg anti thymoglobulin might distinct effects regulation allorective cells leading distinct regulation graft versus host gvl effects transplantation propose randomize first time 2 brands anti thymoglobulin association fludarabine treosulfan ric 50 years age transplanted aml mds impact graft versus host disease prophylaxis immune reconstitution role pharmacokinetic anti thymoglobulin lymphocyte counts graft versus host disease prophylaxis anti thymoglobulin impact post transplant immune reconstitution mainly delaying naive cd4 cd8 cell reconstitution 26 36 38 delayed immune reconstitution associated increased risk infections relapse 39 40 recent shown clearance pharmacokinetic anti thymoglobulin thymoglobulin impact immune reconstitution allo hematopoietic stem cell transplantation 41 remaining active anti thymoglobulin peripheral blood measurable flow cytometry slow clearance active anti thymoglobulin associated slower immune reconstitution increased risk infections relapse fast clearance associated higher risk graft versus host disease increased non relapse mortality 41 clearance anti thymoglobulin related dose type anti thymoglobulin brand 42 furthermore pharmacokinetic anti thymoglobulin influenced lymphocyte counts administration anti thymoglobulin constant dose anti thymoglobulin high lymphocyte counts faster clearance active anti thymoglobulin low lymphocyte counts slower clearance thus dose adaptation anti thymoglobulin might adapted lymphocyte counts rather body weight 41 43 however calculation optimal dose anti thymoglobulin according lymphocyte counts requires perform exploration correlations lymphocyte counts conditioning pharmacokinetic anti thymoglobulin conditioning regimen since conditioning impact lymphocyte counts 41 44 propose explore ancillary lymphocyte counts pharmacokinetic atlg determine dose calculation formula adapted fludarabine treosulfan ric could applied future benefits evaluated terms potential reduction incidence grade ii intravenous infusion acute graft versus host disease affects quality life risk secondary infections risk toxic mortality sct risks related atlg grafalon anti thymoglobulin thymoglobulin include infusion reactions symptoms related cytokine release hypersensitivity reactions anaphylaxis allergic phenomena increased susceptibility infections appearance secondary malignancies lymphoproliferative syndromes lymphoma risks also related sct randomization anti thymoglobulin vs atlg arm essentially risk non engraftment due reduced intensity conditioning infectious complications due immune deficiency post transplant events obviously studied carefully engraftment graft versus host disease infectious complications relapse survival risks also related blood samples mild bleeding hematoma mild pain according article 37 4 european regulation n536 2014 irrespective outcome within one year end member states concerned sponsor shall submit ctis summary results summary shall accompanied summary written manner understandable laypersons specific documents medicinal product human use archived investigator sponsor 25 years end research indexed archiving includes particular sealed envelope investigator containing copy information notes consent forms signed individuals centre participated sealed envelope sponsor containing copy information notes consent forms signed individuals centre participated binders investigator sponsor including non exhaustive list successive versions protocol identified version number date appendices competent authority authorisations research ethics committee decisions correspondence enrolment list register appendices specific research final report data collection documents supported two pharmaceutical companies medac sas neovii pharmaceuticals ag duration sponsor take insurance policy covering sponsors public liability well public liability physicians involved sponsor also provide full compensation damages caused participant enrolled beneficiaries unless sponsor prove harm fault sponsor collaborator compensation cannot refused grounds third party act voluntary withdrawal person initially consented participate assistance publique hopitaux de paris ap hp taken insurance hdi global se insurance broker biomedic insure full period covers public liability collaborator physician research staff accordance article 76 1 regulation eu 536 2014 european parliament council 16 april 2014 article l 1121 10 code de la sante publique french public health code author publication relating must include ap hp among affiliations must name sponsor ap hp délégation à la recherche clinique et à l’innovation source funding see rules governing affiliation naming sponsor funders author several affiliations order institutions mentioned ap hp university inserm etc unimportant however funded context internal ap hp call tender first affiliation must ap hp affiliations must identified address separated semicolon ap hp institution must feature acronym ap hp first address specifically followed ap hp hospital department city postcode france sponsor assistance publique hopitaux de paris direction de la recherche clinique et de linnovation funded medac sas neovii pharmaceuticals ag registered website http clinicaltrials gov number add registration number registered 1 harbi jb n milpied p chevallier r peffault de la tour f malard francois charbonnier e hermet ce bulabois huynh berceanu cluzeau mt rubio furst mohty r devillier blaise impact donor search strategy allogeneic hematopoietic stem cell transplantation haploidentical matched unrelated donor older 55 years hematological malignancies randomized prospective phase iii ash abstract 2020 2 robin porcher r ades l raffoux e michallet francois cahn jy delmer wattel e vigouroux others human leukocyte antigen matched allogeneic stem cell transplantation improves outcome higher risk myelodysplastic syndrome prospective behalf sfgm tc gfm leukemia 2015 29 7 1496 1501 3 beelen dw trenschel r stelljes groth c masszi remenyi p wagner drouet em hauptrock b dreger p luft others treosulfan busulfan plus fludarabine conditioning allogeneic haemopoietic stem cell transplantation older acute myeloid leukaemia myelodysplastic syndrome mc fludt 14 l randomised non inferiority phase 3 lancet haematol 2020 7 1 e28 e39 4 bonifazi f rubio mt bacigalupo boelens jj finke j greinix h mohty nagler passweg j rambaldi others rabbit anti thymoglobulin atlg preventing graft versus host disease allogeneic stem cell transplantation consensus based recommendations international expert panel bone marrow transplant 2020 55 6 1093 1102 5 arnaud campidelli mda p charline moulin marie detrait laura boulange gabrielle roth guepin sylvie tarillon nathalie hottier helene jeulin emma verstraete anne beatrice notarantonio pierre feugier marie therese rubio reduced acute graft versus host disease incidence receiving anti lymphocyte globulin atlg comparison anti thymocyte globulin anti thymoglobulin prophylaxis graft versus host disease allogeneic haematopoietic stem cell transplantation bone marrow transplantation 2021 56 21183 2021 6 mohty de lavallade h el cheikh j ladaique p faucher c furst vey n coso stoppa gastaut ja others reduced intensity conditioning allogeneic stem cell transplantation acute myeloid leukemia long term results donor versus donor comparison leukemia 2009 23 1 194 196 7 bacher u kern w schnittger hiddemann w haferlach schoch c population based age specific incidences cytogenetic subgroups acute myeloid leukemia haematologica 2005 90 11 1502 1510 8 levin epstein r oliai c schiller g allogeneic hematopoietic stem cell transplantation older acute myeloid leukemia curr treat options oncol 2018 19 12 63 9 devillier r furst el cheikh j castagna l harbi granata crocchiolo r oudin c mohty b bouabdallah r others antithymocyte globulin reduced intensity conditioning regimen allows high disease free survival exempt long term chronic graft versus host disease biol blood marrow transplant 2014 20 3 370 374 10 baron f labopin blaise lopez corral l vigouroux craddock c attal jindra p goker h socie g others impact vivo cell depletion outcome aml first complete remission given peripheral blood stem cells reduced intensity conditioning allo sct human leukocyte antigen identical sibling donor report acute leukemia working party european group blood marrow transplantation bone marrow transplant 2014 49 3 389 396 11 rubio mt labopin blaise socie g contreras rr chevallier p sanz vigouroux huynh shimoni others impact graft versus host disease prophylaxis reduced intensity conditioning allogeneic stem cell transplant acute myeloid leukemia acute leukemia working party european group blood marrow transplantation haematologica 2015 100 5 683 689 12 campidelli robin remen luc labussiere wallet h dulery r srour ceballos p forcade e nguyen quoc others behalf sfgm tc retrospective comparison reduced higher intensity conditioning high risk myelodysplastic syndrome treated allogeneic stem cell transplantation clin lymphoma myeloma leuk 2022 22 1 34 43 13 zhou z nath r cerny j wang hl zhang mj abdel azim h agrawal v ahmed g al homsi aljurf others reduced intensity conditioning acute myeloid leukemia using melphalan vs busulfan based regimens cibmtr report blood adv 2020 4 13 3180 3190 14 saraceni f labopin hamladji rm mufti g socie g shimoni delage j deconinck e chevallier p blaise others thiotepa busulfan fludarabine compared busulfan fludarabine sibling unrelated donor transplant acute myeloid leukemia first remission oncotarget 2018 9 3 3379 3393 15 baron f labopin peniket jindra p afanasyev b sanz deconinck e nagler mohty reduced intensity conditioning fludarabine busulfan versus fludarabine melphalan acute myeloid leukemia report acute leukemia working party european group blood marrow transplantation cancer 2015 121 7 1048 1055 16 jagasia arora flowers chao nj mccarthy pl cutler cs urbano ispizua pavletic sz haagenson md zhang mj others risk factors acute graft versus host disease survival hematopoietic cell transplantation blood 2012 119 1 296 307 17 lee se chinese hamster ovary bs kim jh yoon jh shin sh yahng sa eom ks kim yj kim hj lee others risk prognostic factors acute graft versus host disease based nih consensus criteria bone marrow transplant 2013 48 4 587 592 18 devillier r legrand f rey j castagna l furst granata charbonnier harbi incan e pagliardini others human leukocyte antigen matched sibling versus unrelated versus haploidentical related donor allogeneic hematopoietic stem cell transplantation aged 60 years acute myeloid leukemia single center donor comparison biol blood marrow transplant 2018 24 7 1449 1454 19 sakellari mallouri gavriilaki e batsis kaliou constantinou v papalexandri lalayanni c vadikolia c athanasiadou others survival advantage comparable toxicity reduced toxicity treosulfan based versus reduced intensity busulfan based conditioning regimen myelodysplastic syndrome acute myeloid leukemia allogeneic hematopoietic cell transplantation biol blood marrow transplant 2017 23 3 445 451 20 shimoni labopin savani b hamladji rm beelen mufti g socie g delage j blaise chevallier p others intravenous busulfan compared treosulfan based conditioning allogeneic stem cell transplantation acute myeloid leukemia behalf acute leukemia working party european society blood marrow transplantation biol blood marrow transplant 2018 24 4 751 757 21 finke j bethge wa schmoor c ottinger high dose stelljes zander ar volin l ruutu heim da schwerdtfeger r others standard graft versus host disease prophylaxis without anti cell globulin haematopoietic cell transplantation matched unrelated donors randomised open label multicentre phase 3 lancet oncology 2009 10 9 855 864 22 socie g schmoor c bethge wa ottinger high dose stelljes zander ar volin l ruutu heim da schwerdtfeger r others chronic graft versus host disease long term results randomized graft versus host disease prophylaxis without anti cell globulin anti thymoglobulin fresenius blood 2011 117 23 6375 6382 23 walker panzarella couban couture f devins g elemary gallagher g kerr h kuruvilla j lee sj others pretreatment anti thymocyte globulin versus anti thymocyte globulin haematological malignancies undergoing haemopoietic cell transplantation unrelated donors randomised controlled open label phase 3 multicentre lancet oncology 2016 17 2 164 173 24 kroger n solano c wolschke c bandini g patriarca f pini nagler selleri c risitano messina g others antilymphocyte globulin prevention chronic graft versus host disease n engl j med 2016 374 1 43 53 25 rubio mt aveni piney labopin hamladji rm sanz blaise ozdogu h daguindeau e richard c santarone others impact vivo cell depletion human leukocyte antigen identical allogeneic stem cell transplantation acute myeloid leukemia first complete remission conditioned fludarabine intravenous infusion busulfan myeloablative regimen report ebmt acute leukemia working party j hematol oncol 2017 10 1 31 26 baron f mohty blaise socie g labopin esteve j ciceri f giebel gorin nc savani bn others anti thymocyte globulin graft versus host disease prevention setting allogeneic peripheral blood stem cell transplantation review acute leukemia working party european society blood marrow transplantation haematologica 2017 102 2 224 234 27 popow leitner j grabmeier pfistershammer k majdic zlabinger gj kundi steinberger p comprehensive quantitative analysis major specificities rabbit antithymocyte globulin preparations j transplant 2013 13 12 3103 3113 28 devillier r crocchiolo r castagna l furst el cheikh j faucher c prebet etienne chabannon c vey n others increase 2 5 5 milligrams kilograms rabbit anti thymocyte globulin dose reduced intensity conditioning reduces acute chronic graft versus host disease myeloid malignancies undergoing allo sct bone marrow transplant 2012 47 5 639 645 29 ayuk f diyachenko g zabelina wolschke c fehse b bacher u erttmann r kroger n zander ar comparison two doses antithymocyte globulin undergoing matched unrelated donor allogeneic stem cell transplantation biol blood marrow transplant 2008 14 8 913 919 30 binkert l medinger halter jp heim gerull holbro lengerke c weisser passweg jr lower dose anti thymocyte globulin graft versus host disease prophylaxis results improved survival allogeneic stem cell transplantation bone marrow transplant 2015 50 10 1331 1336 31 luznik l donnell pv fuchs ej post transplantation cyclophosphamide tolerance induction human leukocyte antigen haploidentical bone marrow transplantation semin oncol 2012 39 6 683 693 32 bashey zhang x sizemore ca manion k brown holland hk morris le solomon standard risk cell replete human leukocyte antigen haploidentical hematopoietic transplantation hematologic malignancies using post transplantation cyclophosphamide results outcomes equivalent contemporaneous human leukocyte antigen matched related unrelated donor transplantation j clin oncol 2013 31 10 1310 1316 33 luznik l donnell pv symons hj chen ar leffell ms zahurak gooley ta piantadosi kaup ambinder rf others human leukocyte antigen haploidentical bone marrow transplantation hematologic malignancies using nonmyeloablative conditioning high dose posttransplantation cyclophosphamide biol blood marrow transplant 2008 14 6 641 650 34 brissot e labopin moiseev cornelissen jj meijer e van gorkom g rovira ciceri f griskevicius l blaise others post transplant cyclophosphamide versus antithymocyte globulin acute myeloid leukemia first complete remission undergoing allogeneic stem cell transplantation 10 10 human leukocyte antigen matched unrelated donors j hematol oncol 2020 13 1 87 35 eolia brissot ml helene labussiere patrice chevallier didier blaise ibrahim yakoub agha claude eric bulabois anne huynh sylvain chantepie anne lise menard marie therese rubio patrice ceballos mohamad mohty post transplantation cyclophosphamide vs antithymocyte globulin ric regimen allo hct first analysis prospective randomized multicenter recipients 10 10 matched donors bone marrow transplantation volume 56 pages1220 2021 36 bosch dhadda hoegh petersen liu hagel lm podgorny p ugarte torres khan fm luider j auer grzesiak others immune reconstitution anti thymocyte globulin conditioned hematopoietic cell transplantation cytotherapy 2012 14 10 1258 1275 37 servais menten dedoyart c beguin seidel l gothot daulne c willems e delens l humblet baron hannon others impact pre transplant anti cell globulin anti thymoglobulin immune recovery myeloablative allogeneic peripheral blood stem cell transplantation plos one 2015 10 6 e0130026 38 makanga dr guillaume willem c legrand n gagne k cesbron gendzekhadze k peterlin p garnier le bourgeois others posttransplant cyclophosphamide antithymocyte globulin versus posttransplant cyclophosphamide graft versus host disease prophylaxis peripheral blood stem cell haploidentical transplants comparison cell nk effector reconstitution j immunol 2020 205 5 1441 1448 39 bejanyan n brunstein cg cao q lazaryan luo x curtsinger j mehta rs warlick e cooley sa blazar br others delayed immune reconstitution allogeneic transplantation increases risks mortality chronic graft versus host disease blood adv 2018 2 8 909 922 40 hiwarkar p gaspar hb gilmour k jagani chiesa r bennett rees n breuer j rao k cale c goulden n others impact viral reactivations era pre emptive antiviral drug therapy following allogeneic haematopoietic sct paediatric recipients bone marrow transplant 2013 48 6 803 808 41 admiraal r nierkens de witte petersen ej fleurke gj verrest l belitser sv bredius rgm raymakers rap knibbe caj others association anti thymocyte globulin exposure survival outcomes adult unrelated haemopoietic cell transplantation multicentre retrospective pharmacodynamic cohort analysis lancet haematol 2017 4 4 e183 e191 42 oostenbrink lve jol van der zijde cm kielsen k jansen hoogendijk ifversen muller kilograms lankester ac van halteren ags bredius rgm schilham mw others differential elimination anti thymocyte globulin fresenius genzyme impacts cell reconstitution hematopoietic stem cell transplantation front immunol 2019 10 315 43 kennedy chen h savani bn greer j kassim aa engelhardt bg goodman sengsayadeth chinratanalab w jagasia optimizing antithymocyte globulin dosing unrelated donor allogeneic hematopoietic cell transplantation based recipient absolute lymphocyte count biol blood marrow transplant 2018 24 1 150 155 44 heelan f mallick r bryant radhwi atkins h huebsch l bredeson c allan kekre n lymphocyte count impact dosing anti thymocyte globulin unrelated donor stem cell transplantation biol blood marrow transplant 2020 26 7 1298 1302 45 de witte bowen robin malcovati l niederwieser yakoub agha mufti gj fenaux p sanz g martino r others allogeneic hematopoietic stem cell transplantation mds cmml recommendations international expert panel blood 2017 129 13 1753 1762 46 davies sm rowe jm appelbaum shortening fraction indications hematopoietic cell transplantation acute leukemia biol blood marrow transplant 2008 14 1 suppl 1 154 164 47 harris ac young r devine hogan wj ayuk f bunworasate u chanswangphuwana c efebera ya holler e litzow others international multicenter standardization acute graft versus host disease data collection report mount sinai acute graft versus host disease international consortium biol blood marrow transplant 2016 22 1 4 10 48 filipovich ah weisdorf pavletic socie g wingard jr lee sj martin p chien j przepiorka couriel others national institutes health consensus development project criteria trials chronic graft versus host disease diagnosis staging working group report biol blood marrow transplant 2005 11 12 945 956 49 ruggeri labopin ciceri f mohty nagler definition graft versus host disease free relapse free survival registry based alwp ebmt analysis aml remission bone marrow transplant 2016 51 4 610 611 50 dohner h wei ah appelbaum shortening fraction craddock c dinardo cd dombret h ebert bl fenaux p godley la hasserjian rp others diagnosis management aml adults 2022 recommendations international expert panel behalf eln blood 2022 140 12 1345 1377 51 greenberg p cox c lebeau millimeter fenaux p morel p sanz g sanz vallespi hamblin oscier others international scoring system evaluating prognosis myelodysplastic syndromes blood 1997 89 6 2079 2088 52 greenberg pl tuechler h schanz j sanz g garcia manero g sole f bennett jm bowen fenaux p dreyfus f others revised international prognostic scoring system myelodysplastic syndromes blood 2012 120 12 2454 2465 allogeneic hematopoietic stem cell transplantation allo hematopoietic stem cell transplantation remains curative therapy acute myeloid leukemia aml myelodysplastic syndrome mds requiring allo hematopoietic stem cell transplantation 50 years age transplanted reduced intensity conditioning ric regimen older recipient age also associated increased risk graft versus host disease graft versus host disease major complication allo hematopoietic stem cell transplantation responsible high morbidity probability mortality 20 population addition disease relapse transplantation ric occurs 30 transplanted aml mds thus probability event free survival event-free survival transplanted aml mds matched unrelated related donor 50 years age 40 50 2 years needs improved 1 2 optimal conditioning graft versus host disease prophylaxis regimen allowing good control disease preventing graft versus host disease remains determined elderly frequently ric regimen used france fludarabine busulfan 6 4 milligrams kilograms flu bu2 phase iii comparing flu bu2 fludarabine treosulfan reported improved 2 year event-free survival fludarabine treosulfan mainly reduction transplant related mortality 3 thus fludarabine treosulfan considered new standard ric regimen aml mds prevention graft versus host disease crucial role post transplant outcomes potentially interfering graft versus leukemia gvl effect immune reconstitution risk fatal infections anti thymocyte globulins anti thymoglobulin recommended reduce risk acute chronic graft versus host disease transplants performed matched unrelated donors 4 however optimal type anti thymoglobulin 2 approved brands anti thymoglobulin thymoglobulin atlg grafalon displaying distinct characteristics optimal dose anti thymoglobulin still unknown ric regimen potential induction higher relapse risk 4 retrospective transplanted mainly ric matched related unrelated donors haematological malignancies observed atlg associated reduction grade ii intravenous infusion acute graft versus host disease comparison anti thymoglobulin without increasing incidence relapse leading improved severe graft versus host disease relapse free survival grfs atlg group 5 phase iii randomized propose compare graft versus host disease prevention anti thymoglobulin versus atlg aml mds 50 years age transplanted matched unrelated donor following fludarabine treosulfan ric hypothesis atlg would better control graft versus host disease population thus limiting risk morbidity mortality procedure main objective compare incidence grade ii intravenous infusion acute graft versus host disease day 100 post transplantation mds aml transplanted 10 10 matched unrelated donor following reduced intensity conditioning fludarabine treosulfan receiving graft versus host disease prophylaxis anti thymoglobulin thymoglobulin versus atlg grafalon evaluate effect 2 graft versus host disease prophylaxis engraftment graft failure evaluate effect 2 graft versus host disease prophylaxis incidence grade acute graft versus host disease chronic graft versus host disease evaluate effect 2 graft versus host disease prophylaxis incidence infections evaluate effect 2 graft versus host disease prophylaxis progression free survival evaluate effect 2 graft versus host disease prophylaxis relapse incidence evaluate effect 2 graft versus host disease prophylaxis non relapse mortality evaluate effect 2 graft versus host disease prophylaxis overall survival evaluate effect 2 graft versus host disease prophylaxis graft versus host disease relapse free survival grfs evaluate effect 2 graft versus host disease prophylaxis health related quality life fact bmt evaluate effect 2 graft versus host disease prophylaxis chimerism evaluate effect 2 graft versus host disease prophylaxis immune reconstitution b nk regulatory cell levels peripheral blood evaluate effect 2 graft versus host disease prophylaxis days hospitalization first 12 months post transplantation evaluate effect 2 graft versus host disease prophylaxis incidence severity vod identify prognostic factors associated primary endpoint prophylaxis arm search covariate interactions primary endpoint evaluate effect 2 graft versus host disease prophylaxis incidence late acute graft versus host disease day 100 overlap syndromes chronic graft versus host disease include plasma collection anti thymoglobulin pharmacokinetic analysis atlg arm samples collected administration atlg days 3 1 day 0 14 month 1 month 2 100 frozen center data analyzed according pre conditioning lymphocyte counts correlated post transplant outcomes graft versus host disease relapse non relapse related mortality able determine formula optimize atlg dose lymphocyte counts future plasma collection start including finding complementary funding bio collection peripheral blood mononuclear cell plasma dry pellets total blood cells performed 9 base line day 14 21 28 56 100 month 6 month 12 60 per arm future biological would performed finding complementary funding collections organized via cryostem https www cryostem org biocollection allow perform comparative immunological two arms explain different effects anti thymoglobulin control alloreactivity immune reconstitution cytokine levels broad immune cell transcriptomic patterns cell repertoire immune modulation multiparameter flow cytometry analyses cell subtypes activation exhaustion phenotype monocytes dendritic cells nk cells cell repertoire reconstitution single cell transcriptomic analyses different immune cell subtypes monocytes dcs b nk cells regulatory cells inkt mdscs early time points allo hematopoietic stem cell transplantation 9 base line day 14 day 21 day 28 day 56 day 100 would interest better understand modulation immune response two anti thymoglobulin brands incidence grade ii intravenous infusion acute graft versus host disease according magic classification 47 appendix 19 9 section 1 day 100 post transplantation hematopoietic recoveries least 7 consecutive days neutrophils 0 5 g l platelets 20 g l immune reconstitution analyzing b nk regulatory cell gammaglobulin levels peripheral blood month 1 100 month 6 month 12 month 24 post transplantation chimerism month 1 100 month 6 month 12 grade acute graft versus host disease incidence appendix 19 9 section 1 acute graft versus host disease treatments first line response steroids courses refractory acute graft versus host disease chronic graft versus host disease incidence date grading month 12 month 24 nih classification 48 appendix 19 9 section 4 relapse incidence month 12 month 24 relapse defined reappearance leukemic cells mds features allo hematopoietic stem cell transplantation bonne marrow cytology cytogenetic analysis bone marrow aspiration extra medullary sites proven biopsy progression free survival month 12 month 24 severe infections ctae grade 3 4 100 month 12 fully described incidences cmv ebv reactivations 100 month 6 month 12 non relapse mortality month 6 month 12 month 24 overall survival month 12 month 24 graft versus host disease relapse free survival grfs defined alive without disease relapse without developed acute grade iii intravenous infusion severe chronic graft versus host disease health related quality life assessed using fact bmt v4 questionnaire inclusion 100 month 6 month 12 post transplantation number days hospitalization transplant hospitalization transplantation related complications month 12 incidence severity vod 100 lymphocyte counts standard blood counts conditioning 7 late acute graft versus host disease overlap syndromes chronic graft versus host disease 100 120 grafalon smpc followed thymoglobuline according smpc case prevention graft versus host disease recommended use 2 5mg kilograms day day 4 day 2 1 resulting cumulative dose 7 5 10 milligrams kilograms anti thymoglobulin thymo used following two possible schedules administration depending investigators usual practice cumulative dose 5mg kilograms schedule either 2 5 milligrams kilograms day day 3 day 2 0 5mg kilograms day 4 2mg kilograms day 3 2 5mg kilograms day 2 described previous sections protocol several tried identify optimal dose anti thymoglobulin thymo reduced conditioning comparing doses ranging 2 5 10 milligrams kilograms crocchiolo 2013 devillier 2013 remberger 2013 butera 2021 showed dose 2 5 milligrams kilograms inefficacious reduce risk graft versus host disease doses 6 milligrams kilograms associated higher risk flare mortality due infections results confirmed american showing probability survival without flare without severe graft versus host disease higher dose 4 5 milligrams kilograms 7 5 milligrams kilograms transplanted acute myeloid leukemia unmatched 10 10 human leukocyte antigen donor attenuated conditioning bashir 2012 based recommended dose anti thymoglobulin thymo reduced attenuated conditioning human leukocyte antigen 10 10 donor 4 5 6 milligrams kilograms baron 2017 dose used france 5 milligrams kilograms second scheme increasing doses proposed reduce intensity immune allergic reaction responsible fever skin reaction potentially blood pressure drop frequent side effect mainly observed first infusion anti thymoglobulin 4 administration schedules shown prevent occurrence graft versus host disease 2 3 addition known pharmacokinetic clearance anti thymoglobulin takes several weeks suggesting administration first 10 total dose dramatically change pharmacokinetic drug elimination 5 administration 5 milligrams kilograms total dose anti thymoglobulin frequently split 3 days many centers therefore would allow possibility use second schedule phase iii multicenter randomized controlled open label comparing 2 parallel groups homogeneous population aml mds age 50 70 fludarabine treosulfan conditioning anti thymoglobulin thymoglobulin versus atlg grafalon participants distributed groups ratio 1 1 1 anti thymoglobulin thymoglobulin 1 atlg grafalon national multi center including 26 adults transplant centres sfgm tc recruitment centres recruited hematology units referred transplant team pre transplant assessment visit inclusion exclusion criteria verified consent collected latest 9 hematopoietic stem cell transplantation information sheet consent form given investigator investigator keep original copy given third copy kept sponsor randomized electronic case report form cleanweb receiving prophylaxis graft versus host disease anti thymoglobulin thymoglobulin atlg grafalon baseline visit also consists physical examination biological testing imagery assessment performed according practice investigator assessment performed usual care allogeneic transplant physical examination reports disease history eastern cooperative oncology group (= performans status (= ecog)) performans status assessment sorror score comorbidities complete physical examination evaluation tumor localization electrocardiogram echocardiogram evaluation left ventricular ejection pulmonary function tests including least forced expiratory volume 1 second fev1 forced vital capacity forced vital capacity liver ultrasound doppler echography baseline values disease assessment pre transplant bone marrow aspiration disease evaluation biological tests complete blood count prothrombin time pt partial thromboplastin time ptt abo rh typing blood cell chemistry panel serum electrolytes creatinine calcium glucose uric acid magnesium levels ferritin c reactive protein liver function tests transaminases alkaline phosphatase gamma gt bilirubine circulating protein electrophoresis human leukocyte antigen compatibility check recipient donor chimerism markers identification viral serologies serology hepatitis b c aspergillus antigen ebv igg cmv igg hsv igg human immunodeficiency virus 2 elisa tests htlv 1 2 toxoplasmosis igg tpha vdrl hcg women childbearing potential imaging dental radiography sinus thorax abdominal ct scan health related quality life fact bmt v4 questionnaire protocol carried societe francophone de greffe de moelle et de therapie cellulaire sfgm tc majority adult centers sfgm tc accepted participate research 26 sites interest validated french scientific council sfgm tc last 3 years sfgm tc registry reported 200 per year eligible illustrate feasibility recruited standard care visit hospital involved centre expects enrol 2 12 year 380 expected 324 required justification sufficient recruitment capacity number participants need included several situations possible temporary suspension investigator must document reason suspending resuming participants source file case report form case report form regarding experimental treatments anti thymoglobulin atlg receive premedication based paracetamol corticoids anti histaminic case occurrence immunological reactions including shock cytokine release syndrome immediately stopped according smpc conditions improved premedication administrated readministered scheduled premature discontinuation participant remains enrolled end participation premature discontinuation withdrawal investigator must document reason collect assessment criteria time ending participation participant agrees schedule follow participant particularly case serious adverse event case severe adverse events investigator must notify sponsor follow participant serious adverse event resolved notification serious adverse event must sent email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction sponsor data safety monitoring board created committee specify validate follow methods participants may exit time reason investigator temporarily permanently withdraw participant safety reason participants best interests participant lost follow participant cannot located investigator must make every effort reconnect participant document attempts source file least determine whether participant alive dead participant exits prematurely withdraws consent data collected prior date premature exit may still used participant exits prematurely participant agrees state procedure schedule collecting data required protocol primary endpoint secondary endpoints safety assessment nb must stated information consent form state premature exit affect participant ongoing care state exactly participant offered case serious adverse events see corresponding section vigilance case report form must list various reasons participant discontinued lack efficacy adverse reaction another medical issue personal reasons participant explicit withdrawal consent lost follow elderly age 50 70 years aml high risk mds receiving allogeneic hematopoietic stem cell transplantation 10 10 human leukocyte antigen matched unrelated donor initial notification severe adverse event must provided written report signed investigator using severe adverse event notification form specific intended purpose case report form item form must completed investigator sponsor carry appropriate analysis initial notification sponsor serious adverse event must quickly followed additional detailed written report reports case outcome may monitored safety department provide information whenever possible investigator provide sponsor documents may useful medical reports laboratory test results results additional examinations etc documents must non identifying addition documents must include following acronym number participants initials adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even participant left initial notification severe adverse event follow reports documents must sent sponsor safety department email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction noted possible send severe adverse event reports safety department fax 33 0 1 44 84 17 99 event failed attempt send severe adverse event report email order avoid duplication investigator completes severe adverse event notification form e case report form validates prints signs form sending email possible connect e case report form investigator complete sign send severe adverse event notification form safety department soon connection restored severe adverse event notification form e case report form must duly completed investigator must respond requests sponsor additional information questions relating notification adverse event safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction cases utero exposure investigator complete notification follow form pregnancy occurring participation investigator must monitor pregnant woman throughout pregnancy pregnancy terminated must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage pregnancy termination foetal death congenital abnormality etc investigator must follow procedure reporting saes initial pregnancy notification severe adverse event follow reports documents sent sponsor according procedures specified herein father exposed investigator must obtain pregnant woman permission collecting information pregnancy computer file used research implemented accordance french amended informatique et libertes law governing data protection european general data protection regulation gdpr regulations commitment comply reference methodology medium risk 001 research governed commission nationale informatique et libertés french data protection agency reference methodology processing personal data used within scope health research amended medium risk 001 ap hp sponsor research signed declaration compliance reference methodology age 50 70 years 50 55 years unfit myeloblative conditioning aml requiring allogeneic stem cell transplantation intermediate high risk aml complete cytologic response cr1 mds requiring allogeneic stem cell transplantation ipss 1 5 ipss r 4 5 ipss r 3 4 5 risk features rapid blast increase life threatening neutropenia 0 3 g l thrombopenia 30g l high transfusion needs 2 month 6 months without human leukocyte antigen matched related donor identified matched human leukocyte antigen 10 10 unrelated donor usual criteria hematopoietic stem cell transplantation eastern cooperative oncology group (= performans status (= ecog)) performans status 2 severe uncontrolled infection cardiac left ventricular ejection fraction 50 lung diffusing capacity of lung for carbon monoxide 40 adequate organ function aspartate amino transferase alanine-aminotransferase 3n total bilirubin 2n creatinine clearance 50 ml min except abnormalities linked hematological disease health insurance coverage signed written informed consent contraception methods must prescribed duration research nb authorized contraceptive methods women childbearing age absence permanent sterilization oral intravaginal transdermal combined hormonal contraception oral injectable implantable progestogen hormonal contraception intrauterine device intrauterine device intrauterine hormonal releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence preferred usual lifestyle participants man absence permanent sterilization sexual abstinence condoms carcinomas last 5 years except basal cell carcinoma skin situ carcinoma cervix uncontrolled infection seropositivity human immunodeficiency virus htlv 1 active hepatitis b c yellow fever vaccine others live virus vaccines within 2 months transplantation heart failure according “new york heart association” ii left ventricular ejection fraction 50 lung diffusing capacity of lung for carbon monoxide 40 preexisting acute hemorrhagic cystitis renal failure creatinine clearance 50ml min pregnancy hcg positive breast feeding debilitating medical psychiatric illness would preclude realization sct understanding protocol state medical aid legal protection protection court curatorship guardianship grafalon contraindication mentioned smpc grafalon thymoglobulin hypersensitivity rabbit proteins excipients participation trials medicinal products human use exclusion period end previous contraindication mentioned smpc auxiliary medicinal products planned used cyclosporine mycophenolate mofetil fludarabine treosulfan persons responsible quality control take necessary precautions ensure confidentiality information relating investigational medicinal products participants particular identity results obtained persons well investigators bound professional secrecy data collected concerning participants sent sponsor investigators specialised collaborators rendered non identifying circumstances shall names addresses participants involved shown participants initials recorded accompanied encoded number specific indicating order enrolment sponsor ensure participant given written permission personal information strictly necessary quality control accessed non identifying data entered electronically via web browser general strategy continuous measures summarized using median interquartile range iqr frequency distributions counts percentages used summarize categorical endpoints disposition subjects disposition subjects described summaries group number subjects enrolled number subjects treated number subjects drug permanently discontinued including reasons discontinuation demographic baseline characteristics demographic baseline characteristics summarized group overall primary endpoint incidence grade ii intravenous infusion acute graft versus host disease according magic classification appendix 19 9 section 1 day 100 post transplantation primary analysis test differences incidence grade ii intravenous infusion acute graft versus host disease tested using gray test gray rj 1988 class k sample tests comparing cumulative incidence competing risk annals statistics 16 1141 1154 test rank based test extendingthe logrank test presence competing risks measure effect based subdistribution hazard ratio shr fine gray model secondary analyses used cause specific hazard ratio chr estimated cox model measure effect secondary endpoints differences incidence hematopoietic recoveries tested using gray test immune reconstitution analysing b nk regulatory cell gammaglobulin levels peripheral blood month 1 100 month 6 month 12 month 24 post transplantation levels b nk regulatory cell gammaglobulin levels compared using linear model random effect intercept proportion chimerism month 1 100 month 6 month 12 compared using logistic model random effect intercept first line response steroids courses refractory acute graft versus host disease fully described within arm differences incidence chronic graft versus host disease relapse incidence cmv ebv reactivations non relapse mortality non relapse related mortality similarly tested using gray test estimations month 12 month 24 given 95 confidence intervals 95 ci using cumulative incidence function competing risks setting differences progression free survival progression-free survival graft versus host disease relapse free survival grfs overall survival overall survival tested using logrank test estimations month 12 month 24 given 95 confidence intervals 95 ci using kaplan meier estimator distribution late acute graft versus host disease overlap syndromes chronic graft versus host disease 100 120 compared handling developed acute graft versus host disease earlier died free graft versus host disease 100 using exact fisher test severe infections ctae grade 3 4 100 month 12 fully described within arm health related quality life assessed using thefact bmt v4 questionnaire 100 month 6 month 12 post transplantation levels compared using linear model random effect intercept number days hospitalization transplant hospitalization transplantation related complications month 12 fully described within arm lymphocyte counts standard blood counts conditioning 7 fully described within arm tests based two sided type error rate alpha 0 05 control multiplicity performed,"graft, transplantation, host, versus, stem, cell, disease, haplo, transplant, donor"
FIBRAPLO_protocole_v4_20221025_MS5,1,26.372715,-39.088974,full title haplo identical transplantation myelofibrosis phase 2 prospective multicentric acronym fibraplo coordinating investigator dr marie robin hopital saint louis assistance publique hôpitaux de paris paris sponsor assistance publique hopitaux de paris scientific justification curative primary secondary myelofibrosis allogeneic hematopoietic stem cells hematopoietic stem cell transplantation reported intermediate higher risk according international prognostic scores benefit hematopoietic stem cell transplantation terms survival kroger others 2015 2013 conducted france prospective testing use ruxolitinib transplantation jak allo nct01795677 outcome better transplanted matched sibling donor unrelated donor confirming kroger others 2009 rondelli others 2014 jak allo acute graft versus host disease incidence high often hyperacute severe recently ebmt group reported registry familial haplo identical transplantation haplo myelofibrosis raj others 2018 post transplant cyclophosphamide used 59 cases one year overall survival overall survival disease free survival disease-free survival 61 58 favorably compared outcome unrelated transplantation genova team also reported impressive results haplo identical transplantation center bregante others 2015 bregante others reported outcome 2 cohorts transplanted 2000 2010 2011 2014 main difference 2 periods frequent use haplo second period 54 versus 5 outcome much better second period overall survival 70 versus 49 authors suggest improvement related best outcome among haplo transplantation improvement outcome haplo attributed better graft versus host disease prophylaxis especially use post transplant cyclophosphamide given poor outcome unrelated transplantation especially human leukocyte antigen mismatched unrelated setting encouraging results family haplo identical transplantation current proposes test haplo identical transplantation myelofibrosis without matched related donor main objective primary endpoint main objective disease free survival without rejection one year haplo identical transplantation primary secondary myelofibrosis main criteria judgement disease rejection free survival 12 months hematopoietic stem cell transplantation secondary objectives endpoints assess incidence acute graft versus host disease grade 2 4 100 days incidence acute graft versus host disease grade 3 4 100 days engraftment 100 days incidence chronic graft versus host disease 12 months non relapse mortality 12 months overall survival 12 months relapse progression incidence 12 months rejection incidence 12 months time neutrophil engraftment 100 days time platelet engraftment 100 days infection incidence 100 days 12 months cytokine profile transplantation day 7 1 day day 0 day 7 1 day impact genetic alterations overall survival 12 months non relapse morality 12 months design phase 2 multicentric population subjects myelofibrosis contraindication transplant advanced disease international scores could proposed human leukocyte antigen matched donor inclusion criteria aged 18 70 years primary myelofibrosis myelofibrosis secondary essential thrombocythemia polycythemia vera proven marrow biopsy myelofibrosis combine least 2 following criteria constitutional symptoms weight loss 10 one year fever without infection recurrent muscle bone join pains extreme fatigue anemia hemoglobin 10 gr deciliter red blood cell transfusion requirement thrombocytopenia 100 g l peripheral blast count 1 least found 2 times white blood cell count 25 g l cytoreductive karyotype 8 7 7q 17q 5 5q 12p inv 3 11q23 performance status according eastern cooperative oncology group (= performans status (= ecog)) 0 1 2 health insurance coverage signed written informed consent women agreed take nomegestrol acetate contraception 6 months treosulfan men agreed conceive child 6 months treosulfan exclusion criteria myelofibrosis transformed acute leukemia poor performance status eastern cooperative oncology group (= performans status (= ecog)) 3 cardiac failure ef 50 currently past even corrected renal failure creatininemia 130 mol l clearance 50ml min respiratory function altered vital capacity 70 forced expired volume 70 biological significant liver abnormalities aspartate amino transferase alanine-aminotransferase 2 x normal range bilirubin 1 5 x normal range human leukocyte antigen matched donor available tutorship curatorship unwilling unable comply protocol pregnant woman breastfeeding contraindications treosulfan hypersensitivity active substance active non controlled infectious disease fanconi anaemia dna breakage repair disorders administration live vaccine contraindications circumstance precludes use drugs involved protocol especially thiotepa fludarabine investigational medicinal product treosulfan investigational medicinal product used conditioning regimen haplo identical transplantation treosulfan received eu wide approval toxicity reduced conditioning therapy prior allogeneic haematopoietic stem cell transplantation june 25 2019 provided medac treosuflan conditioning regimen administered followed 10 gr month 2 per day 4 3 2 intravenous infusion route used combination standard association thiotepa 5 milligrams kilograms day 6 fludarabine 30 milligrams month 2 per day day 5 day 1 therefore thiotepa fludarabine indissociable treosulfan also considered medicinal product comparator na interventions added haplo identical transplantation use treosulfan thiotepa fludarabine conditioning regimen additional plasma sample 5 additional blood samples 5 ml 3 additional blood sample 7 ml risks added risk scope goal show haplo identical hematopoietic stem cell transplantation using thiotepa fludarabine combination treosulfan gives acceptable results even better transplantation human leukocyte antigen mismatched 9 10 donor close matched unrelated donor myelofibrosis number subjects included 28 number sites 22 duration inclusion period 36 months participation period follow 12 months followed 24 months transplantation analyze occurrence graft versus host disease survival relapse status total duration 60 months number enrolments expected per site per month 0 1 per month per site statistical analysis analysis based intent treat basis including whatever administered sensitivity analysis performed actually receive graft consent withdrawals positive report using data excluded baseline summary statistics namely percentages median interquartile range iqr performed right censored endpoint estimated using nonparametric methods kaplan meier curves cumulative incidence curves considered case non informative informative censoring based log rank test gray test respectively adjustment potential confounders used cox proportional hazards models model assumptions checked using test proportional hazards spline smoothing residuals log linearity assumption statistical analyses performed sas sas inc cary nc r https www r project org software packages sources funding industrial grant data safety monitoring board yes justification treosulfan conditioning regimen recommended conditioning regimens myelofibrosis usual conditioning regimens combined alkylan fludarabine prospective trials either used fludarabine melphalan fm fludarabine busulfan fb2 non myelo ablative dosage rondelli others 2014 kroger others 2009 gupta others 2019 comparison 2 regimens showed early toxicity higher using melphalan relapse rate higher using busulfan outside setting myelofibrosis registry comparisons also reported higher non relapse mortality fm fb2 end better control disease especially high risk acute myeloid leukemia kawamura others 2017 conditioning regimens including treosulfan usually considered intermediate intensity regimens retrospective compared fludarabine treosulfan ft fb2 fm showing non relapse related mortality higher using fm similar ft fb2 ft associated lowest rate relapse yerushalmi others 2015 another retrospective compared fb2 ft fb4 showing day 100 non relapse related mortality low similar 3 arms 15 better anti tumoral effect seen tf better results advanced disease shimoni others 2012 also confirmed others sakellari others 2017 prospective trials conducted assess safety efficiency treosuflan based regimen usually associated fludarabine ft phase 2 reported non relapse related mortality low 2 years 8 acute leukemia myelodysplastic syndrome mds 2 year disease-free survival 58 even 88 without high risk cytogenetics compared favourably regimens nemecek others 2011 another phase ii using 3 different doses 10 12 14gr month 2 reported good tolerance non relapse related mortality 18 one year casper others 2010 2 year overall survival 60 78 53 10 12 14gr month 2 prospective phase iii comparing ft fb2 concluded superiority ft acute leukemia mds 64 event-free survival vs 50 2 years non relapse related mortality significantly lower ft arm 12 vs 28 beelen others 2017 2019 thiotepa also reported association ft good tolerance various diseases baronciani others 2016 choudhary others 2013 setting haplo treosulfan also reported combination drugs di bartolomeo reported association cytarabine endoxan treosulfan 14gr month 2 day 3 days use post transplant cyclophosphamide 11 among 80 di bartolomeo others 2013 type conditioning regimen affect non relapse related mortality generally replacing busulfan treosulfan appears good option decreasing non relapse related mortality justifying use current justification addition fludarabine thiotepa conditioning regimen conditioning regimen initially developed baltimore team consisted 2 gy total body irradiation total body irradiation fludarabine regimen gives low non relapse related mortality high relapse rate luznik others 2012 conditioning regimen based fludarabine alkylan melphalan busulfan thiotepa also developed genova team reported regimen based fludarabine busulfan thiotepa fludarabine total body irradiation high dose receiving haplo identical transplantation engraftment full donor chimerism 90 non relapse related mortality 18 busulfan dose reduced 1 2 days order decrease toxicity fragile raiola others 2013 conditioning associating fludarabine melphalan thiotepa also reported md anderson group ciurea others 2012 engraftment rate 90 non relapse related mortality 1 year 16 overall survival 64 justification source stem cells haplo identical transplantation reported acute graft versus host disease incidence lower using marrow source stem cells however engraftment better using peripheral blood stem cells pb setting reduced intensity conditioning regimen overall survival disease free survival significantly different using marrow peripheral stem cells bradstock others 2015 castagna others 2014 odonnel others reported similar graft versus host disease incidence higher relapse rate non myelo ablative regimen odonnell others 2016 cibmtr compared 481 haplo pb 190 haplo marrow acute graft versus host disease chronic graft versus host disease incidences higher using pb relapse higher using marrow overall survival disease-free survival similar using pb marrow myelofibrosis higher risk engraftment poor engraftment justifying choice peripheral blood stem cells specific population however alternatively marrow used proven safe source stem cells receiving haplo transplant graft versus host disease prophylaxis haplo identical transplantation use post transplant cyclophosphamide ptc initially reported baltimore team cell repleted haplo identical marrow engraftment high 90 low rate graft versus host disease low rate non relapse related mortality 15 luznik others 2012 2010 2008 reproduced many teams previously described see transplantation procedure followed standard procedure receive similar outside protocol haplo identical transplantation currently performed using fludarabine alkylan based conditioning regimen post transplant cyclophosphamide guarantee benefit risk similar haplo transplantation performed outside protocol risk acute chronic graft versus host disease risk immune defect mortality disease progression primary aim efficiency haplo terms survival without disease rejection hematopoietic stem cell transplantation myelofibrosis curative primary secondary myelofibrosis allogeneic hematopoietic stem cells hematopoietic stem cell transplantation many registry reported outcome transplantation disease free survival 30 70 according risk factors related disease type transplantation kroger others 2009 ballen others 2010 deeg others 2003 ditschkowski others 2012 robin others 2011 patriarca others 2008 long term outcome hematopoietic stem cell transplantation also reported minimal mortality 2 years post transplant especially younger robin others 2019 hematopoietic stem cell transplantation myelofibrosis specificities usually received chemotherapy transplantation transplanted uncontrolled disease exposing tumour lysis syndrome 5 10 engraftment 5 10 secondary pancytopenia also frequent hematopoietic stem cell transplantation usually transient alchalby others 2016 furthermore management usual splenomegaly still matter debate splenectomy reported increasing relapse risk one prospective confirmed kroger others 2009 10 40 received hematopoietic stem cell transplantation underwent splenectomy proportion possibly lower using ruxolitinib transplantation previous thrombosis chronic hepatic disease well cardiac pulmonary hypertension relatively frequent taken account performing hematopoietic stem cell transplantation iurlo others 2015 brabrand others 2019 sciume others 2017 barraco others 2017 tremblay others 2019 reported intermediate higher risk according international prognostic scores benefit hematopoietic stem cell transplantation terms survival kroger others 2015 international recommendations experts confirm hematopoietic stem cell transplantation performed higher risk discussed young lower risk intermediate 1 2013 initiated france prospective testing use ruxolitinib hematopoietic stem cell transplantation myelofibrosis jak allo nct01795677 outcome better matched sibling donor unrelated donor confirming previous prospective kroger others 2009 rondelli others 2014 gupta others 2019 jak allo acute graft versus host disease incidence high 70 often hyperacute 33 severe grade 3 4 44 majority acute graft versus host disease occurring 9 10 human leukocyte antigen mismatched unrelated transplantation grade 3 4 acute graft versus host disease mortality consequence high disease free survival 1 year 34 compared 82 human leukocyte antigen matched sibling donor haplo identical transplantation myelofibrosis haplo identical transplantation considerably progressed last years better results frequent utilization countries use post transplant cyclosphosphamid reported safe efficient prevent graft versus host disease without impairing engraftment luznik others 2012 bashey others 2013 raj others 2014 majority data concerns either acute leukemia various diseases recently ebmt group reported registry familial haplo identical transplantation haplo myelofibrosis raj others 2018 post transplant cyclophosphamide used 59 cases one year overall survival overall survival disease free survival disease-free survival 61 58 compared favourably outcome unrelated transplantation genova team also reported impressive results haplo identical transplantation center bregante others 2015 bregante others reported outcome 2 cohorts transplanted 2000 2010 2011 2014 main difference 2 periods frequent use haplo second period 54 versus 5 outcome much better second period overall survival 70 versus 49 authors suggest improvement related best outcome among haplo transplantation improvement outcome haplo attributed better graft versus host disease prophylaxis especially use post transplant cyclophosphamide given poor outcome unrelated transplantation especially human leukocyte antigen mismatched unrelated setting encouraging results family haplo identical transplantation current proposes test haplo identical transplantation myelofibrosis without matched related donor hypothesis haplo identical transplantation myelofibrosis gives better results disease free rejection free survival transplantation human leukocyte antigen mismatched unrelated donor expect disease rejection free survival one year 55 haplo comparison 30 9 10 mismatched unrelated donor assess disease free survival without rejection 12 months haplo identical transplantation assess incidence acute graft versus host disease grade 2 4 100 days incidence acute graft versus host disease grade 3 4 100 days engraftment 100 days incidence chronic graft versus host disease 12 months non relapse mortality 12 months overall survival 12 months relapse progression incidence 12 months rejection incidence 12 months time neutrophil engraftment 60 days time platelet engraftment 100 days infection incidence 100 days 12 months cytokine profile transplantation impact genetic alterations outcome blood samples collected via cryostem platform 2 blood samples 5 ml 7 ml inclusion 1 blood sample 5 ml 7 1 days hematopoietic stem cell transplantation conditioning regimen initiation day transplantation 7 1 days transplantation analyses performed genetic alteration malignant cells cytokine release conditioning regimen crbs contacted cryostem setting biology done end saint louis hospital laboratory biology cellular professor stephane giraudier 1 avenue claude vellefaux 75475 paris lymphocyte phenotype b nk done day 30 60 100 180 365 usually done center least day 100 one year primary endpoint disease free survival without rejection 12 months transplantation relapse defined reappearance malignant cells blood associated mixed recipient chimerism rejection defined pancytopenia persisting 60 days transplantation primary rejection cytopenia occurring engraftment graft lost chimerism becomes recipient evidence disease progression point follow secondary rejection secondary endpoints incidence acute grade 2 4 grade 3 4 graft versus host disease according modified glucksberg classification przepiorka others 1995 incidence chronic graft versus host disease limited vs extensive 12 months according revised seattle criteria lee others 2003 neutrophil engraftment day 60 post transplantation engraftment defined neutrophil count 0 5g l higher 3 consecutive days transplantation confirmed donor chimerism platelet recovery first day platelet 20g l without transfusion last 7 days assessed day 100 overall survival 12 months non relapse mortality 12 months incidence relapse progression 12 months incidence rejection 12 months infection incidence 100 days 12 months annexe infection cytokine profile transplantation day 7 1 jour j0 day j7 1 jour impact genetic alterations overall survival 12 months non relapse morality 12 months treosulfan administered intravenous 2 hours 3 consecutive days dose currently recommended countries 10 gr month 2 day 4 day 3 day 2 transplantation intravenous administration performed using safe technique avoid extravasation body surface calculated according mosteller formula taille poids 3600 0 5 phase 2 one group multicenter national multi center including 22 centers recruited hematology units baseline visit takes place 30 14 days transplantation visit consent collected information sheet consent form given investigator original conserved investigator third copy sponsor physical examination reports disease history cf annexe sorror others 2005 eastern cooperative oncology group (= performans status (= ecog)) assessment cf annexe oken others 1982 sorror score comorbidities cf annexe mesa others 2013 complete physical examination evaluation spleen size electrocardiogram general symptoms associated mf mf saf form cf annexe evaluation cardiovascular risk factors dyslipidemia hta obesity smoking radiological examinations pulmonary function tests including least forced expiratory volume 1 second fev1 forced vital capacity forced vital capacity liver ultrasound doppler echography baseline values total body scan echocardiogram evaluation left ventricular ejection biological test complete blood count prothrombin time pt partial thromboplastin time ptt abo rh typing blood cell chemistry panel serum electrolytes creatinine urea calcium glucose uric acid phosphate c reactive protein probnp ldl hdl triglyceride total cholesterol liver function tests transaminases alkaline phosphatase gamma gt bilirubin circulating protein electrophoresis pregnancy test women childbearing age human leukocyte antigen compatibility check recipient donor search anti human leukocyte antigen antibodies luminex technology dsa chimerism markers identification blood karyotype done previously blood collection infectious assessment viral serologies serology hepatitis b c aspergillus antigen ebv igg cmv igg hsv igg human immunodeficiency virus 2 elisa tests htlv 1 2 toxoplasmosis igg tpha vdrl subjects may exit time reason investigator temporarily permanently withdraw subject safety reason subject best interests subject lost follow subject cannot located investigator must make every effort reconnect subject record attempts source file least determine whether subject alive dead subject exits prematurely withdraws consent data collected prior date premature exit may still used case report form must list various reasons subject exited withdrawn lack efficacy adverse reaction medical problem subject personal reasons explicit withdrawal consent lost follow initial notification severe adverse event must provided written report signed investigator using severe adverse event notification form specific intended purpose case report form item form must completed investigator sponsor carry appropriate analysis initial notification sponsor serious adverse event must quickly followed additional detailed written report reports case outcome may monitored safety department provide information whenever possible investigator provide sponsor documents may useful medical reports laboratory test results results additional examinations etc documents must non identifying addition documents must include following acronym number participants initials adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even participant left initial report severe adverse event follow reports documents must sent sponsor safety department email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction noted possible send severe adverse event reports safety department fax 33 0 1 44 84 17 99 event failed attempt send severe adverse event report email order avoid duplication trials use e case report form investigator completes severe adverse event report form e case report form validates prints signs form sending email possible connect e case report form investigator complete sign send severe adverse event notification form safety department soon connection restored severe adverse event notification form e case report form must duly completed investigator must respond requests sponsor additional information questions relating notification adverse event safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction cases utero exposure investigator complete initial notification follow report forms pregnancy occurring participation investigator must monitor pregnant woman throughout pregnancy pregnancy terminated must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage pregnancy termination foetal death congenital abnormality etc investigator must follow procedure reporting saes initial pregnancy notification severe adverse event follow reports documents sent sponsor according procedures specified herein father exposed investigator must obtain pregnant woman permission collecting information pregnancy aged 18 70 years primary myelofibrosis myelofibrosis secondary essential thrombocythemia polycythemia vera proven marrow biopsy performance status according eastern cooperative oncology group (= performans status (= ecog)) 0 1 2 myelofibrosis combine least 2 following criteria constitutional symptoms weight loss 10 one year fever without infection recurrent muscle bone join pains extreme fatigue anemia hemoglobin 10 gr deciliter red blood cell transfusion thrombocytopenia 100 g l peripheral blast count 1 least found 2 times white blood cell count 25 g l cytoreductive karyotype 8 7 7q 17q 5 5q 12p inv 3 11q23 health insurance coverage signed written informed consent women agreed take nomegestrol acetate contraception 6 months treosulfan men agreed conceive child 6 months treosulfan myelofibrosis transformed acute leukemia poor performance status eastern cooperative oncology group (= performans status (= ecog)) 3 cardiac failure ef 50 currently past even corrected renal failure creatininemia 120 mol l clearance 50 ml min respiratory function altered vital capacity 70 forced expired volume 70 biological significant liver abnormalities aspartate amino transferase alanine-aminotransferase 2 x normal range bilirubin 1 5 x normal range human leukocyte antigen matched donor available tutorship curatorship unwilling unable comply protocol pregnant woman breastfeeding contraindications treosulfan hypersensitivity active substance active non controlled infectious disease fanconi anaemia dna breakage repair disorders administration live vaccine contraindications circumstance precludes use drugs involved protocol especially thiotepa fludarabine persons responsible quality control article l 1121 3 french public health code take necessary precautions ensure confidentiality information relating investigational medicinal products participants particular identity participants results obtained persons well investigators bound professional secrecy accordance conditions set articles 226 13 226 14 french criminal code data collected participants sent sponsor investigators specialised collaborators anonymised circumstances names addresses subjects shown sponsor ensure subject agreed writing personal information strictly necessary quality control accessed e case report form data entered electronically via web browser analysis based intent treat basis including whatever administered consent withdrawals positive report using data excluded baseline summary statistics namely percentages median interquartile range iqr performed right censored endpoint estimated using nonparametric methods kaplan meier curves cumulative incidence curves considered case non informative informative censoring based log rank test gray test respectively adjustment potential confounders used cox proportional hazards models model assumptions checked using test proportional hazards spline smoothing residuals log linearity assumption sensitivity analysis performed actually receive graft statistical analyses performed sas sas inc cary nc r https www r project org software packages type error fixed 0 05,"graft, transplantation, host, versus, stem, cell, disease, haplo, transplant, donor"
GRAALL-2014_protocol_V 9-1_20240904,5,32.661407,4.283757,since 2003 graall intergroup gathering 77 hematology centers france belgium switzerland conducted several aim improve results de novo acute lymphoblastic leukemia younger adults aged 15 59 years old included graall 2003 graaph 2003 funded french national cancer institute programme hospitalier de recherche clinique program identification 0200701 sponsor hopitaux de toulouse phase 2 trials enrolled 225 45 respectively trials followed graall 2005 phase 3 funded french national cancer institute programme hospitalier de recherche clinique program identification p040429 sponsor hopital saint louis assistance publique hopitaux de paris divided three randomized sub 1 graall 2005 philadelphia chromosome hydrogen ion concentration negative cd20 negative ball 810 included 2 graall 2005 r hydrogen ion concentration negative cd20 positive b 220 expected 3 graaph 2005 hydrogen ion concentration 270 included altogether 3 sub randomized 1080 graall 2005 yielded following results yet unpublished marked improvement survival younger adults hydrogen ion concentration negative pediatric inspired protocol confirming results graall 2003 spite significant toxicity aged 45 years general schemes graall 2003 graall 2005 indicated figure 1 definition new prognostic score based quantitation minimal residual disease minimal residual disease ig tcr amplification first induction cure mrd1 anomalies notch1 fbxw7 ras pten genes lineage mll ikzf1 genes b lineage hydrogen ion concentration summary mll gene rearrangements including mll af4 fusion ikzf1 gene deletions independent bad prognosis factors b allph notch pathway mutations including notch1 fbxw7 gene mutations independent good prognosis factors absence n k ras gene mutation pten gene deletion leading 4 gene genetic classifier poor post induction ig tcr minimal residual disease level mrd1 10 4 independent bad prognosis factor lineages possibleto decrease intensity chemotherapy hydrogen ion concentration combining first generation tyrosine kinase inhibitor tyrosine kinase inhibitor standard chemotherapy results two randomizations namely interest fractionated sequence cyclophosphamide bolus hyper c induction late intensification interest adding rituximab cd20 hydrogen ion concentration negative bb still pending spite progresses allowing long term disease free survival increase 25 50 comparison historical high risk high risk according new score suffering hydrogen ion concentration remains high risk spite introduction tyrosine kinase inhibitor still present high relapse rates around 30 35 justifying introduction new drugs allogeneic stem cell transplantation sct first complete remission conversely standard risk according new score favorable evolution similar large pediatric series rebutting introduction potentially toxic drugs figure 1 graall 2003 2005 protocol scheme hydrogen ion concentration negative graall 2014 follows graall 2003 2005 trials graall 2014 subdivided three sub graall 2014 b graall 2014 graaph 2014respectively b lineage hydrogen ion concentration negative lineage hydrogen ion concentration france switzerland belgium participate graall 2014 prospectively validate new risk model based mrd1 response level kmt2a mll ikzf1 gene status comparing historical results graall 2005 graall 2014 identical population hydrogen ion concentration b lineage aged 18 59 years old evaluate minimal residual disease level monitored ig tcr evaluate cumulative incidence relapse cumulative incidence of relapse non relapse mortality non relapse related mortality disease free survival disease-free survival overall survival overall survival evaluate relapse-free survival cumulative incidence of relapse non relapse related mortality overall survival censoring sct first complete remission hypothesis demonstrate non inferiority disease-free survival 4 years comparison historical group 60 prospectively validate new risk factors based mrd1 response level notch1 fbxw7 ras pten gene status evaluate efficacy nelarabine based consolidation maintenance therapy term relapse-free survival high risk atriall substudy appreciate toxicity nelarabine consolidation followed allo sct consolidation maintenance therapy evaluate minimal residual disease level monitored ig tcr cumulative incidence relapse cumulative incidence of relapse non relapse mortality non relapse related mortality relapse free survival relapse-free survival overall survival overall survival relapse-free survival cumulative incidence of relapse non relapse related mortality overall survival censoring sct first complete remission non inferiority experimental arm arm b compared control arm arm terms major molecular response major molecular response 4th cycle mrd4 comparison experimental arm control arm terms tolerance cumulative incidence of relapse event-free survival overall survival investigators must notify sponsor immediately day becomes aware serious adverse events requiring immediate notification sponsor notification severe adverse event must initially provided written report using special form reporting severe adverse event see appendix 9 1 thisform must signed investigator item form must completed investigator order allow sponsor perform event analysis assessment initial notification must followed one detailed follow report signed investigator within maximum 8 days case fatal life threatening event within 15 days cases investigator also provide sponsor possible document might useful medical reports laboratory tests results results additional investigations documents must made anonymous addition include following data researchs acronym trialidentification number initials subject except switzerland initials x x nature date occurrence serious adverse event adverse event occurring maintenance phase documented case report form monitored complete resolution stabilization acceptable level investigator return previous status even discontinued saes see section 2 5 initial notification severe adverse event follow reports document must sent sponsor e mail événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction sponsors safety department possible send severe adverse event safety department fax sponsors safety department fax 33 0 1 44 84 17 99 case unsuccessful attempt send severe adverse event e mail order avoid duplicates investigator complete severe adverse event notification form e case report form validation investigator print sign sends e mailto vigilance department possible connect e case report form investigator complete sign fax severe adverse event notification form found appendix soon connection restored severe adverse event notification form e case report form must completed investigator must comply requests additional information sponsor questions relating adverse event report safety department contacted via email événement indésirable grave (see severe adverse event) vigilance assistance publique hôpitaux de paris shortening fraction important informationto provided sponsor following information must completed severe adverse event notification form identification reporters identification seriousness severity adverse event severe adverse event onset date severe adverse event resolution date severe adverse event description diagnosis symptoms chronology actions taken results obtained evolution ongoing diseasesor medical history treatments administered investigational drug concomitant medication causal relationship severe adverse event investigational drug act procedure test investigator must complete addition tothe severe adverse event notification form thenelarabine related neurotoxicity form please refer appendix 9 4 neurological disorder occur receiving nelarabine atriance specific form notify secondary cancers myelosysplasia please refer appendix 9 3 case secondary malignancy investigator considers seriousadverse event related research investigationaldrug provide sponsor possible additional document useful cases assessment medical reports biological tests results additional tests results documents must made anonymous addition include following data researchs acronym trialidentification number initials subject nature date occurrence serious adverse event investigator answer additional queriesfrom sponsor question related notification adverse event investigator contact vigilancedepartment e mailat following address vigilance drcd assistance publique hôpitaux de paris shortening fraction uteroexposure investigator completes returns e mail événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction vigilance department following number 33 1 44 84 17 99 follow form reporting pregnancy occurring investigator must monitor pregnant woman throughout pregnancy pregnancy terminated must notify sponsor outcome usingthe mentioned form pregnancy outcomefulfills one serious adverse eventscriteria miscarriage pregnancy interruption foetal death congenital anomaly investigator must follow procedure severe adverse event notification case paternal exposure investigator must obtain pregnant woman consent collect information pregnancy exposure breast feeding breast feeding exposure occurs breastfed infant may exposed mothers milk investigational drug exposure breast feeding must always reported sponsor investigator soon possible even associated adverse event initial notification pregnancy severe adverse event follow reports document sent sponsor vigilance department e mail événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction whose blood bone marrow explorations completed steroids prephase aged 18 59 years old previously treated b lineage including intrathecal injections newly diagnosed according 2008 definition 20 bone marrow blasts whose karyotype shows 9 22 absence molecular biology bcr abl marker eastern cooperative oncology group (= performans status (= ecog)) 3 without central nervous system central nervous system testis involvement without evolving cancer except basal cell carcinoma skin situ carcinoma cervix finished least since 6 months signed written informed consent efficient contraception women childbearing age excluding estrogens ius health insurance coverage received receiving steroid prephase secondary antecedent chemo radio therapy included lymphoblastic lymphoma bone marrow blasts 20 burkitt type antecedents chronicmyelogenous leukemia myeloproliferative neoplasm contra indication anthracyclines general visceral contra indication intensive therapy except considered related aspartate amino transferase serum glutamic oxaloacetictransferase alanine amino transferase serum glutamopyruvatetransferase 5 x upper limit of normal total bilirubin 2 5 x upper limit of normal creatinine 1 5 x upper limit of normal creatinine clearance 50 ml mn myocardial infarction within 6 months prior inclusion cardiomyopathy “new york heart association” grade iii intravenous infusion levf 50 rf 30 human immunodeficiency virus htlv hcv seropositivity chronic hbv hepatitis hbsag positive pregnant hcg positive nursing woman able bear procedures frequency visits planned unable consent tutelage curatorship judiciary safeguard women childbearing potential willing use effective form contraception participation least three months thereafter willing ensure beget child participation least three months treated investigational agent participation another within 30 days prior entering whose blood bone marrow explorations completed steroids prephase aged 18 to59 years old previously treated including injection newly diagnosed according 2008 definition 20 bone marrow blasts eastern cooperative oncology group (= performans status (= ecog)) 3 without central nervous system central nervous system involvement testis without evolving cancer except basal cell carcinoma skin situ carcinoma cervix finished least since 6 months signed written informed consent efficient contraception women childbearing age excluding estrogens intrauterine device received receiving recommended steroid prephase health insurance coverage secondary antecedent chemo radio therapy included lymphoblastic lymphoma bone marrow blasts 20 burkitt type antecedents chronicmyelogenous leukemia myeloproliferative neoplasm contra indication anthracyclines general visceral contra indication intensive therapy except considered related aspartate amino transferase serum glutamic oxaloacetictransferase alanine-aminotransferase serum glutamopyruvatetransferase 5 x upper limit of normal total bilirubin 2 5 x upper limit of normal creatinine 1 5 x upper limit of normal creatinine clearance 50 ml mn myocardial infarction within 6 months prior inclusion cardiomyopathy “new york heart association” grade iii intravenous infusion levf 50 rf 30 active severe infection known seropositivity human immunodeficiency virus htlv 1 chronic hepatitis b hbsag positive c active malignancy pregnant hcg positive nursing woman women childbearing potential willing use effective form contraception participation least three months thereafter willing ensure beget child participation least three months thereafter treated investigational agent participation another within 30 days prior entering able bear procedures frequency visits planned unable consent tutelage curatorship judiciary safeguard following criteria checked included graall 2014 high risk eastern cooperative oncology group (= performans status (= ecog)) 2 complete remission one two induction cures received three blocks consolidation 1 without central nervous system involvement diagnosiswith without allogeneic donor following criteria checked eastern cooperative oncology group (= performans status (= ecog)) status 3 consolidation 1 symptomatic central nervous system disease uncontrolled epilepsy peripheral neuropathy grade 2 consolidation 1 abnormal laboratory values defined consolidation 1 aspartate amino transferase serum glutamic oxaloacetictransferase alanine-aminotransferase serum glutamopyruvatetransferase 5 x upper limit of normal total bilirubin 1 5 x upper limit of normal creatinine 1 5 x upper limit of normal creatinine clearance 50 ml min serum amylase lipase 1 5 x upper limit of normal active uncontrolled infection concurrent disease medical condition deemed interfere conduct judged investigator women childbearing potential willing use effective form contraception participation least three months thereafter willing ensure beget child participation least three months thereafter known hypersensitivity nelarabine able bear procedures frequency visits planned inclusion done day 1 cycle n1 prephase amendment allocated arm control arm total 4 cycles combining nilotinib chemotherapy administered primary objective assessment hematopoietic stem cell transplantation procedure minimal residual disease monitored 4 cycles bcr abl abl ratio expressed percentage due administration nilotinib inclusion criteria liver function stringent graaph 2014 graall 2014 cf non inclusion criteria whose blood bone marrow explorations completed steroids prephase aged 18 59 years old newly diagnosed non previously treated hydrogen ion concentration according 2008 criteria confirmed diagnosis philadelphia chromosome defined reciprocal translocation chromosomes 9 22 9 22 presence bcr abl molecular maker 20 bone marrow blasts eastern cooperative oncology group (= performans status (= ecog)) 3 without central nervous system central nervous system testis involvement without evolving cancer except basal cell carcinoma skin situ carcinoma cervix chemo radio therapy finished least 6 months received previous hemopathy including injection signed written informed consent efficient contraception women childbearing age excluding estrogens intrauterine device health insurance coverage received beingreceiving recommended steroid prephase note 1 secondary antecedent chemo radio therapy included note 2 case high vascular risk see section management able receive nilotinib unless ultra sound doppler neck lower limbs performed pre phase validated medical coordinators graall via secretariat previously treated tyrosine kinase inhibitor tyrosine kinase inhibitor another active malignancy general visceral contra indication intensive therapy except considered related aspartate amino transferase serum glutamic oxaloacetictransferase alanine-aminotransferase serum glutamopyruvatetransferase 2 5 x upper limit of normal total bilirubin 1 5 x upper limit of normal creatinine 1 5 x upper limit of normal creatinine clearance 50 ml min serum amylase lipase 1 5 x upper limit of normal antecedents acute pancreatitis heart failure including least one following criteria left ventricular ejection fraction lvef 50 lowest normal threshold determined electrocardiogram heart failure “new york heart association” grade iii intravenous infusion impossibility measure qt interval electrocardiogram complete left bundle branch block pacemaker congenital long qt syndrome known familial antecedents long qt syndrome antecedents current ventricular atrial tachyarrhythmia clinically significant baseline bradycardia 50 bpm clinically significant qtc 450 msec established mean 3 baseline electrocardiogram using qtcf formula antecedents myocardial infarct past 6 months instable angor within past 12 months heart condition clinically significant e congestive heart failure uncontrolled hypertension active uncontrolled infection concurrent disease deemed interfere conduct judged investigator severe evolving infection known human immunodeficiency virus htlv1 seropositivity chronic hepatitis b hbsag positive c pregnant hcg nursing woman women childbearing potential willing use effective form contraception participation least three months thereafter willing ensure beget child participation least three months thereafter received another investigational agent participation another within 30 days prior entering able bear procedures frequency visits planned unable consent tutelage curatorship judiciary safeguard primary analyses 3 trials performed whole population included e intention treat intent to treat independently received whatever treatments received whatever objective superiority non inferiority demonstration order address non inferiority questions confidence intervals 95 principal judgment criteria disease-free survival 4 years graall 2014 b percentage major molecular response graaph 2014 aal hydrogen ion concentration calculated lower threshold compared margin non inferiority 15 planned superiority questions secondary criteria effect sizes appreciated one shot confidence interval 95 using statistical tests adapted criterion log rank test non informative data censored right gray test case competition effects measured censored criteria ratio instant risk functions effect proportions measured relative risk difference risks estimations adjusted prognostic factors necessary risk stratified standard risk high risk very high risk besides interim analysis planned hydrogen ion concentration graaph 2014 inclusion 60 first mrd2 molecular response one shot estimation exact binomial confidence interval 95 calculated binomial test null hypothesis equality response probability 80 results transmitted independent surveillance committee decide possible replacement nilotinib imatinib dasatinib 4 cycles pre transplant note interim analysis investigating comparison arms global adjustment population required 0 05 threshold retained hydrogen ion concentration graaph 2014 one planning interim analysis inclusion first 60 objective verifying level mrd2 statistical criterion stopping inclusions 4 planned amendment filed case modification initialstatistical analysis plan,"prevalence, graall, concentration, treated, leukemia, activity, survival, nervous, central, responders"
CAMOVID_protocole_v6.0-20211108_LBD,4,10.438568,-2.7823153,full title camovid multicenter randomized evaluate efficacy safety camostat mesylate sars cov 2 infection covid 19 ambulatory adult acronym reference camovid coordinating investigator dr david boutboul scientific director pr lara zafrani sponsor assistance publique hopitaux de paris scientific justification since december 2019 novel coronavirus called sars cov 2 severe acute respiratory syndrome coronavirus 2 caused international outbreak respiratory illness described covid 19 22nd march 2020 2920142 confirmed cases covid 19 including 12784 deaths reported world health organization 1 31 march 2020 52827 severe cases france including 3532 deaths spectrum symptomatic infection ranges mild critical infections severe 15 infected require hospitalization 5 require intensive care unit admission 2 diagnosis sars cov 2 infection relies symptoms microbiological testing test sars cov 2 infection testing centers use reverse transcription polymerase chain reaction reverse-transcription polymerase chain reaction nasal swab productive cough number investigational agents explored antiviral covid 19 however date controlled data supporting use specific anti viral drugs immunomodulatory drugs efficacy covid 19 unknown 3 sars cov 2 infects human cells binding spike protein membranous aminopeptidase called angiotensin converting enzyme 2 angiotensin converting enzyme 2 among tissues angiotensin converting enzyme 2 expression mainly found pneumocytes enterocytes renal tubular cells podocytes cellular entry sars cov 2 requires protein priming cellular serine protease cellular serine protease entails protein cleavage allows fusion viral cellular membranes 4 murine model sars cov pneumonia iwata yoshikawa others showed cellular serine protease ko mice weakened inflammatory cytokine responses reduced lung injury control mice 5 hoffmann others found cellular serine protease inhibitor camostat mesylate blocked viral entry reduce infection human primary pneumocytes lung cell lines sars cov 2 also showed sera convalescent sars cross neutralized sars 2 driven entry 4 another performed bojkova others 5 showed camostat mesylate reduced cytopathogenic effect due sars cov 2 human colonic cell lines camostat mesylate serine protease inhibitor commonly used japan dose 600 milligrams day successfully safely used treat pancreatitis associated pain 6 post operative reflux oesophagitis 7 side effects reported rare doses nausea diarrhea hypersensitivity 0 1 0 5 cases cytopenias less 0 1 hyperkaliemia abnormal hepatic function less 0 05 hypothesize camostat mesylate initiated early sars cov2 infection reduce viral infection viral cytopathogenic effect blocking sars cov2 entry cells therefore prevent deterioration toward severe forms covid19 main objective primary endpoint objective evaluate efficacy camostat mesylate sars cov 2 infection high risk adult confirmed covid 19 requiring initial hospitalization terms hospitalization needs day 21 randomization primary endpoint proportion hospitalized covid 19 deterioration died without hospitalization day 1 day 21 indicative basis criteria hospitalization presence following respiratory rate 24 min rest sp02 95 room air blood pressure 100 mmhg lethargy unconsciousness brutal overall deterioration lethargy elderly haut conseil à la santé publique reasons requiring hospitalization left discretion physician secondary objectives endpoints secondary objectives adult diagnosed laboratory confirmed covid 19 requiring initial hospitalization evaluate impact camostat mesylate compared placebo safety day 21 efficacy terms need hospitalization covid 19 management independent blinded committee review overall improvement day 21 efficacy terms intensive care needs day 21 efficacy terms time hospitalization day 21 efficacy respiratory functions day 21 overall survival day 21 90 randomization reported outcome initial symptoms day 21 virological serological immunological efficacy day 90 including surrogacy assessment candidate markers day 90 renal complications day 21 liver complications day 21 covid 19 transmission within household secondary endpoints adverse events aes number aes number serious aes saes investigational medication discontinuation reason 21 days independent endpoint adjudication committee reviewed proportion hospitalized day 1 day 21 covid 19 deterioration independent eac review patientsfiles blinded randomized group determine whether hospitalization criteria related covid 19 covid 19 improvement ordinal scale 3 day 7 14 21 admission intensive care unit within 21 days inclusion number days alive without hospitalization 21 days initiation invasive mechanical ventilation covid19 severe within 21 days inclusion initiation oxygen therapy covid19 within 21 days inclusion overall survival day 90 number days alive without symptoms day 21 sars cov 2 virological assessment day 1 day 7 day 14 day 21 nasal swab droplet quantification sars cov2 rnaemia sars cov 2 serological assessment day 1 day 7 day 14 day 21 plasma il 6 il 1b tnfa il 8 levels day 1 7 14 peripheral blood lymphocyte phenotyping telomere length measurement day 1 day 7 day 14 acute kidney failure defined least serum creatinine increase 0 3mg deciliter 1 5 1 9 times baseline oliguria 0 5ml kilograms h kdigo2012 scale within 21 days serum electrolytes estimated glomerular filtration rate day 7 14 21 liver transaminases gamma gt alkaline phosphatase day 7 14 21 percentage covid 19 affected individuals sharing household day 1 7 14 design multicenter single blinded placebo controlled two arm parallel 1 1 randomized phase iii population participants ambulatory adult high risk laboratory confirmed covid 19 requiring initial hospitalization inclusion criteria 1 18 years old 2 increased risk severe covid 19 belonging one following groups age 50 years body mass index 30 kilograms month 2 diabetes hypertension chronic renal failure egfr 60 ml min chronic heart disease asthma chronic obstructive pumonary disease cystic fibrosis chronic liver disease chronic neurological disease solid organ transplant bone marrow transplant sickle cell anemia major thalassemias active currently treated 1 year diagnosed cancer active currently treated 1 year diagnosed malignant blood disease immunosuppressive observed 1 month 3 laboratory confirmed sars cov2 infection mild covid 19 fulfilling following criteria positive sars cov 2 rt pcr nasal saliva swab samples positive sars cov 2 antigen test performed within 96h inclusion visit symptoms signs consistent sars cov2 infection including limited fever upper respiratory tract infection signs digestive signs muscle pain anosmia dysgueusia 1 4 informed consent participate 5 must able willing comply visits procedures exclusion criteria 1 initial need hospitalization covid 19 management defined following severity criteria respiratory rate 24 min rest sp02 95 room air blood pressure 100 mmhg lethargy unconsciousness brutal overall deterioration lethargy elderly recommendations haut conseil à la santé publique reasons requiring immediate hospitalization left discretion physician 2 pregnancy breastfeeding 3 participation another interventional drug 4 subject protected law guardianship curatorship 5 absence health insurance 6 known hypersensitivity camostat mesylate 7 known person sharing household already included 8 participation another covid 19 ambulatory interventional 9 completed full sars cov2 vaccine immunization procedure less 4 weeks prior covid 19 diagnosis last vaccine injection performed less 4 weeks prior covid 19 diagnosis investigational medicinal product camostat mesylate oral administration 600mg day 2 x 100mg every 8 hours 14 days day 1 day 14 comparator placebo tablets following schedule investigational drug interventions added oral medication camostat mesylate placebo expected benefits participants society evaluate candidate therapeutic strategy context sars cov 2 pandemics specifically proposed targets ambulatory high risk newly diagnosed confirmed covid 19 requiring initial hospitalization strategy aims improve short term outcomes ambulatory prevent evolution severe forms requiring hospitalization therefore participate reducing hospitalization needs quantitative qualitative relieving healthcare system may reduce contagiosity moreover useful therapeutic option ambulatory early diagnoses management epidemics upcoming months lockdown removal risks burdens added additional risks camostat mesylate known side effects digestive nausea vomiting diarrhea hypersensitivity 0 5 cytopenias 0 1 liver abnormal function hyperkaliemia 0 05 risk level practical implementation screened consults participating primary care general practitioners gps 4 emergency departments saint louis hospital bichat hospital mondor hospital argenteuil hospital 2 hospital outpatientcovid 19 screening center bichat hospital mondor hospital outpatient consult internal medicine saint louis hospital sickle cell disease inherited red blood cells genetic disorders coordinating referral center henri mondor hospital initial consult screened eligibility standard care sampling sars cov2 rt pcr nasal saliva antigen test upon positive laboratory confirmation covid19 information eligible consent participate randomly assigned one following treatments arm camostat mesylate 600mg 2x100mg 8h n 298 arm b placebo 2 tablets 8h n 298 blinded arm inclusion visit follow visits performed 7 14 21 90 days follow visits include medical interview either person teleconsultation paramedical assessment registered nurses vital signs measurement biological sampling included benefit standard care ambulatory monitoring covid 19 biological monitoring blood sampling serum electrolytes creatinine liver enzymes virological monitoring rt pcr nasal swab day 7 14 21 performed locally following standard practice primary care data collected via web based standardized electronic case report form case hospitalization hospital report used source data collection general practitioner randomization performed centrally via web based system ensure allocation concealment use pre specified randomization lists based permutation blocks number participants included n 596 planned current knowledge sars cov2 infection adults expect roughly 20 newly diagnosed high risk hospitalized within 21 days 8 design initially included planned interim analysis one third observations completed maximum total sample size 536 evaluable 268 per group would allow 90 power detect absolute difference 10 probability hospitalization day 21 groups e g reduction 20 10 using z test one sided 2 5 significance level efficacy using lan demets risk spending functions obrien fleming boundaries approximation efficacy futility stopping rules overall 596 298 group would included anticipate potential 10 drop rate given ambulatory follow however due status pandemics fall 2021 global use vaccines scientific comittee decided stop recruitment eventually discontinue early planned interim sample size reached eventually single final analysis performed 2 5 one sided significance level primary endpoints endpoints analysed planned number centres recruiting centers emergency department saint louis hospital paris covid 19 screening center bichat hospital emergency department argenteuil hospital centre de sante richerand 75010 paris emergency department h mondor hospital creteil outpatient consult infectious disease deparment covid screening center henri mondor hospital creteil outpatient consult sickle cell disease inherited red blood cell genetic disorders coordinating referral center h mondor hospital creteil post emergency internal medicine department h mondor hospital creteil department infectious tropical diseases public health unit groupe hospitalier sud ile de france ghsif melun emergency department lariboisiere hospital paris non recruiting centers follow visits internal medicine department argenteuil hospital office dr k amazzough 75011 paris office dr j marzouk 75017 paris duration inclusion period 12 months participation period follow 90 days total duration 15 months number enrolments expected per site per month 5 month recruiting center average given total required sample size planned inclusion period statistical analysis descriptive analyses use either frequencies percentages categorical variables median interquartile range quantitative variables number missing values reported primary endpoint probability hospitalization within 21 days compared groups using two sided z test secondary endpoints compared across groups using fishers exact test comparing probabilities groups wilcoxons rank sum test comparing quantitative endpoints analyses performed intention treat principle 5 two sided significance level used comparisons secondary endpoints funding sources programme hospitalier de recherche clinique covid 19 20 0095 data safety monitoring board yes several lines evidence indicate camostat could good candidate sars cov 2 infection sars cov 2 infects human cells binding spike protein membranous aminopeptidase called angiotensin converting enzyme 2 angiotensin converting enzyme 2 among tissues angiotensin converting enzyme 2 expression mainly found pneumocytes enterocytes renal tubular cells podocytes cellular entry sars cov 2 requires protein priming cellular serine protease cellular serine protease entails protein cleavage allows fusion viral cellular membranes 4 murine model sars cov pneumonia iwata yoshikawa others showed cellular serine protease ko mice weakened inflammatory cytokine responses reduced lung injury control mice 12 zhou others demonstrated cellular serine protease inhibitor camostat mesylate reduced mortality murine model sars cov infection administered orally dosage 8 milligrams kilograms 13 hoffmann others recently found camostat mesylate blocked entry sars cov 2 human lung cells data obtained vitro primary lung cells lung cancer cell lines using viral pseudotypes integrating spike sequence also using whole sars cov2 showed decreased cellular infection also showed sera convalescent sars cross neutralized sars 2 driven entry 4 paper bojkova others showed camostat reduced cytopathogenic effect sarscov2 cancer cell lines effect superior sars cov 2 sars cov infection 5 data argue potential strong effect camostat evolution covid 19 infection moreover two recent publications gave additional weight possible activity camostat covid 19 course hoffman others 14 showed camostat mesylate also inhibits serine proteases involved cleavage protein activity achievable usual dosage 200 milligrams camostat first published lancet infectious disease 15 indicated camostat may beneficial effect covid 19 course hospitalized severe forms infection finally camostat may display immunoregulatory role decreasing il 6 tnfa production virally infected respiratory cells 16 latter role particular importance due fact severe forms disease related cytokine storm syndrome major roles il 6 tnfa 17 camostat mesylate serine protease inhibitor commonly used japan dose 600 milligrams day successfully safely used treat pancreatitis associated pain 6 post operative reflux oesophagitis 7 side effects reported rare doses nausea diarrhea hypersensitivity 0 1 0 5 cases abnormal cytopenias less 0 1 hyperkaliemia abnormal hepatic function less 0 05 market authorization application addressed fda european medicines agency evaluate candidate therapeutic strategy context sars cov 2 pandemics specifically proposed targets high risk ambulatory newly diagnosed confirmed covid 19 requiring initial hospitalization strategy aims improve short term outcomes ambulatory prevent evolution severe forms requiring hospitalization therefore participate reducing hospitalization needs quantitative qualitative relieving healthcare system moreover useful therapeutic option ambulatory early diagnoses management epidemics upcoming months lockdown removal may also reduce interindividual transmission reducing viral replication host single blinded design precludes inclusion multiple members household one additional secondary endpoint percentage covid 19 affected relatives measured day 7 day 14 compared day 0 population living least one person household additional risks camostat mesylate known side effects nausea diarrhea hypersensitivity 0 1 0 5 cases abnormal cytopenias less 0 1 hyperuricemia reported mild asymptomatic form healthy volunteers recent ono enclosed protocol hyperkaliemia abnormal hepatic function less 0 05 summary product characteristics attached protocol publication date 2019 attached file 18 5 flyers emergency occupational medicine departments participating hospitals see attached file hypothesize camostat mesylate initiated early sars cov2 infection reduce viral infection viral cytopathogenic effect viral spreading blocking sars cov2 entry cells therefore prevent deterioration toward severe forms covid 19 high risk evaluate efficacy camostat mesylate sars cov 2 infection high risk adult confirmed covid 19 requiring initial hospitalization terms hospitalization needs day 21 randomization adult diagnosed laboratory confirmed covid 19 requiring initial hospitalization evaluate impact camostat mesylate compared placebo safety day 21 randomization efficacy terms need hospitalization covid 19 management independent blinded committee review overall improvement day 21 randomization efficacy terms intensive care needs day 21 randomization efficacy terms time hospitalization day 21 randomization efficacy respiratory functions day 21 randomization overall survival day 21 90 randomization reported outcome initial symptoms day 21 randomization virological serological immunological efficacy day 90 randomization including surrogacy assessment candidate markers day 90 renal complications day 21 randomization liver complications day 21 randomization covid 19 transmission within household least 1 person household proportion hospitalized day 1 day 21 covid 19 deterioration died without hospitalization day 1 day 21 investigators collect information hospitalization day 21 visit case hospitalization use hospitalization report data source indicative basis criteria hospitalization presence following respiratory rate 24 min rest sp02 95 room air blood pressure 100 mmhg lethargy unconsciousness brutal overall deterioration lethargy elderly per haut conseil la sante publiques haut conseil à la santé publique recommendations 9 reasons requiring hospitalization left discretion physician adverse events aes number aes number serious aes saes investigational medication discontinuation reason 21 days independent endpoint adjudication committee reviewed proportion hospitalized day 1 day 21 covid 19 deterioration independent eac review patientsfiles blinded randomized group determine whether hospitalization related covid 19 covid 19 improvement ordinal scale 3 day 7 14 21 admission intensive care unit within 21 days inclusion number days alive without hospitalization 21 days initiation invasive mechanical ventilation covid19 severe within 21 days inclusion initiation oxygen therapy covid19 within 21 days inclusion overall survival day 90 number days alive without symptoms day 21 sars cov 2 virological assessment day 7 day 14 day 21 nasal swab droplet quantification sars cov2 rnaemia new candidate surrogate marker defined 18 sars cov 2 serological assessment day 7 day 14 day 21 day 90 il 6 il 1b tnfa il 8 levels day 1 7 14 17 blood sample collected day 1 7 14 21 90 biobanking evaluation potential candidate surrogate markers future peripheral blood lymphocyte phenotyping telomere length measurement day 1 day 7 day 14 acute kidney failure defined least serum creatinine increase 0 3mg deciliter 1 5 1 9 times baseline oliguria 0 5ml kilograms h kdigo2012 scale within 21 days serum electrolytes uricemia estimated glomerular filtration rate day 7 14 21 liver transminases gamma gt alkaline phosphatase levels day 7 14 21 camostat mesylate oral administration empty stomach e 90 minutes meal 600mg day 200mg every 8 hours 14 days day 1 day 14 shown effective safe previous strengthened pharmalogical data moreover oral camostat given dose 8 milligrams kilograms day shown associated decreased mortality sars cov murine model 13 recent publication also showed antiviral activity may achievable usual doses camostat 14 necessity administration empty stomach justified recent pharmalogic data obtained ono healthy volunteers enclosed protocol authorization ono see section 7 information administration product phase iii multicenter single blinded placebo controlled two arm parallel superiority 1 1 randomized screening eligible performed emergency department saint louis hospital paris outpatient consult internal medicine department saint louis hospital paris emergency department bichat hospital paris covid 19 screening center bichat hospital emergency department argenteuil hospital emergency department h mondor hospital creteil outpatient consult infectious disease department covid 19 screening center henri mondor hospital creteil outpatient consult sickle cell disease inherited red blood cell genetic disorders coordinating referral center h mondor hospital creteil emergency department lariboisiere hospital paris centre de sante richerand primary care outpatient clinic center 75010 paris centre medical international primary care outpatient clinic center 75010 paris dr karima amazzough 75011 paris dr laurent haas 75017 paris occupational medicine departments recruiting hospitals recruiting centers eligible referred one following participating centers inclusion treatement allocation emergency department saint louis hospital principal investigator dr olivier peyrony covid 19 screening center bichat hospital principal investigator dr dorothee vallois emergency department argenteuil hospital principal investigator dr gaetan plantefeve centre de sante richerand primary care outpatient clinic center 75010 paris principal investigator dr mariela skendi emergency department henri mondor hospital principal investigator dr c kassasseya outpatient consult sickle cell disease inherited red blood cell genetic disorders coordinating referral center henri mondor hospital creteil principal investigator pr pablo bartolucci outpatient consult infectious disease department covid 19 screening center henri mondor hospital creteil principal investigator dr raphael lepeule post emergency internal medicine department h mondor hospital principal investigator dr c guillaud department infectious tropical diseases public health unit groupe hospitalier sud ile de france ghsif melun emergency department lariboisiere hospital paris follow visits include medical interview one participating centers recruiting non recruiting centres detailed either via physical consultation teleconsultation paramedical registered nurse assessment biological sampling non recruiting centers follow visits internal medicine department argenteuil hospital principal investigator dr claire le pendu office dr k amazzough 75011 paris principal investigator dr karima amazzough office dr j marzouk 75017 paris principal investigator dr jean marzouk unblinding requested reason considered essential investigating physician calling upon emergency cases poison control centre fernand widal hospital telephone 33 0 1 40 05 48 48 apart emergency situation délégation à la recherche clinique et à l’innovation research innovation department délégation à la recherche clinique et à l’innovation project advisor whose contact information listed protocol cover page unblinding applied whenever possible advising sponsor coordinating investigator assess relevance request unblinding case requests unblinding made phone confirmed written unblinding request using studys standardized form unblinding requests contact information délégation à la recherche clinique et à l’innovation tel 01 44 84 17 23 fax 01 44 84 17 01 coordinating investigatordr boutboul tel 01 42 49 91 40 following informed written consent initial biological assessments formally verify inclusion non inclusion criteria follows interviewed collect age sex weight height smoking status medical history comorbidities date diagnosis notably asthma chronic obstructive pulmonary disease chronic respiratory affections diabetes cardiovascular diseases concomitant medications covid 19 history symptoms date first symptoms contact known hypersensitivity camostat mesylate pregnancy examination notably include respiratory rate measurement peripheral oxygen saturation by pulse oxymeter ambient air lung auscultation body temperature blood pressure measurement baseline laboratory results also required inclusion laboratory confirmed sars cov 2 infection determined pcr nasal saliva commercial public health assay including antigen test specimen 96 hours plasma level beta hcg women potential childbearing randomization performed consented participate written informed consent upon inclusion baseline biological assessments performed complete blood count chemistry liver enzymes measurement baseline biobanking 20 ml blood heparinate lithium 5 ml edta cytokine measurement droplet quantification sars cov2 rnaemia detailed 18 sars cov 2 serology also performed inclusion visit contact information collected well closed one contact personne de confiance usual general practitioner contact misses day 21 visit investigating team try contact necessary closed one general practitioner retrieve information endpoints reasons missed visit multicentre relies screening eligible saint louis hospital emergency department bichat hospital emergency department covid 19 screening center emergency department argenteuil hospital emergency department henri mondor hospital creteil ambulatory outpatient clinics centre de sante richerand centre medical international 75010 paris internal medicine outpatient consult saint louis hospital red blood cell diseases center infectious disease outpatient consults h mondor hospital practices dr amazzough dr haas departments occupational medicine recruiting hospitals recruiting centers eligible referred one 8 recruiting ambulatory centers 5 sites inclusion randomization emergency department saint louis hospital covid 19 screening center bichat hospital emergency department argenteuil hospital centre de sante richerand primary care outpatient clinic center 75010 paris emergency department henri mondor hospital creteil outpatient consult infectious disease department covid 19 screening center henri mondor hospital creteil post emergency internal medicine department h mondor hospital creteil outpatient consult sickle cell disease inherited red blood cell genetic disorders coordinating referral center henri mondor hospital creteil department infectious tropical diseases public health unit groupe hospitalier sud ile de france ghsif melun emergency department lariboisiere hospital paris non recruiting centers following centers participate non recruiting centers conduct follow visits day 7 14 21 90 internal medicine department argenteuil hospital office dr k amazzough 75011 paris office dr j marzouk 75017 paris follow visits performed one particpating centers recruiting non recruiting several situations possible temporary suspension investigator must document reason suspending resuming participants source file case report form case report form premature discontinuation participant remains enrolled end participation premature discontinuation withdrawal investigator must document reason collect assessment criteria time ending participation participant agrees schedule follow participant particularly case serious adverse event case severe adverse events investigator must notify sponsor follow participant 3 months following premature discontinuation camostat mesylate placebo notification serious adverse event must sent email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction sponsor serious adverse event monitored resolved data safety monitoring board created committee specify validate follow methods participants may exit time reason course participation participant presents one following exclusion criteria product must discontinued participant continue monitored negative sars cov 2 pcr viral assessment inclusion visit pregnancy breastfeeding platelet count 50 109 l absolute neutrophil count 0 5 109 l aspartate amino transferase alanine-aminotransferase 5 upper limit of normal k 5 mmol l case covid 19 deterioration hospitalization medication maintained planned long status allows discretion physician charge investigator temporarily permanently withdraw participant safety reason participants best interests participant lost follow participant cannot located investigator must make every effort reconnect participant document attempts source file least determine whether participant alive dead participant exits prematurely withdraws consent data collected prior date premature exit may still used participant exits prematurely participant agrees state procedure schedule collecting data required protocol primary endpoint secondary endpoints safety assessment nb must stated information consent form state premature exit affect participant ongoing care state exactly participant offered case serious adverse events see corresponding section vigilance case report form must list various reasons participant discontinued lack efficacy adverse reaction another medical issue personal reasons participant explicit withdrawal consent lost follow replaced initial notification severe adverse event must provided written report signed investigator using severe adverse event notification form specific intended purpose case report form item form must completed investigator sponsor carry appropriate analysis initial notification sponsor serious adverse event must quickly followed additional detailed written report reports case outcome may monitored safety department provide information whenever possible investigator provide sponsor documents may useful medical reports laboratory test results results additional examinations etc documents must non identifying addition documents must include following acronym number participants initials adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even participant left initial notification severe adverse event follow reports documents must sent sponsor safety department email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction noted possible send severe adverse event reports safety department fax 33 0 1 44 84 17 99 event failed attempt send severe adverse event report email order avoid duplication use e crfs investigator completes severe adverse event notification form e case report form validates prints signs form sending email possible connect e case report form investigator complete sign send severe adverse event notification form safety department soon connection restored severe adverse event notification form e case report form must duly completed investigator must respond requests sponsor additional information questions relating notification adverse event safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction cases utero exposure investigator complete notification follow form pregnancy occurring participation investigator must monitor pregnant woman throughout pregnancy pregnancy terminated must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage pregnancy termination foetal death congenital abnormality etc investigator must follow procedure reporting saes initial pregnancy notification severe adverse event follow reports documents sent sponsor according procedures specified herein father exposed investigator must obtain pregnant woman permission collecting information pregnancy computer file used research implemented accordance french amended informatique et libertes law governing data protection european general data protection regulation gdpr regulations commitment comply reference methodology medium risk 001 research governed commission nationale informatique et libertés french data protection agency reference methodology processing personal data used within scope health research amended medium risk 001 ap hp sponsor research signed declaration compliance reference methodology 1 18 years old 2 increased risk severe covid 19 belonging one following groups age 50 years body mass index 30kg month 2 diabetes hypertension chronic renal failure gfr 60 ml min chronic heart disease asthma chronic obstructive pumonary disease cystic fibrosis chronic liver disease chronic neurological disease solid organ transplant bone marrow transplant sickle cell anemia major thalassemias active currently treated 1 year diagnosed cancer active currently treated 1 year diagnosed malignant blood disease immunosuppressive observed 1 month 3 laboratory confirmed sars cov2 infection mild covid 19 fulfilling following criteria positive sars cov 2 rt pcr nasal saliva swab samples positive sars cov 2 antigen test performed within 96h inclusion visit symptoms signs consistent sars cov2 infection including limited fever upper respiratory tract infection signs digestive signs muscle pain anosmia dysgueusia 1 4 informed consent participate 5 must able willing comply visits procedures 1 initial need hospitalization covid 19 management defined following severity criteria respiratory rate 24 min rest sp02 95 room air blood pressure 100 mmhg lethargy unconsciousness brutal overall deterioration lethargy elderly recommendations haut conseil à la santé publique reasons requiring immediate hospitalization left discretion physician 2 pregnancy breastfeeding 3 participation another interventional drug 4 subject protected law guardianship curatorship 5 absence health insurance 6 known hypersensitivity camostat mesylate 7 known person sharing household already included 8 participation another covid 19 ambulatory interventional 9 completed full sars cov2 vaccine immunization procedure less 4 weeks prior covid 19 diagnosis last vaccine injection performed less 4 weeks prior covid 19 diagnosis received sars cov2 vaccine incomplete sars cov2 vaccine immunization scheduled injections performed completed vaccine procedure 4 weeks eligible persons responsible quality control article l 1121 3 code de la sante publique french public health code take necessary precautions ensure confidentiality information relating investigational medicinal products participants particular identity results obtained persons well investigators bound professional secrecy accordance conditions set articles 226 13 226 14 code penal french criminal code research involving human participants data collected concerning participants sent sponsor investigators specialised collaborators rendered non identifying circumstances shall names addresses participants involved shown sponsor ensure participant given written permission personal information strictly necessary quality control accessed data entry data made non identifying carried electronic media via web browser cleanweb linked database stored sponsor server following analysis set considered intent treat intent to treat defined randomized randomized group whatever eligibility criteria received refer primary analyses general strategy categorical efficacy safety endpoints summarized counts percent continuous efficacy safety endpoints summarized using summary measures median interquartile range similarly characteristics presented using summary measures median interquartile range quantitative characteristics counts percentages categorical characteristics analyses group presented according subjects randomized intent to treat endpoints primary secondary mainly analysed without adjustment exploratory analyses include adjustment potential prognostic factors description hospitalization motives characteristics primary endpoint per hospital planned subgroup analyses include analyses stratified age baseline use macrolides vaccine immunization status sars cov2 vaccine yes completed immunization required shots received yes type vaccine primary endpoint probability hospitalization death within 21 days compared groups using one sided z test 2 5 significance level see section 12 2 one interim analysis primary endpoint initially planned conducted one third observations completed efficacy futility decision rules early termination see 12 2 details however fall 2021 decided resume enrolment terminate one final analysis performed 2 5 one sided significance level available sample endpoints analysed planned secondary endpoints compared across groups using fishers exact test comparing probabilities groups wilcoxons rank sum test comparing quantitative endpoints 5 two sided significance level used comparisons secondary endpoints exploratory analyses endpoints conducted using bayesian inference incorporating external information information camostat efficacy published trials data across world anticipated level significance 2 5 one sided primary endpoint comparative analyses performed two sided 5 significance level,"antibiotic, sars, covid, participant, 19, cov, 21, 90, emergency, unit"
2020-000296-21_PROTOCOLE_v8 0_20230405_RECORDS DA_SGD 2,4,3.9710946,-1.1703261,title rapid recognition corticosteroid resistant sensitive sepsis acronym reference records coordinating investigator scientific director pr djillali annane sponsor assistance publique hopitaux de paris sites french adult general icus background estimates yearly 30 million people develop sepsis 11million die aprocchs phase 3 placebo controlled demonstrated 6 absolute reduction sepsis mortality hydrocortisone fludrocortisone number factors may positively negatively impact corticosteroids cs benefits sepsis main objective primary endpoint compare effect hydrocortisone plus fludrocortisone vs placebo composite death persistent organ dysfunction defined continued dependency mechanical ventilation new renal replacement therapy vasopressors assessed 90 days intensive care unit intensive care unit adults different biological profiles immune responses corticosteroids bioactivity primary endpoint death persistent organ dysfunction defined continued dependency mechanical ventilation renal replacement therapy vasopressors sofa score 6 90 days secondary objectives endpoints mortality health related quality life 6 months daily organ function sofa score days 1 2 3 4 7 10 14 28 90 daily secondary infections 90 days daily blood urinary levels glucose sodium potassium 28 day daily gastroduodenal bleeding 28 day daily cognitive function muscles strength days 1 28 90 180 days design multi arms parallel blinded randomized controlled preceded 6 month run observational period observational phase run period interventional phase inclusion criteria observational phase n1 2 3 4 6 7 8 9 interventional phase n1 2 3 4 5 6 7 8 18 years old admitted intensive care unit proven suspected infection main diagnosis community acquired pneumonia related sepsis vasopressors dependency norepinephrine epinephrine vasopressin dopamine phenylephrine septic shock singer 2016 vasopressor maintain mean blood pressure least 65 mmhg lactate levels 2 mmol l acute respiratory distress syndrome ards ranieri 2012 acute onset e within one week apparent insult progression respiratory syndrome b bilateral opacities chest imaging explained pulmonary pathologies e g pleural effusion atelectasis nodules etc c evidence heart failure volume overload pao2 fio2 300 millimeter hg peep 5 cm h2o signed informed written consent whevener able consent ascent representant whenever present time screening inclusion tested one records specific biomarkers circi endocan gilz dusp 1 mdw lymphopenia transcriptomic srs2 endotype b pcr covid 19 pcr influenza pcr respiratory virus cutaneous vasoconstrictor response glucocorticoids affiliation social security system universal health coverage couverture maladie universelle cmu guardianship curatorship included case simple emergency legal definition included managed covid 19 biological samples available exclusion criteria observational phase n1 2 3 interventional phase n 1 2 3 4 5 6 7 8 pregnancy expected death withdrawal life sustaining treatments within 48 hours previously enrolled formal indication corticosteroids according recent international guidelines vaccination live virus within past 6 months hypersensitivity hydrocortisone fludrocortisone microsined betamethasone dipropionate excipients summary of product characteristics women childbearing potential using contraception nursing women included stratum applicable apply cream infected ulcerated area intervention observational phase run period additional biological samples restrospective part covid telephone follow interventional phase investigational products placebo administered basis records signatures investigational products included hydrocortisone hemisuccinate 50 milligrams one intravenous injection every 6 hours 9 alpha fludrocortisone 50 g one tablet per day via nasogastric tube treatments stopped 7 days left intensive care unit whichever occurs first without tapering randomization interventional phase web based randomization system available 24 7 eligible randomized 1 1 ratio corticoseroids matching placebo use permuted blocks undisclosed variable size stratify randomization site biomarkers sample size enroll total 1800 adaptative sites expected enroll least 1or 2 per month enrolling 376 evaluable per arm 80 power detect 10 absolute risk reduction 45 35 corresponds 20 relative risk reduction duration inclusion period 48 months 7 days follow 6 months daily intensive care unit stay telephone follow 6 months total period 54 months adaptive multi arms adapt different arms stopped continued sequentially detecting whether effect may different according biomarkers may potentially stop recruitment presenting certain levels biomarker evidence interacts negatively outcome instance therefore effect assessed safety measure severe adverse events early surrogate efficacy measure research records expected substantial increase chance survive free sequels level customization corticotherapy proposed records dosing randomizing specific biomarkers also expected experience much less harm indeed minimised thanks surveillance adaptive design overall objective programme determine whether different signatures immune status corticosteroids biological activity influence responses hydrocortisone plus fludrocortisone adults sepsis end several predefined biomarker cohorts randomly allocated receive hydrocortisone plus fludrocortisone respective placebos primary objective secondary oobjectives defined compare effect hydrocortisone plus fludrocortisone vs placebo composite death persistent organ dysfunction defined continued dependency mechanical ventilation new renal replacement therapy vasopressors assessed 90 days intensive care unit intensive care unit adults different biological profiles immune responses corticosteroids bioactivity compare effect hydrocortisone plus fludrocortisone vs placebo 6 month mortality 6 month health-related quality of life organ function days 1 2 3 4 7 10 14 28 intensive care unit hyperglyceamia defined glucose levels 8 3 mmol l 150mg deciliter daily day 28 hypernatremia defined serum sodium levels 150mmol l daily day 28 secondary infection daily day 90 beeding gastrointestinal tract defined evidence active bleeding need blood transfusion hemostatic endoscopic surgical procedures neurological cognitive dysfunction defined low score promis adult cognitive function score appendix 15 4 7 neuromuscular weakness defined grade 2 muscular disability rating scale mdrs appendix 15 4 6 several situations possible temporary suspension investigator must document reason suspending resuming participants source file case report form case report form premature discontinuation participant remains enrolled end participation premature discontinuation withdrawal investigator must document reason collect assessment criteria time ending participation participant agrees schedule follow participant particularly case serious adverse event case severe adverse events investigator must notify sponsor follow participant 1 month following premature discontinuation notification serious adverse event must sent email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction sponsor serious adverse event monitored resolved participants may exit time reason course participation participant presents one following exclusion criteria product procedure must discontinued participant continue monitored list relevant criteria pregnancy expected death withdrawal life sustaining treatments within 48 hours previously enrolled ineterventional hypersensitivity hydrocortisone fludrocortisone excipients summary of product characteristics women childbearing potential using contraception nursing women investigator temporarily permanently withdraw participant safety reason participants best interests participant lost follow participant cannot located investigator must make every effort reconnect participant document attempts source file least determine whether participant alive dead vital status searched national registry deaths thanks family first name date birth place residence participant exits prematurely withdraws consent data collected prior date premature exit may still used case premature exit way affect usual care condition case serious adverse events see corresponding section vigilance case report form must list various reasons participant discontinued lack efficacy adverse reaction another medical issue personal reasons participant explicit withdrawal consent lost follow replacement participants planned unblinded case suspected unexpected serious adverse event severe adverse event situation condition warrants knowing whether received hydrocortisone fludrocortisone practice unblinding requested reason considered essential investigating physician calling upon situations requiring unblinding emergency case suspected unexpected serious adverse event severe adverse event situation condition warrants knowing whether received hydrocortisone fludrocortisone poison control centre fernand widal hospital telephone 33 0 1 40 05 48 48 apart emergency situation délégation à la recherche clinique et à l’innovation research innovation department délégation à la recherche clinique et à l’innovation project advisor whose contact informations listed protocol cover page verification inclusion exclusion criteria demographics source infection severity illness saps ii sofa scores le gall 1993 vincent pre existing comorbidities defined charlson comorbidity index addendum 15 4 2 charlson 1994 frailty scale addendum 15 43 rockwood 2005 bagshaw 2014 muscedere 2017 core temperature vital signs central hemodynamic data available standard laboratory data including serum urinary electrolytes creatinine urea cholesterol triglycerides glucose levels arterial lactate levels arterial oxygen tension hemoglobin oxygen saturation arterial hydrogen ion concentration white blood cell counts hemoglobin hematocrit levels inr platelets count total bilirubin levels microbiolology virology e blood potential source infection sampled bacterial culture nasopharyngeal bronchial broncho alveolar lavage fluid sampled testing bypcr sars cov 2 influenza respiratory virus synacthen test e blood sample cortisol measurement immediately 30 60 minutes 250g intravenous bolus corticotrophin whole blood samples collected measurements biomarkers described wp3 wp4 blood samples managed within wp2 interventions mechanical ventilation renal replacement vasopressors unblinded corticosteroids thiamine vitamin c vitamins nutrition intravenous fluids blood products anticoagulants sedatives stress ulcer prophylaxis antimicrobials assessment cutaneous vasoconstrictor response glucocorticoids brown1991 subgroup cutaneous vasoconstrictor response glucocorticoids stratum test noninvasive easily performed bedside leave scar least 12 hours randomization least 12 hours randomization 60l betamethasone 0 05 cream ie dose 30g applied skin surface 2 33 cm diameter diameter 1 euro coin forearm single application full absorption cream 60l corresponds volume necessary cover surface 2 33 cm site occluded plastic degree blanching assessed 12 h blanching assessed semi quantitatively score 0 skin blanching 1 skin blanching less 50 area application 2 blanching thatn 50 area application 3 blanching whole area application 4 blanching beyond area application photo forearm restricted test zone recorded traceability photography strictly limited area skin treated betamethasone contain feature neither face distinctive feature tattoos piercings etc initial notification severe adverse event must provided written report signed investigator using severe adverse event notification form specific intended purpose case report form item form must completed investigator sponsor carry appropriate analysis initial notification sponsor serious adverse event must quickly followed additional detailed written report reports case outcome may monitored safety department research innovation delegation délégation à la recherche clinique et à l’innovation within assistance publique hôpitaux de paris provide information whenever possible investigator provide sponsor documents may useful medical reports laboratory test results results additional examinations etc documents must non identifying addition documents must include following acronym number participants initials adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even participant left initial notification severe adverse event follow reports documents must sent sponsor safety department email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction noted possible send severe adverse event reports safety department fax 33 0 1 44 84 17 99 event failed attempt send severe adverse event report email order avoid duplication uses e case report form investigator completes severe adverse event notification form e case report form validates prints signs form sending email possible connect e case report form investigator complete sign send severe adverse event notification form safety department soon connection restored severe adverse event notification form e case report form must duly completed investigator must respond requests sponsor additional information questions relating notification adverse event safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction computer file used research implemented accordance french amended informatique et libertes law governing data protection european general data protection regulation gdpr regulations research governed commission nationale informatique et libertés reference method medium risk 001 inclusion done emergency situation without obtaining consent time inclusion addition order recover vital status collection name marital name women first name date place birth required query national database snds systeme national des donnees de sante vital status living dead individual retrieved queryingthe national centre epidemiology deaths centre depidemiologie sur les causes de deces cepidc sponsor obtain authorisation commission nationale informatique et libertés french data protection agency implementing data processing involving data required conduct research 1 18 years old 2 admitted intensive care unit proven suspected infection main diagnosis 3 community acquired pneumonia related sepsis vasopressors dependency norepinephrine epinephrine vasopressin dopamine phenylephrine septic shock singer 2016 vasopressor maintain mean blood pressure least 65 mmhg lactate levels 2 mmol l acute respiratory distress syndrome ards ranieri 2012 acute onset e within one week apparent insult progression respiratory syndrome b bilateral opacities chest imaging explained pulmonary pathologies e g pleural effusion atelectasis nodules etc c evidence heart failure volume overload pao2 fio2 300 millimeter hg peep 5 cm h2o 4 signed informed written consent whevener able consent ascent representant whenever present time screening inclusion 5 tested one records specific biomarkers circi endocan gilz dusp 1 mdw lymphopenia transcriptomic srs2 endotype b pcr covd 19 pcr influenza pcr respiratory virus test cutaneous vasoconstrictor response glucocorticoids 6 affiliation social security system universal health coverage couverture maladie universelle cmu 7 guardianship curatorship included 8 case simple emergency legal definition included 1 pregnancy 2 expected death withdrawal life sustaining treatments within 48 hours 3 previously enrolled 4 formal indication corticosteroids according recent international guidelines 5 vaccination live virus within past 6 months 6 hypersensitivity hydrocortisone fludrocortisone microsined betamethasone dipropionate excipients summary of product characteristics 7 women childbearing potential using contraception 8 nursing women included stratum applicable apply cream infected ulcerated area multiple measures place data quality control measures include 1 site training research personnel 2 standard operating procedures guide storage administration drug well processing storage blood samples 3 ongoing assessment quality metrics periodic feedback sites performance benchmarking sites 4 site monitoring visits remotely person 5 ongoing review missing data outliers 6 rapid dissemination responses frequently asked questions via international website monthly newsletter coordinating centre personnel principal investigators available 24 7 answer related questions potential participants referred research team intensivists intensive care unit staff research team confirm eligibility site principal investigator co investigators confirm whether authorized persons may approached consent case research team obtain consent authorized persons enroll obtain consent subsequently per local reb recommendations deferred consent model daily data collected day 1 day 90 time intensive care unit discharge 3 6 months follow achieved telephone coordinating centre outcomes documented electronic crfs electronic case report form assigned unique identification used index case report form documents e case report form developed urc paris saclay ouest using dedicated software cleanweb verify data facilitate follow capture data site investigators assistants well online randomization access e case report form via internet secured username password data flow encrypted using https protocol data collected recorded permanently prospectively end processing requests database frozen transmitted statistics according procedures established promoter data captured real time case report form urc tec persons responsible quality control article l 1121 3 code de la sante publique french public health code take necessary precautions ensure confidentiality information relating investigational medicinal products participants particular identity results obtained persons well investigators bound professional secrecy accordance conditions set articles 226 13 226 14 code penal french criminal code research involving human participants data collected concerning participants sent sponsor investigators specialised collaborators rendered non identifying circumstances shall names addresses participants involved shown participants initials recorded accompanied encoded number specific indicating order enrolment sponsor ensure participant given written permission personal information strictly necessary quality control accessed,"antibiotic, sars, covid, participant, 19, cov, 21, 90, emergency, unit"
Etole_Protocole_V3-0_20151026_Propre_modif_accepted,3,-7.2210097,-27.73423,full title evaluation tomosynthesis characterization management breast acronym etole coordinating investigator professor cedric de bazelaire service de radiologie hopital saint louis paris tel 33 1 42 49 91 33 courriel cedric de bazelaire assistance publique hôpitaux de paris shortening fraction sponsor assistance publique hopitaux de paris rationale tomosynthesis innovative technique developed digital mammography obtaining sectional image breast mammography main disadvantage imaging projection creates overlays eliminates tomosynthesis objective primary endpoint evaluate birads classification obtained tomosythesis superior classification obtained conventional mammography terms specificity non inferior terms sensitivity joint analysis true negative false negative rates according birads scale compared histological results follow outcome see gold standard objectives secondary endpoints evaluate tomosynthesis synthetic tomography allows better detection certain signs poor prognosis malignant lesions size multicentricity tumour lymph node extension skin pectoral infiltration tomosynthesis synthetic tomography modifies number additional views number additional examinations including ultrasound breast magnetic resonance imaging biopsy assess whether tomosynthesis reduces necessary number ultrasound compare differences ratings birads obtained tomosynthesis synthetic mammography ultrasound differences obtained conventional mammography alone combined ultrasound tomosynthesis synthetic mammography changes radiation dose received tomosynthesis synthetic mammography improves reproducibility birads classification abnormalities costs analysis tomosynthesis synthetic mammography compared mammography mammography ultrasound experimental design randomized multi centric phase iii diagnostic according classification gluud gluud 1 inclusion phase 18 months tomosynthesis system installed site manufacturer breast imaging abnormally sites period given informed consent randomized either conventional mammography tomosynthesis 4 incidences synthetic mammography population concerned women breast imaging abnormalities inclusion criteria breast imaging abnormalities classified birads 3 4 5 table 1 5 18 years old signed informed consent non inclusion criteria high risk breast cancer mutations brca 1 2 carriers li fraumeni history thoracic radiation excluded greater sensitivity ionizing radiation 3 3 15 1 4 11 unable give informed consent physical mental legal reasons affiliated french social security insurance breast cancer mammography recommended according good practice french health authority pregnant diagnostic method evaluation tomosynthesis characterization management breast reference diagnostic method conventional digital mammography acts added research conventional digital mammography tomosynthesis added risks research risk b practical course referred abnormalities breast imaging center period agreeing participate informed consent randomized conventional digital mammography arm atomosynthesis armwith synthetic mammography randomization balanced groups stratified center pregnant high risk breast cancer followed breast cancer may included number subjects required 2000 subjects number centers 4 centers saint louis hospital tenon hospital lariboisiere hospital hegp research duration inclusion duration 18 month subject participation 24 month total duration 42 month number inclusions center per month saint louis hospital 70 tenon hospital 70 lariboisiere hospital 30 hegp 30 statistical analysis analysis comparison birads classifications obtained mammography tomosynthesis rely construction simultaneous confidence intervals ratios true negative rates specificity false negative rates 1 sensitivity obtained technics mammography tomosynthesis arm described alonzo others source de financement programme hospitalier de recherche clinique 12 070 data safety monitoring board data safety monitoring board yes hypothesis tomosynthesis synthetic image higher diagnostic value digital mammography use tomosynthesis real diagnostic value could remplace mammography reduce number additional examinations radiation dose hypothesis tomosynthesis synthetic mammography improves diagnostic performance compared conventional mammography tomosynthesis synthetic mammography real diagnostic value could reduce number additional examinations radiation dose evaluate birads classification obtained tomosynthesis synthetic mammography superior classification obtained conventional mammography terms specificity non inferior terms sensitivity evaluate tomosynthesis synthetic mammography allows better detection certain signs poor prognosis malignant lesions size multicentricity tumour lymph node extension skin pectoral infiltration tomosynthesis synthetic mammography modifies number additional views number additional examinations including ultrasound breast magnetic resonance imaging biopsy would like evaluate whether birads classification obtained mammography ultrasound superior birads classification obtained tomosynthesis synthetic mammography birads classification obtained tomosynthesis synthetic mammography ultrasound superior combinations terms specificity non inferior terms sensitivity tomosynthesis synthetic mammography changes radiation dose received tomosynthesis synthetic mammography improve reproducibility birads classification anomalies detected clinically mammographically costs analysis tomosynthesis compared mammography mammography ultrasound joint analysis true negative false negative rates according birads scale compared histological result follow outcome see gold standard adverse events occurring inform consent form signed whether attributed investigational product reported case report form medically significant adverse events considered related investigational product investigator sponsor followed resolved considered stable following attributes must assigned investigator description dates onset resolution severity assessment relatedness investigational product action taken investigator may asked provide follow information left investigators judgment whether adverse event sufficient severity require subjects removal subject may also voluntarily withdraw due perceives intolerable adverse event either occurs subject must undergo end assessment given appropriate care medical supervision symptoms cease condition becomes stable subject permanently withdrawn investigational product due serious adverse event information must included either initial follow serious adverse event report form eos case report form severity adverse events assessed using common terminology criteria adverse events common terminology criteria for adverse events serious adverse events must reported sponsor ap hp within one working day discovery notification event initial serious adverse event information amendments additions must recorded serious adverse event report form faxed sponsor sponsor ap hp drcd fax 01 44 84 17 99 sponsor inform relevant regulatory authorities ethics committee relevant information serious unexpected adverse events suspected related device procedure use device fatal life threatening soon possible case later seven days knowledge case relevant follow information cases subsequently submitted within additional eight days serious unexpected events suspected related medication soon possible within maximum fifteen days first knowledge investigator research assistants clinical research associates representing sponsor perform investigating visits intervals matching monitoring enrollments risk level attributed research sponsor opening visit enrollments establish protocol familiarization various stakeholders biomedical research following visits electronic case report forms electronic case report form reviewed clinical research associates according state advancement research principal investigator investigators agreed receive cras regular intervals visits according good practice following elements reviewed protocol research procedures respected verification informed consent review source documents comparison data reported electronic case report form accuracy missing data data consistency according drcd rules final visit retrieval electronic case report form biomedical research documents archiving outside visits clinical research associates disposal investigators meet needs information advice technician cst recruited assist project compliance protocol circuits well filling electronic case report form recruitment centers information required protocol provided electronic case report form investigator case missing data give explanation data must recorded electronic case report form soon obtained non data signed informed consent breast imaging abnormalities classified birads 3 4 5 table 1 5 18 years old high risk breast cancer mutations brca 1 2 carriers li fraumeni history thoracic radiation excluded greater sensitivity ionizing radiation 11 unable give informed consent physical mental legal reasons affiliated french social security insurance breast cancer mammography recommended according good practice french health authority pregnant items defined chapter 0 filled investigator radiologists including initials first name last name number date place birth prior medical surgical history interest electronic case report form created collect data documents law biomedical research must archived 15 years end research see bpc chapter 8 essential documents indexed archive includes copies letter authorization agence nationale de sécurité du medicament et des produits de santé mandatory opinion comité de protection des personnes successive versions protocol identified version number date correspondences sponsor signed consent forms sealed storage list register enrollments electronic case report form completed validated appendices specified final report statistical analysis quality control double forwarded sponsor audit certificates audits done research reports independent safety committee charge monitoring total radiation dose database statistical analysis also archived person responsible analysis paper computer,"mesenchymal, stromal, cells, breast, radiation, sclerosis, conventional, diagnostic, ultrasound, dose"
TEOREM_protocole-v6_20220306,2,-18.20221,8.565635,full title multicenter randomized double blind assessing benefit adherent invasive e coli eradication adult ileal ileo colonic crohn disease acronym teorem coordinating investigator dr franck carbonnel gastroenterology department kremlin bicetre hospital 78 rue du general leclerc 94275 le kremlin bicetre sponsor assistance publique hopitaux de paris scientific justification current medical crohn disease cd consists immunosuppressive drug therapy corticosteroids azathioprine methotrexate anti tnf monoclonal antibodies agents control symptoms cd withdrawal leads disease relapse also associated serious side effects infections lymphoma cancer liver toxicity anti tnf monoclonal antibodies efficient cost prohibitive moreover year roughly 10 responders anti tnf become refractory often become tolerized drugs future cd drugs small molecules biologics antagonize pro inflammatory cytokines gut homing lymphocytes yet similar safety issues immunosuppressive agents currently use current therapeutic algorithm cd take account site inflammation composition intestinal microbiota moreover dysregulated intestinal immunity overproduction pro inflammatory cytokines components cd pathophysiology intestinal microbiota abnormal plays important role pathogenesis cd e coli specie adhesive invasive properties adherent invasive e coli aiec described ileal mucosa cd aiec found 36 ileal cd 6 controls role aiec cd thoroughly investigated several laboratories around world shown aiec pro inflammatory could play important role intestinal inflammation associated cd 1 may important therapeutic target randomized proposes novel approach cd individualized colonized aiec prescribed fda approved antibiotics shown active bacteria vitro discontinued 12 weeks hope obtain endoscopic remission randomized experimental arm successful first kind facilitate new era research cd concomitant infection aiec primary objective assessment criterion primary objective assess whether 12 week ciprofloxacin rifaximin superior placebo obtain endoscopic remission aiec colonized ileal cd without involvement caecum right colon primary endpoint overall response week 12 using centralized anonymous blinded reading ileocolonoscopies overall response defined segmental response least one segment cdeis 8 baseline 20 increase cdeis segment cdeis 8 segment segmental response segment cdeis 8 baseline defined case isolated aphtoid ileitis colitis decrease 50 lesions otherwise either decrease 50 surface ulcerations either deep superficial loss deep ulcerations present inclusion 20 increase superficial ulcerated surface secondary objectives assessment criteria secondary objectives test correlation endoscopic remission aiec eradication 12 weeks assess evolution endoscopic lesions week 12 assess rate remission without steroids anti tnf surgery 48 weeks whose aiec eradicated reached primary endpoint assess rate biological remission assess side effects experimental placebo group secondary endpoints endoscopic remission 12 weeks assessed centralized reading ileocolonoscopies defined cdeis 6 segments mean variation segmental cdeis 12 weeks centralized reading ileocolonoscopies complete endoscopic remission 12 weeks centralized reading ileocolonoscopies defined cdeis 3 segments ulceration 12 weeks remission defined cdai 150 without steroids anti tnf resection surgery cd 12 48 week biological remission defined c reactive protein serum level 5 milligrams l fecal calprotectin 250 g g week 4 8 12 24 36 48 side effects experimental design phase ii multicentre prospective randomized double blind placebo controlled adaptive two parallel arms experimental arm oral ciprofloxacin 500 milligrams twice a day oral rifaximin 800 milligrams twice a day 12 weeks control arm placebo ciprofloxacin twice a day placebo rifaximin twice a day 12 weeks population involved cd adult infected aiec preinclusion criteria age 18 75 years cd ileum without involvement caecum right colon severe lesions confined within ileum right colon defined segmental cdeis 8 ileum right colon segmental cdeis 8 segments transverse left colon rectum informed consent participate cd either clinically inactive active severe cdai 450 clinically active disease cdai 150 prescription steroid treatments budesonide prednisone prednisolone independently entry note without previous surgery cd without cd anal lesions without draining fistulas setons enrolled inclusion criteria clinically active disease cdai 150 respond budesonide initial dose 9 milligrams prednisone prednisolone initial dose 40 milligrams 70 points decrease cdai pre inclusion inclusion visit clinically inactive disease cdai 150 colonized aiec initial ileal biopsies non preinclusion non inclusion criteria ileal stenosis cannot crossed endoscope methotrexate azathioprine infliximab adalimumab initiated less three months preinclusion vedolizumab ustekinumab initiated less six months preinclusion discontinuation dosage modification methotrexate azathioprine infliximab adalimumab vedolizumab ustekinumab less three months preinclusion hypersensitivity ciprofloxacin quinolones excipients cellulose microcrystalline crospovidone maize starch magnesium stearate silica colloidal anhydrous hypromellose titanium dioxide e171 macrogol 4000 tizanidine probenecid theophylline xanthine derivatives phenytoin oral anticoagulants ropinirole hypersensitivity rifaximin excipients sodium starch glycolate type glycerol distearate colloidal anhydrous silica talc microcrystalline cellulose hypromellose titanium dioxide disodium edentate propylene glycol red iron oxide e172 previous extensive ileal surgery 1 meter measured pathology surgical report short bowel syndrome need intestinal resection fistula abscess intestinal obstruction renal failure creatinine clearance 30 ml min 1 73m2 liver failure v factor 50 past history epilepsy aortic aneurysm dissection atherosclerosis hypertension one pathology congenital pre existing disease cardiac valves connective tissue disorders marfan syndrome ehlers danlos syndrome turners syndrome behcets disease rheumatoid arthritis infectious endocarditis health insurance pregnant lactating women refusal double effective contraception ie hormonal barrier method intrauterine device barrier method double barrier method highly effective methods contraception hormonal contraceptives e g combined oral contraceptives patch vaginal ring injectables implants intrauterine device intrauterine device intrauterine system ius vasectomy tubal ligation effective methods barrier methods contraception e g male condom female condom cervical cap diaphragm contraceptive sponge already included biomedical research observational e g registry cohort tested association two antibiotics oral ciprofloxacin tablets 500 milligrams every 12 hours 12 weeks oral rifaximin tablets 200 milligrams 800 milligrams every 12 hours 12 weeks benchmark association two placebos placebo corresponding antibiotic manufactured tablet appearance administrated every 12 hours 12 weeks procedures added research ciprofloxacin rifaximin placebos 6 additional biopsies including 4 biopsies ileum right colon 2 aiec search 2 biological collection 2 biopsies rectum aiec search 1st ileocolonoscopy ileocolonoscopy week 12 including 6 additional biopsies fecal microbiota using pcr 16s screening fecal aiec lpf risks added research risk c practical procedure 252 cd screened realize biopsies check infection aiec bacteria 62 evaluable anticipated infected bacterium responding eligibility criteria included randomized experimental arm rifaximin ciprofloxacin control double placebo arm ileocolonoscopy biopsies made week 12 research aiec infection thereby assess eradication bacteria taking drugs placebos bacterial infection also sought stool samples number subjects chosen 252 screened needed average obtain 62 randomized number centres 26 research period period inclusion 63 months period pre inclusion 3 months maximum duration participation follow 13 months total duration 79 months number inclusions expected centre month 0 03 statistical analysis data analyzed intent treat basis based upon adaptive scheme allowing estimation required number included sample size estimation ssr design taking account uncertainty endoscopic remission rate week 12 placebo arm thus one interim unblind statistical analysis performed 16 successively enrolled primary endpoint analysis concerns comparison main end point ie percentage endoscopic remission group compared using chi square test unless validity violated fisher exact used secondary endpoints analyzed whole sample size reached funding source broad medical research program mayoly spindler alpha wassermann programme hospitalier de recherche clinique national data safety monitoring board anticipated crohns disease cd chronic inflammatory bowel disease affecting approximately one million people europe including 100 000 france 700 000 united states affected teenagers young adults cd altered quality life increased mortality rate 30 50 compared age matched controls cd undergo intestinal resection least generally complication intestinal obstruction abscess fistula intestinal carcinoma current medical cd consists immunosuppressive drug therapy corticosteroids azathioprine methotrexate anti tnf monoclonal antibodies agents control symptoms cd withdrawal leads disease relapse also associated serious side effects infections lymphoma cancers liver toxicity anti tnf monoclonal antibodies efficient cost prohibitive moreover year roughly 10 responders anti tnf become refractory often become tolerized drugs future cd drugs small molecules biologics antagonize pro inflammatory cytokines gut homing lymphocytes yet similar safety issues immunosuppressive agents currently use current therapeutic algorithm cd take account site inflammation composition intestinal microbiota number fundamental investigated biology aiec role cd role aiec cd discovered laboratory pr arlette darfeuille michaud scientific coordinator project died june 2014 successor dr nicolas barnich head lab scientific coordinator project lab reliably analyse biopsy specimens presence aiec results obtained 30 days less several trials investigated efficacy antibiotics cd none individualized colonized aiec present first kind attempts eradicate aiec aim treat cd individualized colonized aiec prescribed antibiotics active bacteria vitro antibiotics ciprofloxacin rifaximin fewer side effects immunosuppressive used first line cd may safer alternative immunosuppressive therapy colonized aiec primary hypothesis validated first evidence eradication particular bacteria species antibiotic lead remission cd currently cd treated immunosuppressive treatments including anti tnf drugs associated harmful side effects opportunistic infections rarely lymphoma addition approximately 10 loose response anti tnf year antibiotics ciprofloxacin rifaximin fewer side effects immunosuppressive used first line cd may safer alternative immunosuppressive therapy concomitantly colonized aiec antibiotic cd colonized aiec efficient likely go prolonged remission without steroids immunosuppressants avoid hospitalizations surgeries better quality life also antibiotic therapy cost much less immunosuppressive therapies reduce healthcare costs objectives crohns disease cd chronic inflammatory bowel disease intestinal microbiota composed several billions microbes healthy adults dysregulated intestinal immunity overproduction proinflammatory cytokines components cd pathophysiology intestinal microbiota abnormal plays important role pathogenesis cd e coli specie adhesive invasive properties adherent invasive e coli aiec described ileal mucosa cd aiec found 36 ileal cd 6 controls role aiec cd thoroughly investigated several laboratories around world shown aiec proinflammatory could play important role intestinal inflammation associated cd 1 may important therapeutic target research hypothesis antibiotics targeting aiec ciprofloxacin rifaximin achieve mucosal healing cd colonized aiec primary hypothesis validated first evidence eradication particular bacteria species antibiotic lead remission cd results confirmed cd aiec benefit antibiotic terms prolonged remission without use immunosuppressants future trials determine optimal duration biomarkers early response recolonization rate replication results larger scale randomized proposes novel approach cd individualized colonized aiec prescribed fda approved antibiotics shown active bacteria vitro discontinued 12 weeks hope obtain endoscopic remission randomized experimental arm primary objective assess whether 12 week ciprofloxacin rifaximin superior placebo obtain endoscopic remission aiec colonized ileal cd without involvement caecum right colon endoscopic remission chosen primary endpoint associated improvement cd evolution midterm test correlation endoscopic remission aiec eradication week 12 assess evolution endoscopic lesions week 12 assess rate remission without steroids anti tnf surgery 48 weeks whose aiec eradicated reached primary endpoint assess rate biological remission assess side effects experimental placebo group ancillary characteristics aiec compared aiec screened effect antibiotics placebo upon fecal mucosal microbiota assessed using pcr 16s inclusion week 12 week 48 correlated primary secondary endpoints allow assess effects antibiotics upon dysbiosis lead microbiota signature associated endoscopic remission search aiec lpf using pcr within stool specimens performed screening visit week 12 week 48 aimed correlate mucosal fecal aiec well fecal aiec endoscopic remission research plan primary endpoint overall response week 12 assessed panel getaid expert endoscopists using centralized anonymous blinded reading ileocolonoscopies investigator centre anonymisation ileocolonoscopies recorded dvd usb keys dedicated internet platform overall response defined segmental response least one segment cdeis 8 baseline 20 increase cdeis segment cdeis 8 segment segmental response segment cdeis 8 baseline defined case isolated aphtoid ileitis colitis decrease 50 lesions otherwise either decrease 50 surface ulcerations either deep superficial loss deep ulcerations present inclusion 20 increase superficial ulcerated surface crohns disease endoscopic index severity cdeis validated score endoscopic severity cd mary jy modigliani r gut 1989 30 983 9 segmental cdeis adapted included cd limited ileum right colon preinclusion criteria cdeis 8 definition endoscopic response remission defined jy mary segmental cdeis measured endoscopist ileocolonoscopy performed preinclusion visit week 12 two ileocolonoscopies 4 ileal biopsies taken 2 aiec search 2 biological collection edge ulcerations 2 rectal biopsies taken aiec search primary endpoint assessed week 12 randomization least 18 weeks start budesonide prednisone prednisolone lasts 12 weeks therefore moment primary endpoint stopped budesonide avoid interaction steroids budesonide prednisone prednisolone antibiotics endoscopist perform ileocolonoscopy preinclusion visit week 12 ileocolonoscopies performed within gastroenterology unit secondary endpoints endoscopic remission 12 weeks assessed centralized anonymous blinded reading ileocolonoscopies defined cdeis 6 segments mean variation segmental cdeis 12 weeks assessed centralized anonymous blinded reading ileocolonoscopies complete endoscopic remission 12 weeks assessed centralized anonymous blinded reading ileocolonoscopies defined cdeis 3 segments ulceration 12 weeks remission defined cdai 150 without steroids anti tnf resection surgery cd 12 48 week biological remission defined c reactive protein serum level 5 milligrams l fecal calprotectin 250 g g week 4 8 12 24 36 48 side effects unblinding requested reason considered essential investigating doctor calling upon délégation à la recherche clinique et à l’innovation situation emergency work day working hours addressed délégation à la recherche clinique et à l’innovation project referent isabelle vivaldo tel 33 1 40 27 57 24 poison centre fernand widal hospital case emergency see emergency situations requiring unblinding weekends bank holidays délégation à la recherche clinique et à l’innovation closed unblinding cannot carried délégation à la recherche clinique et à l’innovation telephone 33 1 40 05 48 48 procedure research examination act related research investigator collects free informed written consent undergoing research 9 1 1 definitions according article r1123 39 french public health code guideline good pharmacovigilance practices european medicines agency 2012 adverse event untoward medical occurrence subject administered medicinal product necessarily causal relationship adverse reaction adverse event occurred subject causal relationship investigational product adverse reaction investigational medicinal product untoward unintended responses investigational medicinal product related dose administered serious adverse event reaction adverse event reaction dose medication results death threatens life research subject requires hospitalisation prolongs hospitalisation causes severe long term disability handicap results congenital abnormality deformity unexpected adverse reaction investigational medicinal product adverse reaction product whose nature severity frequency outcome inconsistent safety information described reference safety information summary product characteristics investigator brochure product authorised according notice sponsors trials medications agence nationale de sécurité du medicament et des produits de santé emerging safety issue new safety information may lead reassessment risk benefit ratio investigational medicinal product modifications investigational medicinal product use conduct documents suspension interruption modification protocol similar trials trials involving first administration use investigational medicinal product healthy volunteers serious adverse reaction examples clinically significant increase frequency expected serious adverse reaction occurring b suspected unexpected serious adverse reactions susar occurring finished sponsor notified investigator also provides follow reports c new fact relating conduct development experimental medication new fact likely affect participant safety examples serious adverse event likely related investigations diagnostic procedures could modify conduct significant risk participants ineffectiveness experimental medication used treating life threatening illness significant safety results recently completed research carried animals carcinogenicity research premature termination temporary interruption conducted experimental medication another country safety reasons unexpected serious adverse reaction associated non experimental medication required carrying e g challenge agents rescue unexpected serious adverse reaction reported sponsor another sponsor carried different country relating medication notification severe adverse event must initially provided written report using special form reporting severe adverse event see appendix 2 report must signed investigator item form must completed investigator sponsor carry appropriate analysis initial notification must followed one detailed follow report writing signed within maximum 8 days case fatal life threatening event within 15 days cases whenever possible investigator provide sponsor documents may useful medical reports laboratory test results results additional exams etc documents must made anonymous addition documents must include following research acronym number initials subject nature date serious adverse event adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even subject left initial report severe adverse event follow reports documents must sent sponsor e mail événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction sponsors safety department possible send severe adverse event safety department fax sponsors safety department fax 33 0 1 44 84 17 99 case unsuccessful attempt send severe adverse event e mail order avoid duplicates investigator must comply requests sponsor additional information questions relating notification adverse event vigilance division délégation à la recherche clinique et à l’innovation contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction utero exposure investigator completes form monitoring pregnancy developed biomedical research found appendix 3 sends fax vigilance division 01 44 84 17 99 investigator must monitor pregnant woman throughout pregnancy pregnancy terminated must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage pregnancy termination foetal death congenital abnormality etc investigator must follow procedure reporting severe adverse event exposure involves father investigator must obtain mother permission collecting information pregnancy initial pregnancy notification severe adverse event follow reports documents must sent sponsor mail événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction computer file used research implemented accordance french data protection act european general data protection regulation rgpd compliance medium risk 001 reference methodology falls framework reference methodology personal data processing operated context biomedical research medium risk 001 modified sponsor ap hp signed commitment comply reference methodology preinclusion criteria age 18 75 years cd ileum without involvement caecum right colon severe lesions confined within ileum right colon defined segmental cdeis 8 ileum right colon segmental cdeis 8 segments transverse left colon rectum informed consent participate cd clinically inactive cdai 150 clinically active severe cdai 450 clinically active disease cdai 150 prescription steroid treatments budesonide prednisone prednisolone independently entry note without previous surgery cd without cd anal lesions without draining fistulas setons enrolled inclusion criteria clinically active disease cdai 150 respond budesonide initial dose 9 milligrams prednisone prednisolone initial dose 40 milligrams 70 points decrease cdai preinclusion inclusion visit clinically inactive disease cdai 150 colonized aiec initial ileal biopsies testing aiec performed phenotypic analysis interaction bacteria intestinal epithelial cells well macrophages umr inserm universite dauvergne laboratory pr nicolas barnich clermont ferrand france biopsies ileal mucosa taken ileocolonoscopy cultured selective medium enterobacteriaceae identification bacteria performed confirmation e coli species five colonies sampled analysed adhesive invasive properties 407 epithelial cells culture well survival multiplication thp 1 macrophages aiec defined e coli able adhere invade epithelial cells divide within macrophages previous results presented aiec aiec see appendix 8 ileal stenosis cannot crossed endoscope methotrexate azathioprine infliximab adalimumab initiated less three months preinclusion vedolizumab ustekinumab initiated less six months preinclusion discontinuation dosage modification methotrexate azathioprine infliximab adalimumab vedolizumab ustekinumab less three months preinclusion hypersensitivity ciprofloxacin quinolones excipients cellulose microcrystalline crospovidone maize starch magnesium stearate silica colloidal anhydrous hypromellose titanium dioxide e171 macrogol 4000 tizanidine probenecid theophylline xanthine derivatives phenytoin oral anticoagulants ropinirole hypersensitivity rifaximin excipients sodium starch glycolate type glycerol distearate colloidal anhydrous silica talc microcrystalline cellulose hypromellose titanium dioxide disodium edentate propylene glycol red iron oxide e172 previous extensive ileal surgery 1 meter measured pathology surgical report short bowel syndrome need intestinal resection fistula abscess intestinal obstruction renal failure creatinine clearance 30 ml min 1 73m2 liver failure v factor 50 past history epilepsy aortic aneurysm dissection atherosclerosis hypertension one pathology congenital pre existing disease cardiac valves connective tissue disorders marfan syndrome ehlers danlos syndrome turners syndrome behcets disease rheumatoid arthritis infectious endocarditis health insurance pregnant lactating women refusal double effective contraception ie hormonal barrier method intrauterine device barrier method double barrier method highly effective methods contraception hormonal contraceptives e g combined oral contraceptives patch vaginal ring injectables implants intrauterine device intrauterine device intrauterine system ius vasectomy tubal ligation effective methods barrier methods contraception e g male condom female condom cervical cap diaphragm contraceptive sponge already included biomedical research observational e g registry cohort responsible biomedical research quality control article l 1121 3 french public health code take necessary precautions ensure confidentiality information experimental medications research research subjects particular identity subjects results obtained individuals well investigators subject professional secrecy accordance conditions set articles 226 13 226 14 penal code biomedical research data collected research subjects sent sponsor investigators specialised parties made non identifying circumstances names addresses subjects involved shown initials first last names research coded number recorded sponsor ensure research subject given permission writing access personal information strictly necessary quality control research data entered service de biostatistique et information médicale saint louis hospital assistance publique hôpitaux de paris staff dedicated task via independent duplicate data entry forms collecting anonymised data data handling storage done interim analysis made 16 randomized included see details point 11 2 terminal analysis deal end points based population randomized followed 12 weeks first descriptive analysis first conducted following parameters characteristics control experimental groups estimation primary secondary endpoints qualitative data described frequency percentage represented using histograms diagrams distribution quantitative data described using calculations median inter quartile range iqr toxicities rate calculated given 95 confidence intervals 95ci primary secondary end points compared across randomized arms statistical tests models adapted criterion comparison continuous end points based non parametric wilcoxon rank sum test comparison binary end points use chi square exact fisher test comparison right censored end points use log rank test semi parametric proportional hazards models unless competing risks gray test used together cause specific cox model last secondary analyses performed measure correlation endoscopic remission aiec eradication aiec within ileal biopsies 12 weeks well association remission without steroids immunosuppressives anti tnf surgery aiec eradication 48 week logistic models used testing interaction arm tests two sided defining statistical significance,"week, uveitis, bd, vasculitis, cd, adalimumab, disease, 16, remission, tocilizumab"
2022-001316-26_PROTOCOLE_v5-0_20240402-UVB_signé,2,-15.408943,26.96362,full title multicenter randomized prospective comparing efficacy safety adalimumab tocilizumab severe uveitis behcets disease acronym uvb uveitis behcets diseases biologics eu ct number 2024 513371 41 00 coordinating investigator pr bahram bodaghi department ophthalmology centre national de reference des uveites centre national de reference des maladies autoinflammatoires et de lamylose inflammatoire hospital pitie salpetriere tel 01 42 16 37 28 email bahram bodaghi assistance publique hôpitaux de paris shortening fraction scientific director pr david saadoun department internal medicine immunology centre national de reference des maladies autoimmunes systemiques rares centre national de reference des maladies autoinflammatoires et de lamylose inflammatoire pitie salpetriere hospital 43 boulevard de lhopital 75013 paris tel 01 42 17 80 88 email david saadoun assistance publique hôpitaux de paris shortening fraction sponsor assistance publique hopitaux de paris scientific justification uvb first randomized prospective head head comparing adalimumab tocilizumab sight threatening uveitis bd anti tnf used bd uveitis 15 years incidence blindness bd dramatically reduced recent years use biologics firm evidence randomized controlled trials directly addressing best induction therapy severe bd uveitis bd uveitis considered devastating inflammatory ocular disease risk visual loss reaches 25 5 years 80 bilateral involvement contrasting immunosuppressors interferon alpha biotherapies act rapidly highly effective steroids sparing thus preventing occurrence cataract glaucoma however anti tnf failed demonstrate sustainable complete remission 50 severe sight threatening uveitis little published information use biologics anti tnf severe bd uveitis tocilizumab used success severe resistant cases one promising biologics bd il 6 expression correlates bd activity immunological data provide strong rationale targeting bd tocilizumab despite strong rationale compounds yet approved bd guarantees innovative nature aims selecting dropping arm evidence efficacy already exists main objective primary endpoint assess benefit tocilizumab comparatively adalimumab sight threatening behcets disease uveitis week 16 primary endpoint efficacy defined complete remission ocular involvement complete resolution retinal vasculitis macular edema prednisone prednisolone prednisone stock market lower equal 5 milligrams day week 16 randomization secondary objectives endpoints estimate compare change best corrected visual acuity best corrected visual acuity time complete remission week 4 8 12 24 36 48 evaluate compare safety adalimumab tocilizumab evaluate compare change macular edema evaluate compare change signs ocular inflammation evaluate compare effect retinal vessel leakage evaluate compare effect adalimumab tocilizumab steroid sparing evaluate compare change ocular inflammation anterior chamber evaluate compare number time relapse uveitis characteristics uveitis worsening evaluate compare time failure considered failure following criteria met least 1 eye new active inflammatory retinal vascular lesions macular edema worsening best corrected visual acuity best corrected visual acuity 3 lines 2 step increase anterior chamber ac cell grade 2 step increase vitreous haze vh grade relative baseline estimate compare effect extra ophthalmologic manifestations behcets disease estimate compare mean change sf 36 quality life behcets disease quality life measure bd quality of life estimate compare changes behcets disease current activity form bdca behcets syndrome activity score bsas secondary endpoints measures corticosteroid sparing e g percent meeting targets lower 0 1 milligrams day kilograms prednisone prednisolone prednisone stock market mean dose week 16 cumulative dose time response onset measures acute phase reactants erythrocyte sedimentation rate esr c reactive protein c reactive protein week 4 8 12 16 24 36 48 rate time occurrence relapse worsening relapse defined reappearance paraclinical features active disease occurrence new lesions progression preexisting lesions changes behcets disease current activity form bdca week 8 16 24 changes behcets syndrome activity score bsas week 16 changes organs involved bd week 4 8 12 16 24 36 48 changes quality life quality of life sf36v2 tm health survey behcets disease quality life measure bd quality of life week 16 24 safety tolerability treatments bd assessed frequency severity adverse events week 4 8 12 16 24 36 48 time failure time occurence changes tyndall flare vitreous haze week 8 16 24 36 48 changes best corrected visual acuity snellen score week 8 16 24 36 48 changes central retinal thickness measured optical coherence tomography optical coherence tomography week 8 16 24 36 48 percentage central retinal thickness 300 microns week 8 16 24 36 48 percentage without retinal vessel leakage retinal angiography week 16 week 24 36 48 case retinal vasculitis design bayesian design phase ii randomized aims comparing new reference based binary end point offers greater flexibility simplicity inference monitoring safety evidence efficacy small randomized trials category cat 2 phase 2 population participants adult sight threatening behcets disease associated uveitis inclusion criteria age 18 inclusion provide written informed consent prior performance specific procedures diagnosis behcets disease according international criteria behcet disease icbd see appendix 18 2 history aphtosis diagnosis non infectious intermediate posterior pan uveitis least one eye fulfilling international group classification criteria standardization uveitis nomenclature standardization of uveitis nomenclature criteria posterior pan uveitis sight threatening uveitis defined according validated international definition 2 lines drop visual acuity 10 10 scale retinal inflammation macular oedema retinal vasculitis chest x ray postero anterior lateral ct scanner results within 12 weeks prior inclusion evidence active tuberculosis active infection malignancy female subjects childbearing potential premenopausal female capable becoming pregnant negative serum pregnancy test plasmatic urinary subjects reproductive potential willingness use contraceptive measures adequate prevent subject subjects partner becoming pregnant 3 5 months stopping therapy tocilizumab adalimumab respectively birth control methods may considered highly effective methods achieve failure rate less 1 per year used consistently correctly considered highly effective birth control methods according ctfg recommendations methods include female subjects combined estrogen progestogen containing hormonal contraception associated inhibition ovulation oral intravaginal transdermal progestogen hormonal contraception associated inhibition ovulation oral injectable implantable intrauterine device intrauterine device intrauterine hormone releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence context guidance sexual abstinence considered highly effective method defined refraining heterosexual intercourse entire period risk associated treatments reliability sexual abstinence needs evaluated relation duration preferred usual lifestyle subject male subjects use condom vasectomy documentation azoospermia sexual abstinence negative tuberculosis test obtained within 12 weeks prior inclusion potential subject positive interferon gamma release assay igra e g quantiferon tuberculosis gold spot tuberculosis test eligible chest x ray show evidence suggestive active tuberculosis disease signs symptoms pulmonary extra pulmonary tuberculosis disease subjects latent tuberculosis infection already received prophylactic tuberculosis must agree advance complete course started latest inclusion affiliation social security system affiliated universal medical coverage cmu eligible non inclusion criteria infectious uveitis masquerade syndromes uveitis due causes bd uveitis active tuberculosis history untreated tuberculosis severe infection positive human immunodeficiency virus antibody positive hepatitis b surface antigen positive hepatitis c rna results obtained within 1 month prior inclusion history malignancy within 5 years prior inclusion carcinoma situ cervix non metastatic squamous basal cell carcinoma skin history severe allergic anaphylactic reactions monoclonal antibodies history multiple sclerosis demyelinating disorder hypersensitivity active substance excipient investigational medicinal product auxiliary medicine active suspected ocular infection active suspected systemic infection history intestinal ulceration diverticulitis known porphyria laboratory values assessed inclusion neutrophil 1 0 103 cubic millimeter platelet count 80 103 cubic millimeter aspartate amino transferase alanine-aminotransferase 5 upper limit of normal anti tnf tocilizumab therapy within 1 month prior inclusion azathioprine mycophenolate mofetil methotrexate time inclusion drugs must withdrawn prior receiving tocilizumab adalimumab dose day 0 stage iii intravenous infusion new york heart association “new york heart association” cardiac insufficiency severe renal glomerular filtration rates gfr 30ml min liver insufficiency prothrombin 50 without causes live attenuated vaccine within 30 days prior inclusion breastfeeding pregnant women investigational medicinal product collection free informed consent eligible sight threatening behcets disease uveitis randomized one 2 groups randomization visit day 0 arm adalimumab 80 milligrams day 0 40 milligrams subcutaneous week 1 3 5 7 9 11 13 15 arm b tocilizumab 162 milligrams subcutaneous week 15 weeks comparator applicable interventions added visit internist week 4 12 visit ophthalmologist week 4 12 hcg urinary visit monthly 3 5 months stopping therapy tocilizumab adalimumab respectively optical coherence tomography optical coherence tomography w 8 retinal angiography week 24 case retinal vasculitis quality of life questionnaires day 0 16 24 weeks expected benefits participants society bd uveitis considered devastating inflammatory ocular disease anti tnf rapidly acting agent compared methylprednisolone interferon alpha suppressing ocular inflammation however failed demonstrate sustainable complete remission 50 also tnfa antagonists seems suspensive effect ocular inflammation bd tocilizumab used success severe resistant cases one promising biologics bd rapid onset action steroid sparing effect characterize efficacy tocilizumab nowadays management severe bd still remains largely empirical first randomized head head therapeutic management severe uveitis bd biologics may assess benefit tocilizumab comparatively adalimumab sight threatening behcets disease terms safety efficacy steroid sparing could thus improve care bd uveitis general expected benefit individual reducing morbidity rate blindness young bd collective reducing costs hospitalization dependence risks burdens added risks associated toxicities investigational drugs risks associated use contrast medium retinal angiography risk level risk c practical implementation collection free informed consent eligible active sight threatening behcets disease uveitis randomized one 2 groups randomization visit day 0 arm adalimumab 80mg day 0 40 milligrams subcutaneously week 1 3 5 7 9 11 13 15 arm b tocilizumab 162mg subcutaneously every week 15 weeks groups receive corticosteroid regimen receive oral prednisone prednisolone prednisone stock market 1 milligrams kilograms day 80 milligrams day randomization following schedule reduction prednisone prednisolone prednisone stock market apply groups long disease inactive 1 milligrams kilograms day maximum 80 milligrams week day 0 week 4 40 milligrams day week 4 week 6 30 milligrams day week 6 week 8 20 milligrams day week 8 week 10 15 milligrams day week 10 week 12 10 milligrams day week 12 week 14 5 milligrams day week 14 week 16 dose corticosteroids left investigator discretion week 16 number participants included 60 30 arm number sites multicenter national including 26 centers duration inclusion period 36 months participation period follow 12 months total duration 48 months number enrolments expected per site per month 0 07 statistical analysis experimental design open multicenter randomized stratified characteristics initial uveitis behcets disease retinal inflammation retinal vascularitis macular edema according diagnosis newly diagnosed relapsing disease evaluation primary assessment criteria 16 weeks primary assessment criteria reviewed scientific committee blinded randomization rct use bayesian design phase ii randomized national multicenter aims comparing new reference based binary endpoint e complete remission week 16 offers greater flexibility simplicity inference monitoring safety evidence efficacy small randomized trials use beta binomial model non informative prior berry 2006 posterior probability remission rate least 0 65 estimated arms probability rate remission arm b arm computed b indicating tocilizumab group adalimumab group use bayesian inference framework denotes probability remission arm inclusion na arm ya complete remission observed using beta prior posterior probability still beta distribution given due natural conjugate property beta family binomial sampling setting efficacy drug arm first assessed comparison historical minimal value interest sometimes called minimum required remission rate set 0 65 thus compute similar analyses performed arm b however randomized phase ii settings selection new drug mostly based evaluating potential benefits experimental treatments thus one may consider dropping new drug rather low posterior probability drug beneficial targeted minimal level done computing posterior probability difference remission rates two experimental arms kawasaki 2012 greater zero b tocilizumab group adalimumab group consider bayesian design interim analysis performed without alpha spending inclusion 30 0 80 0 80 0 80 stopped 0 10 0 10 corresponding arm stopped following included arm 0 10 0 10 stopped sources funding programme hospitalier de recherche clinique national 2019 ministere des solidarites et de la sante data monitoring committee yes behcets disease bd systemic large vessel vasculitis characterized wide spectrum including recurrent oral genital ulcerations uveitis vascular neurological articular gastrointestinal manifestations therapeutic management bd depends presentation organ involved although colchicine nonsteroidal antiinflammatory agents topical treatments corticosteroids often sufficient mucocutaneous joint involvement aggressive approach immunosuppressive agents warranted severe manifestations posterior uveitis retinal vasculitis vascular neurological gastrointestinal involvement however still refractory disease relapses sight threatening eye disease irreversible organ damage european league rheumatism european league against rheumatism recommendation management bd advocated tnf antagonists adalimumab infliximab steroids sight threatening uveitis 5 interferon alpha used alternative delayed action induces many side effects 11 however firm evidence randomized controlled trials directly addressing best induction therapy severe uveitis bd anti tnf immunosuppressive agents used bd treatments usually non specific tumor necrosis factor alpha tnf identified potential target bd indeed tnf production altered bd spontaneous lps induced production tnf monocytes increased active bd compared healthy control groups found increase tnf levels vitreous sera bd active untreated uveitis compared bd treated infliximab ifx healthy control anti tnf agents increasingly used ocular manifestations bd especially ifx adalimumab anti-drug antibodies prospective observational showed anti tnf rapidly acting agent compared methylprednisolone suppressing ocular inflammation effect anti tnf started within first 24 hours suppressing ocular inflammation well decreasing anterior chamber cells clearing retinal vasculitis resolution retinitis cystoid macular edema 36 contrast indicated retinal infiltrates resolved within 2 weeks infiltration anterior chamber vasculitis macular edema resolved within 4 weeks interferon alpha 37 anti tnf agents used 1000 reported cases mainly refractory ocular bd associated improvement 90 resistant conventional therapies relapse rate uveitis daily corticosteroid doses significantly lower anti tnf agents bd uveitis resistant combination therapy corticosteroids azathioprine cyclosporine rapid onset action steroid sparing effect characterize efficacy tnf antagonists mainly reported resistant conventional therapies monoclonal antibodies infliximab adalimumab seem effective soluble antibodies etanercept notably uveitis 5 adalimumab seems effective infliximab bd uveitis multicenter observational 160 cumulative incidences complete response serious side effects event free survival significantly different anti-drug antibodies ifx 6 however repeated long term infusions warranted sustain remission tnf antagonists likely suspensive according expert panel recommendations use anti tnf drugs ocular inflammatory disorders published 2014 infliximab ifx adalimumab anti-drug antibodies may used first second line corticosteroid sparing therapy ophthalmic manifestations bd 8 2016 food drug administration fda european medicines agency european medicines agency http www fda gov http www european medicines agency europa eu approved anti-drug antibodies use non infectious intermediate posterior panuveitis including due bd based two randomized double blinded 9 10 tocilizumab experimental model autoimmune uveitis mice anti il 6 receptor antibody also yielded dramatic reduction uveal inflammation 20 tcz demonstrated efficacy refractory ocular inflammatory diseases 2124 biologic agents different tnf antagonists rarely reported bd uveitis however tcz one promising bd targeting il6 bd based several reports involving il6 pathogenesis bd active bd showed increased serum levels il 6 cytokines active bd characterized higher increase il 6 compared remission bd 38 il 6 cerebro spinal fluid levels higher acute neurological attacks chronic progressive neurologic involvement progressive neuro bd show marked increase cerebro spinal fluid il 6 activity suggesting il 6 possible marker disease activity longterm outcome increasing number case reports case series published tcz use bd uveitis tcz may effective highly refractory bd related uveitis 914 tcz yielded rapid reduction ocular inflammation led long term remission multicenter retrospective 11 tcz led rapid maintained improvement ocular parameters complete remission eight 13 experienced improvement best visual acuity moreover retinal vasculitis choroiditis retinitis reached complete remission end follow another five bd uveitis failed interferon alfa ifx therapy treated tcz remission obtained one infusion except one achieved complete remission five perfusions remission maintained ocular inflammation flare 14 current international expert recommendation management uveitis use biotherapies e adalimumab infliximab mandatory two distincts situations firstly second line therapy cases non infectious uveitis refractory steroids dmards rubi phrcn 15 0026 tackles population comparing efficacy safety adalimumab anakinra tocilizumab refractory e steroid dependence 10mg refractory least 1 immunosuppressant non infectious uveitis secondly first line therapy sight threatening uveitis however randomized directly evaluated best induction therapy context addition behcets disease considered severe cause noninflammatory uveitis uvb address best biologic adalimumab vs tocilizumab induction therapy sight threatening uveitis therefore positioning rubi phrcn 15 0026 uvb clearly different answer different complementary questions management non infectious uveitis current bd guided organ involvement severity disease bd uveitis considered devastating inflammatory ocular disease 25 blindness high risk bilateral involvement tnfa antagonists used sight threatening bd uveitis 15 years anti tnf rapidly acting agent compared methylprednisolone interferon alpha suppressing ocular inflammation effect anti tnf started within first 24 hours suppressing ocular inflammation well decreasing anterior chamber cells clearing retinal vasculitis resolution retinitis cystoid macular edema however failed demonstrate sustainable complete remission 50 also tnfa antagonists seems suspensive effect ocular inflammation bd tocilizumab used success severe resistant cases one promising biologics bd biologic agents il 1 il 17 blockers also tried il 1 blocker gevokizumab il 17 blocker secukinumab failed meet primary endpoints rcts 39 40 rapid onset action steroid sparing effect characterize efficacy tocilizumab although results several suggested tocilizumab could effective rescue refractory case anti tnf therapy severe bd therapeutic controlled comparing biologics yet thoroughly conducted nowadays management severe bd still remains largely empirical first randomized head head therapeutic management severe uveitis bd biologics may assess benefit tocilizumab comparatively adalimumab sight threatening behcets disease terms safety efficacy steroid sparing could thus improve care bd uveitis general expected benefit individual reducing morbidity rate blindness young bd collective reducing costs hospitalization dependence main rare side effects associated taking biotherapies potentially serious bacterial viral infections allergic reactions skin rash local reaction injection site exceptionally renal failure arterial hypertension decrease white blood cells platelets liver abnormalities described adalimumab common side effects humira may affect 1 10 people infections including nose throat sinuses injection site reactions redness itching bleeding pain swelling headache muscle bone pain humira medicines class may also affect ability immune system fight infections cancer cases serious infections blood cancers using humira rare serious side effects may affect 1 1 000 people include failure bone marrow produce blood cells nerve damage caused breakdown covering around nerve fibres lupus lupus like conditions causing inflammation organ damage stevens johnson syndrome life threatening reaction flu like symptoms painful rash affecting skin mouth eyes genitals fabiani al evaluated efficacy adalimumab anti-drug antibodies large series behcets disease bd related uveitis reported 40 3 month follow anti-drug antibodies withdrawn five cases due lack efficacy ocular inefficacy n 2 intestinal relapses n 2 severe adverse event pneumonia n 1 one lost follow month 3 month 12 regarding safety adverse events severe adverse events recorded addition mentioned pneumonia 41 atienza mateo al compared efficacy infliximab ifx versus adalimumab anti-drug antibodies first line biologic drug 1 year large series refractory uveitis due behcets disease bd 177 316 affected eyes 103 received ifx 74 received anti-drug antibodies minor adverse effects mild infusion reaction ifx local reactions site injection anti-drug antibodies commonly observed side effects severe complications leading discontinuation biologic therapy observed 8 cases ifx group 4 anti-drug antibodies group discontinued due inefficacy 18 cases ifx group 11 anti-drug antibodies group 17 5 14 9 respectively randomized controlled trials comparing ifx anti-drug antibodies head head needed observed favorable results anti-drug antibodies ifx therapy bd related refractory uveitis 1 year significantly greater improvement visual acuity higher drug retention rate anti-drug antibodies group ifx group 42 tocilizumab common side effects tocilizumab include upper respiratory tract infection increased transaminases level dyslipidemia neutropenia thrombocytopenia gastrointestinal perforation headache rash including exfoliative rash muscle bone pain hypersensitivity reaction reaction site injection including erythema rare severe side effects include serious hepatic toxicity rheumatoid arthritis systemic juvenile idiopathic arthritis juvenile idiopathic polyarthritis giant cell arteritis cytokine release syndrome common side effects may affect 1 10 tocilizumab upper respiratory tract infections nose throat infection nasopharyngitis inflammation nose throat headache hypertension abnormal liver function tests serious side effects serious infections complications diverticulitis disease affecting gut hypersensitivity allergic reactions covid 19 treated tocilizumab common reported side effects may affect 1 10 high levels transaminases constipation urinary tract infections atienza mateo al assessed efficacy tcz different phenotypes bd 16 10 men 6 women mean age 36 518 2 years main indications tcz prescription refractory uveitis n 14 refractory neurobehcet n 2 tcz effective bd major involvement however seem effective oral genital ulcers skin lesions tcz overall well tolerated new safety alarms detected 43 akiyama al investigated effectiveness tocilizumab behcet disease performing systematic literature review inception dates april 10 2020 articles reporting tocilizumab administration behcet disease total 47 behcet disease treated tocilizumab retrieved 20 articles analyzed tocilizumab effective serve alternative refractory ocular neuro vasculo behcet disease well secondary amyloidosis recommended mucocutaneous articular involvement tocilizumab well tolerated behcet disease among 47 5 adverse events 2 dyslipidemia 1 scrotal abscess 1 recurrent labial herpes 1 infusion reaction however new safety signal reported 44 atienza mateo al assessed efficacy tocilizumab tcz refractory uveitis behcets disease bd multicentre retrospective 11 7 men 20 affected eyes median age 35 years severe adverse effect found infusion reaction 13 patterns ocular involvement panuveitis n 8 retinal vasculitis 4 anterior uveitis n 2 posterior uveitis n 1 cystoid macular oedema present seven course recurrent n 7 chronic n 4 tcz onset following extraocular manifestations present oral genital ulcers n 7 arthritis n 4 folliculitis pseudofolliculitis n 4 erythema nodosum n 2 livedo reticularis n 1 neurological involvement n 2 tcz yielded rapid maintained improvement ocular parameters complete remission eight however case extraocular manifestations since tcz effective three mean follow 9 5 8 05 months tcz withdrawn two cases due severe infusion reaction arthritis impairment respectively behcets disease bd systemic vasculitis arterial venous vessels size involving young 15 45 years bd significantly increases morbidity mortality 1 ocular disease behcets disease frequent 60 90 may associated poor functional prognosis bd involve anterior posterior segment develops within first years disease onset runs severe course years bilateral involvement observed 7080 beginning becomes 90 followed long term 2 male gender posterior involvement frequent attacks strong vitreous opacity exudates alongside retinal vascular arcade identified poor prognostic factors sight seeing bd include posterior uveitis retinal vasculitis risk visual loss reaches 25 5 years 3 tnf antagonists anti tnf used bd uveitis 15 years 4 incidence blindness bd dramatically reduced recent years use biologics firm evidence randomized controlled trials directly addressing best induction therapy severe bd uveitis european league rheumatism european league against rheumatism recommendation management bd advocated tnf antagonists steroids sight threatening uveitis 5 adalimumab infliximab seems effective refractory non infectious uveitis 6 7 according expert panel recommendations use anti tnf drugs ocular inflammatory disorders published 2014 infliximab ifx adalimumab anti-drug antibodies may used first second line corticosteroid sparing therapy ophthalmic manifestations bd 8 2016 food drug administration fda european medicines agency european medicines agency http www fda gov http www european medicines agency europa eu approved anti-drug antibodies use non infectious intermediate posterior panuveitis including due bd based two randomized double blinded 9 10 interferon alpha used alternative delayed action induces many side effects 11 contrasting immunosuppressors interferon alpha biotherapies act rapidly highly effective steroids sparing thus preventing occurrence cataract glaucoma controlled biologic non randomized observational compared tnf antagonists cyclosporine 3 5 milligrams kilograms number ocular attacks significantly lower md 0 80 95 ci 1 50 0 91 perattacks 6 months number achieving complete remission significantly higher tnf antagonists arm rr 1 83 95 ci 1 071 3 12 12 however anti tnf failed demonstrate sustainable complete remission 50 severe sight threatening uveitis 7 little published information use biologics anti tnf severe bd uveitis controlled comparing biotherapies bd uveitis tocilizumab tcz anti interleukin 6 il6 receptor used success severe resistant cases one promising biologics bd 1318 seems rapidly effective bd uveitis tcz may effective highly refractory bd related uveitis 1318 tcz yielded rapid reduction ocular inflammation led long term remission according several il6 level seems correlated disease activity il6 pro inflammatory cytokine primarily secreted mononuclear phagocytes activated astrocytes cells increase il6 level cerebro spinal fluid neuro bd reported correlated long term outcome disease activity proposed disease activity marker chang others found increase susceptibility bd subjects carrying il6vntr c allele il6prom g il6vntr c haplotype 19 increased il 6 concentrations demonstrated vitreous fluid chronic acute uveitis 20 moreover tcz demonstrated efficacy refractory ocular inflammatory diseases 2124 interestingly experimental model autoimmune uveitis mice anti il 6 receptor antibody also yielded dramatic reduction uveal inflammation 20 uvb first randomized prospective head head comparing adalimumab tocilizumab sight threatening uveitis bd despite strong rationale compounds yet approved bd guarantees innovative nature aims selecting dropping arm evidence efficacy already exists assess benefit tocilizumab comparatively adalimumab sight threatening behcets disease uveitis week 16 estimate compare change best corrected visual acuity best corrected visual acuity time complete remission week 4 8 12 24 36 48 evaluate compare safety adalimumab tocilizumab evaluate compare change macular edema evaluate compare change signs ocular inflammation evaluate compare effect retinal vessel leakage evaluate compare effect adalimumab tocilizumab steroid sparing evaluate compare change ocular inflammation anterior chamber evaluate compare number time relapse uveitis characteristics uveitis worsening evaluate compare time failure considered failure following criteria met least 1 eye new active inflammatory retinal vascular lesions macular edema worsening best corrected visual acuity best corrected visual acuity 3 lines 2 step increase anterior chamber ac cell grade 2 step increase vitreous haze vh grade relative baseline estimate compare effect extra ophthalmologic manifestations behcets disease estimate compare mean change sf 36 quality life behcets disease quality life measure estimate compare changes behcets disease current activity form behcets syndrome activity score efficacy defined complete remission ocular involvement prednisone prednisolone prednisone stock market lower equal 5 milligrams day week 16 randomization complete remission ocular inflammation defined complete resolution retinal vasculitis macular edema prednisone prednisolone prednisone stock market lower equal 5 milligrams day week 16 33 bilateral uveitis eye highest disease activity chosen eye measures corticosteroid sparing e g percent meeting targets lower 0 1 milligrams day kilograms prednisone prednisolone prednisone stock market mean dose week 16 cumulative dose time response onset measures acute phase reactants erythrocyte sedimentation rate esr c reactive protein c reactive protein week 4 8 12 16 24 36 48 rate time occurrence relapse worsening relapse defined reappearance paraclinical features active disease occurrence new lesions progression preexisting lesions changes behcets disease current activity form bdca week 8 16 24 changes behcets syndrome activity score bsas week 16 changes organs involved bd week 4 8 12 16 24 36 48 changes quality life quality of life sf36v2 tm health survey behcets disease quality life measure bd quality of life week 16 24 safety tolerability treatments bd assessed frequency severity adverse events week 4 8 12 16 24 36 48 time failure time occurence changes tyndall flare vitreous haze week 8 16 24 36 48 changes best corrected visual acuity snellen score week 8 16 24 36 48 changes central retinal thickness measured optical coherence tomography optical coherence tomography week 8 16 24 36 48 percentage central retinal thickness 300 microns week 8 16 24 36 48 percentage without retinal vessel leakage retinal angiography week 16 week 24 36 48 case retinal vasculitis arm adalimumab 80 milligrams day 0 40 milligrams subcutaneous week 1 3 5 7 9 11 13 and15 arm b tocilizumab 162 milligrams subcutaneous week 15 weeks experimental design open multicenter randomized stratified main involvement baseline retinal vasculatis macular oedema according newly diagnosed relapsing disease evaluation primary assessment criteria week 16 choose bayesian phase ii randomized aims comparing response rate week 16 experimental tocilizumab reference adalimumab randomized phase ii trials still poorly used still large use single arm phase ii results interpreted relative historical control subjects introducing selection bias confounding may limit validity conclusions thus planning phase ii randomized appears worthy investment considering finite financial resources sharma 2011 moreover choose design bayesian three main reasons first allows incorporating information outside results decrease required sample size due fictive observations secondly bayes designs particularly well suited adaptive designs given inference based accumulated data along allowing interim sequential analyses without inflation type error biased estimation wang 2016 third design adapted binary outcomes observed end fixed follow period analyzed using absolute difference proportions shown greatly reduce sample size requirements thus interim analysis use bayesian inference performed one year enrolment given uncertainty tocilizumab benefit adalimumab severe behcets disease uveitis early stage evaluation fact severe population focused large size selection approach planning sample size worthy consideration thus used approach phase ii randomized trials proposed simon r wittes ellenberg ss 1985 aims controlling probability detecting given difference response rates use beta binomial model non informative prior sensitivity analyses run informative prior posterior probability response rate 0 65 posterior probability arm arm b computed total 60 enrolled 30 arm 30 arm b previously shown allowing conclusive results interim analyse performed inclusion 30 national multicenters involving 26 centers participating centers internal medicine rheumatology opthalmology departments public hospitals located france selection conducted investigator internal medicine rheumatology ophthalmology centers recruitment centres inclusion randomization day 0 performed investigator internal medicine rheumatology center visits follow conducted investigator internal medicine rheumatology non recruitment centres visits follow conducted investigator ophthalmology centers specific intervention research carried e g optical coherence tomography optical coherence tomography retinal angiography french national reference center rare systemic autoimmune diseases autoinflammatory diseases located pitie salpetriere hospital paris leading center field behcets disease cohort 1500 ophthalmology department pitie salpetriere hospital national reference center uveitis french behcets network recently conducted efficacy anti tnf severe behcets disease recruited 124 1 year 7 french behcets research network composed multiple competence centers behcets disease related french national reference center rare systemic autoimmune diseases autoinflammatory diseases uveitis working close collaboration french ophthalmologists rheumatologists including pitie salpetriere hospital paris several situations possible temporary suspension investigator must document reason suspending resuming participants source file case report form case report form premature discontinuation participant remains enrolled end participation premature discontinuation withdrawal investigator must document reason collect assessment criteria time ending participation participant agrees schedule follow participant particularly case serious adverse event case severe adverse events investigator must notify sponsor follow participant 1 month following premature discontinuation notification serious adverse event must sent email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction sponsor serious adverse event monitored resolved data safety monitoring board created committee specify validate follow methods participants may exit time reason investigator temporarily permanently withdraw participant safety reason participant best interests participant lost follow participant cannot located investigator must make every effort reconnect participant record attempts source file least determine whether participant alive dead participant exits prematurely withdraws consent data collected prior date premature exit may still used participant exits prematurely participant agrees state procedure schedule collecting data required protocol primary endpoint secondary endpoints safety assessment nb must stated information consent form state premature exit affect participant ongoing care state exactly participant offered case serious adverse events see corresponding section vigilance case report form must list various reasons participant discontinued lack efficacy adverse reaction another medical issue personal reasons participant explicit withdrawal consent lost follow consent withdrawn data collected prior withdrawal used except allow investigators use already collected data still inclusion period withdrawn implies primary outcome could analysed new included otherwise included analysed replaced intention treat analysis initial notification severe adverse event must provided written report signed investigator using severe adverse event notification form specific intended purpose case report form item form must completed investigator sponsor carry appropriate analysis initial notification sponsor serious adverse event must quickly followed additional detailed written report reports case outcome may monitored safety department provide information whenever possible investigator provide sponsor documents may useful medical reports laboratory test results results additional examinations etc documents must non identifying addition documents must include following acronym number participants initials adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even participant left initial notification severe adverse event follow reports documents must sent sponsor safety department email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction noted possible send severe adverse event reports safety department fax 33 0 1 44 84 17 99 event failed attempt send severe adverse event report email order avoid duplication sending email please adopt standardized nomming email subject following form objet yyyyyy_xxxxxx_jjmmaaaa avec yyyyyy code de la recherche xxxxxx acronyme de la recherche et jjmmaaaa date de transmission send severe adverse event initial notification form follow report concerning single participant given severe adverse event attachment may contain one document follow hospitalization reports example total size email must less 8 mb otherwise please send several e mails ensure documents transmitted e g hospital reports anonymized identified participant identification number use e case report form investigator completes severe adverse event notification form e case report form validates prints signs form sending email possible connect e case report form investigator complete sign send severe adverse event notification form safety department soon connection restored severe adverse event notification form e case report form must duly completed investigator must respond requests sponsor additional information questions relating notification adverse event safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction cases utero exposure investigator complete initial notification follow report forms pregnancy exposure participation investigator must monitor pregnant woman throughout pregnancy pregnancy terminated must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage pregnancy termination foetal death congenital abnormality etc investigator must follow procedure reporting saes initial pregnancy notification severe adverse event follow reports documents sent sponsor according procedures specified herein investigational medicinal product genotoxic father exposed investigator must obtain pregnant woman permission collecting information pregnancy eligibility criteria checked inclusion randomization visit adult meeting following criteria may included age 18 inclusion provide written informed consent prior performance specific procedures diagnosis behcets disease according international criteria behcet disease icbd see appendix 18 2 history aphtosis diagnosis non infectious intermediate posterior pan uveitis least one eye fulfilling international group classification criteria standardization uveitis nomenclature standardization of uveitis nomenclature criteria posterior pan uveitis sight threatening uveitis defined according validated international definition 2 lines drop visual acuity 10 10 scale retinal inflammation macular oedema retinal vasculitis chest x ray postero anterior lateral ct scanner results within 12 weeks prior inclusion evidence active tuberculosis active infection malignancy female subjects child bearing potential premenopausal female capable becoming pregnant negative serum pregnancy test plasmatic urinary subjects reproductive potential willingness use contraceptive measures adequate prevent subject subjects partner becoming pregnant 3 5 months stopping therapy tocilizumab adalimumab respectively birth control methods may considered highly effective methods achieve failure rate less 1 per year used consistently correctly considered highly effective birth control methods according ctfg recommendations methods include female subjects combined estrogen progestogen containing hormonal contraception associated inhibition ovulation 1 oral intravaginal transdermal progestogen hormonal contraception associated inhibition ovulation oral injectable implantable intrauterine device intrauterine device intrauterine hormone releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence context guidance sexual abstinence considered highly effective method defined refraining heterosexual intercourse entire period risk associated treatments reliability sexual abstinence needs evaluated relation duration preferred usual lifestyle subject male subjects use condom vasectomy documentation azoospermia sexual abstinence negative tuberculosis test obtained within 12 weeks prior inclusion potential subject positive interferon gamma release assay igra e g quantiferon tuberculosis gold spot tuberculosis test eligible chest x ray show evidence suggestive active tuberculosis disease signs symptoms pulmonary extra pulmonary tuberculosis disease subjects latent tuberculosis infection already received prophylactic tuberculosis must agree advance complete course started latest inclusion affiliation social security system affiliated universal medical coverage cmu eligible subjects included meet following criteria infectious uveitis masquerade syndromes uveitis due causes bd uveitis active tuberculosis history untreated tuberculosis severe infection positive human immunodeficiency virus antibody positive hepatitis b surface antigen positive hepatitis c rna results obtained within 1 month prior inclusion history malignancy within 5 years prior inclusion carcinoma situ cervix non metastatic squamous basal cell carcinoma skin history severe allergic anaphylactic reactions monoclonal antibodies history multiple sclerosis demyelinating disorder hypersensitivity active substance excipient investigational medicinal product auxiliary medicine active suspected ocular infection active suspected systemic infection history intestinal ulceration diverticulitis known porphyria laboratory values assessed inclusion neutrophil 1 0 103 cubic millimeter platelet count 80 103 cubic millimeter aspartate amino transferase alanine-aminotransferase 5 upper limit of normal anti tnf tocilizumab therapy within 1 month prior inclusion azathioprine mycophenolate mofetil methotrexate time inclusion drugs must withdrawn prior receiving tocilizumab adalimumab dose day 0 stage iii intravenous infusion new york heart association “new york heart association” cardiac insufficiency severe renal glomerular filtration rates gfr 30ml min liver insufficiency prothrombin 50 without causes live attenuated vaccine within 30 days prior inclusion breastfeeding pregnant women persons responsible quality control trials take necessary precautions ensure confidentiality information relating investigational medicinal products participants particular identity results obtained persons well investigators bound professional secrecy data collected concerning participants sent sponsor investigators specialised collaborators rendered non identifying circumstances shall names addresses participants involved shown participants initials recorded accompanied encoded number specific indicating order enrolment sponsor ensure participant given written permission personal information strictly necessary quality control accessed data entered electronically via web browser data processing commission nationale informatique et libertés french data protection authority france research falls methodologie de reference medium risk 001 according provisions article 54 paragraph 5 modified law 78 17 6 january 1978 relating information technology data files privacy change approved decision made 5 january 2006 ap hp research sponsor signed commitment comply methodologie de reference personal data processed accordance chapter ix amended french data protection act 6 january 1978 articles 53 61 general strategy continuous efficacy safety endpoints summarized using summary measures median interquartile range frequency distributions counts percentages used summarize categorical endpoints similarly characteristics presented using summary measures median interquartile range quantitative characteristics counts percentages categorical characteristics analyses group presented according subjects randomized disposition subjects disposition subjects described summaries group number subjects enrolled number subjects treated number subjects drug permanently discontinued including reasons discontinuation demographic baseline characteristics demographic baseline characteristics summarized group exposure compliance frequency distributions number received doses presented group duration compliance randomized subjects described group analysis primary efficacy endpoint primary endpoint complete remission ocular involvement prednisone prednisolone prednisone stock market lower equal 5 milligrams day week 16 randomization modelled binary variable analysis use beta binomial model non informative prior berry 2006 posterior probability remission rate least 0 65 estimated arms well probability rate remission arm b arm computed b tocilizumab group adalimumab group use bayesian inference framework denotes probability remission arm inclusion na arm ya complete response observed using beta prior posterior probability still beta distribution given due natural conjugate property beta family binomial sampling setting efficacy drug arm first assessed comparison historical minimal value interest sometimes called minimum required remission rate set 0 65 thus compute similarly use bayesian inference framework denotes probability remission arm b inclusion nb arm b yb complete response observed using beta prior posterior probability still beta distribution given due natural conjugate property beta family binomial sampling setting efficacy drug arm b first assessed comparison 0 65 thus compute arm however randomized phase ii settings selection new drug mostly based evaluating potential benefits experimental treatments thus one may consider dropping new drug rather low posterior probability drug beneficial targeted minimal level assessed computing value posterior probability difference remission rates two experimental arms kawasaki 2012 greater zero b tocilizumab group adalimumab group consider bayesian design interim analysis performed without alpha spending inclusion 30 0 80 0 80 0 80 stopped 0 10 0 10 corresponding arm stopped following included arm 0 10 0 10 stopped analysis secondary endpoints still b tocilizumab group adalimumab group measures corticosteroid sparing mean dose week 16 cumulative dose subjects randomized arm estimated compared across arms using normal bayesian models non informative priors probability posterior difference means b two experimental arms greater 0 computed time response onset estimated arm kaplan meier estimator compared using log rank test mean acute phase reactants erythrocyte sedimentation rate esr c reactive protein c reactive protein week 4 8 12 16 24 subjects randomized arm estimated compared across arms using normal bayesian models non informative priors probability posterior difference means b two experimental arms greater 0 computed rate time occurrence relapse worsening relapse defined reappearance paraclinical features active disease occurrence new lesions progression preexisting lesions estimated arms kaplan meier estimator appropriate usual estimator depending existence competing risks compared using either log rank test grays test means changes behcets disease current activity form behcets syndrome activity score week 8 16 24 estimated compared across arms using normal bayesian models non informative priors probability posterior difference means b two experimental arms greater 0 computed means changes organs involved bd week 4 8 12 16 24 estimated compared across arms using normal bayesian models non informative priors probability posterior difference means b two experimental arms greater 0 computed means changes quality life quality of life scales week 16 24 estimated compared across arms using normal bayesian models non informative priors probability posterior difference means b two experimental arms greater 0 computed safety tolerability treatments bd assessed frequency severity adverse events week 4 8 12 16 24 analysed primary endpoint means changes tyndall flare vitreous haze week 8 16 24 estimated compared across arms using normal bayesian models non informative priors probability posterior difference means b two experimental arms greater 0 computed means changes best corrected visual acuity snellen score week 8 16 24 estimated compared across arms using normal bayesian models non informative priors probability posterior difference means b two experimental arms greater 0 computed means changes central retinal thickness measured optical coherence tomography optical coherence tomography week 8 16 24 estimated compared across arms using normal bayesian models non informative priors probability posterior difference means b two experimental arms greater 0 computed percentage central retinal thickness 300 microns week 8 16 24 analysed primary endpoint percentage without retinal vessel leakage retinal angiography week 16 week 24 36 48 case retinal vasculitis analysed primary endpoint,"week, uveitis, bd, vasculitis, cd, adalimumab, disease, 16, remission, tocilizumab"
RUBI_protocole_v8-0_20210519_signe,2,-22.54931,32.505444,full title multicenter randomized multi arm comparing efficacy safety adalimumab anakinra tocilizumab subjects non infectious refractory uveitis acronym rubi refractory uveitis biotherapies coordinating investigator pr david saadoun centre national de reference des maladies autoimmunes et systemiques rares department internal medicine immunology hospital pitie salpetriere tel 0142178088 email david saadoun psl assistance publique hôpitaux de paris shortening fraction sponsor assistance publique hopitaux de paris scientific justification rubi first prospective randomized head head comparing adalimumab either anakinra tocilizumab refractory niu firm evidence randomized controlled trials directly addressing best biologic agent severe refractory niu niu cause devastating visual loss 20 legal blindness corticosteroids immunosuppressants failed demonstrate sustainable remission 70 refractory relapsing severe uveitis incidence blindness niu dramatically reduced recent years use biologics raising question whether compounds used earlier severe non infectious uveitis contrasting immunosuppressors biotherapies act rapidly highly effective steroids sparing thus preventing occurrence cataract glaucoma despite strong rationale compounds yet approved uveitis guarantees innovative nature aims selecting dropping arm evidence efficacy already exists primary objective assessment criterion primary objective evaluate efficacy adalimumab 80mg 40mg 14 days compared anakinra 100mg day tocilizumab 162mg 7 days subjects refractory non infectious intermediate posterior pan uveitis niu prednisone dose 0 1 milligrams kilograms day prednisone equivalent oral corticosteroid week 16 primary endpoint efficacy measured percentage least 2 step reduction vitreous haze according miami 9 step scale dose 0 1 milligrams kilograms day prednisone equivalent oral corticosteroid week 16 secondary objectives assessment criteria secondary objectives evaluate change best corrected visual acuity best corrected visual acuity evaluate safety adalimumab anakinra tocilizumab niu evaluate change macular edema evaluate change signs ocular inflammation evaluate effect retinal vessel leakage evaluate effect adalimumab anakinra tocilizumab steroid sparing evaluate change ocular inflammation anterior chamber evaluate effect underlying systemic disease appropriate evaluate effect ocular disease evaluate number time relapse uveitis characteristics uveitis worsening evaluate time failure secondary endpoints measured 16 weeks best corrected visual acuity best corrected visual acuity change macular edema change signs ocular inflammation retinal vessel leakage steroid sparing ocular inflammation anterior chamber underlying systemic disease appropriate ocular disease number time relapse uveitis characteristics uveitis worsening adverse events time failure experimental design prospective phase ii multicenter multi arm randomized 1 1 1 comparing efficacy safety adalimumab anakinra tocilizumab subjects active refractory non infectious intermediate posterior pan uveitis oral corticosteroids stable dose 30 days prior first drug administration day 0 systemic immunosuppressants must discontinued 30 days prior first drug administration day 0 access oral corticosteroids needed day 0 population involved adult active refractory non infectious uveitis niu 1 active disease either presence vh 4 miami 9 step scale macular edema crt 300 microns signs intraocular inflammation eg perivascular sheathing retinal vessels leakage retinal vessel fa 2 recently active disease evidence activity within 3 months prior inclusion visit per vh 4 miami 9 step scale vh 1 according standardization of uveitis nomenclature classification macular edema crt 300 microns signs intraocular inflammation e g perivascular sheathing retinal vessels leakage retinal vessels fa activity status active disease recently active disease confirmed randomization reading center evaluation vh optical coherence tomography fa assessments 3 refractory disease inclusion subjects must receiving oral corticosteroids 10 milligrams day prednisone equivalent 80mg day least one immunosuppressive azathioprine methotrexate mycophenolate mofetyl cyclosporine leflunomide cyclophosphamide interferon ifn intolerant immunosuppressive therapies inclusion criteria eligibility criteria checked selection visit takes place four weeks maximum prior inclusion visit inclusion randomization visit adult meeting following criteria may included 1 provide written informed consent prior performance specific procedures 2 diagnosis non infectious intermediate posterior pan uveitis least one eye fulfilling international group classification criteria standardization uveitis nomenclature standardization of uveitis nomenclature criteria posterior pan uveitis confirmed documented medical history 3 currently uncontrolled uveitic disease uncontrolled uveitic disease defined fulfilling 1 two following criteria within 4 weeks prior inclusion active inflammatory chorioretinal inflammatory retinal vascular lesions macular edema crt 300 microns b vitreous haze grade 4 miami 9 step scale vh 1 according standardization of uveitis nomenclature national eye institute classification 4 receiving prednisone 10 milligrams day 80mg day equivalent dose another corticosteroid stable dose 30 days prior first drug administration day 0 received least 1 systemic immunosuppressant systemic immunosuppressants must discontinued 30 days prior first drug administration day 0 b received ifn systemic immunosuppressants must discontinued 30 days prior first drug administration day 0 c intolerant immunosuppressant 5 best corrected visual acuity best corrected visual acuity early treatment diabetic retinopathy study 20 400 either eye 6 stable dose two weeks prior inclusion topical corticosteroids nsaids 7 male female age 18 years inclusion 8 weight 40 120 kilograms 88 2 264 lbs inclusion 9 chest x ray thoracic ct scan results postero anterior lateral within 12 weeks prior inclusion evidence active tuberculosis active infection malignancy 10 female subjects child bearing age negative serum urine pregnancy test 11 subjects reproductive potential willingness use contraceptive measures adequate prevent subject subjects partner becoming pregnant 3 5 months stopping therapy roactemra adalimumab respectively birth control methods may considered highly effective methods achieve failure rate less 1 per year used consistently correctly considered highly effective birth control methods according ctfg recommendations methods include combined estrogen progestogen containing hormonal contraception associated inhibition ovulation 1 oral intravaginal transdermal progestogen hormonal contraception associated inhibition ovulation 1 oral injectable implantable intrauterine device intrauterine device intrauterine hormone releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence context guidance sexual abstinence considered highly effective method defined refraining heterosexual intercourse entire period risk associated treatments reliability sexual abstinence needs evaluated relation duration preferred usual lifestyle subject 12 quantiferon tuberculosis tuberculosis test within 6 months prior screening non inclusion criteria subjects included meet following criteria 1 infectious uveitis masquerade syndromes idiopathic uveitis permitted 2 isolated anterior uveitis 3 presence cataract posterior capsular opacification severe assessment posterior segment either eye inadequate impossible 4 contraindication mydriasis either eye presence posterior synechiae eye mydriasis inadequate posterior segment examination 5 intraocular pressure 25mmhg goldmann tonometry advanced glaucoma either eye 6 monocular 7 active tuberculosis 8 known positive syphilis serology human immunodeficiency virus antibody hepatitis b surface antigen anti nucleocapsid antibody hepatitis b virus hepatitis c virus within 1 month prior inclusion 9 history malignancy within 5 years prior inclusion carcinoma situ cervix non metastatic squamous basal cell carcinoma skin 10 history severe allergic anaphylactic reactions monoclonal antibodies 11 infectious disease fever infection requiring antibiotics within 3 weeks prior inclusion b history recurrent infection predisposition infection 12 known immunodeficiency 13 history multiple sclerosis demyelinating disorder 14 laboratory values assessed inclusion hemoglobin 8g deciliter b white blood cell count 2 0 103 cubic millimeter c platelet count 80 103 cubic millimeter glomerular filtration rates gfr 30ml min e transaminases 3 times upper normal value 15 use following systemic treatments specified periods previous systemic biologic therapy b systemic alkylating agents within 12 months prior inclusion inclusion day 0 e g cyclophosphamide chlorambucil c live attenuated vaccine within 3 months prior inclusion 16 use following ocular treatments specified periods previous anti vegf intravitreal therapy applies eyes within 3 months prior inclusion anticipated use period b dexamethasone intravitreal implant ozurdex within 6 months prior inclusion c intravitreal corticosteroids within 3 months prior inclusion previous subtenons corticosteroid injections permitted administered least 2 months prior inclusion 17 stage iii intravenous infusion new york heart association “new york heart association” cardiac insufficiency tested eligible active refractory niu randomized 1 1 1 ratio arm 1 adalimumab 80mg 40mg 14 days subcutaneously n 40 16 weeks arm 2 anakinra 100 milligrams day subcutaneously n 40 16 weeks arm 3 tocilizumab 162 milligrams 7 days subcutaneously n 40 16 weeks three groups receive corticosteroid regimen niu receive oral prednisone 0 5 milligrams kilograms day maximum 40 milligrams day prednisone equivalence following schedule reduction prednisone apply groups long disease inactive 0 5 milligrams kilograms day prednisone week 4 0 4 milligrams kilograms day prednisone week 4 week 6 0 3 milligrams kilograms day prednisone week 6 week 8 0 2 milligrams kilograms day prednisone week 8 week 12 0 1 milligrams kilograms day prednisone week 12 week 16 due csi recommendation 18 06 2019 inclusion anakinra arm stopped investigational medicinal product anakinra discontinued undergoing follow thus modified planned analyses randomisation accordingly inclusion randomisation 54 next randomized 1 1 either 2 remaining arms arm 1 adalimumab 80mg 40mg 14 days subcutaneously n 40 16 weeks arm 3 tocilizumab 162 milligrams 7 days subcutaneously n 40 16 weeks practice means remaining 66 planned randomized 33 arm 1 33 arm 3 procedures added research ophthalmologic visit weeks 8 16 fluorescein indocyanine green angiogram fa icg week 16 ocular coherence tomography optical coherence tomography weeks 8 16 risks added research risk c practical procedure randomization stratified retinal vasculitis macular oedema underlying disease randomization prednisone one eye selected eyes eligible per inclusion exclusion criteria following rules respected eye active disease selected versus eye recently active disease defined protocol eyes present active disease documented unique parameter eye worse score selected eyes present active disease defined several parameters eye worse score ranked follows selected 1 vitreous haze 2 cystoid macular edema cme 3 retinal vascular leakage 4 best corrected visual acuity best corrected visual acuity eyes equivalent score right eye selected receive ocular coherence tomography optical coherence tomography enrolment month 1 2 3 4 6 fluorescein indocyanine green angiogram fa icg enrolment month 2 4 visits case vasculitis worsening number subjects chosen 120 number centres 37 departments 17 french public hospitals research period duration inclusions 56 months duration participation 7 months maximum total duration 63 months number inclusions expected per centre per month 0 4 month centre statistical analysis use bayesian multi arm multi stage mams design aim comparing several new treatments multi arm order select drop arm move forward evidence already exists based interim analyses randomization stratified retinal vasculitis macular oedema underlying disease randomization prednisone single therapy funding source programme hospitalier de recherche clinique 2015 data safety monitoring board anticipated yes objective compare effectiveness safety adalimumab anakinra tocilizumab subjects refractory non infectious intermediate posterior pan uveitis evaluate efficacy adalimumab 80mg 40mg 14 days compared anakinra 100mg day tocilizumab 162mg 7 days subjects refractory non infectious intermediate posterior pan uveitis niu prednisone dose 0 1 milligrams day prednisone equivalent oral corticosteroid week 16 evaluate change best corrected visual acuity best corrected visual acuity week 4 8 12 16 24 evaluate safety adalimumab anakinra tocilizumab niu week 4 8 12 16 24 evaluate change macular edema week 4 8 12 16 24 evaluate change signs ocular inflammation week 4 8 12 16 24 evaluate effect retinal vessel leakage week 16 evaluate effect adalimumab anakinra tocilizumab steroid sparing week 4 8 12 16 24 evaluate change ocular inflammation anterior chamber week 4 8 12 16 24 evaluate effect underlying systemic disease appropriate week 4 8 12 16 24 evaluate effect ocular disease week 4 8 12 16 24 evaluate number time relapse uveitis characteristics uveitis worsening evaluate time failure considered failure new active inflammatory lesions relative baseline two step increase anterior chamber cell vitreous haze grade worsening best corrected visual acuity 15 letters relative best state previously achieved least one eye percentage anterior chamber score 0 least 2 step reduction score tyndall flare according standardization uveitis nomenclature standardization of uveitis nomenclature classification week 4 8 12 16 24 estimated compared using beta binomial models non informative uniform priors mean change baseline best corrected visual acuity continuous endpoint week 4 8 12 16 24 subjects randomized arm estimated compared across arms using normal bayesian models non informative priors mean change baseline central retinal thickness measured optical coherence tomography optical coherence tomography week 4 8 12 16 24 subjects randomized arm estimated compared across arms using normal bayesian models non informative priors mean change baseline vitreous haze week 4 8 12 16 24 subjects randomized arm estimated compared across arms using poisson gamma models non informative priors percentage crt 300 microns week 4 8 12 16 24 estimated compared using beta binomial models non informative uniform priors percentage without retinal vessel leakage fluorescein angiography week 16 estimated compared using beta binomial models non informative uniform priors measures corticosteroid sparing mean change week 4 8 12 16 24 mean dose week 16 cumulative dose arm estimated compared across arms using normal bayesian models non informative priors time response onset estimated compared across arms using kaplan meier estimator log rank test respectively underlying systemic disease appropriate week 4 8 12 16 24 estimated compared using beta binomial models non informative uniform priors ocular disease week 4 8 12 16 24 estimated compared using beta binomial models non informative uniform priors time relapse uveitis characteristics uveitis worsening estimated compared across arms using kaplan meier estimator log rank test respectively time failure estimated compared across arms using kaplan meier estimator log rank test respectively number relapse estimated compared across arms using poisson gamma models non informative priors presence adverse events including serious adverse events severe adverse event week 4 8 12 16 24 estimated compared using beta binomial models non informative uniform priors references statistics jacob l boscher ib boulet uvarova chevret evaluation multi arm multi stage bayesian design phase ii drug selection trials hemato oncology submitted jung sh randomized phase ii trials prospective control stat med 2008 27 568 586 kawasaki miyaoka e bayesian inference pfor two proportions journal biopharmaceutical statistics 2012 22 425 437 notification severe adverse event must initially provided written report using special form reporting severe adverse event report must signed investigator item form must completed investigator sponsor carry appropriate analysis initial notification must followed one detailed follow report writing signed within maximum 8 days case fatal life threatening event within 15 days cases whenever possible investigator provide sponsor documents may useful medical reports laboratory test results results additional exams etc documents must made anonymous addition documents must include following research acronym number initials subject nature date serious adverse event adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even subject left initial report severe adverse event follow reports documents must sent ap hp e mail événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction possible send severe adverse event ap hps safety department fax 33 0 1 44 84 17 99 case unsuccessful attempt send severe adverse event e mail avoid duplicated reports investigator must comply requests sponsor additional information questions relating notification adverse event vigilance division délégation à la recherche clinique et à l’innovation contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction utero exposure investigator completes form monitoring pregnancy developed biomedical research found sends e mail vigilance division événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction investigator must monitor pregnant woman throughout pregnancy pregnancy terminated must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage pregnancy termination foetal death congenital abnormality etc investigator must follow procedure reporting severe adverse event exposure involves father investigator must obtain mother permission collecting information pregnancy initial pregnancy notification severe adverse event follow reports documents must sent sponsor via e mail vigilance division délégation à la recherche clinique et à l’innovation e mail événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction eligibility criteria checked selection visit takes place within four weeks prior inclusion visit inclusion randomization visit adult meeting following criteria may included provide written informed consent prior performance specific procedures diagnosis non infectious intermediate posterior pan uveitis least one eye fulfilling international group classification criteria standardization uveitis nomenclature standardization of uveitis nomenclature criteria posterior pan uveitis confirmed documented medical history currently uncontrolled uveitic disease uncontrolled uveitic disease defined fulfilling 1 two following criteria within 4 weeks prior inclusion active inflammatory chorioretinal inflammatory retinal vascular lesions macular edema crt 300 microns vitreous haze grade 4 miami 9 step scale vh 1 according standardization of uveitis nomenclature national eye institute classification receiving prednisone 10 milligrams day 80mg day equivalent dose another corticosteroid stable dose 30 days prior first drug administration day 0 received least 1 systemic immunosuppressant systemic immunosuppressants must discontinued 30 days prior first drug administration day 0 received ifn systemic immunosuppressants must discontinued 30 days prior first drug administration day 0 intolerant immunosuppressant best corrected visual acuity best corrected visual acuity early treatment diabetic retinopathy study 20 400 either eye stable dose two weeks prior inclusion topical corticosteroids nsaids male female age 18 inclusion weight 40 120 kilograms 88 2 264 lbs inclusion chest x ray thoracic ct scan results postero anterior lateral within 12 weeks prior inclusion evidence active tuberculosis active infection malignancy female subjects child bearing age negative serum urine pregnancy test subjects reproductive potential willingness use contraceptive measures adequate prevent subject subjects partner becoming pregnant 3 5 months stopping therapy roactemra adalimumab respectively birth control methods may considered highly effective methods achieve failure rate less 1 per year used consistently correctly considered highly effective birth control methods according ctfg recommendations methods include combined estrogen progestogen containing hormonal contraception associated inhibition ovulation 1 oral intravaginal transdermal progestogen hormonal contraception associated inhibition ovulation 1 oral injectable implantable intrauterine device intrauterine device intrauterine hormone releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence context guidance sexual abstinence considered highly effective method defined refraining heterosexual intercourse entire period risk associated treatments reliability sexual abstinence needs evaluated relation duration preferred usual lifestyle subject quantiferon tuberculosis tuberculosis test within 6 months prior screening subjects included meet following criteria infectious uveitis masquerade syndromes idiopathic uveitis permitted isolated anterior uveitis presence cataract posterior capsular opacification severe assessment posterior segment either eye inadequate impossible contraindication mydriasis either eye presence posterior synechiae eye mydriasis inadequate posterior segment examination intraocular pressure 25mmhg goldmann tonometry advanced glaucoma either eye monocular active tuberculosis known positive syphilis serology human immunodeficiency virus antibody hepatitis b surface antigen anti nucleocapsid antibody hepatitis b virus hepatitis c virus within 1 month prior inclusion history malignancy within 5 years prior inclusion carcinoma situ cervix non metastatic squamous basal cell carcinoma skin history severe allergic anaphylactic reactions monoclonal antibodies infectious disease fever infection requiring antibiotics within 3 weeks prior inclusion history recurrent infection predisposition infection known immunodeficiency history multiple sclerosis demyelinating disorder laboratory values assessed inclusion hemoglobin 8 g deciliter white blood cell count 2 0 103 cubic millimeter platelet count 80 103 cubic millimeter glomerular filtration rates gfr 30ml min transaminases 3 times upper normal value use following systemic treatments specified periods previous systemic biologic therapy systemic alkylating agents within 12 months prior inclusion e g cyclophosphamide chlorambucil dose modification immunosuppressant 30 days inclusion live attenuated vaccine within 3 months prior inclusion use following ocular treatments specified periods previous anti vegf intravitreal therapy applies eyes within 3 months prior inclusion anticipated use period dexamethasone intravitreal implant ozurdex within 6 months prior inclusion intravitreal corticosteroids within 3 months prior inclusion previous subtenons corticosteroid injections permitted administered least 2 months prior inclusion stage iii intravenous infusion new york heart association “new york heart association” cardiac insufficiency responsible biomedical research quality control article l 1121 3 french public health code take necessary precautions ensure confidentiality information experimental medications research research subjects particular identity subjects results obtained individuals well investigators subject professional secrecy accordance conditions set articles 226 13 226 14 penal code biomedical research data collected research subjects sent sponsor investigators specialised parties made non identifying circumstances names addresses subjects involved shown sponsor ensure research subject given permission writing access personal information strictly necessary quality control research data entered electronic case report form electronic case report form staff dedicated task due csi recommendation 18 06 2019 inclusion anakinra arm stopped thus modified planned analyses randomisation accordingly inclusion randomisation 54 next randomized 1 1 either 2 remaining arms arm 1 adalimumab 80mg 40mg 14 days subcutaneously n 40 16 weeks arm 3 tocilizumab 162 milligrams 7 days subcutaneously n 40 16 weeks practice means remaining 66 planned randomized 33 arm 1 33 arm 3 general strategy continuous efficacy safety endpoints summarized using summary measures median interquartile range frequency distributions counts percentages used summarize categorical endpoints similarly characteristics presented using summary measures median interquartile range quantitative characteristics counts percentages categoriel characteristics analyses group presented according subjects randomized,"week, uveitis, bd, vasculitis, cd, adalimumab, disease, 16, remission, tocilizumab"
ITAC_protocole v4.0 20200608_,2,-13.016511,20.14643,full title multicenter randomized prospective comparing efficacy safety infliximab cyclophosphamide severe behcets disease acronym itac induction therapy anti tnf vs cyclophosphamide severe behcet disease coordinating investigator pr david saadoun centre de reference des maladies autoimmunes et systemiques rares department internal medicine immunology 83 bd de lhopital 75013 paris hospital pitie salpetriere tel 0142178088 email david saadoun psl assistance publique hôpitaux de paris shortening fraction sponsor assistance publique hopitaux de paris scientific justification itac first randomized prospective head head comparing infliximab cyclophophamide severe manifestations bd behcets disease bd systemic vasculitis arterial venous vessels size involving young 12 45 years bd significantly increases morbidity mortality therape utic management bd depends presentation organ involved although colchicine nonsteroidal antiinflammatory agents topical treatments often sufficient mucocutaneous joint involvement aggressive approach immunosuppressive agents warranted severe manifestations retinal vasculitis cardio vascular neurological involvement early recognition vigorous use immunosuppressives high dose steroids changed prognosis severe bd bd severe systemic vasculitis leading 5 year mortality rate 15 major vessel neurological involvement cyclophosphamide used life threatening bd 40 years however outcome severe complications bd still poor european league rheumatism european league against rheumatism recommendation updated 2016 management bd advocated cyclophosphamide anti tnf plus glucocorticoids life threatening manifestations e neurological major vessel involvement recommendations vascular disease neurological involvement based largely expert opinion uncontrolled evidence open trials observational need properly designed controlled trials apparent tnfa antagonists used success severe resistant cases addition incidence blindness bd dramatically reduced recent years use anti tnf however firm evidence randomized controlled trials directly addressing best induction immunosuppressive therapy severe bd manifestations physicians still prescribing compounds label use therefore aimed assess best induction therapy severe difficult treat bd main objective primary endpoint assess benefit infliximab comparatively cyclophosphamide severe life threatening behcets disease primary assessment criterion complete response week 22 randomization secondary objectives endpoints estimate compare rate time occurrence relapses worsening estimate compare cumulative dose steroids estimate compare adverse events estimate compare mean change sf 36 quality life see appendix 3 estimate compare rate remission according organs involved compare changes acute phase reactants estimate compare changes central nervous system involvement estimate compare changes cardio vascular involvement survival event free survival estimate compare changes bd manifestations estimate compare changes behcets disease current activity form see appendix 2 assess serum concentration measurement tnfa inhibitor secondary endpoints complete response week 12 48 remission central nervous system cardiovascular involvement week 12 22 48 measures corticosteroid sparing percent meeting targets 0 1 milligrams day kilograms prednisone week 22 48 mean dose week 12 22 48 cumulative dose week 12 22 48 time response onset measures acute phase reactant c reactive protein c reactive protein every 4 weeks relapse time relapse relapse defined reappearance paraclinical features active disease occurrence new lesions week 48 rate relapse worsening time occurrence worsening worsening defined progression preexisting lesions week 22 48 rate worsening gobal survival week 22 48 event free survival week 22 48 defined occurrence death relapse worsening safety tolerability treatments bd assessed frequency severity adverse events week 22 change quality life quality of life sf 36v2tm health survey week 12 22 see appendix 3 changes central nervous system involvement physical exam cerebral medullar magnetic resonance imaging week 12 22 changes vascular involvement physical exam vascular doppler us angio ct imaging biologically normalization c reactive protein week 12 22 changes cardiological involvement physical exam echocardiography normalization left ventricular function disappearance cardiac thrombosis cardiac magnetic resonance imaging diseappearance gadolinium enhancement normalization left ventricular function biologically normalization troponin c reactive protein week 12 22 changes organs involved bd serum concentration measurement tnfa inhibitor week 22 change behcets disease current activity form see appendix 2 week 12 22 design bayesian design phase ii randomized aims comparing new reference based binary end point offers greater flexibility simplicity inference monitoring safety evidence efficacy small randomized trials population subjects adult pediatric severe life threatening behcets disease inclusion criteria 1 age 12 years old 2 written inform consent informed consent obtained legal guardian accordance regional laws regulations 12 17 years age 3 diagnosis bd according international criteria bd icbd see appendix 1 4 life threatening active bd defined 1 following disease categories according validated international definition major vessel disease arterial aneurysms arterial stenosis myocarditis major deep vein thrombosis e inferior vena cava superior vena cava cardiac cavity thrombosis pulmonary embolism supra hepatic vessels renal mesenteric vessels diagnosis major vessel involvement done using vascular doppler sonography echocardiography angio ct scan cardiac magnetic resonance imaging magnetic resonance imaging central nervous system involvement encephalitis meningoencephalitis myelitis diagnosis neuro behcets central nervous system involvement based objective neurological symptoms associated neuroimaging central nervous system medullar magnetic resonance imaging findings suggestive bd related central nervous system involvement cerebrospinal fluid cerebro spinal fluid findings showing aseptic inflammation may associated 6 chest x ray results postero anterior lateral within 12 weeks prior inclusion evidence active tuberculosis active infection malignancy 7 female subjects child bearing age negative pregnancy test 8 subjects reproductive potential willingness use contraceptive measures adequate prevent subject subjects partner becoming pregnant 6 months stopping therapy adequate contraceptive measures include hormonal methods used two cycles prior inclusion e g oral contraceptive pills contraceptive patch contraceptive vaginal ring barrier methods e g contraceptive sponge diaphragm used conjunction contraceptive foam jelly condom used conjunction contraceptive foam jelly intrauterine methods intrauterine device sterilization e g tubal ligation monogamous relationship vasectomized partner abstinence 9 potential subject positive interferon gamma release assay igra e g quantiferon tuberculosis gold spot tuberculosis test positive tuberculin skin test 6 months eligible chest x ray show evidence suggestive active tuberculosis disease signs symptoms pulmonary extra pulmonary tuberculosis disease subjects latent tuberculosis infection already received prophylactic tuberculosis must agree advance complete course 10 human immunodeficiency virus negative serology negative hbs ag test 1 month non inclusion criteria subjects included meet following criteria 1 evidence active tuberculosis 2 human immunodeficiency virus active hbv infection hbs ag 3 pregnancy lactation 4 taking oral daily dose glucocorticoid 20 milligrams prednisone equivalent 6 weeks continuously prior inclusion visit taking 3000 milligrams methylprednisolone 4 weeks prior inclusion visit 5 alcohol drug dependance 6 severe renal creatinine clairance 30ml min 1 73m2 pre existing hemorrhagic cystitis liver insufficiency hepatic encephalopathy urinary obstruction 7 heart failure stage iii intravenous infusion “new york heart association” 8 history malignancy within 5 years prior inclusion carcinoma situ cervix excised basal cell squamous cell carcinoma skin 10 history multiple sclerosis demyelinating disorder 11 history severe allergic anaphylactic reactions cyclophosphamide infliximab 12 infectious disease infection requiring intravenous antibiotics within 2 weeks prior inclusion history recurrent infection 14 laboratory values assessed inclusion hemoglobin 8 g deciliter white blood cell count 2 0 x 103 cubic millimeter platelet count 70 x 103 cubic millimeter 15 use following systemic treatments specified periods systemic biologic therapy cyclophosphamide within 3 months prior inclusion azathioprine mycophenolate mofetil methotrexate time inclusion drugs must withdrawn prior receiving cyclophosphamide infliximab dose day 1 16 live attenuated vaccine within 4 weeks prior inclusion recombinant killed virus vaccines permitted 17 lack affiliation social security benefit plan beneficiary assignee affiliated universal medical coverage cmu eligible investigational medicinal product infliximab 5mg kilograms intravenously week 0 2 6 12 18 comparator cyclophosphamide 0 7g month 2 1 2 g month 2 intravenously week 0 4 8 12 16 20 interventions added evaluations serum concentration anti tnf week 22 risks added risk c intermediate scope collection free informed consent eligible active behcets disease randomized one 2 groups randomization visit day 0 arm infliximab 5mg kilograms intravenously week 0 2 6 12 18 arm b cyclophosphamide 0 7g month 2 1 2 g month 2 intravenously week 0 4 8 12 16 20 receive corticosteroid regimen inclusion randomisation visit oral prednisone 1 milligrams kilograms day 80 milligrams day following schedule reduction prednisone apply groups long disease inactive week 4 0 8mg kilograms day week 6 0 7mg kilograms day week 8 0 6mg kilograms day week 10 0 5mg kilograms day week 12 0 4mg kilograms day week 14 0 3mg kilograms day week 16 0 2mg kilograms day week 22 0 1mg kilograms day number subjects included 52 26 arm number sites multicentre national including 28 centres duration duration inclusions 36 months duration participation 12 months total duration 48 months number enrolments expected per site per month 0 07 month centre statistical analysis experimental design multicentric open multicenter randomized stratified characteristics initial behcets disease evaluation primary assessment criteria 22 weeks primary assessment criteria final measures corticosteroid sparing reviewed scientific committee blinded randomization rct use bayesian design phase ii randomized national multicentre aims comparing new reference based binary endpoint e complete response week 22 offers greater flexibility simplicity inference monitoring safety evidence efficacy small randomized trials sources funding programme hospitalier de recherche clinique data monitoring committee yes recent case series reported 85 complete response anti tnf agents bd major vessel involvement 9 one randomized controlled performed date mild form bd concluded etanercept eta efficient mucocutaneous manifestations arthritis 11 current bd guided organ involvement severity disease intravenous cyclophosphamide still recommended management life threatening manifestations bd however fails control inflammation maintain remissions 30 develop relapse irreversible organ damage severe even life threatening complications rapid onset action steroid sparing effect characterize efficacy tnf antagonists mainly reported resistant conventional therapies although results several suggested anti tnf therapy infliximab 5mg kilograms severe bd could effective rescue refractory case cyclophosphamide therapeutic comparing cyclophosphamide infliximab yet thoroughly conducted nowadays management severe bd still remains largely empirical first randomized head head therapeutic management severe bd allow validation difficult treat behcets disease may confirm efficacy biologic therapy terms efficacy steroid sparing may assess benefit anti tnf therapy cyclophosphamide terms safety efficacy fertility women reproductive potential steroid sparing could thus improve care bd expected benefit individual reduced morbidity bd collective reducing costs hospitalization surgery endovascular procedures behcets disease bd systemic vasculitis arterial venous vessels size involving young 12 45 years bd significantly increases morbidity mortality 1 therapeutic management bd depends presentation organ involved although colchicine nonsteroidal antiinflammatory agents topical treatments often sufficient mucocutaneous joint involvement aggressive approach immunosuppressive agents warranted severe manifestations posterior uveitis retinal vasculitis cardio vascular neurological involvement 2 early recognition vigorous use immunosuppressives high dose steroids changed prognosis severe bd bd severe systemic vasculitis leading blindness 20 4 years 5 year mortality rate 15 major vessel neurological involvement 3 4 cyclophosphamide used life threatening bd 40 years 5 outcomes severe complications bd improved immunosuppressants failed demonstrate sustainable remission 70 refractory relapsing bd cases 3 4 6 8 tnf expression correlate bd activity immunological data provide strong rationale targeting bd biologics recent case series reported 85 complete response anti tnf agents bd major vessel involvement 9 incidence blindness bd dramatically reduced recent years use anti tnf raising question whether anti tnf agents used earlier bd european league rheumatism european league against rheumatism recommendation updated 2016 paper submitted management bd advocated cyclophosphamide anti tnf plus glucocorticoids life threatening manifestations e neurological major vessel involvement 10 recommendations vascular disease neurological involvement based largely expert opinion uncontrolled evidence open trials observational need properly designed controlled trials apparent one randomized controlled performed date mild form bd concluded etanercept eta efficient mucocutaneous manifestations arthritis 11 however firm evidence randomized controlled trials directly addressing best induction immunosuppressive therapy severe bd manifestations physicians still prescribing compounds label use therefore aimed assess best induction therapy severe difficult treat bd itac first randomized prospective head head comparing infliximab cyclophophamide severe manifestations behcets disease bd assess benefit infliximab comparatively cyclophosphamide severe life threatening behcets disease estimate compare rate time occurrence relapses worsening estimate compare cumulative dose steroids estimate compare adverse events estimate compare mean change sf 36 quality life estimate compare rate remission according organs involved compare changes acute phase reactants estimate compare changes central nervous system involvement estimate compare changes cardio vascular involvement estimate compare changes bd manifestations survival event free survival estimate compare changes behcets disease current activity form see appendix 2 assess serum concentration measurement tnfa inhibitor primary assessment criterion complete response week 22 randomization complete response defined remission affected organs involved baseline prednisone 0 1mg kilograms per day life threatening manifestations central nervous system cardiovascular involvement cardiac remission evaluated clinically improvement chest pains cardiac events echocardiography normalization left ventricular function disapearance cardiac thrombosis cardiac magnetic resonance imaging diseappearance gadolinium enhancement normalization left ventricular function biologically normalization troponin c reactive protein esr 17 vascular remission defined resolution laboratory features active disease normalization inflammatory syndrome absence new vascular lesions previously unaffected vascular territories progression preexisting vascular lesions detected serial imaging e doppler sonography angio ct scan 18 remission neurological involvement defined complete imaging evaluated central nervous system magnetic resonance imaging remission absence neurological sequelae defined rankin score 1 3 manifestations behcets disease also evaluated skin articular remissions evaluated clinically disappearance skin lesions ulcers disappearance arthralgia arthritis digestive remission evaluated clinically improvement abdominal pain gastrointestinal symptoms endoscopy improvement potential gastrointestinal lesions seen baseline remission ocular inflammation defined percentage decrease 2 steps vitreous haze resolution haze 1 haze baseline based standardization of uveitis nomenclature standardized grading 19 associated complete resolution retinal vasculitis macular edema bilateral uveitis eye highest disease activity chosen eye complete response week 12 48 remission central nervous system cardiovascular involvement week 12 22 48 measures corticosteroid sparing percent meeting targets 0 1 milligrams day kilograms prednisone week 22 48 mean dose week 12 22 48 cumulative dose week 12 22 48 time response onset measures acute phase reactants c reactive protein c reactive protein every 4 weeks relapse time relapse relapse defined reappearance paraclinical features active disease occurrence new lesions week 48 rate relapse worsening time occurrence worsening worsening defined progression preexisting lesions week 22 48 rate worsening gobal survival week 22 48 event free survival week 22 48 defined occurrence death relapse worsening safety tolerability treatments bd assessed frequency severity adverse events week 22 change quality life quality of life sf 36v2tm health survey week 12 22 see appendix 3 changes central nervous system involvement physical exam cerebral medullar magnetic resonance imaging week 12 22 changes vascular involvement physical exam vascular doppler us angio ct magnetic resonance imaging imaging biologically normalization c reactive protein week 12 22 changes cardiological involvement physical exam echocardiography normalization left ventricular function disapearance cardiac thrombosis cardiac magnetic resonance imaging diseappearance gadolinium enhancement normalization left ventricular function biologically normalization troponin c reactive protein week 12 22 changes organs involved bd serum concentration measurement tnfa inhibitor week 22 change behcets disease current activity form see appendix 2 week 12 22 arm infliximab 5mg kilograms intravenously week 0 2 6 12 18 arm b cyclophosphamide 0 7g month 2 1 2 g month 2 intravenously week 0 4 8 12 16 20 experimental design multicentric open multicenter randomized stratified characteristics initial behcets disease evaluation primary assessment criteria week 22 primary assessment criteria final measures corticosteroid sparing reviewed endpoint adjudication committee blinded randomization committee role validating blind conditions following assignments complete remission failure relapse disease consist persons external clinicians specializing pathology consideration prof b wechsler pitie salpetriere hospital radiologist dr boussouar pitie salpetriere hospital dr leclercq pitie salpetriere hospital meet end rct use adaptive bayesian design phase ii randomized national multicentre aims comparing new reference based binary endpoint e complete response week 22 offers greater flexibility simplicity inference monitoring safety evidence efficacy small randomized trials day 0 eligibility enrollment determined satisfy entry criteria including informed consent included inclusion randomization 1 1 ratio arm infliximab 5mg kilograms intravenously week 0 2 6 12 18 arm b cyclophosphamide 0 7g month 2 1 2 g month 2 intravenously week 0 4 8 12 16 20 receive corticosteroid regimen receive oral prednisone 1 milligrams kilograms day 80 milligrams day randomization following schedule reduction prednisone apply groups long disease inactive week 4 0 8mg kilograms day week 6 0 7mg kilograms day week 8 0 6mg kilograms day week 10 0 5mg kilograms day week 12 0 4mg kilograms day week 14 0 3mg kilograms day week 16 0 2mg kilograms day week 22 0 1mg kilograms day positive interferon gamma release assay igra e g quantiferon tuberculosis gold spot tuberculosis test positive tuberculosis skin test inclusion receiving rifampicin 300mg day isoniazid 150mg day prophylactic tuberculosis 3 months prednisone dosage increase 20 due interaction isoniazid prednisone prophylactic tuberculosis period e 3 months week 12 22 evaluation secondary assessment criteria week 22 evaluation primary assessment criteria week 36 48 evaluation secondary assessment criteria reviewed systemic physical examination visits day 0 inclusion randomization follow visits arm infliximab 5mg kilograms week 2 6 12 18 22 36 48 arm b cyclophosphamide 0 7g month 2 1 2 g month 2 4 8 12 16 20 22 36 48 monitoring also include laboratory testing every month imaging echocardiography vascular doppler us angiographic ct scan cardiac magnetic resonance imaging cerebral medullar magnetic resonance imaging week 12 week 22 randomization additional visits take place case laboratory findings suggestive flare disease figure 1 scheme multicentre national including 28 centres subjects may exit time reason investigator temporarily permanently withdraw subject safety reason subject best interests subject lost follow subject cannot located investigator must make every effort reconnect subject record attempts source file least determine whether subject alive dead subject exits prematurely withdraws consent data collected prior date premature exit may still used case report form must list various reasons subject exited withdrawn lack efficacy adverse reaction medical problem subject personal reasons explicit withdrawal consent lost follow investigator initially complete severe adverse event reporting form contained case report form report must signed investigator investigator must complete every section severe adverse event form sponsor carry appropriate assessment initial report sent sponsor must rapidly followed one additional written reports describing course event complementary information whenever possible investigator provide sponsor documents may useful medical assessment case medical reports laboratory test results results additional exams etc documents must anonymized addition investigator must state acronym number initials participant paper adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even subject terminated participation reception severe adverse event form vigilance department centralized allow immediate processing severe adverse event soon received initial severe adverse event notification severe adverse event monitoring reports document sent sponsor represented vigilance department fax 33 1 44 84 17 99 possible transmit severe adverse event form vigilance department e mail événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction case unsuccessful attempt send severe adverse event form fax nb transmit e mail documents initially successfully transmitted fax avoid duplication trials use e case report form investigator completes severe adverse event report form e case report form validates prints signs form sending fax case failure connect e case report form investigator complete sign send severe adverse event report form safety department soon connection restored investigator must complete severe adverse event report form e case report form investigator must comply requests additional information sponsor questions relating adverse event report safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction cases utero exposure investigator complete initial notification follow report forms pregnancy exposure participation investigator must monitor pregnant woman throughout pregnancy pregnancy ends must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage termination foetal death congenital abnormality etc investigator must follow procedure reporting saes initial pregnancy report form severe adverse event follow forms documents sent sponsor using modalities described father exposed investigator must obtain mother permission collecting information pregnancy special rules trials involving administration radioactive product e g pet scan subject develops secondary cancer cancer develops hereditary deficiency following exposure ionising radiation investigator shall complete special form reporting cancer eligibility criteria checked selection visit takes place two weeks prior inclusion visit inclusion randomization visit adult meeting following criteria may included 1 age 12 years old 2 written inform consent informed consent obtained legal guardian accordance regional laws regulations 12 17 years age 3 diagnosis bd according international criteria bd icbd see appendix 1 4 life threatening active bd defined 1 following disease categories according validated international definition major vessel disease arterial aneurysms arterial stenosis myocarditis major deep vein thrombosis e inferior vena cava superior vena cava cardiac cavity thrombosis pulmonary embolism supra hepatic vessels renal mesenteric vessels diagnosis major vessel involvement done using vascular doppler sonography echocardiography angio ct scan cardiac magnetic resonance imaging magnetic resonance imaging central nervous system involvement encephalitis meningoencephalitis myelitis diagnosis neuro behcets central nervous system involvement based objective neurological symptoms associated neuroimaging central nervous system medullar magnetic resonance imaging findings suggestive bd related central nervous system involvement cerebrospinal fluid cerebro spinal fluid findings showing aseptic inflammation may associated 6 chest x ray results postero anterior lateral within 12 weeks prior inclusion evidence active tuberculosis active infection malignancy 7 female subjects child bearing age negative pregnancy test 8 subjects reproductive potential willingness use contraceptive measures adequate prevent subject subjects partner becoming pregnant 6 months stopping therapy adequate contraceptive measures include hormonal methods used two cycles prior inclusion e g oral contraceptive pills contraceptive patch contraceptive vaginal ring barrier methods e g contraceptive sponge diaphragm used conjunction contraceptive foam jelly condom used conjunction contraceptive foam jelly intrauterine methods intrauterine device sterilization e g tubal ligation monogamous relationship vasectomized partner abstinence 9 potential subject positive interferon gamma release assay igra e g quantiferon tuberculosis gold spot tuberculosis test positive tuberculin skin test 6 months eligible chest x ray show evidence suggestive active tuberculosis disease signs symptoms pulmonary extra pulmonary tuberculosis disease subjects latent tuberculosis infection already received prophylactic tuberculosis must agree advance complete course 10 human immunodeficiency virus negative serology negative hbs ag test 1 month subjects excluded meet following criteria subjects included meet following criteria 1 evidence active tuberculosis 2 human immunodeficiency virus active hbv infection hbs ag 3 pregnancy lactation 4 taking oral daily dose glucocorticoid 20 milligrams prednisone equivalent 6 weeks continuously prior inclusion visit taking 3000 milligrams methylprednisolone 4 weeks prior inclusion visit 5 alcohol drug dependance 6 severe renal creatinine clairance 30ml min 1 73m2 pre existing hemorrhagic cystitis liver insufficiency hepatic encephalopathy urinary obstruction 7 heart failure stage iii intravenous infusion “new york heart association” 8 history malignancy within 5 years prior inclusion carcinoma situ cervix excised basal cell squamous cell carcinoma skin 10 history multiple sclerosis demyelinating disorder 11 history severe allergic anaphylactic reactions cyclophosphamide infliximab 12 infectious disease infection requiring intravenous antibiotics within 2 weeks prior inclusion history recurrent infection 14 laboratory values assessed inclusion hemoglobin 8 g deciliter white blood cell count 2 0 x 103 cubic millimeter platelet count 70 x 103 cubic millimeter 15 use following systemic treatments specified periods systemic biologic therapy cyclophosphamide within 3 months prior inclusion azathioprine mycophenolate mofetil methotrexate time inclusion drugs must withdrawn prior receiving cyclophosphamide infliximab dose day 1 16 live attenuated vaccine within 4 weeks prior inclusion recombinant killed virus vaccines permitted 17 lack affiliation social security benefit plan beneficiary assignee affiliated universal medical coverage cmu eligible persons responsible quality control article l 1121 3 french public health code take necessary precautions ensure confidentiality information relating investigational medicinal products participants particular identity participants results obtained persons well investigators bound professional secrecy accordance conditions set articles 226 13 226 14 french criminal code data collected participants sent sponsor investigators specialised collaborators anonymised circumstances names addresses subjects shown subject initials recorded along identification code specific indicating order enrolment sponsor ensure subject agreed writing personal information strictly necessary quality control accessed data entry carried electronic media via web browser bayesian phase ii randomized aims evaluating best strategy severe behcets disease based difference response rate measured week 22 randomization randomized phase ii trials still poorly used still large use single arm phase ii results interpreted relative historical control subjects introducing selection bias confounding may limit validity conclusions thus planning phase ii randomized appears worthy investment considering finite financial resources sharma 2011 moreover chose design bayesian three main reasons first allows incorporating information outside results decrease required sample size due fictive observations secondly bayes designs particularly well suited adaptive designs given inference based accumulated data along allowing interim sequential analyses without inflation type error biased estimation wang 2016 third design adapted binary outcomes observed end fixed follow period analyzed using absolute difference proportions shown greatly reduce sample size requirements thus interim analysis use bayesian inference performed one year enrolment described interim analysis performed one half projected numbers recruited use beta binomial model non informative prior berry 2006 posterior probability response rate least 0 70 rate response experimental arm observed control computed use bayesian inference framework denotes probability response arm k k 1 2 using beta prior k posterior probability k still beta distribution given due natural conjugate property beta family binomial sampling setting inefficacy drug first assessed comparison historical minimal value interest sometimes called minimum required response rate set 0 70 thus compute arm 1 however randomized phase ii settings selection new drug mostly based evaluating potential benefits experimental control arm whitehead 2014 thus one may consider dropping new drug rather low posterior probability drug beneficial control targeted minimal level done computing value posterior probability difference response rates experimental arm control xie 2012 2,"week, uveitis, bd, vasculitis, cd, adalimumab, disease, 16, remission, tocilizumab"
2022-002319-43_PROTOCOLE_v3.0_20231026_Shortcut_clean,4,-5.380798,-6.8827653,full title efficacy 7 days versus 14 days antibiotic therapy acute pyelonephritis kidney transplant recipients multicentre randomized non inferiority acronym shortcut coordinating investigator dr matthieu lafaurie infectious diseases saint louis hospital paris sponsor assistance publique hopitaux de paris scientific justification infections major cause morbidity mortality solid organ transplant recipients kidney transplant recipients ktr urinary tract infection uti represent 4572 infections 30 hospitalizations sepsis acute transplant pyelonephritis common complications occurring 20 mainly first year transplantation associated increased risk acute kidney rejection long term kidney graft dysfunction gram negative bacteria mainly e coli account 70 uti ktr infections favored urinary tract modifications defects immunosuppression often recurrent necessitate repeated courses antibiotics selective pressure due antibiotic consumption along frequent hospital admissions immunosuppression well known risk factors development antibiotic resistant infections multidrug mdr extensively xdr drug resistant enterobacteriaceae including esbl carbapenemase producing organisms thus increasingly observed transplant units represent global threat new antibiotics expected next decade one main strategy limit antimicrobial resistance reduce duration antibiotic 7 day course recommended simple acute pyelonephritis apn treated fluoroquinolones parenteral b lactams prolonged 10 14 days presence underlying disease risk complications kt teams treat 1421 days recommended american guidelines however need extend duration immunosuppressed poorly defined concept optimal duration apn ktr known excluded urgent need reduce antibiotic consumption population high risk developing infections due resistant pathogens hypothesis 7 day sufficient cure apn good response 48h ktr effective 14 days main objective primary endpoint show 7 day antibiotic therapy inferior 14 day antibiotic therapy acute pyelonephritis kidney transplant recipients primary endpoint cure additional antibiotic since end antibiotic main evaluation day 30 cure defined fever 38c symptoms uti secondary objectives endpoints compare arms cure day 90 day 180 microbiological cure day 30 90 180 tolerance safety antibiotics hospitalization length stay antibiotic consumption total follow acquisition antibiotic resistant enterobacteriaceae kidney graft function transplant rejection day 90 day 180 total costs evaluate risk factors failure relapse recurrence evaluate efficacy antibiotic end day 7 experimental arm day 14 control group secondary endpoints cure day 90 180 microbiological cure day 30 90 180 incidence relapse recurrence day 30 day 90 incidence adverse events imputable antibiotic kidney function assessed according mdrd modification diet renal disease ckd chronic kidney disease epidemiology collaboration epi hospitalization length stay defined delay date inclusion date hospital discharge antibiotic consumption rectal carriage antibiotic resistant enterobacteriaceae inclusion day 30 microbiological cure defined sterile urine uropathogene 103 cfu ml urine culture design multicenter controlled randomized non inferiority open label 2 parallel groups 1 1 7 days versus 14 days antibiotic randomization stratified date renal transplantation 1 year 1 year center sex potential confounders population subjects ktr acute pyelonephritis inclusion criteria age 18 years ktr apn defined fever t38c without signs symptoms uti pyuria 104 white blood cells ml 10 cubic millimeter positive urine culture uropathogen 103 cfu ml susceptible empirically administrated antibiotic confirmed suspected febrile non urinary bacterial infection urologic renal complication baseline imaging abscess obstruction favourable early response antibiotic 48 60 hours first dose antibiotic effective causative uropathogen defined 38c improvement resolution signs symptoms urinary tract infection present diagnosis written informed consent exclusion criteria following conditions severe complicated condition rapidly progressing disease immediately life threatening illness including limited septic shock current impeding respiratory failure acute heart liver failure admission stay intensive care unit baseline obstruction urinary tract renal perinephric prostatic abscess prior inclusion current participation another interventional dual antibiotic therapy prophylactic antibiotic cotrimoxazole allowed 1 dose aminoside allowed randomization first month post transplantation current indwelling catheter including bladder catheter ureteral stents percutaneous nephrostomy tubes neurogenic bladder enterocystoplasty immunodeficiency immunosuppressive therapy related kidney transplantation including hematologic malignancy cancer asplenia neutropenia 500 neutrophils cubic millimeter pregnancy breastfeeding hypersensitivity previous severe adverse drug reaction antibiotic therapy unable unwilling judgment investigator comply protocol life expectancy 1 month legal guardianship without healthcare coverage homeless women childbearing potential using adequate contraception comparator standard 14 days antibiotic duration interventions added 2 swabs bacterial resistance rectal carriage 1 follow consultation added standard procedure risks added uti could relapse frequently short duration arm non inferiority demonstrated require new antibiotic scope phase intravenous infusion number subjects included 470 number sites 10 duration length participation 6 months length inclusion period 36 months total duration 42 months number enrolments expected per site per month 1 2 statistical analysis sample sizes 235 group achieve 80 power detect non inferiority margin difference group proportions 0 05 reference group proportion 0 95 group proportion assumed 0 90 null hypothesis inferiority power computed case actual group proportion 0 90 test statistic used one sided z test unpooled significance level test 0 05 sources funding ministry health data monitoring committee yes present relevant data concern non complicated complicated uti non immunocompromised ktr thus excluded several randomized control trials rct shown that7 days safe non inferior longer antibiotic duration treat acute non complicated pyelonephritis 8 efficacy short duration well demonstrated oral fluoroquinolones parenteral b lactams 11 14 data short duration antibiotic efficacy complicated uti scarce include complicated cystitis pyelonephritis 15 immunocompromised excluded apart diabetes isno considered risk factor complications 8 sandberget al 2012 included 282 women apnincluding 9 complicated pyelonephritis 27 bacteremia ciprofloxacin 7 days non inferior ciprofloxacin 14 days terms microbiological efficacy 14 meta analysis 8 rct including 3 rct 20 urogenital abnormalities comparing 7 days less versus longer apn septic urinary tract infection showed difference short long arms regarding failure end even small subgroup bacteraemic 16 based 7 day course recommended non complicated apn treated fluoroquinolones parenteral b lactams prolonged 10 14 days presence underlying disease risk complications 8 kt teams treat 1421 days recommended american guidelines 4 however need extend duration immunosuppressed poorly defined concept optimal duration apn ktr remain defined knowledge reviewing published literature ongoing trials registered shortcut first randomized double blind could provide scientific evidence efficacy safety short antibiotic regimen duration acute pyelonephritis ktr results shortcut may change national international guidelines providing high quality evidence demonstration short duration safe ktr originality shortcut design pragmatic fits requirements usual nephrology process ktr apn expected benefit shorten duration antibiotic many advantages decreases risk related adverse events risk c difficile infection emergence resistant strain intestinal microbiota immunosuppression enhances risk mdr xdr infection due extended spectrum betalactamase esbl carbapenemase producing enterobacteriaceae cpe point crucial ktp urinary tract infections mostly due enterobacteriaceae indeed frequent infection ktp mdr xdr uti difficult treat enhance duration hospitalization parenteral antibiotic almost always needed due lack effective oral antibiotics cpe uti enhances mortality compared uti due non resistant bacteria risk participant urinary tract infection could relapse frequently short duration arm non inferiority demonstrated require new antibiotic urgent need reduce antibiotic consumption kidney transplant recipients ktr population high risk developing infections due resistant pathogens antibiotic induced clotridioides difficile infections cdi hypothesis 7 day sufficient cure acute pyelonephritis apn good response 48h effective 14 days show 7 day antibiotic therapy inferior 14 day antibiotic therapy acute pyelonephritis kidney transplant recipients good response 48h compare arms cure day 90 day 180 microbiological cure day 30 90 180 tolerance safety antibiotics hospitalisation length stay antibiotic consumption total follow acquisition antibiotic resistant enterobacteriaceae kidney graft function transplant rejection day 90 day 180 total costs evaluate risk factors failure relapse recurrence evaluate efficacy antibiotic end day 7 experimental arm day 14 control group cure additional antibiotic since end antibiotic main evaluation day 30 cure defined fever 38c symptoms uti cure day 90 180 microbiologicalcure day 30 90 180 incidence relapse recurrence day 30 day 90 incidence adverse events imputable antibiotic kidney function assessed according mdrd modification diet renal disease ckd chronic kidney disease epidemiology collaboration epi day 90 day 180 mdrd definition could find following reference levey bosch jp lewis jb greene rogers n roth accurate method estimate glomerular filtration rate serum creatinine new prediction equation modification diet renal disease group ann intern med 1999 mar 16 130 6 46170 ckd epi definition could find following reference new equation estimate glomerular filtration rate andrew levey md lesley stevens md ms christopher h schmid phd yaping lucy zhang ms alejandro f castro iii mph harold feldman md msce john w kusek phd paul eggers phd frederick van lente phd tom greene phd josef coresh md phd mhs ckd epi chronic kidney disease epidemiology collaboration annals internal medicine 2009 150 9 604 613 hospitalisation length stay defined delay date inclusion date hospital discharge antibiotic consumption rectal carriage antibiotic resistant bacteria inclusion day 30 stated ward physicians responsibility antibiotic prescription however guidelines encourage prescriptions according current french recommendations non ktr choice prescribed icd posology route mode administration independent research depend characteristics pathogen national local recommendations renal function parameters characteristic icd specialities generic group speciality considered equivalent local comedims susceptible prescribed acceptable contraceptive measures accordance ctfg recommendation acceptable contraceptive methods progesterone oral hormonal contraception inhibition ovulation primary mode action male female condom without spermicide 5 cap diaphragm spermicide 5 combination male condom either cap diaphragm sponge spermicide also considered acceptable phase intravenous infusion multicenter controlled randomized non inferiority open label 2 parallel groups 1 1 7 days versus 14 days antibiotic open design selected heterogeneity microorganisms responsible apn kt thus multiplicity antibiotics prescribed making blind unfeasible 10 several situations possible temporary suspension investigator must document reason suspending resuming participants source file case report form case report form premature discontinuation participant remains enrolled end participation premature discontinuation related withdrawal investigator must document reason collect assessment criteria moment subject exits participant agrees schedule follow visits participant especially case serious adverse event case severe adverse events investigator must notify sponsor follow participant 1 months following premature discontinuation notification serious adverse event must sent email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction sponsor serious adverse event monitored resolved data safety monitoring board created committee specify validate follow methods participants may exit time reason course participation participant presents one following exclusion criteria product procedure must discontinued participant continue monitored list relevant exclusion criteria investigator temporarily permanently withdraw participant safety reason participants best interests participant lost follow participant cannot located investigator must make every effort reconnect participant document attempts source file least determine whether participant alive dead participant exits prematurely withdraws consent data collected prior date premature exit may still used participant exits prematurely participant agrees state procedure schedule collecting data required protocol primary endpoint secondary endpoints safety assessment nb must stated information consent form state premature exit affect participant ongoing care state exactly participant offered case serious adverse events see corresponding section vigilance case report form must list various reasons participant discontinued lack efficacy adverse reaction another medical issue personal reasons participant explicit withdrawal consent lost follow initial notification severe adverse event must provided written report signed investigator using severe adverse event notification form specific intended purpose case report form item form must completed investigator sponsor carry appropriate analysis initial notification sponsor serious adverse event must quickly followed additional detailed written report reports case outcome may monitored safety department provide information whenever possible investigator provide sponsor documents may useful medical assessment case medical reports laboratory test results results additional examination etc documents must non identifying addition documents must include following acronym number participant initials adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even subject left initial notification severe adverse event follow reports documents must sent sponsor safety department email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction noted possible send severe adverse event reports safety department fax 33 0 1 44 84 17 99 event failed attempt send severe adverse event report email order avoid duplication use e crfs investigator completes severe adverse event report form e case report form validates prints signs form sending email possible connect e case report form investigator complete sign send severe adverse event report form safety department soon connection restored investigator must complete severe adverse event report form e case report form investigator must respond requests additional information sponsor questions relating adverse event report safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction cases utero exposure investigator complete report follow form pregnancy participation investigator must monitor pregnant woman throughout pregnancy pregnancy terminated must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage pregnancy termination foetal death congenital abnormality etc investigator must follow procedure reporting saes initial pregnancy notification severe adverse event follow reports documents sent sponsor according procedures specified herein investigator allow sponsors representatives monitor frequency defined contract depending enrolment center case report forms crfs related source documents reviewed detail monitoring visits completeness adherence guidelines accuracy compared source documents sponsors representative also review regulatory documents drug storage accountability investigator must keep comprehensive centralized filing system related documents would suitable inspection sponsors monitors representatives regulatory agency computer file used research implemented accordance french amended informatique et libertes law governing data protection european general data protection regulation gdpr regulations research governed commission nationale informatique et libertés french data protection agency reference methodology processing personal data used within scope health research amended medium risk 001 ap hp sponsor research signed declaration compliance reference methodology age 18 years ktr apn defined fever t38c without signs symptoms uti pyuria 104 white blood cells ml 10 cubic millimeter positive urine culture uropathogen 103 cfu ml susceptible empirically administrated antibiotic confirmed suspected febrile non urinary bacterial infection urologic renal complication baseline imaging abscess obstruction favourable early response antibiotic 48 60 hours first dose antibiotic effective causative uropathogen 38c improvement resolution signs symptoms urinary tract infection present diagnosis written informed consent following conditions severe complicated condition rapidly progressing disease immediately life threatening illness including limited septic shock current impeding respiratory failure acute heart liver failure admission stay intensive care unit baseline obstruction urinary tract renal perinephric prostatic abscess dual antibiotic therapy prophylactic antibiotic cotrimoxazole allowed 1 dose aminoside allowed randomization first month post transplantation current indwelling catheter including bladder catheter ureteral stents percutaneous nephrostomy tubes prior inclusion current participation another interventional neurogenic bladder enterocystoplasty immunodeficiency immunosuppressive therapy related kidney transplantation including hematologic malignancy cancer asplenia neutropenia 500 cubic millimeter pregnancy breastfeeding hypersensitivity previous severe adverse drug reaction antibiotic therapy unable unwilling judgment investigator comply protocol life expectancy 1 month legal guardianship without healthcare coverage homeless women childbearing potential using adequate contraception persons responsible quality control article l 1121 3 french public health code take necessary precautions ensure confidentiality information relating investigational medicinal products participants particular identity participants results obtained persons well investigators bound professional secrecy accordance conditions set articles 226 13 226 14 french criminal code data collected participants sent sponsor investigators specialised collaborators anonymised circumstances names addresses subjects shown sponsor ensure subject agreed writing personal information strictly necessary quality control accessed data entered electronically via web browser primary analyses performed whole population included e intention treat intent to treat independently received whatever treatments received whatever objective non inferiority superiority demonstration disposition subjects disposition subjects described summaries group number subjects enrolled number subjects treated number subjects drug permanently discontinued including reasons discontinuation order address non inferiority questions confidence intervals 95 main endpoint calculated lower threshold compared margin non inferiority 5 planned superiority questions secondary criteria effect sizes appreciated using point estimates confidence interval 95 using statistical tests adapted criterion effects measured right censored criteria hazard ratios effect proportions measured relative risks difference risks estimations adjusted prognostic factors tests two sided p values 0 05 less denoting statistical significance tests based two sided alpha risk 0 05 primary endpoint corresponds unilateral test considering alpha risk 0 025,"antibiotic, sars, covid, participant, 19, cov, 21, 90, emergency, unit"
CAALL F01_protocole_v10_20211209(2),5,38.872185,-4.166707,primary objectives compare within non high risk group treated 1 250 iu month 2 x 2 pegaspargase group treated 2 500 iu month 2 x 1 pegaspargase b evaluate within group high risk receiving 2 500 iu month 2 day x 2 pegaspargase induction phase based co primary end point incidence adequate 100 iu l asparaginase activity induction phase 21 days one pegaspargase infusion 7 days second infusion case 2 infusions day 33 incidence severe grade 3 toxicities directly asparaginase related e g central nervous system thrombosis pancreatitis anaphylaxia bilirubine within first 7 weeks day 49 anyway day 8 consolidation secondary objectives compare group treated 1250 iu month 2 day x 2 infusions pegaspargase group treated 2 500 iu month 2 x 1 infusion pegaspargase b evaluate group receiving 2 500 iu month 2 day x 2 pegaspargase terms pharmacokinetics pharmacodynamics immunogenicity efficacy safety secondary endpoints listed sections 2 2 1 2 2 2 2 2 3 eligible inclusion meet following criteria acute lymphoblastic leukemia b lineage nb children syndrome eligible randomization see section 5 3 2 12 months 18 years old written informed consent obtained day 8 eligible must meet following criteria l3 burkitt leukemia defined french american british fab morphology classification secondary leukemia mixed phenotype acute leukemia mpal according previously treated chemotherapy steroid exposed pts included stratified according section 3 5 known allergy pegylated products pregnancy women child bearing potential defined women physiologically capable becoming pregnant must negative serum pregnancy inclusion reliable contraception except oral contraceptives contraception maintained throughout 3 months discontinuation known human immunodeficiency virus positivity central nervous system thrombosis prophase philadelphia positive bcr abl acute lymphoblastic leukemia central nervous system thrombosis day 12 persons responsible quality control interventional research article l 1121 3 public health code shall take necessary precautions ensure confidentiality information related experimental medicines research subjects notably relation identity well results obtained like investigators persons bound professional secrecy according conditions defined articles 226 13 226 14 criminal code interventional research conclusion data collected concerning subjects transmitted sponsor investigators specialized intervening party shall depersonalized circumstances names addresses information allowing identification persons visible initials first name surname shall recorded accompanied coded research number indicating order inclusion sponsor shall ensure subject gives written consent access personal data concerning strictly necessary quality control research data entry carried electronic media via web browser analysis performed based intent treat principle randomized analyzed policy known intent treat intent to treat analysis principle cornerstone good practice participants randomized entered included analysis group assigned including loss follow regardless whether completed switched receive different similar principle surround analysis uncontrolled part primary aims randomized part provide two hypotheses testing therefore sample size computed reach adequate statistical power detecting effects present see section 10 2 stated numbers included adjusted according results interim analysis uncontrolled design sample size computed basis expected prevalence enrolment randomized allow precision around estimates appeared satisfactory see section 10 2 actually given uncertainties estimates one interim analysis performed based randomized january 1 2018 requested data safety monitoring board november 2017 two main goals estimating effect event-free survival ii assessing validity estimates sample sizes computed possible adjustment described statistical report based consolidated standards reporting trials consort baseline e randomization characteristics randomized groups compared roughly based estimations 95 confidence intervals without statistical tests significance randomization best means creating balanced groups right censored endpoints event free survival disease free survival overall survival estimated nonparametric kaplan meier method compared randomized groups log rank test checking proportionality hazard functions comparisons adjusted imbalances prognostic covariates using multivariable cox model stratified lignage risk group models evaluated based testing assumptions proportionality hazard functions log linear relationships predictors hazard competing risks endpoints relapse incidence etc analyzed using competing risks methods specifically cumulative incidences events estimated considering deaths prior event interest competing risk outcomes compared using gray test adjustments potential confounders based cause specific cox model tests two sided p values 0 05 less denoting statistical significance analyses performed using sas sas inc cary nc r http www r project org software packages,"prevalence, graall, concentration, treated, leukemia, activity, survival, nervous, central, responders"
Protocole KapKey _ extension Cohorte_06042022_lb,0,14.833595,20.192692,full title phase ii multicentric pembrolizumab classic endemic kaposis sarcoma acronym kapkey coordinating investigator pr celeste lebbe dermatologie hopital saint louis paris 0142494679 celeste lebbe assistance publique hôpitaux de paris shortening fraction sponsor assistance publique hopitaux de paris scientific justification classic endemic kaposis sarcoma ks lymphangioproliferations associated human herpes virus 8 hhv8 poorly codified chemotherapies give best 30 60 transient responses interferon responses frequent drug often poorly tolerated elderly therefore new therapies needed classic ks represents ideal model evaluating new drugs since receive concomitant immunosuppressive regimens antiviral therapies pembrolizumab anti pd1 monoclonal antibody recently shown improve survival several solid tumors ks data available role pd1 pharmacodynamic l1 axis significant pharmacodynamic l1 expression hhv8 associated pleural effusion lymphomas ks samples recently reported experience classical endemic ks supports role pathway expression pharmacodynamic l1 subpopulations cells also nk cells peripheral blood cells expression pharmacodynamic l1 tumor cells ks lesions evaluate benefit safety profile pembrolizumab classic endemic ks primary objective assessment criterion simons 2 stage optimal design main objective assess whether pembrolizumab clinically inactive partial complete response probability 0 5 truly active partial complete response probability 1 30 classic endemic kaposis sarcoma ks using simons 2 stage optimal design primary endpoint best overall response rate borr defined occurrence complete response partial response following actg criteria recorded start 6 months beginning specific systemic therapy ks occurs 6 months extension stage case truly active conclusion simons 2 stage optimal design extension stage would performed assess precisely efficacy pembrolizumab setting 20 included obtain precise estimation effect 24 months primary endpoint extension stage best overall response rate according actg criteria recorded start 6 months beginning specific systemic therapy ks occurs 6 months included simons 2 stage optimal design followed 24 months secondary objectives assessment criteria secondary objectives simons 2 stage optimal design extension stage assess safety profile pembrolizumab classic endemic kaposis sarcoma characterize efficacy pembrolizumab related pharmacodynamics assessment secondary endpoints efficacy endpoints different aspects response evaluated best overall response rate according physical global assessment pga score 6 months beginning specific systemic therapy ks occurs 6 months response rate month 3 month 6 according actg pga criteria response rate number lesions month 3 month 6 best response defined following primary endpoint response rate size target lesions month 3 month 6 best response defined following primary endpoint response rate tumor infiltration target lesions month 3 month 6 best response defined following primary endpoint response rate lymphedema circumference scale 0 absence 3 painful oozing month 3 month 6 best response defined following primary endpoint time response defined time first response recorded start time progression response rate according actg pga criteria month 9 month 12 month 18 month 24 extension stage duration response defined time starting progression achieving partial complete response quality life following qlc 30 dlqi_kaposi baseline cycle 5 cycle 10 cycle 15 every 3 months eot early termination months 24 safety endpoints safety assessed terms drug toxicity evaluated clinic laboratory parameters scored according common terminology criteria adverse events common terminology criteria for adverse events version 5 0 experimental design uncontrolled open label multicentric phase ii population involved adult classic endemic kaposis sarcoma inclusion criteria meeting following criteria may included simons 2 stage optimal design extension stage classic endemic histologically confirmed ks progressive disease ks 10 lesions involving one limb segment involvement 3 body surface ks least 4 cutaneous lesions 5mm ks least 1 cutaneous tumor available repeated pharmacodynamics evaluation willing provide tissue cutaneous biopsy tumor lesion least 4 weeks washout ks specific therapies including chemotherapy immunotherapy provide written informed consent prior performance specific procedures age 18 years day signing informed consent performance status 0 1 eastern cooperative oncology group (= performans status (= ecog)) performance scale demonstrate adequate organ function hematological absolute neutrophil count absolute neutrophil count 1 000 cubic millimeter platelets 100 000 cubic millimeter hemoglobin 8 g deciliter renal calculated creatinine clearance 30ml min using mdrd formula hepatic aspartate amino transferase serum glutamic oxaloacetictransferase alanine amino transferase serum glutamopyruvatetransferase 2 5xuln serum total bilirubin 1 5xuln direct bilirubin upper limit of normal subjects total bilirubin levels 1 5xuln female subject childbearing potential negative serum pregnancy within 72 hours prior receiving first dose medication health insurance non inclusion criteria meeting following criteria must included simons 2 stage optimal design extension stage known history organ transplantation human immunodeficiency virus human immunodeficiency virus 1 2 antibodies detected selection receiving systemic steroid therapy form immunosuppressive therapy within 7 days prior first dose ks symptomatic visceral involvement unless therapeutic option available previously received treatments anti pharmacodynamic 1 anti pharmacodynamic l1 anti pharmacodynamic l2 anti ctla4 antibody antibody drug specifically targeting cell costimulation immune checkpoint pathways active infectious hepatitis type b hbsag detected c hcv rna detected active tuberculosis bacillus tuberculosis active infection requiring systemic therapy hypersensitivity pembrolizumab excipients prior anti cancer monoclonal antibody monoclonal antibody within last 4 weeks recovered e grade 1 selection adverse events due agents administered 4 weeks earlier prior chemotherapy targeted small molecule therapy radiation therapy within 3 weeks 5 half lives prior day 1 recovered e grade 1 selection adverse events due previously administered agent note subjects grade 2 neuropathy exception criterion may qualify note subject received major surgery must recovered adequately toxicity complications intervention prior starting therapy known additional malignancy progressing requires active exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer active autoimmune disease required systemic past 2 years e use disease modifying agents corticosteroids immunosuppressive drugs replacement therapy eg thyroxine insulin physiologic corticosteroid replacement therapy adrenal pituitary insufficiency etc considered form systemic vitiligo type diabetes mellitus hypothyroidism psoriasis non requiring systemic permitted enroll active non infectious pneumonitis known history non infectious pneumonitis required steroids severe pulmonary disease hypoxia known psychiatric substance abuse disorders would interfere cooperation requirements pregnant breastfeeding expecting conceive father children within projected duration willing use adequate contraceptive methods visit 1 throughout period 120 days last dose therapy received live vaccine within 30 days prior first dose participating currently participating participated investigational agent within 4 weeks first dose history current evidence condition therapy laboratory abnormality might confound results interfere subjects participation full duration best interest subject participate opinion treating investigator guardianship curatorship tested simons 2 stage optimal design phase development phase ii pembrolizumab route intraveinous infusion dose regimen 200 milligrams per infusion every 3 weeks duration 6 months 8 cycles extension stage phase development phase ii pembrolizumab route intraveinous infusion dose regimen 200 milligrams per infusion every 3 weeks duration 24 months 35 cycles confirmed complete response defined simons 2 stage optimaldesign occurs 24 months 6 months pembrolizumab cycle 8 complete response observed confirmed least 1 month pembrolizumab stopped benchmark uncontrolled procedures added research pharmacodynamic evaluations based tumor tissue collection cutaneous biopsy correlative blood sampling risks added research risk c practical procedure simons 2 stage optimal design receive pembrolizumab 200 milligrams intraveinously every 3 weeks assessed drug safety efficacy continue 6 months unless experience disease progression unacceptable adverse events period extended 3 months case delay due adverse event resolved extension stage included extension stage receive pembrolizumab 200 milligrams intraveinously every 3 weeks assessed drug safety efficacy continue 24 months unless experience disease progression unacceptable adverse events confirmed complete response occurring 6 months lasting least 1 month number subjects chosen simons 2 stage optimal design 9 enrolled first part another 8 second part total 17 implies screen maximum 34 extension stage 20 additional enrolled number centers multicenter french simons 2 stage optimal design 8 participating centers french national group groupe de cancerologie cutanee extension stage 11 participating centers french national group groupe de cancerologie cutanee research period simons 2 stage optimal design duration inclusion 18 months duration participation follow 11 months maximum 1 month selection 6 months 8 cycles extended 3 months case delay due adverse event resolved 1 month follow extension stage duration inclusion 24 months duration participation follow 37 months maximum 1 month screening inclusion period 24 months 35 cycles extended 3 months case delay due adverse event resolved 12 months follow otal duration including extension stage months number inclusions expected per centre per month simons 2 stage optimal design ap hp saint louis 6 ap hp avicenne 2 ap hp cochin 2 ap hp bichat 2 chru de lille 1 centre hospitalier lyon sud 2 chru montpellier hopital saint eloi 1 chu grenoble 1 extension stage ap hp saint louis 10 ap hp avicenne 2 ap hp cochin 0 1 ap hp bichat 2 chru de lille 0 1 centre hospitalier lyon sud 2 chru montpellier hopital saint eloi 0 1 chu grenoble 0 1 chu marseille 0 1 chu toulouse 0 1 ch nice 0 1 statistical analysis simons 2 stage optimal design multicenter uncontrolled phase ii based 2 stage phase ii simons optimal design sample size computation based statistical hypotheses regards effect main endpoint best overall response rate 0 05 type error 90 statistical power sample size computed assess whether drug inactive partial complete response probability 0 5 truly active partial complete response probability 1 30 based hypotheses computed 9 would accrued stage 1 necessary inclusion stopped 6 months 9th inclusion waiting primary endpoint stop conclusion inactivity response observed stage otherwise 8 additional recruited total sample size 17 least 3 responses indicate drug effective enough case observed response end stage 1 stage 2 directly begin without stop extension stage 20 included extension stage considered main analysis expected complete best overall response rate complete response partial response 24 months 14 20 70 would obtain 95 ci interval complete response rate equal 46 88 secondary analysis performed 20 included extension stage plus 17 included simons 2 stage optimal design expected best overall response rate 6 months 26 37 70 3 analysis reach 95 ci interval complete response rate equal 53 84 funding source merck data safety monitoring board anticipated yes importance intact immune surveillance controlling outgrowth neoplastic transformation known decades accumulating evidence shows correlation tumor infiltrating lymphocytes tils cancer tissue favorable prognosis various malignancies particular presence cd8 cells ratio cd8 effector cells foxp3 regulatory cells seems correlate improved prognosis long term survival many solid tumors pharmacodynamic 1 receptor ligand interaction major pathway hijacked tumors suppress immune control normal function pharmacodynamic 1 expressed cell surface activated cells healthy conditions modulate unwanted excessive immune responses including autoimmune reactions pharmacodynamic 1 encoded gene pdcd1 ig superfamily member related cd28 ctla 4 shown negatively regulate antigen receptor signaling upon engagement ligands pharmacodynamic l1 pharmacodynamic l2 mechanism pharmacodynamic 1 modulates cell responses similar distinct ctla 4 molecules regulate overlapping set signaling proteins pharmacodynamic 1 shown expressed activated lymphocytes including peripheral cd4 cd8 cells b cells regs natural killer cells expression also shown thymic development cd4 cd8 double negative cells well subsets macrophages dendritic cells ligands pharmacodynamic 1 pharmacodynamic l1 pharmacodynamic l2 constitutively expressed induced variety cell types including non hematopoietic tissues well various tumors binding either pharmacodynamic 1 ligand pharmacodynamic 1 inhibits cell activation triggered cell receptor pharmacodynamic l1 expressed low levels various non hematopoietic tissues notably vascular endothelium whereas pharmacodynamic l2 protein detectably expressed antigen presenting cells found lymphoid tissue chronic inflammatory environments pharmacodynamic l2 thought control immune cell activation lymphoid organs whereas pharmacodynamic l1 serves dampen unwarranted cell function peripheral tissues although healthy organs express little pharmacodynamic l1 variety cancers demonstrated express abundant levels cell inhibitor pharmacodynamic 1 suggested regulate tumor specific cell expansion suggests pharmacodynamic 1 pharmacodynamic l1 pathway plays critical role tumor immune evasion considered attractive target therapeutic intervention modulation expression pharmacodynamic 1 receptors implicated numerous settings involving persistent antigen stimulation derived chronic infections cancer expression pharmacodynamic 1 exhausted virus specific cells characteristic chronic viral infections prevents proliferation function virus specific effector cells clearance virus 9 1 0 blocking pharmacodynamic 1 pathway vitro vivo revives exhausted cd8 cells chronically infected mice primates humans identifying pathway key therapeutic target recently pharmacodynamic 1 pathway inhibitors demonstrated profound positive effect advanced melanoma non virus associated cancers human 11 12 virus associated cancers pembrolizumab recently shown effective merkel cell carcinoma 13 ongoing head neck cancers 14 15 pembrolizumab effect regression classic endemic ks benefit drug evaluated larges series refer investigators brochure detailed background information pembrolizumab programmed cell death 1 pharmacodynamic 1 pathway represents major immune control switch may engaged tumor cells overcome active cell immune surveillance pembrolizumab potent highly selective humanized monoclonal antibody monoclonal antibody igg4 kappa isotype designed directly block interaction pharmacodynamic 1 ligands pharmacodynamic l1 pharmacodynamic l2 kaposi sarcoma ks data available role pd1 pharmacodynamic l1 axis significant pharmacodynamic l1 expression hhv8 associated pleural effusion lymphomas ks samples recently reported 1 experience classical endemic ks supports role pathway expression pharmacodynamic l1 subpopulations cells also nk cells peripheral blood cells expression pharmacodynamic l1 tumor cells ks lesions caillat zucman submitted consequently anti pd1 antibody pembrolizumab may useful restore antitumoral immune response ks simons 2 stage optimal design main objective assess whether pembrolizumab keytruda clinically inactive partial complete response probability 0 5 truly active partial complete response probability 1 30 classic endemic kaposis sarcoma using simons 2 stage optimal design extension stage case truly active conclusion simons 2 stages optimal design extension stage would performed 20 included assess greater precision estimation effect 6 months primary endpoint stage best overall response rate according actg criteria included simons 2 stage optimal design also followed 24 months want explain efficacy pembrolizumab keytruda measure pharmacodynamics drug also assess safety pembrolizumab keytruda collateral research performed measure pharmacodynamics pembrolizumab keytruda immunomonitoring based sequential tumor biopsies peripheral blood order characterize immune tumor infiltrate immune cells quantification immune check points expression expression pdl1 2 tumor cells analyze immunomodulation nk cells induced identify immune markers response hhv8 viral load hhv8 expression profiles monitored blood tumor cells primary endpoint best overall response rate borr defined occurrence complete response partial response following actg criteria recorded start 6 months beginning specific systemic therapy ks occurs 6 months refer section 8 1 description parameters efficacy secondary objectives assess safety profile pembrolizumab keytruda classic endemic ks characterize efficacy pembrolizumab keytruda 1 efficacy endpoints different aspects response evaluated best overall response rate according physical global assessment pga score 6 months beginning specific systemic therapy ks occurs 6 months response rate month 3 month 6 according actg pga criteria response rate number lesions month 3 month 6 best response defined following actg criteria response rate size target lesions month 3 month 6 best response defined following actg criteria response rate tumor infiltration target lesions month 3 month 6 best response defined following actg criteria response rate lymphedema circumference scale 0 absence 3 painful oozing month 3 month 6 best response defined following actg criteria time response defined time first response recorded start time progression duration response defined time starting progression achieving partial complete response see chapter 8 1 actg pga criteria 2 safety endpoints safety assessed terms drug toxicity evaluated clinic laboratory parameters scored according common terminology criteria adverse events common terminology criteria for adverse events version 4 0 http ctep cancer gov reporting ctc html 3 pharmacodynamic virological analyses immunological sub include characterization tumor microenvironnement immunohistochemistry immune cells infiltration quantification cd3 cd4 cd8 cells cd56 nk cells analysis expression pd1 immune check points markers cytotoxicity granzyme expression pdl1 2 tumor cells analysis immunomodulation induced peripheral blood cells cd4 cd8 anti hhv 8 cells nk cells phenotypes flow cytometry pbmcs activation exhaustion immune check point expression blood inflammation markers luminex plama virological analyses hhv8 viral load quantified blood tumor sample using quantitative real time pcr polymerase chain reaction amplification assay hhv 8 dna detection performed using whole blood biopsy specimens dna extracted using dsp dna mini kit qiasymphony system qiagen courtabeuf france real time quantitative amplification carried abi 7500 system perkin elmer applied biosystems foster city california dilutions known amounts 10 107 copies fragment viral dna cloned plasmid used establish standard curve hhv 8 loads normalized according quantity cells present sample quantification albumin gene using real time pcr assay hhv8 expression profiles determined samples loads 4 log10 copies 106 cells using micro array targeting khv gene transcripts described 16 expression analysis biopsy samples stored rnaprotect medium right collection blood samples collected paxgene tubes primary endpoint stage best overall response rate according actg criteria recorded start 6 months beginning specific systemic therapy ks occurs 6 months refer section 8 1 description parameters efficacy notably complete response definition pembrolizumab administered intraveinously every 3 weeks dose 200 milligrams per infusion see chapter 7 pharmacokinetic data analysis pembrolizumab showed typical profile iggmabs half life 2 3 weeks pharmacodynamic data suggested peripheral target engagement durable 21 days early pharmacokinetic pharmacodynamic data provides scientific rationale testing q3w dosing schedule choice 200 milligrams q3w appropriate fixed dose based simulations performed using population pharmacokinetic model pembrolizumab showing fixed dose 200 milligrams every 3 weeks provide exposures 1 optimally consistent obtained 2 milligrams kilograms dose every 3 weeks 2 maintain individual exposures exposure range established melanoma associated maximal efficacy response 3 maintain individual exposure exposure range established melanoma well tolerated safe per protocol duration fixed simons 2 stages optimal design 6 months 8 cycles extension stage 24 months 35 cycles case severe adverse event according investigator decision stopped case progression could continued allow delayed response consultation principal investigator center investigator coordinator information least 6 months pembrolizumab complete response observed least 1 month pembrolizumab stopped extension stage multicenter non randomized phase ii receive pembrolizumad keytruda 200 milligrams intravenous infusion every 3 weeks 8 cycles receive pembrolizumad keytruda 200 milligrams intravenous infusion every 3 weeks 35 cycles multicentric french national number centers simons 2 stage optimal stage 8 extension stage 11 recruitment delivery performed outpatient basis dermatology departments different situations temporary suspension investigator must document reason suspending resuming subject source file case report form case report form premature termination subject remains enrolled end subject participation investigator must document reason premature termination exit investigator must document reason collect endpoints moment subject subject agrees schedule follow visits especially case serious adverse event subjects may exit time reason investigator temporarily permanently withdraw subject safety reason subject best interests subject lost follow subject cannot located investigator must make every effort reconnect subject record attempts source file least determine whether subject alive dead subject exits prematurely withdraw consent data collected prior date premature exit may still used relating case report form must list various reasons subject exited withdrawn lack efficacy adverse reaction medical problem subject personal reasons explicit withdrawal consent lost follow pharmacodynamic virological evaluations performed sequential first dose cycle 3 cycle 7 end visit early expected termination peripheral blood collected around 43 ml 4 time points first dose cycle 3 cycle 7 end visit 5 heparinate sample total 20 ml 2 edta tube 1 dry tube one paxgene tube skin biopsy collected 3 time points first dose cycle 3 end visit 6 month progression two 3mm punch biopsy samples performed kaposi lesion one flash frozen liquid nitrogen stored 80c fixed formalin afa follow biopsy performed residual disease possible kaposi lesion another lesion contiguous first lesion extension stage peripheral blood skin biopsy collected ollow p disease progression observed proposed classical endemic kaposis progressive disease checking following criteria classic endemic histologically confirmed ks progressive disease ks 10 lesions involving one limb segment involvement 3 body surface ks least 4 cutaneous lesions 5mm ks least 1 cutaneous tumor available repeated pharmacodynamics evaluation willing provide tissue cutaneous biopsy tumor lesion least 4 weeks washout ks specific therapies including chemotherapy immunotherapy interferon order eligible participation subject must willing able provide written informed consent aged 18 years older day signing informed consent performance status 0 1 eastern cooperative oncology group (= performans status (= ecog)) performance scale demonstrate adequate organ function defined table 5 health insurance table 5 adequate organ function laboratory values female subject childbearing potential negative serum pregnancy within 72 hours prior receiving first dose medication negative urine pregnancy test prior receiving dose urine test positive cannot confirmed negative serum pregnancy test required subject included known history organ transplantation human immunodeficiency virus human immunodeficiency virus 1 2 antibodies detected selection receiving systemic steroid therapy form immunosuppressive therapy within 7 days prior first dose ks symptomatic visceral involvement unless therapeutic option available previously received treatments anti pharmacodynamic 1 anti pharmacodynamic l1 anti pharmacodynamic l2 anti ctla4 antibody antibody drug specifically targeting cell costimulation immune checkpoint pathways active infectious hepatitis type b hbsag detected c hcv rna detected active tuberculosis bacillus tuberculosis active infection requiring systemic therapy hypersensitivity pembrolizumab keytruda excipients prior anti cancer monoclonal antibody monoclonal antibody within last 4 weeks recovered e grade 1 selection adverse events due agents administered 4 weeks earlier prior chemotherapy targeted small molecule therapy radiation therapy within 3 weeks 5 half lives prior day 1 recovered e grade 1 selection adverse events due previously administered agent note subjects grade 2 neuropathy exception criterion may qualify note subject received major surgery must recovered adequately toxicity complications intervention prior starting therapy known additional malignancy progressing requires active exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer active autoimmune disease required systemic past 2 years e use disease modifying agents corticosteroids immunosuppressive drugs replacement therapy eg thyroxine insulin physiologic corticosteroid replacement therapy adrenal pituitary insufficiency etc considered form systemic vitiligo type diabetes mellitus hypothyroidism psoriasis non requiring systemic permitted enroll active non infectious pneumonitis known history non infectious pneumonitis required steroids severe pulmonary disease hypoxia known psychiatric substance abuse disorders would interfere cooperation requirements pregnant breastfeeding expecting conceive father children within projected duration willing use adequate contraceptive methods visit 1 throughout period 120 days last dose therapy refer section 7 4 received live vaccine within 30 days prior first dose examples live vaccines include limited following measles mumps rubella varicella zoster yellow fever rabies bcg typhoid vaccine refer section 7 2 note seasonal influenza vaccines injection generally inactivated flu vaccines allowed however intranasal influenza vaccines e g flu mist live attenuated vaccines allowed currently participating participated investigational agent within 4 weeks first dose history current evidence condition therapy laboratory abnormality might confound results interfere subjects participation full duration best interest subject participate opinion treating investigator guardianship curatorship persons responsible quality control article l 1121 3 french public health code take necessary precautions ensure confidentiality information relating investigational medicinal products participants particular identity participants results obtained persons well investigators bound professional secrecy accordance conditions set articles 226 13 226 14 french criminal code data collected participants sent sponsor investigators specialised collaborators anonymised circumstances names addresses subjects involved shown subject initials recorded along identification code specific indicating order enrolment sponsor ensure subject agreed writing personal information strictly necessary quality control accessed data entry carried paper case report form information required according protocol must entered crfs information reported medical record data must collected obtained clearly recorded case report forms missing data item must coded digital case report form implemented centers thanks web based data collection medium multicenter non randomized phase ii based 2 stage phase ii simons optimal design main end point best overall response rate borr defined occurrence complete response partial response following actg criteria recorded start 6 months beginning specific systemic therapy ks occurs 6 months description general strategy continuous efficacy safety endpoints summarized using summary measures median interquartile range frequency distributions counts percentages used summarize categorical endpoints similarly characteristics presented using summary measures median interquartile range quantitative characteristics counts percentages categoriel characteristics 2 stage phase ii simons optimal design interim analysis interim analysis based first successively included 9 response recorded 6 months inclusion according design exposed interim analysis efficacy based observation responses based hypotheses computed 9 would accrued stage 1 necessary inclusion stopped 6 months 9th inclusion waiting primary endpoint stop conclusion inactivity response observed stage otherwise 8 additional recruited total sample size 17 least 3 responses indicate drug effective enough case observed response end stage 1 stage 2 directly begin without stop terminal analysis terminal analysis done included data quality checked based intent treat principle analysed whatever administered unless consent withdrawal point estimates 95 exact confidence intervals computed either efficacy safety criteria distribution time response time progression estimated kaplan meier approach unless competing events precluding occurrence deaths latter case cumulative incidence competing risks setting used extension stage terminal analysis done included extension stage data quality checked based intent treat principle analysed whatever administered unless consent withdrawal point estimates 95 exact confidence intervals computed either efficacy safety criteria distribution time response time progression estimated kaplan meier approach unless competing events precluding occurrence deaths latter case cumulative incidence competing risks setting used main analysis extension stage performed newly included stage secondary analysis performed included extension stage pooled included simons 2 stage optimal design analyses performed sas sas inc cary nc r http www r project org software packages,"response, ks, tumor, stage, pharmacodynamic, met, pembrolizumab, simons, endemic, l1"
MSC-LES_protocole_V6.0_20210728,3,-22.801817,-16.416311,full title severe refractory systemic lupus erythematosus injection allogeneic mesenchymal stem cells derived umbilical cord acronym mesenchymal stromal cells sle coordinating investigator professor dominique farge bancel internal medicine auto immune diseases vascular pathology uf 04 hopital st louis 1 avenue claude vellefaux paris 75010 paris sponsor assistance publique hopitaux de paris scientific justification systemic lupus erythematosus sle rare prevalence 40 50 100 000 persons heterogeneous auto immune auto inflammatory disease autoimmune disease affecting sexes races peak incidence prevalence among black people predilection women 3rd 4th decade life sle characterized successive periods flares remission may vary duration quality prognosis severe forms sle affect lung heart brain addition renal involvement improved still evolution remains pejorative subset whose 10 years mortality remains 10 15 even tertiary referral centers 20 years new prospective course sle demonstrated effectiveness new biological therapies yet made long awaited breakthrough severe sle anti blys monocolonal antibody gained indication moderately active sle addition serious adverse side effects progressive multifocal leukoencephalopathy observed several biologics autoimmune disease dampened expected benefits sle subjects resistant 1er 2nd line conventional need develop effective therapies fewer long term side effects based new immunomodulatory immunosuppressive strategies scientific justification according vitro immunomodulatory properties ability induce tissue repair mechanisms mesenchymal stem cells mesenchymal stromal cells proposed new therapy several autoimmune disease including sle use allogeneic umbilical cord derived mesenchymal stromal cells based experimental human data particularly produced nanjing team pr standardization of uveitis nomenclature china also logical select sle severity criteria used worldwide validate efficacy anti blys therapies similarly analysis expected results take account criteria similar comparable used pivotal trials unique opportunity set collaboration saint louis assistance publique hôpitaux de paris expert center cell therapy autoimmune disease university college london cell manufacturing main objective primary endpoint main objective assess tolerance allogeneic umbilical cord derived mesenchymal stromal cells administration severe sle refractory standard therapies cyclophosphamide mycophenolate mofetil corticosteroids without anti cd20 primary endpoint immediate tolerance assessed first injection 10 days allogeneic mesenchymal stromal cells injection according standards common terminology criteria for adverse events side effects secondary objectives endpoints secondary objectives feasibility allogeneic uc mesenchymal stromal cells administration severe sle subjects refractory conventional therapies tolerance three months injection considering observed morbidity overall survival sle treated subjects 1 year procedure analysis biological response routine biological examination criteria monitoring lupus using selena sledai bilag sf36 eq5d sri slicc sle scores analysis efficacy 3 months injection allogeneic uc mscs according proportion subjects major response rcm percentage subjects partial response cpr 12 months follow evaluation immunomodulatory effect mesenchymal stromal cells routine laboratory criteria including immunophenotyping every 3 months follow period analysis specific cytokine production month 0 month 1 month 3 analysis mesenchymal stromal cells immunogenicity month 0 month 1 month 3 secondary endpoints safety tolerance assessed injection within first 10 days following mesenchymal stromal cells injection month 1 month 3 month 6 month 12 according side effects defined common terminology criteria for adverse events standards miller results cancer cancer 1981 47 1 207 214 related toxicity analyzed according international world health organization maximum degree toxic attacks body injection considered tolerated toxicity criteria grade 3 proportion subjects major response mcr proportion subjects partial response clinic pcr 12 months follow 3 6 9 12 months month 3 month 6 month 9 month 12 disease activity measured bilag scores 0 72 selena sledai 0 105 every 3 months compared inclusion end follow period month 3 month 6 month 9 month 12 sri response rate measured every three months month 3 month 6 month 9 month 12 follow sri response defined 4 points reduction selena sledai score new bilag score organ one new bilag b score worsening increase 0 3 overall evaluation physician compared inclusion values presence comorbidities according sclicc sle index month 0 every three months follow month 3 month 6 month 9 month 12 charlson comorbidity index eligibility quality life assessed short form 36 version 2 sf 36v2 eq5d injection every 3 months end monitoring period month 3 month 6 month 9 month 12 month 1 percentage subjects average dose prednisone reduced 25 compared month 0 7 5 milligrams day weeks 40 52 average daily corticosteroid dose measured every 3 months end monitoring period mo month 3 month 6 month 9 month 12 number failure defined one following end stage renal disease requiring dialysis transplantation sustained doubled creatinine value two lowest values observed screening baseline confirmed four weeks later active lupus nephritis attributed active sle defined either two criteria doubling value proteinuria proteinuria 1 g 24 hours subjects 0 5 g 24 hours baseline proteinuria 2 g 24 hours subjects 1g 24 hours baseline ii nephropathy 25 increase serum creatinine respect value baseline simultaneously value proteinuria doubled least 2 g 24 hours hematuria two positive urine test strips presence cell cylinders two criteria must confirmed twice 2 week intervals need steroid therapy intravenously plasmapheresis immunoglobulin intravenous infusion immunosuppressive therapy treat aggravation sle 9 standard immunological biological markers including lymphocytes immuno phenotyping complete blood count creatinine proteinuria 24h autoantibodies anti dna antibodies native anas complement system c3 c4 ch50 immunophenotyping month 0 month 1 every three months follow period month 3 month 6 month 9 month 12 10 specific cytokines production month 0 month 1 month 3 inclusion 11 analysis mesenchymal stromal cells immunogenicity month 0 month 1 month 3 according anti human leukocyte antigen antibodies dosage cross match analysis design single center phase ii open national recruitment within fai2r network population subjects sle active subjects refractory prior standard therapies inclusion criteria age 18 years 70 years diagnosis systemic lupus erythematosus sle according american college of rheumatology criteria positive antinuclear antibodies subjects sustained disease activity defined selena sledai sle activity index 6 baseline inefficacy adverse effects necessitating discontinuation first second line therapies sle including prednisone orally 6 milligrams day equivalent least 28 days least one following immunosuppressive therapies 3 months total cyclophosphamide intravenous infusion bolus 500 milligrams month 3 months minimum ii mycophenolate mofetil orally equivalent dose 2000 milligrams day least 90 days iii azathioprine orally dose 2 milligrams kilograms day least 90 days intravenous infusion methotrexate orally parenterally doses 20mg week least 90 days v leflunomide orally dose 10 milligrams day least 90 days vi rituximab anti cd20 intravenous bolus 375 milligrams month 2 week four weeks total dose 1 g twice day two weeks vii cyclosporine orally dose 2 5 5 milligrams kilograms day least 90 days viii belimumab intravenously subcutaneous monthly bolus 10 milligrams kilograms infusion least 3 months received sle stable doses minimum 30 days prior eligibility including one following treatments prednisone equivalent alone combined antimalarial anti inflammatory steroidal immunosuppressant negative pregnancy test women childbearing age men women using effective contraceptive methods within 3 months end men partner childbearing age signed informed consent affiliation social security exclusion criteria subjects pregnancy breastfeeding lack appropriate contraception duration presence renal failure calculated creatinine clearance 30 ml min b cardiac failure signs congestive heart failure left ventricular ejection fraction 40 echocardiography uncontrolled ventricular arrhythmia c hepatitis defined abnormal levels transaminases aspartate amino transferase alanine amino transferase 2 x normal related disease activity respiratory disease mean pap 50 mmhg echocardiography respiratory failure defined resting blood pressure oxygen pao 2 70 mmhg paco2 50 mmhg without oxygen severe psychiatric disorders including severe psychosis related sle would prevent give informed consent undergo procedure active neoplasia concomitant myelodysplasia except basal cell carcinoma squamous cell carcinoma situ cervix carcinoma bone marrow failure defined neutropenia 0 5 109 l thrombocytopenia 30 109 l anemia 8 g deciliter lymphopenia cd4 200 x 106 l caused another disease sle acute chronic uncontrolled infection human immunodeficiency virus 1 2 htlv 1 2 hepatitis b hbs ag surface antigen hepatitis c positive pcr optional pcr received belimumab intravenously subcutaneous within 2 months baseline received rituximab b cell depleting biologic therapy within 6 months baseline current substance abuse recent within 60 days history substance abuse periods exclusion national roster researchers linguistic psychological incapacity sign informed consent already included another time poor compliance legal protection investigational medicinal product phase ii allogeneic umbilical cord derived mscs injected slow intravenous infusion according weight recipient groups doses 1 106 csm kilograms 2 106 csm kilograms 4 106 csm kilograms 1 injection 30min 1h intravenous infusion comparator na interventions added na risks added risks level scope immunosuppressive immunomodulatory action allogeneic mscs umbilical cords healthy donor allow beneficial action severe sle resistant conventional treatments number subjects included 10 number sites monocentric st louis hospital duration inclusion period 42 months participation period follow 12 months total duration 54 months number enrolments expected per site per month 0 2 inclusion per month per site statistical analysis initially 5 subjects initial dose 2 106 csm kilograms recipient weight included following 5 subjects enrolled dose 1 106 ms kilograms high probability excessive toxicity 2 106 mesenchymal stromal cells kilograms 4 106 csm kilograms low probability excessive toxicity 2 106 csm kilograms toxicity criteria described common terminology criteria for adverse events classification cohort scanned sequential bayesian approach estimate probability toxicity administered dose allowing adaptation function toxicity observed dose previous subjects sources funding subvention de recherche therapie genique et cellulaire en nephrologie subv therapie genique fdr afm_airg 2014 funding fondation du rein lassociation francaise contre les myopathies afm telethon collaboration lairg france délégation à la recherche clinique et à l’innovation sponsor ap hp data monitoring committee yes benefits injection mscs must allow immunomodulatory immunosuppressive action slow progression disease trying regress intensity fibrosis particular renal immunosuppressive immunomodulatory anti fibrosing properties mesenchymal stromal cells demonstrated team systemic sclerosis many authors laboratory animals also used humans especially china pr standardization of uveitis nomenclature usa pr gikelson first injections csm promising results carried 2001 published 2005 chronic marrow transplant rejection since mscs umbilical cords injected humans many autoimmune diseases including lupus results reported lupus show improvement signs activity lupus disease improvement renal function joint damage proteinuria regression significant way 400 england united states china usa risks concerning risks associated examinations described table table 2 risks associated examinations present serious adverse reactions expected human use mscs transient benign adverse effects associated injection procedure risk intervention biopsy likely occur pain redness point puncture respiratory discomfort chest pain erythema headache dyspnea rash chills hyperthermia changes rt pulse period eligibility inclusion exceed four months limit disease progression period inclusion injection mscs shall exceed two months bold acts usual monitoring boldface disease specific acts research bold specific acts research immunosuppressive immunomodulatory effects allogenic umbilical cord derived mscs well tolerated allow improve spectrum severe sle resistant prior conventional treatments assess early tolerance allogeneic uc derived mesenchymal stromal cells administration severe sle refractory standard therapies cyclophosphamide cy mycophenolate mofetil mycophenolate mofetil corticosteroids without prior anti cd20 therapy ten days feasibility allogeneic uc mesenchymal stromal cells administration severe sle subjects refractory conventional therapies tolerance three months injection considering observed morbidity overall survival sle treated subjects 1 year procedure analysis biological response routine biological examination criteria lupus monitoring using selena sledai bilag indices quality life sf36 eq5d systemic lupus erythematosus responders index sri evaluation comorbidity damage index slicc sle scores daily dose corticosteroid charlson comorbidity index analysis efficacy 3 months injection allogeneic uc mscs according proportion major response mcr percentage partial response pcr 12 months follow evaluation immunomodulatory effect standard immunological biological markers including lymphocytes immuno phenotyping complete blood count creatinine proteinuria 24h autoantibodies anti dna antibodies native anas complement system c3 c4 ch50 immunophenotyping month 0 month 1 every three months follow period month 3 month 6 month 9 month 12 analysis specific cytokine production month 0 month 1 month 3 k tarte siti laboratory chu rennes 7 analysis mesenchymal stromal cells immunogenicity month 0 month 1 month 3 immediate tolerance assessed injection within first 10 days following mesenchymal stromal cells injection according side effects defined common terminology criteria for adverse events standards miller results cancer cancer 1981 47 1 207 214 related toxicity analyzed according international world health organization maximum degree toxic attacks body injection considered tolerated toxicity criteria grade 3 tugwell p others omeract omeract trials 2007 ten day primary endpoint chosen analogy another phase ii cell therapy currently underway programme hospitalier de recherche clinique aom 11 250 analyzing tolerance allogeneic mesenchymal stromal cells administration systemic sclerosis diffuses severe rapidly progressive refractory conventional treatments cyclophosphamide previous prior authorization agence nationale de sécurité du medicament et des produits de santé obtained criterion seemed important homogenize practices criteria judgment ultimately analyzes moreover following remark decided explicitly continue analysis tolerance adding secondary endpoints tolerance course month 1 month 3 month 6 month 12 safety tolerance assessed month 1 month 3 month 6 month 12 according side effects defined common terminology criteria for adverse events standards miller results cancer cancer 1981 47 1 207 214 related toxicity analyzed according international world health organization maximum degree toxic attacks body injection considered tolerated toxicity criteria grade 3 proportion major response mcr proportion partial response clinic pcr 12 months follow 3 6 9 12 months month 3 month 6 month 9 month 12 mesenchymal stromal cells injection month 0 doses corticosteroids immunosuppressive therapies reduced according status improvement following evaluation month 1 month 3 month 6 month 9 month 12 responder dose prednisone reduced 5mg every 2 weeks months mesenchymal stromal cells administration responders defined according evaluation month 1 injection bilag score c e one organ bilag b score without new bilag b score non responders defined according evaluation month 1 injection index disease activity indices regress ongoing treatments reduced treatments introduced flare defined least one new domain bilag score two new domains bilag b scores mesenchymal stromal cells infusion mcr defined achieving bilag c scores better organs 6 months without experiencing severe flare maintenance response throughout 12 month period pcr defined 1 bilag c scores better maintenance response without new bilag b score within 3 months 2 one organ bilag b score 6 months without achieving least one new bilag b score throughout 12 month period relapse defined development least one new domain bilag b score previous mcr pcr response defined failure meet definition mcr pcr 2 disease activity measured bilag scores 0 72 selena sledai 0 105 every 3 months compared inclusion end follow period month 0 month 1 month 3 month 6 month 9 month 12 3 sri response rate measured every three months month 3 month 6 month 9 month 12 follow sri response defined 4 points reduction selena sledai score new bilag score organ one new bilag b score worsening increase 0 3 overall evaluation physician compared inclusion values 4 quality life assessed short form 36 version 2 sf 36v2 eq5d injection every 3 months end monitoring period month 0 month 3 month 6 month 9 month 12 month 1 5 percentage subjects average dose prednisone reduced 25 compared month 0 7 5 milligrams day weeks 40 52 average daily corticosteroid dose measured every 3 months end monitoring period mo month 3 month 6 month 9 month 12 6 number failure defined one following end stage renal disease requiring dialysis transplantation sustained doubled creatinine value two lowest values observed screening baseline confirmed four weeks later active lupus nephritis attributed active sle defined either two criteria doubling value proteinuria proteinuria 1 g 24 hours subjects 0 5 g 24 hours baseline proteinuria 2 g 24 hours subjects 1g 24 hours baseline ii nephropathy 25 increase serum creatinine respect value baseline simultaneously value proteinuria doubled least 2 g 24 hours hematuria two positive urine test strips presence cell cylinders two criteria must confirmed twice 2 week intervals need steroid therapy intravenously plasmapheresis immunoglobulin intravenous infusion immunosuppressive therapy treat aggravation sle 7 presence comorbidities according sclicc sle index month 0 every three months follow month 3 month 6 month 9 month 12 charlson comorbidity index eligibility 8 standard immunological biological markers month 0 month 1 month 3 month 6 month 9 month 12 complete blood count creatinine proteinuria 24h complement system c3 c4 ch50 month 0 month 9 9 immune profile detailed analysis lymphocytes immunophenotyping month 0 month 1 month 3 month 6 month 12 k tarte siti laboratory rennes cytokines month 0 month 1 month 3 k tarte siti laboratory rennes autoantibodies month 0 month 1 month 3 month 6 month 12 laboratory immunology hospital st louis paris 10 analysis mesenchymal stromal cells immunogenicity month 0 month 1 month 3 according anti human leukocyte antigen antibodies dosage cross match analysis initially 5 subjects initial dose 2 106 allogeneic umbilical cord derived mscs kilograms recipient weight included intermediate analysis inclusion 5th within 3 months inclusion dbim saint louis hospital data safety monitoring board permit validate following 5 subjects enrolled dose 1 106 ms kilograms high probability excessive toxicity according observed toxicity 2 106 mesenchymal stromal cells kilograms 4 106 csm kilograms low probability excessive toxicity 2 106 csm kilograms allogeneic uc mesenchymal stromal cells injected slow intravenous infusion according weight recipient groups doses 1 106 csm kilograms 2 106 csm kilograms 4 106 csm kilograms 1 injection 30min 1h intravenous infusion see appendix 3 notice dinjection du produit experimental essai clinique mesenchymal stromal cells sle information administration product phase ii non comparative randomised controlled blinding open label single center phase ii open national recruitment within fai2r network subjects recruited hospital table 4 summary table specialist doctor type visit visit reported protocol baseline visit verification inclusion exclusion criteria performed month 0 following assessments performed month 0 detailed physical examination particularly skin heart lungs skeletal muscles joints detailed examination including date birth gender weight size concomitant therapy evaluation tolerance according criteria common terminology criteria adverse events common terminology criteria for adverse events version 4 02 sle activity scores bilag selena sledai sri sle damage index sle slicc american college of rheumatology quality life sf 36 questionnaire eq5d biological examinations including hematology sedimentation rate hemoglobin hematocrit wbcs leukocyte platelets counts biochemistry serum electrolytes creatinine clearance renal liver function serum protein electrophoresis 24 h proteinuria urinary cyto bacteriological analysis ecbu immunology 24ml gel free lithium heparin tubes 14ml dry tube cytokines phenotypic analysis lymphocytes lb lymphocytes nk monocytes dendritic cells lymphocyte subpopulations b nk cells conducted facs analysis including cd4 treg cells identified double marking cd25 cd127 110 nk cells characterized double marking cd16 cd56 cd19 cd5 b cells involved autoimmunity also characterized following associations used autoimmune disease ho cell surface markers cd45 cd3 cd4 cd8 cd16 56 cd19 cd45 cd14 cd16 cd56 cd3 cd45 cd5 cd19 cd10 cd38 cd27 igd cd45 cd127 cd3 cd4 cd25 cd31 cd45ra mesenchymal stromal cells immunogenicity detection identification anti human leukocyte antigen antibodies crossmatch analysis determination anti dna autoantibodies elisa 7 ml dry tube anti dna antibody igg igm soluble nuclear antigen antibody anti ssa ssb anti sm anti rnp anti nuclear antibodies igg anti cardiolipin igg igm antibody antibody anti beta2 glycoprotein 1 igg igm c3 c4 ch50 complement factors levels daily dose corticosteroids pulmonary chest x ray ekg injection csm takes 30min 1h supervision nurse principal investigator analyses tolerance injection mesenchymal stromal cells administration therefater one hour 24 hours injection mscs data reported 0 5 10 15 30 45 60 90 min arterial pressure frequency tc sat o2 remarks mesenchymal stromal cells injection observation 24 hours performed including among things reportable incident incident injected delayed incident hypotension hypertension thrill hyperthermia local inflammation tachycardia bradycardia nausea vomiting symptoms interest investigator reserves right interrupt participation subject consideration case presents criterion non inclusion time surgery occurrence ar événement indésirable grave (see severe adverse event) compromising future assessments violation protocol withdrawal consent lost view non compliance uc mesenchymal stromal cells subjects may exit time reason investigator temporarily permanently withdraw subject safety reason subject best interests subject lost follow subject cannot located investigator must make every effort reconnect subject record attempts source file least determine whether subject alive dead subject exits prematurely withdraws consent data collected prior date premature exit may still used case report form must list various reasons subject exited withdrawn lack efficacy adverse reaction medical problem subject personal reasons explicit withdrawal consent lost follow investigator initially complete severe adverse event reporting form contained case report form report must signed investigator investigator must complete every section severe adverse event form sponsor carry appropriate assessment initial report sent sponsor must rapidly followed one additional written reports describing course event complementary information whenever possible investigator provide sponsor documents may useful medical assessment case medical reports laboratory test results results additional exams etc documents must anonymized addition investigator must state acronym number initials participant paper adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even subject terminated participation initial report severe adverse event follow reports documents must completed signed soon investigator becomes aware severe adverse event without delay safety department délégation à la recherche clinique et à l’innovation e mail événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction sponsors safety department possible send severe adverse event safety department fax sponsors safety department fax 33 0 1 44 84 17 99 case unsuccessful attempt send severe adverse event e mail order avoid duplicates trials use case report form investigator completes severe adverse event report form validates prints signs form sending fax email investigator must comply requests additional information sponsor questions relating adverse event report safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction procedures reporting biovigilance sponsor definitions according article r12 31 french public health code incident accident error related activities relating elements products derivatives mentioned item 1 article r 1211 29 resulting likely result adverse reaction persons mentioned item 30 article r 1211 29 b loss element product derivative c defect quality safety element product derivative serious incident incident causing likely result serious adverse reaction unexpected adverse reaction persons mentioned item 30 article r 1211 29 significant loss element product derivative preventing graft performed administration product b unusually high incidence incidents expected adverse reactions c information concerning donor donation discovered incidentally collection consequences likely entail risk health recipients obligation health professionals investigator correspondant local de biovigilance producer head cell therapy unit health professional aware serious incident must report sponsor without delay soon becomes aware may investigator producer head cell therapy unit correspondant local de biovigilance clb complements specific section observation booklet case report form case serious incident health professional completes biovigilance form see appendix 3 protocol signed soon investigator becomes aware severe adverse event without delay safety department délégation à la recherche clinique et à l’innovation e mail événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction sponsors safety department possible send severe adverse event safety department fax sponsors safety department fax 33 0 1 44 84 17 99 case unsuccessful attempt send severe adverse event e mail order avoid duplicates cases necessary elements expected investigation incident adverse reaction report sponsor additional information sent necessary useful documents hospitalization report batch release form chimerism results forwarded sponsor whenever possible sponsor requests additional information correspondant local de biovigilance health professional absence shall carry appropriate investigations inform sponsor results investigations correspondant local de biovigilance responsible reporting agence de la biomedecine french health competent authority biovigilance serious incidents informing potentially affected health professionals clbs institutions vigilant fields computer file used research implemented accordance french amended informatique et libertes law governing data protection european general data protection regulation gdpr regulations research governed commission nationale informatique et libertés french data protection agency reference methodology processing personal data used within scope health research amended medium risk 001 ap hp sponsor research signed declaration compliance reference methodology view public use public public data based personal data cliniqual biological genetic data etc implemented analyze results purpose medical data concerning data relating lifestyle well ethnic background data relating sex life necessary research transmitted promoter persons companies acting behalf france abroad data identified registration number data may also conditions ensuring confidentiality transmitted french foreign health authorities medical data concerning document file competent authorities drug evaluated research may transmitted industrialist benefit results research transmission made conditions ensuring confidentiality data may used research analysis complementary research collaboration private public partners france abroad conditions ensuring confidentiality level protection european legislation may withdraw consent time use data doctor following research computer file used research implemented accordance french regulations data protection act modified european general regulation data protection rgpd right access rectification opposition processing privileged data used research rights exercised doctor charge research knows identity identified front page information document decides stop participating research data collected previously stop used accordance regulations exclusively purposes research indeed erasure would likely compromise validity results research case data used later search event difficulties exercise rights may contact ap hp data protection officer following address protection donnees dsi assistance publique hôpitaux de paris shortening fraction may particular explain remedies available commission nationale informatique et libertés also access directly doctor choice medical data pursuant provisions article l 1111 7 public health code age 18 years 70 years diagnosis systemic lupus eythematosus sle according american college of rheumatology criteria positive antinuclear antibodies subjects sustained disease activity defined selena sledai sle activity index 6 baseline inefficacy adverse effects necessitating discontinuation first second line therapies sle including prednisone orally 6 milligrams day equivalent least 28 days least one following immunosuppressive therapies 3 months total cyclophosphamide intravenous infusion bolus 500 milligrams month 3 months minimum ii mycophenolate mofetil orally equivalent dose 2000 milligrams day least 90 days iii azathioprine orally dose 2 milligrams kilograms day least 90 days intravenous infusion methotrexate orally parenterally doses 20mg week least 90 days v leflunomide orally dose 10 milligrams day least 90 days vi rituximab anti cd20 intravenous bolus 375 milligrams month 2 week four weeks total dose 1 g twice day two weeks vii cyclosporine orally dose 2 5 5 milligrams kilograms day least 90 days viii belimumab intravenously subcutaneous monthly bolus 10 milligrams kilograms infusion least 3 months received sle stable doses minimum 30 days prior eligibility including one following treatments prednisone equivalent alone combined antimalarial anti inflammatory steroidal immunosuppressant negative pregnancy test women childbearing age men women using effective contraceptive methods within 3 months end men partner childbearing age signed informed consent affiliation social security pregnancy breastfeeding lack contraception adapted duration presence severe renal insufficiency calculated creatinine clearance 30 ml min altered cardiac function signs congestive heart failure left ventricular ejection fraction 40 echocardiography uncontrolled ventricular arrhythmia hepatitis defined abnormal levels transaminases aspartate amino transferase alanine amino transferase 2 times normal related disease activity respiratory disease mean pap 50 mmhg echocardiography respiratory failure defined resting blood pressure oxygen pao 2 70 mmhg paco2 50 mmhg without oxygen severe psychiatric disorders including severe psychosis related sle would prevent give informed consent undergo procedure active neoplasia concomitant myelodysplasia except basal cell carcinoma squamous cell carcinoma situ cervix carcinoma bone marrow failure defined neutropenia 0 5 109 l thrombocytopenia 30 109 l anemia 8 g deciliter lymphopenia cd4 200 x 106 l caused another disease sle acute chronic uncontrolled infection human immunodeficiency virus 1 2 htlv 1 2 hepatitis b aghbs hepatitis c positive pcr optional pcr received belimumab intravenously subcutaneous within 2 months baseline received rituximab b cell depleting biologic therapy within 6 months baseline current substance abuse recent within 60 days history substance abuse periods exclusion national roster researchers linguistic psychological incapacity sign informed consent already included another time risk poor compliance legal protection persons responsible quality control article l 1121 3 french public health code take necessary precautions ensure confidentiality information relating investigational medicinal products participants particular identity participants results obtained persons well investigators bound professional secrecy accordance conditions set articles 226 13 226 14 french criminal code data collected participants sent sponsor investigators specialised collaborators anonymised circumstances names addresses subjects shown sponsor ensure subject agreed writing personal information strictly necessary quality control accessed e g paper case report form data entered duplicate anonymised data entry forms done dedicated research personnel hospital research assistant coordinating investigator register eligible required separately contact informations kept medical file saved computerized database information required protocol must provided case report form explanation given investigator missing data data must transferred case report form obtained whether paraclinical data data must copied net readable manner black ink crfs facilitate duplication computer input detected erroneous data case report form clearly barred new data copied case report form initials date member investigators team made correction anonymity insured code number initials person lends research documents necessary research deleting appropriate means personal data copies source documents intended documentation research computerized data file shall declared commission nationale informatique et libertés procedure adapted case statistical analysis conducted pr matthieu resche rigon research unit st louis lariboisiere hospital group data collection quality control statistical analysis performed sequentially observation main criterion e proportion procedure tolerated dose 1 x 106 mesenchymal stromal cells per kilograms weight receiver e 10 days maximally inclusion included estimate probability intolerance using bayesian beta binomial model approach 51 111 bayesian approach consider rate intolerance p random centered priori density variable expected rate immediate intolerance 20 updated sequentially observations called law ex post priori density chosen family combined laws beta defined two parameters b hope variance bayes intolerance rate estimator hope act retrospectively e beta parameters act et bn defined prior act number n inclusions follows r et bn b n r r number tolerance observed included n following estimator stop bayesian rules calculated sequentially inclusion first 5 dose 2 x 106 mesenchymal stromal cells per kilograms weight receiver eventually take decision stop inclusions increase 4 106 mesenchymal stromal cells per kilograms weight receiver decrease 1 106 mesenchymal stromal cells per kilograms weight receiver dose two following criteria 43 criterion 1 probability posteriori intolerance rate greater 20 threshold intolerance considered criterion 2 retrospectively probability rate intolerance less 20 threshold intolerance considered judgment decisions follows criterion 1 0 70 judgment inclusions dose reduction dose 5patients following criterion 2 0 70 judgment inclusions dose increase dose 5patients following main motivation choosing sequential bayesian strategy provide continuous monitoring results throughout ensure protection overly toxic results recorded posterior distribution probability toxicity updated applying bayes theorem depending later distribution criteria used modify doses administered choices different thresholds results discussions clinicians involved methodologists charge design starting hypothesis increase dose potentially implies increase expected effect also toxicities considered considering pathology complications treatments expected toxicities following stem cell injection maximum 20 intolerance toxicity reasonable let probability intolerance toxicity criterion 1 corresponds posteriori probability intolerance rate greater 20 ie p 0 2 criterion 2 posteriori probability intolerance rate less 20 ie p 0 2 decided take threshold ensuring easily de escalation doses case suspicion possible toxicity soon p 0 2 0 7 dose stem cells decreased usual thresholds stopping falling rules usually higher around 0 9 yao b zhu l jiang q xia ha 2013 trials pharmaceutics 5 1 94 106 choice lower value quickly avoids risk exposure doses high conversely criterion 2 low probability less 0 3 observed toxicity greater 0 2 p 0 2 1 p 0 2 therefore criterion 2 corresponds p 0 2 0 3 increase dose thus allow benefit larger quantity stem cells none criteria filled included starting dose e 2 106msc kilograms independent committee meet order validate decision stop inclusions decrease dose increase light results sequential analysis,"mesenchymal, stromal, cells, breast, radiation, sclerosis, conventional, diagnostic, ultrasound, dose"
2021-000932-70_protocole_v2.0_20240311_ErythroSIM_signé,1,9.66595,-20.429651,full title randomized prospective evaluating efficacy anticd38 monoclonal antibody isatuximab pcra major abo mismatch allogeneic hematopoietic stem cell transplantation acronym reference erythrosim coordinating investigator dr xhaard alienor sponsor assistance publique hopitaux de paris scientific justification quarter allogeneic hematopoietic stem cell transplantation performed situation major abo mismatch exposing risk immunological pure red cell aplasia prca transplant pcra transplant defined anemia low reticulocytes count 10 g l day 60 despite good leucocytes platelet engraftment full donor chimerism associated persistence recipients hemagglutinins anti anti b antibodies bone marrow evaluation performed show erythroid hypoplasia red blood cells transfusions necessary every two weeks remission leading impaired quality life anemia repeated hospitalization iron overload need iron chelation therapy treatments currently used inefficient anti cd20 monoclonal antibodies epo steroids plasma exchanges proteasome inhibitors risk severe acute graft versus host disease donor lymphocytes infusion prca demonstrated associated persistence recipients plasma cells anti cd38 monoclonal antibodies targets plasma cells secreting hemagglutinins responsible pcra promising 6 cases reported literature support rapid sustain efficacy chapuy nejm 2018 bathini amjhematol 2019 rautenberg bmt 2019 salas others eur j haematol 2019 preethi others blood cell mol dis 2020 yates others transfusion 2021 prospective randomized evaluation efficacy safety context necessary main objective primary endpoint main objective efficacy prca isatuximab allogeneic hematopoietic stem cell transplant compared supportive care control group reduction prca resolution time days primary endpoint time obtention transfusion independence prca time interval randomization corresponding month 6 post transplant resolution prca date resolution reticulocytopenia treated anti cd 38 monoclonal antibody isatuximab secondary objectives endpoints secondary objectives 1 evaluate two arms term biological outcomes reduction red blood cells transfusion needs isatuximab evolution iron overload adverse events related isatuximab context allogeneic sct ctc adverse event grade 2 group month 6 post transplant quality life functional repercussions chronic anemia iterative transfusions iron overload day 29 3 6 9 months randomization overall survival without relapse month 6 month 9 month 12 month 15 post transplant 2 identify prognostic factors spontaneous resolution prca major abo mismatch day 60 month 6 type donor cell stem cell conditioning regimen occurrence acute chronic graft versus host disease discontinuation immunosuppression 3 evaluate interest follow group hemagglutinins 4 compare arms term cost effectiveness cost isatuximab hospitalizations transfusion support chelation treatments secondary endpoints number red blood cell transfusions randomization ferritin levels month 6 month 9 month 15 post transplant adverse events ctc adverse event grade 2 randomization quality life questionnaire eortc qlq c30 v3 day 60 day 100 month 6 month 9 month 12 month 15 post transplant factors associated spontaneous resolution prca day 60 month 6 post transplant antibody level anti anti b titers day 60 day 100 month 6 post transplant visit day 15 day 29 day 45 month 3 month 6 month 9 post randomization number days hospitalization transfusions support chelation treatments design randomized prospective phase ii assessing efficacy safety anticd38 antibody isatuximab persistent prca 6 months allogeneic hematopoietic stem cell transplantation including day 60 transplant help define factors associated unresolved prca month 6 thus identify could benefit isatuximab earlier future interim analysis performed observations 22 events primary endpoint category cat 2 phase 2 population participants allogeneic stem cell transplant recipient 15 years age older prca inclusion criteria aged 15 years older receiving allogeneic hematopoietic stem cell transplantation condition major abo mismatch pcra defined persistent red blood cell transfusion dependence day 60 post transplant reticulocytes count 10 g l despite full donor chimerism good leucocytes 1 g l platelet 50g l recovery relapse progression underlying disease contraception methods must prescribed duration using effective contraceptive methods women childbearing age continue abstinence heterosexual intercourse accepted man period least 5 months last dose refrain donating sperm period health insurance coverage signed written informed consent 2 parents aged less 18 exclusion criteria aged 15 years relapse underlying disease leucocyte chimerism 95 prca related parvovirus b19 infection positive blood pcr known human immunodeficiency virus hepatitis b c active infection active tuberculosis pregnancy hcg positive breast feeding receiving recombinant human erythropoietin receiving proteasome inhibitor bortezomib example receiving thrombopoietin receptor agonists artpo receiving plasma plasmapheresis exchanges transplant planned receive investigational drug within 14 days 5 half lives investigational drug whichever longer clinically significant uncontrolled medical conditions investigator opinion would expose excessive risk may interfere compliance interpretation results hypersensitivity active substance history intolerance steroids mannitol pregelatinized starch sodium stearyl fumarate histidine base hydrochloride salt arginine hydrochloride poloxamer 188 sucrose components therapy amenable premedication steroids h2 blockers would prohibit agents debilitating medical psychiatric illness tutorship curatorship understand informed consent optimal follow experimental isatuximab dose 10 milligrams kilograms intravenous route first injection isatuximab performed randomization month 6 2 days second injection may performed day 15 2d reticulocytes 10 g l third day 29 2d reticulocytes 10 g l assessed day 1 day 15 day 29 day 45 2 months 3 months 6 months 9 months randomization control group supportive care allowed interventions added pre medication infusion isatuximab follow hemagglutinin antibody titers anti anti b titers kinetic immunologic reconstitution pcr hbv donor recipient history hbv infection expected benefits participants society early prca remission first injection isatuximab improvement quality life group global costs reduction isatuximab arm risks added major risks added experimental adverse events expected occurrence reaction infusion fever chills asthenia nausea desaturation bronchospasm grade 1 2 diarrheas grade 1 2 occurrence pneumonia hypogammaglobulinemia number participants included 90 45 randomized inclusion period increased include even 90 expected randomize 45 needed notably less 50 90 enrolled still prca month 6 number centres 24 centers pediatrics adults france duration inclusion period 36 months participation period 13 months post transplant 9 months post randomization total duration 49 months number enrolments expected per site per month 1 2 year center 0 10 month center statistical analysis bilateral logrank test considering sample size 45 randomized 2 1 30 experimental group median transfusion independence h1 1 5 months 15 control group median transfusion independence h1 4 5 months achieves power 86 4 alpha risk 0 05 considering 50 included day 60 randomized 6 months 90 included interim analysis performed observations 22 events primary endpoint funding sources ministry health programme hospitalier de recherche clinique 2019 experimental free supply sanofi company data safety monitoring board yes efficacy anti cd38 monoclonal antibodies prca major abo mismatch six cases anti cd38 monoclonal antibodies prca major abo mismatch post hematopoietic stem cell transplantation reported literature chapuy others 2018 bathini others 2019 rautenberg others 2019 salas others 2019 preethi others 2020 yates others 2021 first one published new england journal medicine august 2018 chapuy others 2018 72 year old man received transplant abo major mismatch presented persistent prca major abo mismatch day 390 post transplant despite strong doses steroids four weekly injections rituximab erythropoietin epo one week first injection daratumumab dose 16 milligrams kilograms resolution prca major abo mismatch observed transfusions stopped continued six weeks total follow 10 months relapse observed anti titer remained high injection daratumumab went negative afterwards immediate delayed secondary effect noted second case published june 2019 bathini others 2019 found similar results prca major abo mismatch completely resolved day 411 despite immunosuppression withdrawal four injections rituximab first injection daratumumab 16 milligrams kilograms isohemagglutinins titer reported rapidly diminished injection four months remained remission prca major abo mismatch presented side effects third case published september 2019 rautenberg others confirms data prca major abo mismatch case resolved first injection daratumumab day 206 post transplant despite previous four rituximab injections day 77 immunosuppression withdrawal day 170 reticulocytes increased rapidly first injection anti titer went 1 1024 zero days three others including two children 17 8 years respectively nonmalignant diseases 2 aplastic anemia 1 immune deficiency experienced successful anti cd38 monoclonal antibodies similar prca allogeneic hematopoietic stem cell transplantation histories details summarized following table another use anti cd38 monoclonal antibodies immune cytopenia post hematopoietic stem cell transplantation daratumumab used three presenting immunological hemolytic anemia post hematopoietic stem cell transplantation refractory four nine lines including strong dose corticosteroid therapy rituximab plasmapheresis bortezomib mycophenolate mofetil amongst others schuetz others 2018 three responded daratumumab first injection received four 11 weekly injections dose 16 milligrams kilograms week two responded sustainably one relapsed died complication two remained persistent remission presenting transient hypogammaglobulinemia requiring intravenous substitution immunoglobulin two 12 months afterwards without possible confirm exact cause hypogammaglobulinemia given treatments already received severe delayed side effect reported potential side effects anti cd38 monoclonal antibodies specific context hematopoietic stem cell transplantation publications specifically reporting side effects anti cd38 monoclonal antibodies hematopoietic stem cell transplantation certain number transplanted multiple myeloma plasma cell leukemia nonetheless exposed due frequent post transplant relapses order get better idea risk specific complications reviewed data 25 exposed daratumumab 2016 2019 due post hematopoietic stem cell transplantation relapse cases 24 25 first exposure median timeframe transplantation daratumumab 4 4 years minimum 1 1 years maximum 8 8 years two severe uncontrolled steroid resistant graft versus host disease together relapse presented aggravation graft versus host disease daratumumab injection without chronology able determine aggravation linked daratumumab injection two died two four months daratumumab due uncontrolled graft versus host disease hematological malignancy responding eleven presented graft versus host disease including two active graft versus host disease time daratumumab begun suffer relapse aggravation data favor increase graft versus host disease risk exposure daratumumab 25 specific complication observed daratumumab hematological tolerance excellent characteristics isatuximab data main secondary effects anti cd38 monoclonal antibodies reported context multiple myeloma association dexamethasone anti plasma cell therapies suffering relapse refractory therapeutic lines commonly observed side effect occurrence reactions injection prevented pre medication link daratumumab cd38 responsible analytical interference indirect antiglobulin test iat due presence cd38 red blood cells interference iat initially complicated transfusional management nevertheless order ensure optimal care anti cd38 complementary techniques developed freeing us technical difficulty also ensuring transfusional safety iats routinely carried test panels dtt treated red blood isatuximab new ig g1 kappa anti cd38 monoclonal antibody deckert others 2014 links selectively specific epitope cd38 pre suggest isatuximab target plasma cells combination mechanisms including antibody dependent cellular cytotoxicity antibody complement dependent cellular phagocytosis cellular cytotoxicity monotherapy main side effects observed martin others 2017 population treated multiple myeloma relapsed failed prior average five lines 1 13 including 81 cases hematopoietic stem cell transplantation doses five 20 milligrams kilograms every two weeks order frequency cytopenias anemia thrombocytopenia neutropenia 98 64 45 respectively including 20 17 12 grade 3 4 however new cytopenia described context treated post hstc prca major abo mismatch post hematopoietic stem cell transplantation immune cytopenia suggesting link underlying illness therapeutic precedents one hand occurrence side effects fatigue 37 nausea 32 diarrhea 20 vomiting 17 diarrhea reported cohort transplanted treated immune mediated hemolytic anemia infection pneumonia 7 seem increased risk given underlying illness neutropenia observed context side effects similar observed treated daratumumab salomon perzynski others 2019 case relapse refractory disease daratumumab seems associated increased risk hepatitis b virus hbv reactivation risk described isatuximab kept mind moment selection pre transplant hbv nuclear antigen testing systematically carried donor recipient randomization hbv nuclear antigen testing hhs antigen systematically carried day 100 post transplant recipient high risk reactivation history hbv infection donor recipient receive specific antiviral prophylaxis line international national recommendations benefits expected receiving experimental reduction number packed red blood cells received six months post transplant reduction number day hospitalizations six months post transplant reduction iron overload consequently duration chelation phlebotomies improvement quality life due anemia resolution diminished iron overload reduction day hospitalizations reduction risk metabolic complications organ damage linked iron overload given data exposed concerning transplanted treated anti cd38 monoclonal antibodies theoretical risks respect administration isatuximab occurrence reaction injection fever asthenia nausea chills desaturation bronchospasm pre medication occurs 45 cases first injection 8 cases subsequent injections reactions grade 1 2 resolved spontaneously dexchlorpheniramine dexamethasone paracetamol day onset diarrhea grade 1 2 20 cases occurrence pneumonitis 7 cases occurrence hypogammaglobulinemia hypersensibility drug used premedication could also observed exceptional examinations carried part follow experimental similar carried follow transplant supplementary blood samples 15 ml taken protocol visit follow isohemagglutinins titers immune reconstitution invasive radiological examination required within protocol absence grade 2 side effects reported treated anti cd38 antibodies post hematopoietic stem cell transplantation prca major abo mismatch auto immune hemolytic anemia favor favorable benefit risk balance pure red cell aplasia prca major abo mismatch observed 10 transplanted major abo mismatch donor b ab recipient anti anti b isohemagglutinins commonly defined persistence erythroblastopenia reticulocytes lower 10 g l despite predominantly donor leukocyte chimerism 60 days transplant presenting prca major abo mismatch produce red blood cells transfusions needed rate two packs red blood cells every 14 days average 50 evolution favorable day 60 day 180 due natural disappearance plasma cells producing antibodies transfused months years extreme cases repeated transfusions associated allo immunization risk potentially leading transfusional deadlock side effects repeated transfusions significant iron overload requiring chelators phlebotomies upon resolution sometimes side effects alteration quality life repeated day hospitalizations asthenia arising chronic anemia liver damage heart failure endocrinological problems large iron overload extra costs treatments evaluated anglophone literature strong doses corticoids monoclonal anti cd20 antibodies plasmapheresis proteasome inhibitors proven efficacy responsible significant side effects notably increased immunodeficiency donor lymphocytes injections may effective associated risk acute chronic graft versus host disease graft versus host disease monoclonal anti cd38 antibody isatuximab targets cd38 plasma cells responsible synthesis anti anti b isohemagglutinins could reduce timeframe red blood cell recovery literature concerning use anti cd38 antibodies presenting post transplant immune mediated cytopenia auto immune hemolytic anemia erythroblastopenia unresponsive treatments supports rapid response median one injection therefore aims evaluate efficacy monoclonal anti cd38 antibodies prca persistent major abo mismatch six months post transplant knowing whether received median transfusional independence nine months hypothesis reduce time resolution isatuximab group six weeks main objective demonstrate efficacy prca isatuximab allogeneic hematopoietic stem cell transplant compared supportive care control group reduction prca resolution time days secondary objectives evaluate two arms term biological outcomes reduction erythrocyte transfusion needs isatuximab evolution iron overload adverse events related isatuximab context allogeneic sct ctc adverse event grade 2 group month 6 post transplant quality life functional repercussions chronic anemia iterative transfusions iron overload day 29 3 6 9 months month 6 post transplant overall survival without relapse month 6 month 9 month 12 month 15 post transplant identify prognostic factors spontaneous resolution prca major abo mismatch day 60 month 6 type donor cell stem cell conditioning regimen occurrence acute chronic graft versus host disease early withdrawal immunosuppressive therapy evaluate interest follow group hemagglutinins compare arms term cost effectiveness cost isatuximab hospitalizations transfusion support chelation treatments time transfusion independence prca time interval randomization corresponding month 6 post transplant resolution prca date resolution reticulocytopenia treated anti cd 38 monoclonal antibody isatuximab number red blood cell transfusions randomization arm date last transfusion ferritin levels month 6 month 9 month 15 post transplant adverse events ctc adverse event grade 2 randomization arm quality life questionnaire eortc qlq c30 v3 day 60 day 100 month 6 month 9 month 12 month 15 post transplant factors associated spontaneous resolution prca day 60 month 6 post transplant hemagglutinins titers anti anti b titers day 60 day 100 month 6 post transplant visit day 15 day 29 day 45 month 3 month 6 month 9 post randomization number days hospitalization transfusions support chelation treatments antibody level anti anti b titers day 60 day 100 month 6 post transplant visit day 15 day 29 day 45 month 3 month 6 month 9 post randomization number days hospitalization transfusions support chelation treatments therapeutic phase ii multicenter national open randomized parallel group 2 1 ratio experimental national multi center including 22adult pediatric transplant centers sfgm tc arm randomization assigned visit randomization recruited adult pediatric hematology departments affiliated sfgm tc perform allo hematopoietic stem cell transplantation two thousand allo hematopoietic stem cell transplantation currently performed france inclusion period increased include even 90 expected randomize 45 needed notably less 50 90 enrolled still prca month 6 different situations temporary discontinuation investigator document reason discontinuation recurrence subject source file case report form early discontinuation subject remains end participation investigator document reason early discontinuation termination participation investigator must document reason collect assessment criteria time ending participation participant agrees plan follow subject especially event serious adverse event detailed guidelines management infusion reactions isatuximab intravenous infusion provided paragraph 7 1 case serious adverse events reported investigator sponsor followed protocol follow period notification serious adverse event sent email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction sponsor serious adverse event tracked resolved independent monitoring committee set may specify validate terms monitoring participants may exit time reason investigator temporarily permanently withdraw participant safety reason participants best interests participant lost follow participant cannot located investigator must make every effort reconnect participant document attempts source file least determine whether participant alive dead participant exits prematurely withdraws consent data collected prior date premature exit may still used case serious adverse events see corresponding section vigilance case report form must list various reasons participant discontinued lack efficacy adverse reaction another medical issue personal reasons participant explicit withdrawal consent lost follow follow subjects following discontinuation participation discontinuation subject participation change usual take care disease event serious adverse events early discontinuation participation see paragraph 6 4 1 procedures replacement subjects analysis intention treat included analyzed therefore replacement procedure unless consent withdrawn inclusion period still open full partial discontinuation ap hp sponsor competent authority prematurely discontinue part temporarily permanently recommendations data safety monitoring board following situations first suspected unexpected serious adverse reactions susars observed one arms discrepancy serious adverse reactions arms requiring reassessment benefit risk ratio similarly ap hp sponsor competent authority may decide prematurely discontinue due unforeseen issues new information product light objectives program unlikely achieved ap hp sponsor reserves right permanently suspend enrolment time appears inclusion objectives met prematurely discontinued safety reasons decision justification provided sponsor ap hp competent authority research ethics committee without undue delay later 15 days date temporary halt early termination shall include reasons action specify follow measures along recommendations data safety monitoring board case substantial modification initial notification severe adverse event must provided written report signed investigator using severe adverse event notification form specific intended purpose case report form item form must completed investigator sponsor carry appropriate analysis initial notification sponsor serious adverse event must quickly followed additional detailed written report reports case outcome may monitored safety department provide information whenever possible investigator provide sponsor documents may useful medical reports laboratory test results results additional examinations etc documents must non identifying addition documents must include following acronym number participants initials adverse event monitored fully resolved stabilization level considered acceptable investigator return previous state even participant left initial notification severe adverse event follow reports documents must sent sponsor safety department email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction noted possible send severe adverse event reports safety department fax 33 0 1 44 84 17 99 event failed attempt send severe adverse event report email order avoid duplication use e crfs investigator completes severe adverse event notification form e case report form validates prints signs form sending email possible connect e case report form investigator complete sign send severe adverse event notification form safety department soon connection restored severe adverse event notification form e case report form must duly completed investigator must respond requests sponsor additional information questions relating notification adverse event safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction cases utero exposure investigator complete notification follow form pregnancy occurring participation investigator must monitor pregnant woman throughout pregnancy pregnancy terminated must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage pregnancy termination fetal death congenital abnormality etc investigator must follow procedure reporting saes initial pregnancy notification severe adverse event follow reports documents sent sponsor according procedures specified herein father exposed investigator must obtain pregnant woman permission collecting information pregnancy computer file used implemented accordance french amended informatique et libertes law governing data protection european general data protection regulation gdpr regulations france commitment comply reference methodology medium risk 001 governed commission nationale informatique et libertés french data protection agency reference methodology processing personal data used within scope health research amended medium risk 001 ap hp sponsor signed declaration compliance reference methodology aged 15 years older receiving allogeneic hematopoietic stem cell transplantation condition major abo mismatch pcra defined persistent red blood cell transfusion dependence day 60 post transplant reticulocytes count 10 g l despite full donor chimerism good leucocytes 1 g l platelet 50g l recovery relapse progression underlying disease contraception methods must prescribed duration using effective contraceptive methods women childbearing age continue abstinence heterosexual intercourse accepted man period least 5 months last dose refrain donating sperm period health insurance coverage signed written informed consent 2 parents aged less 18 aged 15 years relapse underlying disease leucocyte chimerism 95 prca related parvovirus b19 infection positive blood pcr known human immunodeficiency virus hepatitis b c active infection active tuberculosis pregnant hcg positive breast feeding receiving recombinant human erythropoietin receiving proteasome inhibitor bortezomib example receiving thrombopoietin receptor agonists artpo receiving plasma plasmapheresis exchanges transplant planned receive investigational drug within 14 days 5 half lives investigational drug whichever longer clinically significant uncontrolled medical conditions investigator opinion would expose excessive risk may interfere compliance interpretation results hypersensitivity active substance history intolerance steroids mannitol pregelatinized starch sodium stearyl fumarate histidine base hydrochloride salt arginine hydrochloride poloxamer 188 sucrose components therapy amenable premedication steroids h2 blockers would prohibit agents debilitating medical psychiatric illness tutorship curatorship understand informed consent optimal follow persons responsible quality control take necessary precautions ensure confidentiality information relating investigational medicinal products participants particular identity results obtained persons well investigators bound professional secrecy data collected concerning participants sent sponsor investigators specialised collaborators rendered non identifying circumstances shall names addresses participants involved shown sponsor ensure participant given written permission personal information strictly necessary quality control accessed non identifying data entered electronically via web browser analysis populations following analysis sets considered intent treat analysis included considered randomization arms refer primary analyses analysis per protocol consider arm effectively received analyses intent to treat per protocol analyses performed sensitivity analysis general strategy characteristics presented using summary measures median interquartile range quantitative characteristics counts percentages categoriel characteristics flow chart summarize screened included analysed analysis primary efficacy endpoint delays obtention transfusion independence prca compared using logrank test impacts resolutions estimated arm using kaplan meier estimator 95 confidence intervals censored end follow case competing event occurring follow death without resolution logrank test replaced gray test kaplan meier estimator gray cumulative incidence estimator interim analysis performed observations 22 events primary endpoint case significant logrank test interim analysis stopped final analyses performed still going final p value calculated using combination p values first step second step using wassmer approach wassmer gernot planning analyzing adaptive group sequential survival trials biometrical journal journal mathematical methods biosciences 48 4 2006 714 729 moreover requested data safety monitoring board sample size recalculation could performed analysis secondary endpoints number red blood cells received result pcra randomization month 6 post transplant group month 15 number described per arm median iqr compared arms using wilcoxon test event death number units considered maximum date last transfusion time last transfusion date compared arms using logrank test censored end follow case competing event occurring follow death without stopping transfusions logrank test replaced gray test evolution ferritin month 6 month 9 month 15 transplant modelled using random effect general linear regression model time effect evaluation adverse events grade 2 observed group randomization month 6 post transplant severe adverse event described arm frequencies compared using fisher test quality life assessment eortc c30 v3 day 60 month 6 month 9 month 12 month 15 post transplant questionnaires described arm median iqr modelled using random effect general linear regression model time effect overall survival without relapse month 6 month 9 month 12 month 15 post transplant estimated per arm using kaplan meier estimator 95 confidence intervals censored end follow compared using logrank test factors associated spontaneous resolution pcra day 60 month 6 post transplant explored using cox model follow plasma anti anti b antibody titers day 60 month 6 post transplant visit day 15 day 29 day 45 3 6 9 months randomization visit described arm median iqr modelled using random effect general linear regression model time effect assessment costs pcra without isatuximab cost day full hospitalizations directly related pcra erythrocyte transfusion support necessary chelation treatments economic evaluation assess costs effectiveness safety treatments analysis conducted health system perspective 9 month period health resources necessary collected prospectively include inpatient outpatient testing consultations imaging home care health care costs estimated using combination resource event based methods total length stay extracted hospital information system indexed admission thus subsequent admissions related event 9 month follow period hospitalization costs allocated according groups related severity diagnosis adjusted according length stay cost admission estimated national cost using actual length stay daily cost non hospital resources estimated electronic case report form medical records discharge orders interviews follow visits addition collect information consultations drugs laboratory tests non hospital resources assessed using recent price rate schedule total average cost per calculated group 95 start interval estimated costs compared using non parametric tests,"graft, transplantation, host, versus, stem, cell, disease, haplo, transplant, donor"
EQUAALL01_PROTOCOLE - VF_v4-0_20240403,5,41.869793,5.845483,full title evaluation long term health status quality life adult survivors philadelphia negative acute lymphoblastic leukemia lymphoma treated intensive pediatric pediatric inspired inspired protocol acronym equaall01 coordinating investigator pr nicolas boissel hematology department saint louis hospital 33142499643 nicolas boissel assistance publique hôpitaux de paris shortening fraction sponsor assistance publique hopitaux de paris scientific justification overall survival adult 15 59y philadelphia negative acute lymphoblastic leukemia lymphoma dramatically improved use full pediatric pediatric inspired protocols graall2003 05 ll03 fralle2000 aimed reduce risk relapse adopting intensive chemotherapeutical schedule approach led global improvement overall survival 5y overall survival 57 whatever age responsible excess related mortality older 45 years 5y trm 45y 19 pediatric longitudinal pointed long term leukemia survivors increased risk developing specific adverse events like dysmetabolic syndrome obesity decreased fertility organ dysfunction osseous events impaired cognitive functions aims evaluate impact term long term events quality of life adult received intensified therapeutic approach recently implemented adult cooperative groups main objective primary endpoint evaluate prevalence late effects adult treated 10 years ago intensified pediatric inspired protocol graall2003 05 ll03 fralle2000 exposed increased cumulative doses chemotherapy central nervous system irradiation w allogeneic transplant total body irradiation based regimen w boost irradiation central nevous system primary endpoint thus defined prevalence adverse events including metabolic troubles dysmetabolic syndrome dyslipidemia diabetes osseous events osteoporosis cardiac vascular troubles neurologic troubles lung dysfunctions endocrinal troubles ophthalmological troubles fertility disorders secondary neoplasia secondary objectives endpoints evaluate quality life correlate prevalence late effect quality of life status previous social situation previous medical condition schemes including administration protocols phases delayed intensification maintenance central nervous system irradiation allogeneic sct graft versus host disease occurrence elaborate risk adapted recommendations long term follow adult treated reinforced therapeutic strategies secondary endpoints thus prevalence metabolic troubles dysmetabolic syndrome dyslipidemia diabetes prevalence osseous events osteoporosis prevalence cardiac vascular troubles prevalence neurologic troubles prevalence lung dysfunctions prevalence endocrinal troubles quality life sf 36 prevalence ophthalmological troubles prevalence fertility disorders prevalence secondary neoplasia design multicenter cross sectional interventional minimal risks constraints human research population participants adult aged 15 59y diagnosis treated ten years ago ph1 negative acute lymphoblastic leukemia lymphoma inclusion criteria philadelphia negative treated according pediatric like pediatric inspired protocol graall fralle without allogeneic transplant older 15 years old less 60 years old diagnosis follow first complete remission 10 years gave informed signed consent baseline examination exclusion criteria experienced relapse within 5 past years philadelphia positive interventions product investigation none interventions added hormons tests antral follicle count us questionnaire expected benefits participants society expected individual benefit since systematic reviews used detect take early care late complications related minimal risks constraints added none scope risk minimal number participants included 300 number sites approximatively 36 centers graall network schedule state inclusion period 66 months participation period 9 months total duration 75 months number enrolments expected per site per month 300 36 sites 66 months inclusion period 1 month site statistical analysis analysis handle left data truncation given survive 2016 able included approximately 1000 included graall 2003 2005 among 630 august 2009 considering 363 630 alive last follow opportunity include treated according protocols 80 inclusion success approximately 300 recruited allows assessing prevalence troubles 95 ci width 7 assuming 10 prevalence 0 10 assuming 30 prevalence detection 2 5 2 respectively also allows reaching statistical power least 80 detecting 2 sources monetary support ministry health primary objective equaall evaluate global prevalence late effects adult treated 10 years ago intensified pediatric inspired protocol graall2003 05 ll03 fraall2000 exposed increased cumulative doses chemotherapy central nervous system irradiation without allogeneic transplant total body irradiation based regimen w boost irradiation central nevous system secondary objectives equaall evaluate quality life correlate prevalence late effect quality of life status previous current social situation previous medical condition schemes including administration protocols phases delayed intensification maintenance central nervous system irradiation graft versus host disease occurrence allogeneic sct elaborate risk adapted recommendations long term follow adult treated reinforced therapeutic strategies binary composite endpoint defined prevalence adverse events including following adverse events metabolic troubles dysmetabolic syndrome dyslipidemia diabetes osseous events osteoporosis cardiac vascular troubles neurologic troubles lung dysfunctions endocrinal troubles ophthalmological troubles fertility disorders secondary neoplasia prevalence metabolic troubles dysmetabolic syndrome dyslipidemia diabetes prevalence osseous events osteoporosis prevalence cardiac vascular troubles prevalence neurologic troubles prevalence lung dysfunctions prevalence endocrinal troubles quality life sf 36 prevalence ophthalmological troubles prevalence fertility disorders prevalence secondary neoplasia multicentre cross sectional interventional philadelphia negative treated according graall2003 05 ll03 fraall2000 trials invited participate previously included graall03 05 trials also treated according protocols considered inclusion actually trials included 225 730 respectively 94 276 died table 1 table 1 sample sizes outcomes included graall03 05 trials representativeness sample recruited final proportions graall network trials match original trials attempt made balance exactly across cross stratifications centre thus representative sampling estimate potential accrual phone call performed among participating centres cross sectional design commonly used epidemiologic advantage design information whole history obtained time require expensive follow cohort especially rare diseases moreover included standardized protocols exposure variables including exposures potential confounders already available original trials thus mostly avoiding recall bias note epidemiology setting benefit early diagnosis health troubles may benefit medical care however important aware data truncation distorts data set potential cause large biases indeed cross sectional survey right left truncation occur due selection random time particular individuals longer lifetimes favoured sampling process thus one hand died adverse events sampled left truncation hand late adverse events represented right truncation way avoiding truncation bias design apply cross sectional one collect data old enough late adverse events requires long term recall alternatively bias handled analysis using statistical modelling used project see statistical methods section conducted among centers cooperative graall network initially treated network used federate translational academic industrial research programs includes 36 centers research subjects identified follows centre 3 numerical positions selection order person center 4 numerical positions surname initial first name initial reference unique retained entire research period enrolment period 66 months duration participation 9 months total duration 75 months selected informed agreed participation protocol contacted inclusion visit visit eligibility evaluated inclusion non inclusion criteria consent signed investigator included connecting electronic case report form selected unable visit site due distance relocation informed research telephone agrees take part protocol receive written information consent form post address asked sign return investigator received form send duplicate signed parties appointment made teleconsultation quality life questionnaire sf 36 stamped letter sent completion return identification number allocated detailed data collection would vital characterize participants functional status assess current health identify cases prevalent diseases actually different measures performed realized year except blood tests concerning metabolic syndrom 6 months within three months inclusion according centers policy antral follicle count us amh non menopausal females questionnaires quality of life sf 36 assess investigator center inclusion visit procedures added research measures exams performed outside center investigator give prescription report send results investigator center conducted among centers cooperative graall network initially treated near present place residence network used federate translational academic industrial research programs graall network comprises 33 french centers involved acute leukemia center responsible recruitment inclusion measurements performed enrolled participants may exit time reason participant lost follow participant cannot located investigator must make every effort reconnect participant document attempts source file least determine whether participant alive dead investigator temporarily permanently withdraw participant safety reason participant best interests participant exits prematurely data participant may used consent withdrawn participant exits prematurely state procedure schedule collecting data required protocol primary endpoint secondary endpoints safety assessment state premature exit affect participant ongoing care state exactly participant offered participant exits prematurely withdraws consent data collected prior date premature exit may still used case report form must list various reasons participant exited withdrawn medical problem subject personal reasons explicit withdrawal consent computer file used research implemented accordance french amended informatique et libertes law governing data protection european general data protection regulation gdpr regulations request authorisation commission nationale informatique et libertés french data protection agency included eligibility criteria inclusion criteria none exclusion criteria must fulfilled checked persons philadelphia negative treated according pediatric like pediatric inspired protocol graall fralle without allogeneic transplant older 15 years old less 60 years old diagnosis follow first complete remission 10 years gave informed signed consent baseline examination experienced relapse within 5 past years philadelphia positive data entry carried electronic media via web browser staff dedicated task center restricted access investigators cross sectional survey collects data make inferences population interest universe one point time analysis handle data truncation given survive free relapse 2016 able included adverse events occur within first years end protocol could observed yet common method modelling binomial health data related observation adverse event cross sectional long logistic analysis model estimate prevalence ratios 95 confidence interval 95 ci instead odds ratios search potential risk factors using log binomial models previously recommended cross sectional diseases injuries rare barros 2003 petersen 2008 however due cross sectional sampling included virtue survived time enrolment could died diagnosis enrolment therefore removed risk set two time points leave risk set would bias survival estimates resulting called left data truncation words estimate incidence adverse events time first enrolment would observe survival bias thus nonparametric maximum likelihood estimator npmle distribution function observed truncation used efron 1999 finally inverse probability weighting ipw approach used causal inference purposes robins1999 analysis based r software http www r project org packages survival therneau 2014 dtda moreira 2010 barros aj hirakata vn alternatives logistic regression cross sectional empirical comparison models directly estimate prevalence ratio bmc med res methodol 2003 3 21 efron b petrosian v 1999 nonparametric methods doubly truncated data journal american statistical association 94 824 834 carla moreira jacobo de una alvarez rosa crujeiras dtda r package analyze randomly truncated data journal statistical software 2010 37 7 1 20 url http www jstatsoft org v37 i07 petersen medium risk deddens ja comparison two methods estimating prevalence ratios bmc med research methodol 2008 8 9 doi 10 1186 1471 2288 8 9 robins jm marginal structural models versus structural nested models tools causal inference halloran berry eds statistical models epidemiology environment trials new york ny springer verlag new york 1999 95134 therneau 2014 package survival analysis r package version 2 37 7 url http cran r project org package survival,"prevalence, graall, concentration, treated, leukemia, activity, survival, nervous, central, responders"
D1_2023-505977-34-00_Protocol_V1.1_16102024_MSC-AT-SSC,3,-28.995077,-17.345552,full title phase ii randomized allogeneic adipose tissue derived mesenchymal stromal cells systemic infusion severe systemic sclerosis acronym reference mesenchymal stromal cells systemic sclerosis coordinating investigator scientific director prof dominique farge mathec centre de reference des maladies auto immunes systemiques rares dile de france filiere fai2r irsl ea 3518 universite de paris hopital saint louis 1 avenue claude vellefaux 75010 paris sponsor assistance publique hopitaux de paris scientific justification systemic sclerosis systemic sclerosis rare severe chronic systemic autoimmune disease autoimmune disease characterized vasculopathy immune dysregulation fibrosis leading multi organ dysfunction primarily skin lungs heart gastrointestinal tract kidneys high morbidity mortality altered health related quality life high cost society mostly symptomatic autologous hematopoietic stem cell transplantation autologous hematopoietic stem cell transplantation shown long term improvement overall event free survival disease modifying properties however autologous hematopoietic stem cell transplantation contra indicated case advanced visceral involvement eligible still associated risk toxicity urgent need identify safe effective treatments severe systemic sclerosis mesenchymal stromal cells mesenchymal stromal cells multipotent cells carry immunomodulatory pro angiogenic anti fibrotic properties target systemic sclerosis pathogenesis manifestations increasing use mesenchymal stromal cells harvested bone marrow mesenchymal stromal cells adipose tissue mesenchymal stromal cells umbilical cord mesenchymal stromal cells uc variety indications provides consistent evidence supporting safety humans efficacy mesenchymal stromal cells intravenous intravenous infusion injection treating acute graft versus host disease led marketing approval 2012 mesenchymal stromal cells alofisel approved severe crohns fistula 2018 mesenchymal stromal cells represent promising therapeutic approach systemic sclerosis previously shown disease specific abnormalities mesenchymal stromal cells systemic sclerosis providing strong rationale use allogeneic mesenchymal stromal cells treat systemic sclerosis b published first phase ii dose escalation using allogenic mesenchymal stromal cells infusion 20 severe systemic sclerosis clinicaltrials gov nct02213705 programme hospitalier de recherche clinique aom 11 250 safety issues significant improvement skin fibrosis 3 6 months infusion appeared lower thereafter thereby supporting need repeated infusions vitro experimental suggest mesenchymal stromal cells properties vary according tissue origin source demonstrated compared mesenchymal stromal cells mesenchymal stromal cells easier harvest display higher proliferative capability entering senescence higher genetic stability superior immunosuppressive properties considering rationale hypothesize use healthy donors allogeneic mesenchymal stromal cells produced etablissement francais du sang event-free survival demonstrate safety issues b efficacy profile increase repeated infusion allogeneic mesenchymal stromal cells treat systemic sclerosis main objective primary endpoint main objective evaluate safety one month allogeneic 2x106 mesenchymal stromal cells kilograms intravenous administration twice 3 months interval month 0 month 3 severe systemic sclerosis primary endpoint rate related severe adverse events severe adverse event defined adverse events adverse event grade equal 3 using national cancer institute common terminology criteria adverse events common terminology criteria for adverse events v5 0 classification one month infusion month 1 month 4 adverse events adjudicated data safety monitoring committee secondary objectives endpoints secondary objectives safety infusion within first 24 hours infusion follow efficacy signals inform future using outcome measures skin sclerosis lung function quality life previously validated systemic sclerosis used cell therapy trials analysis response progression free survival progression-free survival global rank composite score global rank composite score month 3 m6and month 12 american college of rheumatology provisional composite response index trials early diffuse cutaneous systemic sclerosis acr provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis early systemic sclerosis month 3 month 6 month 12 analysis overall survival assess causes death impact allogeneic mesenchymal stromal cells intravenous infusion twice 3 months interval immune response including immunophenotyping alloimmunization month 6 starting therapy cost effectiveness allogeneic mesenchymal stromal cells infusion twice versus severe systemic sclerosis secondary endpoints rate related severe adverse event defined adverse event grade equal 3 common terminology criteria for adverse events v5 0 time within first 24 hours infusion follow month 0 month 3 month 6 month 9 month 12 main efficacy endpoint modified rodnan skin score modified rodnan skin score difference month 0 month 12 efficacy disease related endpoints modified rodnan skin score month 3 month 6 month 9 performance status performans status (= ecog) health related quality life health-related quality of life questionnaires scleroderma health assessment questionnaire scleroderma-health assessment questionnaire short form 36 health survey sf 36v2 eq 5d 5l month 0 month 3 month 6 month 12 forced vital capacity forced vital capacity diffusing capacity lung carbon monoxide diffusing capacity of lung for carbon monoxide month 0 month 6 month 12 response defined following decreased modified rodnan skin score 25 increased forced vital capacity 10 increased diffusing capacity of lung for carbon monoxide 10 without need immunosuppression except low dose steroids 10mg daily month 3 month 6 month 12 progression-free survival month 12 progression defined following decreased forced vital capacity 10 diffusing capacity of lung for carbon monoxide 15 decrease lvef 15 decrease weight 15 decrease creatinine clearance 30 increased modified rodnan skin score 25 increase scleroderma-health assessment questionnaire 0 5 global rank composite score values month 3 month 6 month 12 acr provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis values early systemic sclerosis month 3 month 6 month 12 overall survival month 12 myeloid lymphocyte sub populations included month 0 month 1 month 3 month 4 month 6 alloimmunization included detection identification donor specific anti human leukocyte antigen antibodies month 0 month 3 month 6 extra cost per quality-adjusted life year quality adjusted life year gained unique repeated intravenous infusion infusion allogeneic mesenchymal stromal cells severe systemic sclerosis 12 months extra cost per severe adverse event grade equal 3 common terminology criteria for adverse events avoided unique repeated intravenous infusion infusion allogeneic mesenchymal stromal cells severe systemic sclerosis 12 months design multi centre three arm randomized placebo controlled double blind phase ii category category 2 population participants adult refractory severe systemic scleroderma inclusion criteria provide signed dated informed consent willing comply procedures available duration male female aged 18 70 years age systemic sclerosis according american college rheumatology european league rheumatism american college of rheumatology european league against rheumatism 2013 classification criteria systemic sclerosis severe disease either disease duration 2 years less modified rodnan skin score modified rodnan skin score 20 abnormal c reactive protein 5 milligrams l hemoglobin 11 g deciliter modified rodnan skin score 15 without restriction disease duration plus least one major organ involvement defined respiratory involvement consisting lung diffusion capacity carbon monoxide diffusing capacity of lung for carbon monoxide forced vital capacity forced vital capacity 80 predicted evidence interstitial lung disease chest x ray high resolution computed tomography hrct scan moderate pulmonary hypertension baseline resting systolic pulmonary arterial pressures 35 mmhg 50 mmhg cardiac echocardiography mean pulmonary artery pressure 20 mmhg 40 millimeter hg right heart catheterization renal involvement consisting past renal crisis microangiopathic hemolytic anemia renal insufficiency explained causes systemic sclerosis cardiac involvement consisting reversible congestive heart failure atrial ventricular rhythm disturbances recurrent episodes atrial fibrillation flutter recurrent atrial paroxysmal tachycardia 2nd 3rd degree av block mild moderate pericardial effusion presence magnetic resonance imaging involvement increased t1 t2 mapping late gadolinium enhancement septal sign causes organ involvement attributed systemic sclerosis contraindication inadequate response unwillingness undergo autologous hematopoietic stem cell transplantation determined physician judgement contraindication inadequate response unwillingness adverse events necessitating discontinuation conventional immunosuppressive therapy mycophenolate mofetil methotrexate women reproductive potential must use highly effective contraception men reproductive potential must use condoms health insurance nb authorized contraceptive methods women childbearing age absence permanent sterilization oral intravaginal transdermal combined hormonal contraception oral injectable implantable progestogen hormonal contraception intrauterine device intrauterine device intrauterine hormonal releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence preferred usual lifestyle participants man absence permanent sterilization sexual abstinence condoms exclusion criteria age 18 years 70 years pregnancy unwillingness use adequate contraception life threatening end organ damage defined diffusing capacity of lung for carbon monoxide corrected hemoglobin 30 predicted left ventricular ejection fraction 40 cardiac echocardiography pulmonary hypertension baseline resting systolic pulmonary arterial pressures 50 mmhg cardiac echocardiography mean pulmonary artery pressure 40 mmhg right heart catheterization glomerular filtration rate 30ml min active chronic hepatitis aspartate amino transferase alanine-aminotransferase 3 upper limit normal neoplasms less 5 years except basal cell situ cervix carcinoma concurrent myelodysplasia uncontrolled hypertension uncontrolled acute chronic infection human immunodeficiency virus 1 human immunodeficiency virus 2 infection body mass index 16 5 kilograms month 2 severe psychiatric disorder bone marrow insufficiency defined neutropenia 1 x 109 l thrombopenia 50 x 109 l anemia 8 g deciliter lymphopenia 0 5 x 109 l inability provide informed consent included another interventional tutelle investigational medicinal product allogeneic adipose tissue derived mscs mesenchymal stromal cells placebo injected slow intravenous infusion according recipient body weight experimental arms arm 0 placebo month 0 month 3 arm 1 1 mesenchymal stromal cells 2x106 cells kilograms injection month 0 1 placebo injection month 3 arm 2 1 mesenchymal stromal cells 2x106 cells kilograms injection month 0 1 mesenchymal stromal cells 2x106 cells kilograms injection month 3 allogeneic mesenchymal stromal cells administered intravenously 45 min 1h infusion second infusions drug product mesenchymal stromal cells placebo performed absence related severe adverse events trsae included arm 1 arm 0 opportunity according willingness receive either 1 arm 1 1 2 arm 0 mesenchymal stromal cells 2x106 cells kilograms injection end unblinding evidence mesenchymal stromal cells injection safety provided comparator placebo interventions added administration allogeneic adipose tissue derived mscs mesenchymal stromal cells 1 two injections placebo 1 two injections supplementary visits 1 month injection basic blood urine evaluation supplementary blood sampling eligibility evaluation infectious serology hcg women advanced immunophenotyping alloimmunisation investigations baseline follow evaluations constitution biological samples collection skin biopsies optional month 0 month 3 month 6 notebook cost effectiveness analysis expected benefits participants society based strong experimental data copi k tarte published results team 20 severe systemic sclerosis previously treated single intravenous infusion allogeneic mesenchymal stromal cells infusion nct02213705 strong rationale systemic sclerosis symptoms improved mesenchymal stromal cells least fibrosis skin score regression lung function stabilization 3 6 months results proposed used inform larger phase ii iii multi center mesenchymal stromal cells systemic sclerosis trials auto immune diseases potential accelerate systemic sclerosis allow france playing leadership role regenerative medicine autoimmune disease fibrotic diseases risks burdens added increasing use mscs wide variety therapeutic indications currently provides wealth data favour safety humans foreseeable serious adverse effects associated injection mscs transient benign adverse reactions linked procedure injecting cells placebo may occur number participants included 18 number centres 1 centre unite de medecine interne uf 04 mathec centre de reference des maladies auto immunes systemiques rares dile de france filiere fai2r irsl urp 3518 universite de paris hopital st louis ap hp 1 avenue claude vellefaux 75010 paris france dominique farge md phd 2 centres recruitment follow unite de medecine interne uf 04 mathec centre de reference des maladies auto immunes systemiques rares dile de france filiere fai2r irsl urp 3518 universite de paris hopital st louis ap hp 1 avenue claude vellefaux 75010 paris france dominique farge md phd service de medecine interne et immunologie clinique pole hospitalo universitaire des maladies digestives chu rangueil bat h2 3eme etage 1 avenue du pr jean poulhes tsa 50032 31059 toulouse cedex 9 gregory pugnet md phd duration inclusion period 12 months participation period follow 12 months plus possibly 3 months additional follow placebo arm arm 0 arm 1 chosen opportunity receive one two mesenchymal stromal cells injection end unblinding evidence mesenchymal stromal cells injection safety provided 2 months unblinding mesenchymal stromal cells injection total duration 29 months number enrolments expected per site per month 0 5 inclusion per site per month statistical analysis propose conduct multi center three arm randomized double blind placebo controlled enroll total 18 systemic sclerosis 1 1 1 randomized one two arms 1 infusion mesenchymal stromal cells month 0 2 infusions mesenchymal stromal cells month 0 month 3 placebo arm total 6 per arm using randomization block size 6 inclusions staggered allow detection severe adverse event prior inclusion subsequent according following waiting rules least one week two consecutive randomizations interval least one month every three randomizations continuous monitoring primary endpoint sponsor implemented allow continuous bayesian toxicity monitoring stopping rule implemented primary endpoint cell infusions see section 13 details first analysis first 3 completed month 1 visits analysis trsae month 1 month 4 visits final analysis stopping rule defined based estimated probability risk related severe adverse events trsae 15 criterion 1 probability posteriori probability severe adverse event 15 posterior probability trsae trsae estimated using bayesian approach beta density stopping rule fulfilled criterion 1 0 70 meaning high probability greater 15 risk trsae interim analyses results presented data safety monitoring board recommendation case early stopping subsequent randomized treated thus far followed results analyzed described formal statistical test sample size bayesian framework nevertheless one invoke frequentist framework anticipate expected precision terms safety indeed 18 infusions 6 1 infusion 6 2 infusions able estimate risk severe adverse events severe adverse event 10 width exact 95 confidence interval equal 32 considering independence infusions data safety monitoring board yesthe data safety monitoring board data safety monitoring board composed 3 external reviewers expertise systemic sclerosis mesenchymal stromal cells early phase trials case safety data reported safety department data safety monitoring board informed hold meeting determine whether held proceed vitro early support use allogeneic mesenchymal stromal cells systemic sclerosis reviewed details team 30 vitro mesenchymal stromal cells immunomodulatory immunosuppressive properties mesenchymal stromal cells exert immunomodulatory immunosuppressive effects innate adaptive immune cells wide panel mechanisms 35 36 vitro data showed mesenchymal stromal cells modulate immunological activity different cell populations engaged pathogenesis systemic sclerosis led us others evaluate mesenchymal stromal cells potential therapeutic values systemic sclerosis 29 30 first mesenchymal stromal cells inhibit dc differentiation maturation cytokine expression capacity present antigens lymphocytes 69 70 influence antigen presentation dc via downregulation dc cell surface expression mhc class ii cd11c cd83 modulate anti inflammatory action 71 mesenchymal stromal cells directly modulate cell activation proliferation differentiation effector function mesenchymal stromal cells inhibit proliferation naive memory cd4 cd8 cells arrest g0 g1 phase cell cycle 72 abrogate cell activation 7376 interestingly mesenchymal stromal cells also influence differentiation naive cd4 helper cells promoting anti inflammatory immune responses affect balance cell polarization 77 thereby inflammatory setting mesenchymal stromal cells appear increase number activity treg cells il 10 expression suppressing t helper 1 cell th2 t helper 17 cell cells 78 79 mesenchymal stromal cells reduce release pro inflammatory cytokines different cell populations including ifn tnf il 6 il 7 increase anti inflammatory cytokines il 4 il 10 77 80 mesenchymal stromal cells also inhibit il 2 induced proliferation resting nk cells partially inhibit proliferation activated nk cells thereby nk mediated cytotoxicity 81 besides mesenchymal stromal cells also inhibit b cell proliferation antibody production chemotaxis inflammatory conditions 73 82 favour breg expansion inhibition b cell proliferation appears indirect requires presence cd4 cd8 cell lymphocytes 83 mesenchymal stromal cells effects mediated part direct cell cell contact mesenchymal stromal cells effects paracrine exerted secretion soluble factors typically mechanism action mesenchymal stromal cells first involves release chemokines allowing attraction activated cells 33 produce proinflammatory cytokines responsible priming mesenchymal stromal cells towards immunosuppressive phenotype turn mesenchymal stromal cells secrete growth factors cytokines enzymes hormones e g vegf pdgf ang 1 il 11 pge2 tsg 6 sdf 1 hgf igf 1 ido 3134 central mesenchymal stromal cells paracrine activities immunosuppressive soluble factors secreted mesenchymal stromal cells vitro include indoleamine 2 3 dioxygenase ido enzyme catalyzes transformation tryptophane kynurenine 81 84 involved inhibition b cell cell proliferation polarization monocytes il10secreting month 2 macrophages 85 mesenchymal stromal cells also produce extracellular vesicles evs including exosomes microvesicles apoptotic bodies small 44 100 nanomolar diameter membrane vesicles exosomes immunosuppressive immunomodulatory activity 86 contribution mesenchymal stromal cells secretome inhibiting reversing fibrosis systemic sclerosis pathologic microenvironment well understood mesenchymal stromal cells proangiogenic antifibrotic properties vitro evidence angiogenic potential mesenchymal stromal cells first demonstrated capacity differentiate towards endothelial cell lineage 87 mesenchymal stromal cells secrete angiogenic antiapoptotic factors vegf hepatocyte growth factor hgf 88 leptin 89 basic fibroblast growth factor bfgf ang 1 ang 2 platelet derived growth factor pdgf 9092 well mesenchymal stem cell like protein mscp1 stromal cell derived factor 1 sdf1 essential vascular remodelling 93 combination vegf shear stress enhance endothelial differentiation mesenchymal stromal cells 94 recently angiogenic angiostatic signaling pathways mesenchymal stromal cells support neo vessel formation stabilization described elucidating functional interaction mesenchymal stromal cells endothelial cells 9599 mesenchymal stromal cells appear effective regard counterparts bone marrow currently consensus assays used assess anti fibrotic activity mesenchymal stromal cells vitro crucial selection mesenchymal stromal cells products used therapeutic setting including trials mesenchymal stromal cells immunopotency assays 2016 mesenchymal stromal cells committee isct published guidelines addressing characterization mesenchymal stromal cells immune modulatory properties 24 since mesenchymal stromal cells deploy panel immunomodulatory regenerative properties largely dependent interaction microenvironment standard functional markers mesenchymal stromal cells potency well release potency assays defined conducting advanced potential registration 24 100 standardized methods proposed assess mesenchymal stromal cells functional properties 101 preferred analytic methods matrix assays evaluating immunosuppressive immunomodulatory capacities mesenchymal stromal cells 102 103 currently include quantitative rna analysis selected gene products 104 b flow cytometry analysis functionally relevant surface markers c protein based assay secretome recently combination transcriptome secretome analysis proposed predictive cell immunosuppressive properties 102 additional quantitative assays urgently required capture whole mesenchymal stromal cells immunosuppressive anti inflammatory regenerative potential could synergistically improve systemic sclerosis behaviour similarly standardized high throughput multiparametric immunomonitoring tools set characterize immunological status various immune cell subsets mesenchymal stromal cells identify responders thereby optimize trials design mesenchymal stromal cells investigated several animal models systemic sclerosis 105 106 although none encompass features disease 105 systemic sclerosis hypochlorite hoci injected mouse model daily subcutaneous injections hocl balb c mice produce ros anti dna topoisomerase 1 antibodies progressive collagen deposition early continued skin lung fibrosis best reproduce human pathological findings 107 model maria others showed single infusion allogeneic mesenchymal stromal cells immediately hocl exposure balb c mice 2 5x105 5x105 5x106 cells significantly reduced skin lung fibrosis 108 lowest dose 2 5 x105 examined effective sustained reduction fibrosis advanced oxidative protein products total collagen content 42 days markers fibrosis cytokine expression lower lung tissue mesenchymal stromal cells infusion fibrosis marker expression significantly reduced skin lowest dose serum levels anti scl 70 auto antibodies also lower mice received mesenchymal stromal cells infusions mesenchymal stromal cells transiently improved skin thickness hocl exposed mice rate disease progression similar untreated mice day 21 additional benefit point mice received second mesenchymal stromal cells infusion day 21 significantly slower progression skin thickening day 21 42 observed mice established systemic sclerosis effects late single mesenchymal stromal cells infusion observed 1 week onward significant reductions skin lung fibrosis allogeneic xenogeneic mesenchymal stromal cells examined systemic sclerosis hoci induced mouse model 109 balb c mice exposed hoci infused syngeneic balb c mscs allogeneic c57bl 6 mesenchymal stromal cells xenogeneic human mesenchymal stromal cells isolated either bone marrow adipose tissue condition mesenchymal stromal cells collected 3 donors sources mesenchymal stromal cells appeared similar therapeutic effects including decrease skin thickness collagen levels skin lung expression collagen 1 collagen 3 sma 109 110 feasibility using allogeneic mesenchymal stromal cells systemic sclerosis feasibility using allogeneic mesenchymal stromal cells first supported several small severe systemic sclerosis follow varying 6 44 months improvement skin ulcers reduction skin fibrosis reported 6 date 111 112 one case reported allogeneic mesenchymal stromal cells transplant father 41 year old daughter diffuse cutaneous systemic sclerosis 111 vascular ultrasound 6 months transplantation revealed marked improvement perfusion hands fingers revascularization extremities confirmed angiography follow group investigated interfamilial allogeneic mesenchymal stromal cells 5 severe systemic sclerosis follow ups ranging 6 44 months without major adverse events 112 two received fresh mesenchymal stromal cells 3 injected mesenchymal stromal cells isolated cryopreserved tissue one died cardiac arrest related disease progression 18 months another chinese investigated combination plasmapheresis pe allogeneic mesenchymal stromal cells uc 14 systemic sclerosis 113 received three repeated pe treatments subsequent pulse cyclophosphamide days 1 2 5 mesenchymal stromal cells uc infusion day 8 12 month follow exhibited improvements modified rodnan skin score 20 1 3 1 versus 13 8 10 2 p 0 001 subset interstitial lung disease experienced improvement lung function computed tomography ct scans scl70 antibodies serum tgf egf levels also significantly decreased 12 month follow recent report chinese group retrospectively analysed 41 systemic sclerosis treated one n 24 multiple injections one two years interval n 17 mesenchymal stromal cells uc completed five year follow showing 92 7 overall 5 year survival rate stable improved modified rodnan skin score interstitial lung disease ild ct scann images 1 3 5 years adverse events related umsct follow period 114 2022 team published results first open label non randomized monocentric dose escalation phase ii 20 severe systemic sclerosis programme hospitalier de recherche clinique aom 11250 clinicaltrials gov nct02213705 derived intra familial bone marrow bone marrow donors demonstrated safety primary objective 1 3 106 allogenic mesenchymal stromal cells kilograms single infusion least one year follow also observed regression skin sclerosis early injection stable pulmonary function one year 65 trials included longitudinal depth characterization circulating immune cells mesenchymal stromal cells treated systemic sclerosis furthermore demonstrated regulatory b cells contribute response systemic sclerosis mesenchymal stromal cells infusion 115 experience gained first 65 allowed following major learning conclusions improved knowledge next design longstanding efforts 4 years necessary find adequate interfamilial allogenic bone marrow donors b large heterogeneity found mesenchymal stromal cells production despite using well standardized techniques due multiple donors c absence dose effect 1x106 3x106 allogenic mesenchymal stromal cells kilograms within limit single dose mesenchymal stromal cells injection promising value observed results mesenchymal stromal cells allowed improvement skin score one year e large heterogeneity systemic sclerosis disease f therefore need different statistical approach control repeated injections search meaningful dose effect better assess early trends efficacy inform future design larger trials results first phase ii retrospectively underline critical importance 1 improving homogeneity process allogeneic mesenchymal stromal cells production 2 adding control placebo arm first designed ten years ago experts recommend placebo controlled trials systemic sclerosis 116 mesenchymal stromal cells 117 addition use placebo arm justified fact systemic sclerosis failed standard care background use stable dose prednisone 6 milligrams allowed duration 1 year short 5 additional trials mesenchymal stromal cells systemic sclerosis may 2024 registered clinicaltrials gov 1 involve allogeneic mesenchymal stromal cells netherlands nct03211793 using intra muscular injections severe digital ischemia 1 involves allogeneic mesenchymal stromal cells france nct04356755 surgical intramuscular injection specific finger sites 3 involves allogeneic mesenchymal stromal cells uc canada nct04356287 colombia nct04432545 antigua barbuda nct05016804 intravenous infusion infusion dosing considerations heterogeneity dose mesenchymal stromal cells used animal human hocl induced mouse model systemic sclerosis 3 separate doses mesenchymal stromal cells 2 5x105 5x105 1x106 mesenchymal stromal cells kilograms investigated best results obtained lowest dose reductions markers fibrosis col1 col3 tgf1 sma skin lung inversely proportional dose 110 human autoimmune diseases used one infusion 1 5 million mesenchymal stromal cells kilograms never 12 million kilograms 118 example keyszer others 112 treated five systemic sclerosis 106 cells kilograms modified rodnan skin score score improved 4 5 refractory crohn disease 16 received 4 weekly doses 2x106 cells kilograms mesenchymal stromal cells 119 12 15 experiencing response 8 remission multiple sclerosis 10 injected 106 cells kilograms autologous mesenchymal stromal cells 9 4x106 cells kilograms serious adverse events benefit relatively low 120 phase ii allogenic mesenchymal stromal cells diffuse systemic sclerosis clinicaltrials gov identifier nct02213705 used 1x106 mesenchymal stromal cells kilograms first 10 systemic sclerosis 3x106 mesenchymal stromal cells kilograms next 10 systemic sclerosis found safety signals dose effects evolution either groups intravenous administration best way deliver mesenchymal stromal cells obtain general effect considering mesenchymal stromal cells bio distribution rapid disappearance intravenous infusion mechanism action secreted factors concept repeated infusions gaining momentum field data suggests one dose likely underestimates benefits cell therapy duration exposure mesenchymal stromal cells probably important intensity exposure 121 bleomycin model systemic sclerosis moroncini showed superiority 2 doses 2 5 x105 mesenchymal stromal cells uc days 1 7 compared single infusion 122 repeated infusions tested several trials number indications graft versus host disease crohns myocardial infarction 121 123 may optimize therapeutic effect cells shown graft versus host disease proposing test 2 infusions optimal interval repeated doses may depend disease changes skin visceral fibrosis systemic sclerosis evolve months 8 experts recommend assessing systemic sclerosis quarterly basis 2 results phase ii allogenic mesenchymal stromal cells 20 diffuse systemic sclerosis showed improvement skin fibrosis peaks 3 months infusion mean modified rodnan skin score modified rodnan skin score falls 26 17 marginally thereafter 17 14 month 3 month 24 therefore proposing repeat second infusion 3 months first chose inject fixed dose 2x106 mesenchymal stromal cells kilograms based previsous experience using mesenchymal stromal cells bone marrow systemic sclerosis 65 mesenchymal stromal cells uc lupus erythematosus farge others lancet rheumatology press plus systematic review meta analysis randomized control trials mesenchymal stromal cells autoimmune diseases 124 125 showed evidence dose effect addition recently reviewed greco others 126 refer supplementary data data literature using bone marrow umbilical cord derived mesenchymal stromal cells systemic sclerosis showed mesenchymal stromal cells doses varied 0 5 3 x106 kilograms adverse effects given established safety profile mesenchymal stromal cells wide therapeutic window considering present aim analyze effect repeated injections mesenchymal stromal cells chose dose 2x106 mesenchymal stromal cells kilograms increasing use mesenchymal stromal cells variety indications provides consistent evidence supporting safety humans recently updated meta analysis trials including 2700 treated mesenchymal stromal cells detect associations mesenchymal stromal cells organ system complications infection death malignancy 128 common side effect noted transient fever claims genetic instability tumorigenicity human culture expanded mscs refuted 43 five reported setting previous malignancy 5 case series n 67 local recurrence reported 129 54 previous breast cancer one developed recurrence 11 months adipose derived regenerative cells 130 mesenchymal stromal cells injected prostate cancer 3 none reported oncological safety issues 131133 chinese long term retrospective single center 404 autoimmune diseases treated mesenchymal stromal cells uc rate grade 3 serious adverse events severe adverse event one month infusion 2 2 134 rate severe adverse event month post infusion consistently well 5 120 135137 recent phase ii dose escalation single infusion allogenic bone marrow derived mesenchymal stromal cells family donors diffuse systemic sclerosis refractory standard therapy clinicaltrials gov identifier nct02213705 safety signal first 10 treated 1x106 mesenchymal stromal cells kilograms subsequent 10 higher dose 3x106 mesenchymal stromal cells kilograms 65 infusion related severe adverse event three infusion related adverse events occurred first 10 days one grade 1 flushing another grade 1 nausea grade 2 asthenia although foresee risks low safety nevertheless primary outcome theoretical risk respiratory complications randomized acute pulmonary reactions mesenchymal stromal cells observed conducted chronic ischemic heart failure received intracoronary mscs 138 risk seems limited underlying condition risk develop pulmonary edema 135 according article 37 4 european regulation n536 2014 irrespective outcome within one year end member states concerned sponsor shall submit ctis summary results summary shall accompanied summary written manner understandable laypersons specific documents medicinal product human use archived investigator sponsor 25 years end research indexed archiving includes particular sealed envelope investigator containing copy information notes consent forms signed individuals centre participated sealed envelope sponsor containing copy information notes consent forms signed individuals centre participated binders investigator sponsor including non exhaustive list successive versions protocol identified version number date appendices competent authority authorisations comité de protection des personnes research ethics committee decisions correspondence enrolment list register appendices specific research final report data collection documents pursuant article l 1121 10 code de la sante publique french public health code insurance policies must guarantee civil liability sponsor contributor cover pecuniary consequences damages arising involving human participants duration sponsor take insurance policy covering sponsors public liability well public liability physicians involved sponsor also provide full compensation damages caused participant enrolled beneficiaries unless sponsor prove harm fault sponsor collaborator compensation cannot refused grounds third party act voluntary withdrawal person initially consented participate assistance publique hopitaux de paris ap hp taken insurance hdi global se insurance broker biomedic insure full period covers public liability collaborator physician research staff accordance article 76 1 regulation eu 536 2014 european parliament council 16 april 2014 article l 1121 10 code de la sante publique french public health code sponsor assistance publique hopitaux de paris direction de la recherche clinique et de linnovation vitro experimental suggest mesenchymal stromal cells properties vary according tissue origin source demonstrated mesenchymal stromal cells compared mesenchymal stromal cells easier harvest display higher proliferative capability entering senescence higher genetic stability superior immunosuppressive properties completed first phase ii dose escalation using allogenic mesenchymal stromal cells infusion 20 severe systemic sclerosis clinicaltrials gov nct02213705 safety issues found significant improvement skin fibrosis 3 months infusion appeared lower thereafter 65 thereby supporting need repeated infusions accelerate translation mesenchymal stromal cells therapeutic cell product systemic sclerosis propose test safety mesenchymal stromal cells systemic sclerosis seek evidence possible efficacy signal phase ii considering rationale hypothesize use healthy donor allogeneic mesenchymal stromal cells produced event-free survival demonstrate safety issues b efficacy profile increase repeated infusion 3 months interval allogeneic mesenchymal stromal cells treat systemic sclerosis evaluate safety one month allogeneic 2x106 mesenchymal stromal cells kilograms intravenous administration twice 3 months interval month 0 month 3 severe systemic sclerosis safety infusion within first 24 hours infusion follow efficacy signals inform future using outcome measures skin sclerosis lung function quality life previously validated systemic sclerosis used cell therapy trials analysis response progression free survival progression-free survival global rank composite score global rank composite score month 3 month 6 month 12 american college of rheumatology provisional composite response index trials early diffuse cutaneous systemic sclerosis acr provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis early systemic sclerosis month 3 month 6 month 12 analysis overall survival causes death impact allogeneic mesenchymal stromal cells intravenous infusion twice 3 months interval immune response including immunophenotyping alloimmunization month 6 starting therapy cost effectiveness allogeneic mesenchymal stromal cells infusion twice versus severe systemic sclerosis month 12 exploring immune landscape systemic sclerosis skin biopsies mesenchymal stromal cells signatures predicting response evaluating new mesenchymal stromal cells potency assays interrogating mesenchymal stromal cells efferocytosis safety injections evaluated rate related serious adverse events severe adverse event defined adverse events adverse event grade equal 3 using national cancer institute common terminology criteria adverse events common terminology criteria for adverse events v5 0 classification one month infusion according arms month 1 month 4 adverse events adjudicated data safety monitoring committee related toxicity analyzed according international world health organization maximum degree toxic attacks body injection considered tolerated toxicity criteria grade 3 139 safety time within first 24 hours infusion follow evaluated rate related severe adverse event defined adverse event grade equal 3 common terminology criteria for adverse events v5 0 time within first 24 hours infusion follow month 0 month 3 month 6 month 9 month 12 related toxicity analyzed according international world health organization maximum degree toxic attacks body injection considered tolerated toxicity criteria grade 3 139 main efficacy endpoint assessed modified rodnan skin score difference month 0 month 12 efficacy disease related secondary endpoints modified rodnan skin score month 3 month 6 month 9 performance status performans status (= ecog) health related quality life health-related quality of life questionnaires scleroderma health assessment questionnaire scleroderma-health assessment questionnaire short form 36 health survey sf 36v2 eq 5d 5l month 0 month 3 month 6 month 12 forced vital capacity forced vital capacity diffusing capacity lung carbon monoxide diffusing capacity of lung for carbon monoxide month 0 month 3 month 6 month 12 response defined following decreased modified rodnan skin score 25 increased forced vital capacity 10 increased diffusing capacity of lung for carbon monoxide 10 without need immunosuppression except low dose steroids 10mg daily 140 month 3 month 6 month 12 progression free survival 12 months defined percentage enrolled still alive without evidence progression 12 months mesenchymal stromal cells injection progression defined following compared baseline evaluation decreased forced vital capacity 10 diffusing capacity of lung for carbon monoxide 15 decrease lvef 15 decrease weight 15 decrease creatinine clearance 30 increased modified rodnan skin score 25 increase scleroderma-health assessment questionnaire 0 5 140 global rank composite score month 3 month 6 month 12 calculated previously described 141 142 acr provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis early systemic sclerosis month 3 month 6 month 12 calculated previously described 143 144 overall survival 12 months defined percentage enrolled still alive 12 months mesenchymal stromal cells injection myeloid lymphocyte sub populations analyzed included month 0 month 1 month 3 month 4 month 6 measured 2 mass cytometry panels cytof assess proportion activation status alloimmunization mesenchymal stromal cells evaluated included detection donor specific anti human leukocyte antigen antibodies identification positive month 0 month 3 month 6 extra cost per quality-adjusted life year quality adjusted life year gained unique repeated intravenous infusion infusion allogeneic mesenchymal stromal cells severe systemic sclerosis 12 months quality-adjusted life year measured combining survival data health related quality life data collected eq 5d 5l transformed utilities qalys related medical productivity costs extra cost per related adverse event grade equal 3 common terminology criteria for adverse events avoided unique repeated intravenous infusion infusion allogeneic mesenchymal stromal cells severe systemic sclerosis 12 months severe adverse event related medical productivity costs well efficiency 2 schemes allogeneic mesenchymal stromal cells injections assessed cost utility cost effectiveness analyses recommended french national authority health incremental cost effectiveness ratios icer estimated two health economic endpoints expressed cost per quality-adjusted life year gained ii cost per adverse event 3 common terminology criteria for adverse events avoided arm 1 placebo arm arm 2 placebo arm primary analysis bayesian safety analysis performed first safety set continuous monitoring primary endpoint sponsor month 1 month 4 visits participant implemented allow continuous bayesian toxicity monitoring stopping rule implemented primary endpoint receiving cell infusions interim analyses performed unblinded independent statistician course primary safety analyses performed sequentially initiation first analysis performed first 3 complete month 1 visits analysis triggered trsae within one month infusion observed ensure blinding investigating team stopping rule defined based estimated probability risk related severe adverse events trsae 15 cell infusion define criterion 1 probability posterior probability trsae greater 15 posterior probability trsae trsae estimated using bayesian approach beta density trsae considered random variable beta distribution centered prior specified expected probability severe adverse event 10 expected probability updated sequentially observations collected called posterior density prior density chosen family combined beta densities defined two parameters b mean variance weakly informative beta density considered 0 1 b 0 9 parameters posterior beta density bn calculated prior beta density number n infusions follows r bn b n r r number trsae observed among n infusions n infusions following estimator stopping rule fulfilled criterion 1 0 70 meaning high probability greater 15 risk trsae cell infusion interim analyses results presented data safety monitoring board recommendation case early stopping decision subsequent randomized treated thus far followed results analyzed described final analysis based beta binomial conjugate posterior distribution prob trsae 0 15 data may increase trsae observed accordingly initial analysis first 3 complete month 1 visits interim analyses thereafter triggered trsae within one month infusion observed month 1 month 4 visits ensure blinding analysis performed unblinded independent statistician presented data safety monitoring board using cell infusions available data compute criterion 1 criterion 1 rule translates stopping rules reported table table 15 toxicity stopping rules non binding rules presented data safety monitoring board recommendation note chose probability trsae 15 stopping rule based 3 reasons 1 expectation low risk 5 trsae month post infusion 2 cumulative rates trsae trials systemic sclerosis approximately 30 2 years 3 desire minimize risk settings cancer usual threshold fixed 30 phase consider observations infusion independent following reasons first time first infusions observations necessarily independent second especially early insufficient observations model accounting correlations would require least 3 parameters fact parameters model would result disproportionate impact priors rather observations results third experience early phase adaptive designs parsimonious models efficient finally expect safety events given rapid clearance cells infusion unlikely correlated finally end model account within correlations sum approach aims optimizing safety obtaining best estimates end sensitivity analyses performed considering priors including beta 0 05 0 95 prior mean equal 0 05 beta 0 01 0 99 prior mean equal 0 01 end final safety analysis performed fitting logistic regression model taking account repeated measures thus intra correlation e observations longer considered independent follows model 1 logit p least one trsae infusion j a0 b0 bi infusionij a0 intercept bi random effect n 0 s2 b0 effect infusion use bayesian estimator gibbs sampling incorporating weakly informative normal prior distributions parameters a0 b0 normal 0 10000 fairly weakly informative uniform s2 u 0 100 estimations accompanied 95 credible intervals credible interval b0 includes zero conclude infusion 2 million mesenchymal stromal cells kilograms safe systemic sclerosis moreover perform secondary analysis considering cumulative dose repeated infusions answer question whether repeated doses safe using following logistic regression model model 2 logit p least one trsae a0 b0 at_least_one_infusioni b1 two_infusionsi a0 intercept b0 effect first infusion b1 effect second infusion use weakly informative normal prior distributions parameters a0 b0 b1 normal 0 10000 credible interval b1 includes zero conclude additional risk second dose analyses performed intent treat set except safety endpoints analysed safety set safety rate severe adverse event grade equal 3 common terminology criteria for adverse events v5 0 time within first 24 hours infusion follow month 0 month 3 month 6 month 12 rates severe adverse event described arm credible intervals b0 b1 primary analysis doesnt include 0 final safety analysis repeated according primary analysis methodology rate severe adverse event month 0 month 3 month 6 month 12 efficacy main efficacy endpoint modified rodnan skin score modified rodnan skin score difference month 0 month 12 concerning difference r modified rodnan skin score month 12 month 0 efficacy assessed using following linear model ri a0 b0 at_least_one_infusioni b1 two_infusionsi ei ri difference r modified rodnan skin score month 12 modified rodnan skin score month 0 a0 intercept b0 effect first infusion b1 effect second infusion ei n 0 s2 use weakly informative normal prior distributions parameters a0 b0 b1 normal 0 10000 inverse gamma distribution 1 1 s2 estimations accompanied 95 credible intervals credible intervals b0 b1 allow us conclude whether single second infusions efficacious systemic sclerosis secondary endpoints modified rodnan skin score month 3 month 6 month 9 evolution modified rodnan skin score assessed using linear random effect model take account repeated measurements interaction time number infusions assessed tested performance status performans status (= ecog) health related quality life health-related quality of life questionnaires scleroderma health assessment questionnaire scleroderma-health assessment questionnaire short form 36 health survey sf 36v2 eq 5d 5l month 0 month 3 month 6 month 12 evolution different scales assessed using linear random effect model take account repeated measurements interaction time number infusions assessed tested forced vital capacity forced vital capacity diffusing capacity lung carbon monoxide diffusing capacity of lung for carbon monoxide month 0 month 6 month 12 evolution different scales assessed using linear random effect model take account repeated measurements interaction time number infusions assessed tested response month 3 month 6 month 12 defined following decreased modified rodnan skin score 25 increased forced vital capacity 10 increased diffusing capacity of lung for carbon monoxide 10 without need immunosuppression except low dose steroids 10mg daily analyzed similarly using model 2 primary analysis overall survival month 12 estimated using kaplan meier estimator globally within arm progression free survival month 12 progression defined following decreased forced vital capacity 10 diffusing capacity of lung for carbon monoxide 15 decrease lvef 15 decrease weight 15 decrease creatinine clearance 30 increased modified rodnan skin score 25 increase scleroderma-health assessment questionnaire 0 5 progression free survival month 12 estimated using kaplan meier estimator globally within arm global rank composite score global rank composite score composite response index dcssc acr provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis early systemic sclerosis values month 3 month 6 month 12 evolution different scales assessed using linear random effect model take account repeated measurements interaction time number infusion assessed tested immunological myeloid lymphocyte sub populations month 0 month 1 month 3 month 4 month 6 described time point globally according arm allo immunisation mesenchymal stromal cells detection donor specific anti human leukocyte antigen antibodies identification positive month 0 month 3 month 6 described time point globally according arm allogeneic adipose tissue derived mscs mesenchymal stromal cells placebo injected slow intravenous infusion 3 5 ml mn minimum infusion time 16 min via 200 transfusion filter mesenchymal stromal cells bags cell suspension prepared according recipient body weight experimental arms arm 0 placebo month 0 month 3 arm 1 1 mesenchymal stromal cells 2x106 cells kilograms injection month 0 1 placebo injection month 3 arm 2 1 mesenchymal stromal cells 2x106 cells kilograms injection month 0 1 mesenchymal stromal cells 2x106 cells kilograms injection month 3 propose conduct multicenter phase ii three arm randomised placebo controlled double blind 18 systemic sclerosis 1 1 1 randomized randomization blocks size 6 one following arms arm 0 placebo month 0 month 3 arm 1 1 mesenchymal stromal cells 2x106 cells kilograms injection month 0 1 placebo injection month 3 arm 2 1 mesenchymal stromal cells 2x106 cells kilograms injection month 0 1 mesenchymal stromal cells 2x106 cells kilograms injection month 3 second infusions performed absence previous related severe adverse event trsae defined primary endpoint continuous monitoring primary endpoint sponsor implemented allow continuous bayesian toxicity monitoring stopping rule implemented primary endpoint see section 13 details first analysis first 3 completed month 1 visits analysis trsae month 1 month 4 visits final analysis medical team blinded arm blinding broken 1 presumably related saes occurred investigators want know assigned proper management 2 required local regulatory authorities figure 1 design 1 1 1 randomized design 3 randomization blocks size 6 staggered inclusions cohorts 3 1 week 1 month interval every three continuous toxicity bayesian monitoring toxicity stopping rule first analysis first 3 cell infusions arms 1 2 completed month 1 visits trsae month 1 month 4 visits final analysis n0 total number arm 0 n1 arm 1 n2 arm 2 n number per arm per randomization block arm 0 placebo month 0 month 3 arm 1 mesenchymal stromal cells 2x106 cells kilograms injection month 0 1 placebo injection month 3 arm 2 1 mesenchymal stromal cells 2x106 cells kilograms injection month 0 1 mesenchymal stromal cells 2x106 cells kilograms injection month 3 included arm 1 arm 0 opportunity according willingness receive either 1 arm 1 1 2 arm 0 mesenchymal stromal cells 2x106 cells kilograms injection end unblinding evidence mesenchymal stromal cells injection safety provided case followed usual care three months multi centre involve 2 different hospitals within mathec network filiere des maladies auto immunes et auto inflammatoires rares fai2r auspices good practices societe francophone de greffe de moelle et therapie cellulaire sfgm tc recruitment following centres participants recruited hospital consultation hospitalisation outpatients 2 different sites followed recruiting centre centre involved mesenchymal stromal cells injections participants receive mesenchymal stromal cells placebo injections saint louis hospital table 1 summary table centres involved recruitment follow pr mathieu puyade internal medicine centre competence rare systemic autoimmune disease chu poitiers dr alexandre maria department internal medicine centre competence rare systemic autoimmune disease chru montpellier contribute recruitment send eligible pr dominique farge paris pr gregory pugnet toulouse respectively non recruitment centres following centre involved specific intervention excluding recruitment follow table 2 summary table non recruitment centres specific intervention research following assessment scheduled inclusion performed quarterly base systemic sclerosis pnds systemic sclerosis janvier 2020 2 corresponds baseline evaluation month 0 verification inclusion exclusion criteria general physical exam including weight height concomitant medications modified rodnan skin score health related quality life forms completion scleroderma-health assessment questionnaire sf 36v2 eq 5d 5l physician global assessment acr provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis early systemic sclerosis performance status chest x ray ekg biological examinations including hematology sedimentation rate hemoglobin hematocrit wbcs lymphocytes platelets counts biochemistry serum electrolytes creatinine clearance renal liver function serum protein electrophoresis urine protein creatinine ratio urine dipstick urinary cyto bacteriological analysis systemic sclerosis autoantibody detection antinuclear antibodies scl 70 anti topoisomerase antibodies anti centromere antibodies anti rnp anti ribonucleoprotein antibodies anti rna pol iii antibodies blood samples externalized extensive immunology assessments biobanking sent room temperature siti laboratory chu rennes pr tarte day puncture 6 gel free lithium heparin tubes 24ml detailed immuno phenotyping cell bank analyzed stocked rennes proportion activation status lymphoid myeloid subpopulations cytof frozen peripheral blood mononuclear cell 1 dry tube 4ml mesenchymal stromal cells immunogenicity analyzed rennes detection identification donor specific anti human leukocyte antigen antibodies serum 1 edta tube 4ml human leukocyte antigen typing analyzed rennes 1 rna paxgene tube 2 5 ml rna bank stocked rennes blood sample serum 1 dry tube 7ml plasma banking 1 heparin tube lithium 7 ml plasma prepared stocked day puncture described section 5 10 biological samples collection given individual notebook asked complete outpatient consultations physician visits general practitioners visits paramedical visits direct non healthcare costs number hours care professional caregivers needed per week productivity loss sick leaves unemployment disability status asked bring back following visits notebook well reports biological acts medical imaging drug prescriptions order measure volume price ambulatory healthcare consumption optional samples dedicated mention informed consent 2 skin biopsies prepared stocked described section 5 10 biological samples collection appendix technique 2 edta tubes 2x7ml efferocytosis analysis analyzed rennes systemic sclerosis recruitment performed investigator sites see 4 1 4 throughout standard hospitalization practitioner networks mathec fai2r french association systemic sclerosis autoimmune diseases case public announcements advertisements documents submitted comité de protection des personnes research ethics committee approval along protocol 18 participants included enrolment period 12 months 0 5 participants need enrolled per site per month based number sites duration enrolment period table 9 summary table recruitment subjects per site per month case severe adverse events investigator must notify sponsor follow participant 12 months following premature discontinuation notification serious adverse event must sent email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction sponsor serious adverse event monitored resolved case safety data reported safety department data safety monitoring board informed hold meeting determine whether held proceed second infusions performed presence related severe adverse event first injection several situations possible temporary suspension investigator must document reason suspending resuming participants source file case report form case report form premature discontinuation participant remains enrolled end participation premature termination withdrawal investigator must document reason collect assessment criteria time ending participation participant agrees schedule follow participant particularly case serious adverse event case withdraw inclusion period replacement performed initial notification severe adverse event must provided written report signed investigator using severe adverse event notification form specific intended purpose case report form item form must completed investigator sponsor carry appropriate analysis initial notification sponsor serious adverse event must quickly followed additional detailed written report reports case outcome may monitored safety department provide information whenever possible investigator provide sponsor documents may useful medical reports laboratory test results results additional examinations etc documents must non identifying addition documents must include following acronym number participants initials adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even participant left initial notification severe adverse event follow reports documents must sent sponsor vigilance department email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction noted possible send severe adverse event reports safety department fax 33 0 1 44 84 17 99 event failed attempt send severe adverse event report email order avoid duplication sending email please adopt standardized nomming email subject following form objet yyyyyy_xxxxxx_jjmmaaaa avec yyyyyy code de la recherche xxxxxx acronyme de la recherche et jjmmaaaa date de transmission send severe adverse event initial notification form follow report concerning single participant given severe adverse event attachment may contain one document follow hospitalization reports example total size email must less 8 mb otherwise please send several e mails ensure documents transmitted e g hospital reports anonymized identified participant identification number use e crfs investigator completes severe adverse event notification form e case report form validates prints signs form sending email possible connect e case report form investigator complete sign send severe adverse event notification form safety department soon connection restored severe adverse event notification form e case report form must duly completed investigator must respond requests sponsor additional information new information must also recorded e case report form questions relating notification adverse event safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction cases utero exposure investigator complete report follow form pregnancy participation investigator must monitor pregnant woman throughout pregnancy pregnancy terminated must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage pregnancy termination foetal death congenital abnormality etc investigator must follow procedure reporting saes initial pregnancy notification severe adverse event follow reports documents sent sponsor according procedures specified herein father exposed investigator must obtain mother permission collecting information pregnancy case onset secondary cancer investigator completes specific form cancers data collected e case report form data entry performed centre research assistants clinical research associates physicians monitoring data performed clinical research associates superivison urc délégation à la recherche clinique et à l’innovation statistical analysis performed dr lucie biard saint louis hospital paris computer file used research implemented accordance french amended informatique et libertes law governing data protection european general data protection regulation gdpr regulations france commitment comply reference methodology medium risk 001 research governed commission nationale informatique et libertés french data protection agency reference methodology processing personal data used within scope health research amended medium risk 001 ap hp sponsor research signed declaration compliance reference methodology provide signed dated informed consent willing comply procedures available duration male female aged 18 70 years age systemic sclerosis according american college rheumatology european league rheumatism american college of rheumatology european league against rheumatism 2013 classification criteria systemic sclerosis severe disease either disease duration 2 years less modified rodnan skin score modified rodnan skin score 20 abnormal c reactive protein 5 milligrams l hemoglobin 11 g deciliter modified rodnan skin score 15 without restriction disease duration plus least one major organ involvement defined respiratory involvement consisting lung diffusion capacity carbon monoxide diffusing capacity of lung for carbon monoxide forced vital capacity forced vital capacity 80 predicted evidence interstitial lung disease bronchiolar involvement areas ground glass contusions fibrosis chest x ray high resolution computed tomography hrct scan moderate pulmonary hypertension baseline resting systolic pulmonary arterial pressures 35 mmhg 50 mmhg cardiac echocardiography mean pulmonary artery pressure 20 mmhg 40 millimeter hg right heart catheterization renal involvement consisting past renal crisis microangiopathic hemolytic anemia renal insufficiency explained causes systemic sclerosis cardiac involvement consisting reversible congestive heart failure atrial ventricular rhythm disturbances recurrent episodes atrial fibrillation flutter recurrent atrial paroxysmal tachycardia 2nd 3rd degree av block mild moderate pericardial effusion presence magnetic resonance imaging involvement increased t1 t2 mapping late gadolinium enhancement septal sign causes organ involvement attributed systemic sclerosis contraindication inadequate response unwillingness undergo autologous hematopoietic stem cell transplantation determined physician judgement contraindication inadequate response unwillingness adverse events necessitating discontinuation conventional immunosuppressive therapy mycophenolate mofetil methotrexate women reproductive potential must use highly effective contraception men reproductive potential must use condoms health insurance age 18 years 70 years pregnancy unwillingness use adequate contraception life threatening end organ damage defined diffusing capacity of lung for carbon monoxide corrected hemoglobin 30 predicted left ventricular ejection fraction 40 cardiac echocardiography pulmonary hypertension baseline resting systolic pulmonary arterial pressures 50 mmhg cardiac echocardiography mean pulmonary artery pressure 40 mmhg right heart catheterization glomerular filtration rate 30ml min active hepatitis aspartate amino transferase alanine-aminotransferase 3 normal neoplasms less 5 years except basal cell situ cervix carcinoma concurrent myelodysplasia uncontrolled hypertension uncontrolled acute chronic infection human immunodeficiency virus 1 human immunodeficiency virus 2 infection body mass index 16 5 kilograms month 2 severe psychiatric disorder bone marrow insufficiency defined neutropenia 1 x 109 l thrombopenia 50 x 109 l anemia 8 g deciliter lymphopenia 0 5 x 109 l inability provide informed consent included another interventional tutelle persons responsible quality control take necessary precautions ensure confidentiality information relating investigational medicinal products participants particular identity results obtained persons well investigators bound professional secrecy data collected concerning participants sent sponsor investigators specialised collaborators rendered non identifying circumstances shall names addresses participants involved shown participants initials recorded accompanied encoded number specific indicating order enrolment sponsor ensure participant given written permission personal information strictly necessary quality control accessed data entry carried electronic media via web browser following analysis sets considered intent treat set includes randomized subjects randomized arm refer primary analyses per protocol set includes subjects intent treat set without major violations could affect evaluation primary efficacy endpoint moreover considered arm corresponding actually received used sensitivity analyses safety set includes subjects receive amount drug general strategy continuous efficacy safety endpoints summarized using summary measures median interquartile range frequency distributions counts percentages used summarize categorical efficacy safety endpoints similarly characteristics presented using summary measures median interquartile range quantitative characteristics counts percentages categorical characteristics analyses arm presented according arm subjects randomized disposition subjects disposition subjects described summaries arm number subjects enrolled number subjects treated number subjects drug permanently discontinued including reasons discontinuation demographic baseline characteristics demographic baseline characteristics summarized globally arm exposure compliance frequency distributions number received doses presented arm duration compliance randomized subjects described group 95 credible intervals 95 ci calculated bayesian analyses analyses performed frequentist framework tests two sided alpha risk equal 0 05,"mesenchymal, stromal, cells, breast, radiation, sclerosis, conventional, diagnostic, ultrasound, dose"
2018-A01454-51_PROTOCOLE_RI_V3.1_20220614_DREPA-RIC_MCT_EL_ModifsAcceptés,1,5.133845,-27.708996,full title prospective multicenter comparing allogeneic matched related haematopoietic stem cell transplantation reduced intensity conditioning regimen standard care adolescents adults severe sickle cell disease acronym drepa ric coordinating investigator dr nathalie dhedin hematology saint louis hospital ap hp paris scientific director adult scientific director dr jean benoit arlet internal medicine georges pompidou hospital ap hp paris pediatric scientific director dr corinne pondarre pediatric hematology chi creteil sponsor assistance publique hopitaux de paris scientific justification although survival children sickle cell disease scd dramatically improved last decades us europe mortality remains high adults moreover many children adults develop chronic debilitating condition due organ damage allogeneic hematopoietic stem cell transplantation hematopoietic stem cell transplantation currently unique curative approach allows cure 95 children transplanted matched related donor minimal residual disease myeloablative conditioning regimen 1 2 date addressed role hematopoietic stem cell transplantation scd adults due risk graft versus host disease graft versus host disease toxicity expected older higher risk organ damage development safe non myeloablative conditioning regimens allow stable mixed chimerism avoid graft versus host disease appears attractive option hematopoietic stem cell transplantation cure adults severe scd four groups previously reported encouraging results total 81 transplanted matched related mobilized peripheral blood cells non myeloablative conditioning regimen alemtuzumab low dose total body irradiation total body irradiation followed post transplant sirolimus demonstrate high scd free survival rate death related transplant 6 graft failures graft versus host disease ninety two percent cured normalized hemoglobin levels resolution hemolysis stable hemoglobin levels identical proportion observed donor 36 however outcome comparison transplanted transplanted lacking design prospective multicenter targeting 15 years severe scd compare non myeloablative transplant matched related donor minimal residual disease identified versus hematopoietic stem cell transplantation lacking minimal residual disease main objective primary endpoint main objective assess benefit hematopoietic stem cell transplantation 2 year event free survival calculated inclusion compared standard care primary endpoint 2 year event free survival event defined death cause acute grade ii intravenous infusion graft versus host disease according magic consortium 2016 appendix 20 3 moderate severe chronic graft versus host disease according nih classification 3 hospitalizations voc defined according usual criteria one acs defined usual criteria pulmonary infiltrate chest film thoracic computed tomography ct scan stroke defined event confirmed magnetic resonance imaging cerebral cervical stenosis 25 new territory evaluated magnetic resonance imaging mra increased least 10 tricuspid regurgitation velocity confirmed 2 echocardiographies performed delay least 3 months compared pre inclusion value trv 2 7 inclusion apparition silent infarct cerebral cervical stenosis 25 new territory increase 25 previous stenosis evaluated magnetic resonance imaging mra hypothesize 2 year event free survival 80 hematopoietic stem cell transplantation versus 40 transplant group secondary objectives endpoints secondary objectives compare groups 2 years overall survival total days requiring hospitalization first 5 months post inclusion acute complications scd voc acs priapism stroke silent infarct cerebral cervical stenosis mra magnetic resonance imaging hemolytic index hematologic biochemical parameters organ function kidney eyes heart lung liver bone grade iii intravenous infusion infectious complications need transfusion 6 months post inclusion alloimmunization rate iron overload chronic used oral opioids nutritional involvement gonadic function fertility quality life anxiety depression cost red blood cells white blood cell count adherence evaluate transplant group chimerism engraftment graft versus host disease free sirolimus 1 2 year post transplant secondary end points death number days requiring hospitalization exclusion 5 first months post inclusion adverse events number voc acs requiring hospitalization number hospitalization intensive care unit number priapism number stroke changes biological parameters ldh aminotransferase gamma gt alkaline phosphatase bilirubin pr aptt hemoglobin level hematocrit mean corpuscular volume percentage hemoglobin variants reticulocyte white blood cells platelets counts estimated glomerular function rate microalbuminuria creatininuria ratio ferritin transferrin saturation level gonadic function spermogram men lh fsh oestrogen women testosterone men month 24 number amenorrhea women number parity eye function heart pulmonary hypertension auricular ventricular dilatation left ventricular mass function transthoracic echocardiography lung function pulmonary function tests 6 min walk test bone function new episode avascular osteonecrosis fracture central nervous system function mra magnetic resonance imaging liver heart magnetic resonance imaging iron overload evaluation ferritin 1000 microg l inclusion month 12 month 24 number red blood cell packed transfused 6 months post inclusion number delayed hemolytic transfusion reaction dhtr oral opioid consumption quality life questionnaire mos sf36 hospital anxiety depression scale hads questionnaire change weight severe infections ctae score grade 3 4 graft versus host disease incidence grading hematopoietic stem cell transplantation chimerism hematopoietic stem cell transplantation assessed total blood population lymphocyte subset cost evaluated days hospitalization inclusion red blood cells white blood cell count adherence expression red blood cells white blood cell count surface markers lymphocytes subpopulation design quasi experimental design phase 3 prospective controlled multicenter cohort 2 groups defined genetic randomization eligibility criteria informed consent obtained human leukocyte antigen typing performed identify potential human leukocyte antigen minimal residual disease define 2 groups group 1 exposed human leukocyte antigen identical sibling identified receive hematopoietic stem cell transplantation group 2 unexposed lacking human leukocyte antigen identical sibling received best standard care transplant arm red cell exchange performed reduce hemoglobin levels 30 less preparative regimen conditioning regimen consist 300cgy total body irradiation 2 alemtuzumab intravenous infusion total dose 1mg kilograms 5 days 7 3 stem cell source g cerebro spinal fluid mobilized peripheral blood stem cells cd34 target dose 10 x 106 per kilograms body weight graft versus host disease prophylaxis consist sirolimus 1 year sirolimus tapered stopped 15 months post transplant transplant arm receive best standard care according situation previous initiation hydroxyurea continuation optimization dose hydroxyurea initiation continuation transfusion program time point initiation new drug proved improve scd authorization use france population participants adolescents young adults 15 45 years inclusion criteria scd ss s0 aged 15 45 years least one non scd sibling 18 years parental couple presented least one following criteria 2 voc requiring hospitalization last 2 years least 1 severe acs within past 2 years defined followed acs requiring red cell transfusion hospitalization intensive care unit acs pao2 60mmhg arterial blood hydrogen ion concentration 7 35 pac02 50mmhg need 4 liters 02 mn reaching sat02 98 1 voc requiring hospitalization last 2 years history recurrent acs three history ischemic stroke cerebral cervical arterial stenosis 25 apparition silent infarct last 2 years pulmonary hypertension defined mean pulmonary artery pressure 25 mmhg rest determined right heart catherization osteonecrosis least 2 joints including one diagnosed past 2 years sickle nephropathy estimated glomerular filtration rate ckd epi formula 100 ml min 1 73m2 persistant microalbuminuria microalbuminuria creatininuria ratio 10 milligrams mmol without cause nephropathy requiring hydroxyurea chronic transfusion already treated hydroxyurea transfusion program time point inclusion already receiving chronic transfusions voc acs responding hydroxyurea eligible provided least 3 voc requiring hospitalization one year within past 2 years initiation chronic transfusions least past history acs contraception period sirolimus women child bearing potential signed informed consent amenable human leukocyte antigen typing hematopoietic stem cell transplantation human leukocyte antigen identical sibling available affiliated french health care insurance inclusion criteria donors age 10 60 years hb electrophoresis aa ac donor usual biological eligibility criteria g cerebro spinal fluid mobilization peripheral blood stem cell bone collection including legal viral serologies assessment authorizing transplant human leukocyte antigen identical negative covid 19 test time hematopoietic stem cell transplantation mobilization exclusion criteria performance status eastern cooperative oncology group (= performans status (= ecog)) scale 1 pulmonary function fev1 et forced vital capacity 50 theorical value post capillary severe pre capillary pulmonary hypertension measured mean pulmonary artery pressure rest 35 mmhg cardiac ejection fraction 45 estimated glomerular fraction rate gfr 50ml mn 1 73m2 conjugate bilirubin 50 mole l cirrhosis alanine-aminotransferase 4n uncontrolled infection known hypersensitivity alemtuzumab known hypersensitivity murin proteins following excipients disodium edetate polysorbate 80 potassium chloride potassium phosphate monobasic sodium chloride dibasic sodium phosphate water injections positivity human immunodeficiency virus pregnancy breast feeding women alloimmunization delayed hemolytic transfusion reaction precluding red cell transfusions previous solid organ transplant hematopoietic stem cell transplant interventions product investigation transplanted within 1 6 months inclusion human leukocyte antigen matched related hematopoietic stem cell transplantation red cell exchange performed reduce hemoglobin levels 30 less preparative regimen consider fertility preservation techniques according age pregnancy wish evaluation ovarian function conditioning regimen consist 300cgy total body irradiation 2 alemtuzumab intravenous infusion total dose 1mg kilograms 5 days 7 3 stem cell source g cerebro spinal fluid mobilized peripheral blood stem cells cd34 target dose 10 x 106 per kilograms body weight number cd34 cells obtained one leukapheresis second planned next day reach goal graft versus host disease prophylaxis consisted sirolimus 1 year sirolimus tapered stopped 15 months post transplant comparator arm receive best standard care according situation previous initiation hydroxyurea continuation optimization dose hydroxyurea initiation continuation time point initiation new drug proved improve scd authorization use france interventions added hematopoietic stem cell transplantation expected benefits participants society transplant arm benefit expected cure disease e absence post transplant new complications related scd risks added transplant arm risks complications disease despite supportive care including hydroxyurea transfusions programs chronic transfusions lead iron overload alloimmunization hydroxyurea lead hypofertility arm consultation every 3 months month 24 transplant arm hospitalization 4 6 weeks followed weekly consultations 3 first months post transplant 1 monthly consultation 3 6 months consultation every 3 months month 24 common toxicities associated transplantation including reduced conditioning regimen graft versus host disease prophylaxis graft versus host disease according magic consortium 2016 appendix 20 3 criteria chronic graft versus host disease according nih classification infection fever aplasia pancytopenia neutropenia thrombopenia anemia gastrointestinal nausea vomiting cardiovascular arterial hypertension neurological disorders visual disorders miscellaneous serum sickness skin rashes pain swelling joints anaphylaxis hypotension difficulty breathing severe hives mucositis transplant may potentially lead transplant related mortality graft versus host disease case observed first 81 cases reported literature risk long term complications infertility remains evaluated setting ric transplant scope hematology haemovigilance therapeutic transfusion number participants included 78 number valued sites 30 centres 19 recruiting centres 11 transplant centres recruiting site also transplant schedule state inclusion period 3 years participation period follow 2 years total duration 5 years number enrolments expected per site per month 2 expected per recruiting site per year statistical analysis single efficacy analysis planned event-free survival compared two groups using log rank test effect hematopoietic stem cell transplantation assessed hazard ratio using cox model primary endpoint event free survival 2 years calculated inclusion event defined followed death cause acute grade ii intravenous infusion graft versus host disease according magic consortium 2016 appendix 20 3 moderate severe chronic graft versus host disease according nih classification 3 hospitalizations voc defined according usual criteria one acs defined usual criteria pulmonary infiltrate chest film thoracic computed tomography ct scan stroke defined event confirmed magnetic resonance imaging cerebral cervical stenosis 25 new territory evaluated magnetic resonance imaging mra increased least 10 tricuspid regurgitation velocity confirmed 2 echocardiographies performed delay least 3 months compared pre inclusion value trv 2 7 inclusion apparition silent infarct cerebral cervical stenosis 25 new territory increase 25 previous stenosis evaluated magnetic resonance imaging mra event free survival 2 years calculated inclusion also described hematopoietic stem cell transplantation group overall survival defined time date inclusion death due cause date last follow propensity score matching analysis also performed sensitivity analysis handle potential residual imbalances arms confounders sequential analysis tolerance data performed using bayesian methods hypothesize 2 year event free survival 80 hematopoietic stem cell transplantation versus 40 transplant group sources monetary support french ministry health programme hospitalier de recherche clinique n 2017 data monitoring committee yes transplant arm benefit expected cure disease ie absence post transplant new complications related scd common toxicities associated transplantation including reduced conditioning regimen graft versus host disease prophylaxis graft versus host disease according revised magic consortium 2016 criteria chronic graft versus host disease according nih classification appendix 20 4 infection fever aplasia pancytopenia neutropenia thrombopenia anemia gastrointestinal nausea vomiting neurological disorders visual disorders cardiovascular arterial hypertension miscellaneous serum sickness skin rashes pain swelling joints anaphylaxis hypotension difficulty breathing severe hives mucositis risks transplant severe graft versus host disease transplant related mortality morbidity due organ toxicity related conditioning immunosuppression therapy infections 81 currently reported literature using modalities transplant toxic death graft versus host disease reported impact fertility conditioning regimen post transplant sirolimus evaluated nih series 4 women 4 men among 30 transplanted able total 10 children naturally transplant hsieh personal data due absence data effect sirolimus fetal development human adequate contraception recommended sirolimus prevent pregnancy continue use least 12 weeks last sirolimus transplant arm risks complications disease despite best supportive care including hydroxyurea transfusions programs chronic transfusions lead iron overload alloimmunization hydroxyurea lead fertility impairment main objective assess benefit hematopoietic stem cell transplantation 2 year event free survival calculated inclusion compared standard care compare groups 2 years overall survival total days requiring hospitalization first 5 months post inclusion acute complications scd voc acs priapism stroke silent infarct cerebral cervical stenosis mra magnetic resonance imaging hemolytic index hematologic biochemical parameters organ function kidney eyes heart lung liver bone grade iii intravenous infusion infectious complications need transfusion 6 months post inclusion alloimmunization rate iron overload chronic used oral opioids nutritional involvement gonadic function fertility quality life anxiety depression cost red blood cells white blood cell count adherence objectives exploratory experiments best understand role allograft red blood cells white blood cell count adherence rheology red blood cells white blood cell count surface markers subpopulation including nk cells change mast cell mediator release inflammatory cytokines well perform inclusion month 12 month 24 comparison 3 groups allograft success allograft failure control without exposure chemotherapy radiotherapy plasma serum cells banked red blood cells white blood cell count adherence performed fresh samples collection stored gr ex laboratory laboratoire excellence du globule rouge institut imagine hopital necker 24 boulevard du montparnasse 75015 paris supervision pr olivier hermine supervisor duration 5 years 80c storage evaluate transplant group chimerism engraftment graft versus host disease 2 year event free survival event defined death cause acute grade ii intravenous infusion graft versus host disease according magic consortium 2016 appendix 20 3 classification moderate severe chronic graft versus host disease according nih classification appendix 20 4 3 hospitalizations voc defined according usual criteria one acs defined usual criteria pulmonary infiltrate chest film thoracic computed tomography ct scan stroke defined event confirmed magnetic resonance imaging cerebral cervical stenosis 25 new territory increase 25 previous stenosis evaluated magnetic resonance imaging mra increased least 10 tricuspid regurgitation velocity confirmed 2 echocardiographies performed delay least 3 months compared pre inclusion value trv 2 7 inclusion apparition silent infarct cerebral cervical stenosis 25 new territory increase 25 previous stenosis evaluated magnetic resonance imaging mra death cause number days requiring hospitalization 1 2 years post inclusion exclusion 5 first months post inclusion plan count days hospitalization first 5 months post inclusion considering hematopoietic stem cell transplantation performed median delay 3 months inclusion considering time hospitalization need transplant adverse events number voc acs requiring hospitalization number hospitalization intensive care unit number priapism 1 2 years post inclusion number stroke episodes 1 2 years post inclusion changes biological parameters ldh aminotransferase gamma gt alkaline phosphatase bilirubin time point tck hemoglobin level hematocrit mean corpuscular volume percentage hemoglobin variants reticulocyte white blood cells platelets counts estimated glomerular function rate every 3 months inclusion 24 months standard arm transplant arm tests also made month 1 month 2 month 3 microalbuminuria creatininuria ratio month 3 month 6 month 12 month 24 ferritin transferrin saturation level month 3 month 6 month 12 month 24 gonadic function 24 months lh fsh men women testosterone spermogram men oestrogen amh women incidence amenorrhea women number parity women evaluation ovarian function performed 3 months hormonal cessation eye function change retinopathy status appearance disappearance improvement aggravation month 12 month 24 eyes involvement keratitis uveitis heart pulmonary hypertension auricular ventricular dilatation left ventricular mass function transthoracic echocardiography explored data tricuspid regurgitant jet velocity left atrial ventricular dimension indexed body surface ventricular mass index left ventricular ejection fraction month 12 month 24 lung function pulmonary function tests 6 min walk test month 12 month 24 bone function new episode avascular osteonecrosis location episode fracture central nervous system function magnetic resonance imaging mra magnetic resonance imaging month 24 liver heart magnetic resonance imaging iron overload evaluation ferritin 1000 microg l inclusion month 12 month 24 number red blood cell packed transfused 6 months post inclusion pre early post transplant transfusion standard care may counted number delayed hemolytic transfusion reaction dhtr defined associated hemoglobinuria dark urine month following transfusion bone pain increased hemolytic markers drop hba new red blood cells allo ab new red blood cells alloantibodies assessed month 3 month 6 12 month 24 oral opioid consumption diary recall questionnaire 24th last month follow assessed month 3 month 6 12 month 24 medical visit addenda 20 3 quality life questionnaire mos sf 36 assessed month 3 month 6 12 month 24 addenda 20 3 hospital anxiety depression scale hads questionnaire assessed month 3 month 6 12 medical visit addenda 20 3 change weight month 3 month 6 12 month 24 medical visit height month 24 severe infections ctae score grade 3 4 graft versus host disease incidence grading magic consortium 2016 appendix 20 3 nih classification hematopoietic stem cell transplantation chimerism hematopoietic stem cell transplantation assessed total blood population subset month 1 month 2 month 3 month 6 month 9 month 12 month 18 month 24 every 6 months month 48 cost evaluated days hospitalization inclusion red blood cells white blood cell count adherence expression red blood cells white blood cell count surface markers lymphocytes subpopulation including nk cells change mast cell mediator release inflammatory cytokines mast cells demonstrated role voc physiopathology vincent l others blood 2013 analyses performed inclusion month 12 month 24 comparison 3 groups allograft success allograft failure control without exposure chemotherapy radiotherapy plasma serum cells banked red blood cells white blood cell count adherence performed fresh samples dna collection performed analyses collection stored gr ex laboratory laboratoire excellence du globule rouge institut imagine hopital necker 24 boulevard du montparnasse 75015 paris supervision pr olivier hermine supervisor duration 5 years 80c storage samples may used explicit agreement subject consent form analyses included protocol could beneficial pathology specify based evolution scientific knowledge collection declared agence nationale de sécurité du medicament et des produits de santé context biomedical research end research samples destroyed transplant modalities reported nih group conditioning regimen consist alemtuzumab 1 03 milligrams kilograms associated total body irradiation 300 rad radiation shielding male gonads stem cell source pbsc human leukocyte antigen identical sibling donor goal 10 106 cd34 cells per kilogram recipients weigh sirolimus administered graft versus host disease prophylaxis first 12 months post transplant nih protocol sirolimus continued donor chimerism reaches 50 thymphocytes however data showing impact lymphocyte chimerism myeloid chimerism stable engraftment hematopoietic stem cell transplantation non malignancies setting human leukocyte antigen identical sibling myeloablative transplant scd shown myeloid chimerism cd14 monocytesand cd15 neutrophils could predict red cell chimerism cure disease independently cell chimerism confidential data magnani cavazzana necker paris france considering important data chose discontinue sirolimus 12 months transplant whatever level chimerism phase 3 design comparative controlled quasi experimental genetic randomization cohort 2 groups exposed human leukocyte antigen identical sibling identified receive hematopoietic stem cell transplantation unexposed lacking human leukocyte antigen identical sibling receive standard care anticipate 30 matched related donors among siblings 1 2 ratio exposed unexposed group thirty valued centers france participate recruit recruited site taking charge scd addressed center transplant hematopoietic stem cell transplantation planned participants research identified follows site number 3 digits sequential enrolment number site 4 digits surname initial first name initial reference number unique used entire duration methods informing obtaining consent research participants enrolment period 3 years duration participation 2 years total duration 5 years inclusion human leukocyte antigen typing performed identify potential human leukocyte antigen minimal residual disease following data collected morphological explorations performed last 6 months considered baseline visit explorations performed 2 months inclusion past medical history scd complications voc acs stroke silent infarct pulmonary hypertension retinopathy nephropathy osteonecrosis hepatopathy related scd priapism oral opioid consumption number hospitalizations last 2 years hospitalization intensive care unit quality life questionnaire mos sf36 hospital anxiety depression scale hads addenda 20 3 indication participation going medical examination eastern cooperative oncology group (= performans status (= ecog)) blood pressure weight height general examination biological parameters ldh aminotransferase gamma gt alkaline phosphatase bilirubin pr aptt hemoglobin level hematocrit mean corpuscular volume reticulocyte count percentage hemoglobin variants white blood cells platelets counts estimated glomerular function rate microalbuminuria creatininuria ratio erythrocyte group red blood cells alloantibodies ferritin transferrin saturation level spermogram time sperm storage men already treated hydroxyurea treated hydroxyurea collect results spermogram performed onset hydroxyurea time sperm storage dosage lh fsh men women testosterone men oestrogen amh inhibin women amenorrhea women number parity examination retina heart pulmonary hypertension auricular ventricular dilatation left ventricular mass function transthoracic echocardiography explored data tricuspid regurgitant jet velocity left atrial ventricular dimension indexed body surface ventricular mass index left ventricular ejection fraction lung function pulmonary function tests 6 min walk test pelvis radiography central nervous system function magnetic resonance imaging vessel parenchym liver heart magnetic resonance imaging iron overload evaluation ferritin 1000 microg l inclusion transplant arm blood sample chimerism analysis serology b et c hepatitis ebv igg cmv igg hsv igg human immunodeficiency virus htlv 1 et 2 toxoplasmosis igg et tpha et vdrl pcr b c hepatitis human immunodeficiency virus g6 pharmacodynamic dosage blood samples 4 tubes 2 edta 7ml 1 protease inhibitor 5ml 1 tube heparin 7ml plasma serum bank cell bank red blood cells white blood cell count adherence fresh experiments white blood cell count subpopulation taken part research included biological collection oral consumption opioids questionnaire human leukocyte antigen minimal residual disease transplanted compared fertility preservation contraception transplanted men considering potential impact fertility conditioning regimen including 3 gy total body irradiation 87 sirolimus sperm storage performed transplant receiving hydroxyurea sperm storage performed hydroxyurea initiation important stress point radiation shielding applied male gonads decrease risk post transplant hypofertility pre clinic models teratogenicity reported sirolimus data crat centre de reference sur les agents teratogenes women theory 3 gy ovarian radiation doesnt induce immediate post ovarian failure 90 data concerning pregnancy conditioning 3 4 considering egg ovarian pre transplant conservation associated scd complications thrombosis voc acs dont propose systematically pre transplant technic fertility preservation decision performing fertility preservation transplant take account results pre transplant ovarian function evaluation age pregnancy wish risk procedure necessary investigators contact pr c poirot fertility preservation specialist catherine poirot assistance publique hôpitaux de paris shortening fraction discussing indication pre transplant fertility preservation fertility preservation transplant ovarian function monitor transplant post transplant fertility preservation egg storage could proposed sirolimus cessation contraception performed onset conditioning regimen continued duration sirolimus could stopped 12 weeks cessation sirolimus screening physicians charge scd screening addressed investigator charge transplant receive informations hematopoietic stem cell transplantation agreeing design included investigators charge physicians charge transplant sites recruitment pediatric adult units human leukocyte antigen matched sibling donor referred transplant unit hematopoietic stem cell transplantation participants may exit time reason investigator temporarily permanently withdraw participant safety reason participant best interests participant exits prematurely data participant may used consent withdrawn participant exits prematurely withdraws consent data collected prior date premature exit may still used case report form must list various reasons participant exited withdrawn adverse reaction another medical issue personal reasons participant explicit withdrawal consent participant exits prematurely due serious adverse event serious adverse event notification form sent mail sponsor serious adverse event monitored resolved data safety monitoring board data safety monitoring board specify validate monitoring methods start alemtuzumab suffers adverse event particular interest see section 12 1 2 2 1 develops contraindication alemtuzumab first administration experienced related disease considered severe evolving withdrawn ending subject participation affect normal management subject illness way withdraws alemtuzumab follow entire planned according protocol agenda subject discontinues availability human leukocyte antigen tests e choice group replaced otherwise subjects included analysis investigator initially complete severe adverse event reporting form contained case report form report must signed investigator investigator must complete every section severe adverse event form sponsor carry appropriate assessment initial report sent sponsor must rapidly followed one additional written reports describing course event complementary information whenever possible investigator provide sponsor documents may useful medical assessment case medical reports laboratory test results results additional exams etc documents must anonymized addition investigator must state acronym number initials participant paper adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even subject terminated participation initial report severe adverse event follow reports documents must sent sponsor safety department e mail événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction sponsors safety department possible send severe adverse event safety department fax sponsors safety department fax 33 0 1 44 84 17 99 case unsuccessful attempt send severe adverse event e mail order avoid duplicates trials use e case report form investigator completes severe adverse event report form e case report form validates prints signs form sending mail case failure connect e case report form investigator complete sign send severe adverse event report form safety department soon connection restored investigator must complete severe adverse event report form e case report form investigator must comply requests additional information sponsor questions relating adverse event report safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction cases utero exposure investigator complete follow form reporting pregnancy occurring investigator must monitor pregnant woman delivery premature interruption must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage termination foetal death congenital abnormality etc investigator must follow procedure reporting saes initial pregnancy report form severe adverse event follow forms documents sent sponsor using modalities described section father exposed investigator must obtain mother permission collecting information pregnancy computer file used research used accordance french amended informatique et libertes law governing data protection european general data protection regulation gdpr regulations assistance publique hôpitaux de paris sponsor signed declaration compliance reference method specific documents medicinal product human use archived investigator sponsor 15 years end research indexed archiving applies sealed envelope investigator containing one original information sheets consent forms signed individuals site participated research sealed envelope sponsor containing one copy information sheets consent forms signed individuals site participated research binders investigator sponsor containing non exhaustive list successive versions protocol identified version date appendices decisions comité de protection des personnes correspondence enrolment list register appendices specific research final report case report forms computer file used research implemented accordance french amended informatique et libertes law governing data protection european general data protection regulation gdpr regulations commitment comply reference methodology medium risk 001 research governed commission nationale informatique et libertés french data protection agency reference methodology processing personal data used within scope health research amended medium risk 001 ap hp sponsor research signed declaration compliance reference methodology scd ss s0 aged 15 45 years least one non scd sibling 18 years parental couple presented least one following criteria history 2 voc requiring hospitalization one year within past 2 years least past history acs least 1 severe acs within past 2 years defined followed acs requiring red cell transfusion hospitalization intensive care unit acs pao2 60mmhg arterial blood hydrogen ion concentration 7 35 pac02 50mmhg need 4 liters 02 mn reaching sat02 98 1 voc requiring hospitalization last 2 years history recurrent acs three history ischemic stroke cerebral cervical arterial stenosis 25 apparition silent infarct last 2 years pulmonary hypertension defined mean pulmonary artery pressure 25 mmhg rest determined right heart catherization osteonecrosis least 2 joints including one diagnosed past 2 years sickle nephropathy estimated glomerular filtration rate ckd epi formula 100 ml min 1 73m2 persistant microalbuminuria microalbuminuria creatininuria ratio 10 milligrams mmol without cause nephropathy requiring hydroxyurea chronic transfusion already treated hydroxyurea transfusion program time point inclusion already receiving chronic transfusions voc acs responding hydroxyurea eligible provided least 3 voc requiring hospitalization one year within past 2 years initiation chronic transfusions least past history acs contraception period sirolimus women child bearing potential signed informed consent amenable human leukocyte antigen typing hematopoietic stem cell transplantation human leukocyte antigen identical sibling available affiliated french health care insurance performance status eastern cooperative oncology group (= performans status (= ecog)) scale 1 pulmonary function fev1 et forced vital capacity 50 theorical value pulmonary hypertension measured mean pulmonary artery pressure rest 35 mmhg trv 2 7m cardiac doppler confirmed 2 repeated measures 3 6 months period perform right heart catheterization recommended french guideline management adult scd pulmonary hypertension confirmed mean pulmonary pressure 25 mmhg rest mean pulmonary artery pressure rest 35 mmhg appear marker severity could increase significantly risk hst cardiac ejection fraction 45 creatinine clearance 50ml mn 1 73m2 conjugate bilirubin 50 mole l active hepatitis cirrhosis alanine-aminotransferase 4n uncontrolled infection known hypersensitivity alemtuzumab known hypersensitivity murin proteins following excipients disodium edetate polysorbate 80 potassium chloride potassium phosphate monobasic sodium chloride dibasic sodium phosphate water injections positivity human immunodeficiency virus pregnancy breast feeding women alloimmunization delayed hemolytic transfusion reaction precluding red cell transfusions specific cases discussed scd transplant transfusion specialists previous solid organ transplant hematopoietic stem cell transplant age 10 60 years hb electrophoresis aa ac beta thalassemia trait donor usual biological eligibility criteria g cerebro spinal fluid mobilization peripheral blood stem cell collection including legal viral serologies assessment authorizing transplant dosage g6pd genotyping performed human leukocyte antigen identical negative covid 19 test several potential donors several matched sibling donor abo matched donor chosen priority data entered electronically via web browser following analysis sets considered intent treat includes randomized subjects analysed according planned group refer primary analyses per protocol set includes subjects intent treat set without major violations could affect evaluation primary efficacy endpoint analysed according actually group used secondary exploratory sensitivity analyses safety set includes subjects take amount drug quantitative data described median interquartile range qualitative data count percentage statistical analyses perform intent treat intent to treat population meaning analyzed according planned group exposed hematopoietic stem cell transplantation non exposed standard care regardless fact finally transplanted efficacy interim analysis performed final analysis take place two years last inclusion primary endpoint 2 years event free survival time inclusion non parametrically assessed using kaplan meier estimate compared two arms using log rank test effect transplantation assessed hazard ratio high risk 95 confidence interval fitting cox proportional hazards regression model complementary primary analysis sensitivity analysis based per protocol population sensitivity analysis based propensity score matching analysis performed analysis seeks ensure robustness primary analysis handling potential residual imbalances arms confounders propensity score constructed based known observed prognostic factors known observed factors associated arm methods analysing secondary endpoints time event secondary endpoints analysed way primary outcome binary endpoints compared two arms using fishers exact test continuous endpoints compared two arms using wilcoxon rank sum test endpoints multiple measurement across follow analysed using mixed effect regression model take account within correlation statistical analysis safety data safety analyses involve examination incidence severity type emergent adverse events reported changes vital signs laboratory test results baseline day 0 pre dose specified time points throughout concomitant medications use population analysis included according actually received regardless duration adverse events adverse events reported coded using medical dictionary for regulatory activities dictionary incidence emergent adverse events summarized group following system organ class preferred term system organ class preferred term severity summaries presented following subsets serious adverse events adverse events drug related adverse events adverse events resulting discontinuation drug outcome adverse events action taken tables reporting adverse events severity subject multiple occurrences adverse event organ class preferred term severe event presented summary subject listing provided subjects experienced adverse events serious adverse events adverse events resulting discontinuation drug sequential analysis tolerance data performed using bayesian methods allow detecting increased rate serious adverse events differing across arms using bayesian beta binomial model rate saes sequentially computed 95 credible interval arms maximum rate acceptable saes set 30 probability rate saes 30 computed adverse events special interest aesi defined section 12 1 2 2 1 tolerable risk difference 20 two arms aesis involve arms considered using bayesian beta binomial model event rate aesis two arms assessed data safety monitoring board upon request dsi along 95 credible interval saes aess involved arms probability risk difference exceed assessed data safety monitoring board upon request dsi method taking account missing unused invalid data case missing data complete case analyses performed confirmatory analyses performed using multiple imputation chained equation impute outcome well missing characteristics least 20 imputed datasets considered,"graft, transplantation, host, versus, stem, cell, disease, haplo, transplant, donor"
2020-004519-29_protocole_v2-0_20211112_TRIBECA_signe,2,-25.93567,16.32194,full title multicenter randomized double blind comparing efficacy safety belimumab non infectious active cryoglobulinemia vasculitis compared placebo acronym tribeca rituximab belimumab cryoglobulinemia associated vasculitis coordinating investigator pr david saadoun department internal medicine immunology centre national de reference des maladies autoimmunes et systemiques rares hospital pitie salpetriere tel 0142178009 email david saadoun assistance publique hôpitaux de paris shortening fraction sponsor assistance publique hopitaux de paris scientific justification cryoglobulinemia vasculitis associated significant morbidity mortality requires therapeutic intervention management noninfectious mixed cryoglobulinemia vasculitis currently based corticosteroids rituximab last decade several groups reported efficacy anti cd20 monoclonal antibody rituximab cryoglobulinemia vasculitis rituximab infusions proved effective main vasculitis signs complete response 65 70 however cryoglobulinemic vasculitis relapse noted 40 within days nineteen months last rituximab infusion previously shown serum blys concentration correlated serum cryoglobulin level cryoglobulinemia vasculitis cryoglobulinemia associated b non hodgkins lymphoma agreement data systemic lupus erythematosus sjogrens syndrome also observed decrease blys binding br3 staining correlated disease severity following rituximab serum blys concentration significantly increased may favour survival autoreactive b cell clones relapses cryoglobulinemia vasculitis recent shown rituximab reset defective early b cell tolerance checkpoints obvious solution prevent rise baff levels precipitating flare disease following rituximab therapy thus achieve sustained remission disease would combine rituximab baff blockade mice combination b cell depletion baff inhibition removes b cells marginal zone follicular compartments effectively either alone combination b cell depletion baff blockade superior b cell depletion alone respect reducing numbers plasmablasts plasma cells well reducing disease severity three different mouse models lupus addition promising results observed cryoglobulinemia vasculitis treated rituximab plus belimumab good safety profile main objective primary endpoint evaluate efficacy belimumab compared placebo non infectious active cryoglobulinemia vasculitis complete response rate vasculitis symptoms week w 25 corticosteroid withdrawal prednisone 0 milligrams day week w 12 secondary objectives endpoints secondary objectives safety tolerability treatments assessed frequency severity adverse events complete partial improvement organs involved baseline non improvement response rate rate complete renal response rate cryoglobulinemia clearance rate negativation rheumatoid factor activity rate normalization c4 complement level early failure rate week 5 non response week 5 relapse rate time relapse two treatments groups cumulative dose corticosteroids received two treatments groups evolution gammaglobulin cd19 b cells levels quality life scores sf 36 appendix 1 two groups rate infections severe complications lymphoma bvas activity score appendix 2 secondary endpoints safety tolerability treatments assessed frequency severity adverse events week 25 week 48 complete partial non response rate week 13 week 25 week 48 complete renal response rate week 13 week 25 week 48 rate cryoglobulinemia clearance negativation rheumatoid factor activity normalization c4 complement level week 13 week 25 week 48 rate early failures non response week 5 relapse rate defined de novo appearance reappearance manifestation attributable cryoglobulinemia vasculitis 48 weeks follow rate time relapse baseline week 48 cumulative dose prednisone week 25 week 48 quality life score sf 36 baseline week 25 week 48 rate infections severe complications 48 weeks follow evolution gammaglobulin cd19 b levels baseline week 48 bvas activity score baseline week 13 week 25 week 48 design bayesian phase ii randomized aims evaluating best strategy cryoglobulinemia vasculitis based difference response rate measured week 25 randomization population subjects adult non infectious active cryoglobulinemia vasculitis inclusion criteria age 18 years written inform consent active cryoglobulinemia vasculitis initiation rituximab define clinically active vasculitis skin joint renal peripheral nerve central neurological digestive pulmonary cardiac involvement history positive cryoglobulinemia affiliated national french social security system received rituximab induction therapy within 6 weeks 1 4 infusions dose discretion investigator female subjects childbearing potential must negative serum urinary pregnancy test inclusion visit confirmed monthly least 92 days 5 half lives post last dose subjects reproductive potential male female willingness use contraceptive measures adequate prevent subject subjects partner becoming pregnant 2 weeks prior administration 1st dose agent 92 days last dose agent therefore subjects agree 1 following complete abstinence intercourse 2 weeks prior administration 1st dose agent 92 days last dose agent sexual inactivity abstinence must consistent preferred usual lifestyle subject periodic abstinence e g calendar ovulation symptothermal post ovulation methods withdrawal acceptable methods contraception consistent correct use 1 following acceptable methods birth control 1 month prior start agent 92 days last dose agent oral contraceptive either combined progestogen alone injectable progestogen implants levonorgestrel etonogestrel estrogenic vaginal ring percutaneous contraceptive patches intrauterine device intrauterine device intrauterine system ius 1 failure rate stated product label male partner sterilization vasectomy documentation azoospermia prior female subject entry male sole partner subject definition documented refers outcome investigator designees medical examination subject review subject medical history eligibility obtained via verbal interview subject subjects medical records double barrier method condom occlusive cap diaphragm cervical vault caps plus spermicidal agent foam gel film cream suppository allowed methods contraception effective used consistently correctly accordance product label investigator responsible ensuring subjects understand properly use methods contraception human immunodeficiency virus negative serology negative hbs ag test hbc ab test hcv negative serology negative hcv rna positive hcv serology within 3 months inclusion neutrophils absolute neutrophil count 1x109 l exclusion criteria vasculitis unrelated cryoglobulinemia non active cryoglobulinemia vasculitis initiation rituximab inactive vasculitis following rituximab administration may included excluded concomitant medications 365 days prior investigational medicinal product belimumab placebo biologic investigational agent e g abetimus sodium anti cd40l antibody bg9588 idec 131 investigational agent applies drug approved sale country used 180 days prior investigational medicinal product belimumab placebo intravenous cyclophosphamide 30 days prior investigational medicinal product belimumab placebo 5 half lives whichever greater non biologic investigational agent investigational agent applies drug approved sale country use live vaccines within 30 days prior baseline concurrently investigational medicinal product belimumab placebo history malignant neoplasm within last 5 years carcinoma situ cervix excised basal cell squamous cell carcinoma skin low grade hemopathy indication specific progressive multifocal leukoencephalopathy evidence serious suicide risk including history suicidal behaviour last 6 months suicidal ideation last 2 months investigator judgment pose significant suicide risk history primary immunodeficiency significant igg deficiency igg level 400 milligrams deciliter significant iga deficiency iga level 10 milligrams deciliter according results obtained within 1 month prior inclusion visit history major organ transplant hematopoietic stem cell marrow transplant renal transplant infection history currently suppressive therapy chronic infection tuberculosis pneumocystis cytomegalovirus infection requiring hospitalization use parenteral intravenous infusion intramuscular antibiotics antibacterials antivirals anti fungals anti parasitic agents within 60 days inclusion visit current drug alcohol abuse dependence history drug alcohol abuse dependence within 365 days prior inclusion visit historically positive human immunodeficiency virus test according results obtained within 3 months prior inclusion visit hepatitis status according results obtained within 3 months prior inclusion visit serologic evidence current past hepatitis b hb infection based results testing hbsag hbcab follows positive hbsag hbcab excluded positive test hepatitis c rna history hypersensitivity anaphylactic reaction parenteral administration belimumab corticosteroids excipients treatments administered women child bearing potential wcbp included please see special instructions inclusion criteria pregnant breast feeding women intercurrent significant medical psychiatric illness investigator considers would make candidate unsuitable legal protection unable consent participation another interventional investigational medicinal product belimumab benlysta administered subcutaneously 200 milligrams weekly week 1 week 24 comparator placebo belimumab administered subcutaneously weekly week 1 week 24 risks added risk c scope phase ii prospective randomized multicentre double blind group belimumab administered subcutaneously 200mg weekly week 1 week 24 group ii placebo belimumab administered subcutaneously weekly week 1 week 24 randomization centralized stratified previous history naive versus relapsing severity vasculitis e extensive skins necrosis glomerulonephritis multiple mononeuropathy myocarditis digestive central nervous system specific involvement 1 1 ratio groups groups corticosteroid tapering scheme initial dose 30 milligrams day following schedule reduction prednisone apply groups long disease inactive 30 milligrams day week w 0 week 2 20 milligrams day week 2 week 4 15 milligrams day week 4 week 6 10 milligrams day week 6 week 8 5 milligrams day week 8 week 10 week 10 week 12 strategy stopping glucocorticoids left investigator discretion stopping glucocorticoid therapy week 12 step prednisone dose reduced absence signs vasculitis activity number subjects included 48 24 arm number sites multicentre national including 20 centres duration duration inclusions 36 months duration participation 12 months duration 24 weeks total duration 48 months number enrolments expected per site per month 0 06 month centre statistical analysis bayesian phase ii randomized aims evaluating strategy cryoglobulinemia vasculitis based difference response rate measured week 25 randomization randomized phase ii trials still poorly used still large use single arm phase ii results interpreted relative historical control subjects introducing selection bias confounding may limit validity conclusions thus planning phase ii randomized appears worthy investment considering finite financial resources design adapted binary outcomes observed end fixed follow period analyzed using absolute difference proportions shown greatly reduce sample size requirements thus used approach phase ii randomized trials proposed simon r wittes ellenberg ss aims controlling probability detecting given difference response rates hypothesize 70 receiving placebo belimumab 85 treated belimumab achieve complete remission cryoglobulinemia vasculitis week 25 week 25 steroid therapy stopped 0 milligrams day week 12 sources funding gsk also provide belimumab benlysta placebo belimumab data monitoring committee yes belimumab combination rituximab trials using belimumab combination rituximab ongoing sjogrens syndrome nct02631538 immune thrombocytopenia nct03154385 lupus nephritis nct02260934 tribeca rituximab belimumab cryoglobulinemia associated vasculitis first double blind randomized controlled comparing efficacy safety belimumab placebo non infectious active cryoglobulinemia vasculitis current first line therapy active cryoglobulinemia vasculitis rituximab failed demonstrate sustainable remission 65 70 following rituximab serum blys concentration significantly increased may favour survival autoreactive b cell clones relapses cryoglobulinemia vasculitis cryoglobulinemia associated increased risk developing lymphoid neoplasm mainly marginal zone lymphoma mice combination b cell depletion baff inhibition removes b cells marginal zone compartments effectively either alone addition promising results observed cryoglobulinemia vasculitis treated rituximab plus belimumab good safety profile provides strong rationale targeting b cell depletion baff blockade cryoglobulinemia vasculitis management cryoglobulinemia vasculitis remains largely empirical strong immunological rationale immunomodulation b cell depletion baff inhibition cryoglobulinemia vasculitis immunomodulatory activity rituximab associated belimumab potential effective cryoglobulinemia vasculitis preliminary safety results encouraging first randomized synergistic b cell immunomodulation therapeutic management noninfectious mixed cryoglobulinemia vasculitis validate naive relapsing also assess complete withdrawal corticosteroids following five month period compared strategy never validated using maintenance low dose corticosteroids 10 milligrams immunosuppressive therapy could confirm superiority rituximab belimumab association compared rituximab associated placebo terms efficacy steroid sparing could improve management non infectious mixed cryoglobulinemia vasculitis expected benefit individual improving quality life cryoglobulinemia vasculitis collective reducing costs hospitalization side effects immunosuppressants major side effects corticosteroids e g osteoporosis abnormal behavior infection diabetes related cumulative dose administered although relapses progression exacerbation symptoms cryoglobulinemia vasculitis may appear steroids tapering frequently reported adverse events belimumab lupus incidence 5 among treated belimumab combination standard therapy 1 compared placebo arm nausea diarrhea fever stuffy runny nose sore throat persistent cough trouble sleeping leg arm pain depression headache pain redness itching swelling site injection proportion discontinued due adverse events 7 benlysta treated 8 placebo treated exceptionally cases progressive multifocal leukoencephalopathy described lupus cryoglobulinemia vasculitis associated significant morbidity mortality require therapeutic intervention 1 management noninfectious mixed cryoglobulinemia vasculitis currently based corticosteroids rituximab last decade several groups reported efficacy anti cd20 monoclonal antibody rituximab cryoglobulinemia vasculitis rituximab infusions proved effective main vasculitis signs complete response 65 70 2 however cryoglobulinemic vasculitis relapse noted 40 within days nineteen months last rituximab infusion previously shown serum blys concentration correlated serum cryoglobulin level cryoglobulinemia vasculitis cryoglobulinemia associated b non hodgkins lymphoma 3 agreement data systemic lupus erythematosus sjogrens syndrome also observed decrease blys binding br3 staining correlated disease severity 3 following rituximab serum blys concentration significantly increased may favour survival autoreactive b cell clones relapses cryoglobulinemia vasculitis recent shown rituximab reset defective early b cell tolerance checkpoints 4 obvious solution prevent rise baff levels precipitating flare disease following rituximab therapy thus achieve sustained remission disease would combine rituximab baff blockade mice combination b cell depletion baff inhibition removes b cells marginal zone follicular compartments effectively either alone 5 combination b cell depletion baff blockade superior b cell depletion alone respect reducing numbers plasmablasts plasma cells well reducing disease severity three different mice models lupus cryoglobulinemia associated increased risk developing lymphoid neoplasm mainly marginal zone lymphoma addition promising results observed cryoglobulinemia vasculitis treated rituximab plus belimumab unpublished observations good safety profile provides strong rationale targeting b cell depletion baff blockade cryoglobulinemia vasculitis tribeca rituximab belimumab cryoglobulinemia associated vasculitis first double blind randomized controlled comparing efficacy safety belimumab placebo rituximab non infectious active cryoglobulinemia vasculitis evaluate efficacy belimumab compared placebo non infectious active cryoglobulinemia vasculitis safety tolerability treatments assessed frequency severity adverse events complete remission affected organs involved baseline absence relapse partial improvement organs involved baseline non improvement response rate rate complete renal response rate cryoglobulinemia clearance rate negativation rheumatoid factor activity rate normalization c4 complement level early failure rate week 5 non response week 5 relapse rate time relapse two treatments groups cumulative dose corticosteroids received two treatments groups evolution gammaglobulin levels cd19 b cells levels quality life scores sf 36 two groups rate infections severe complications lymphoma bvas activity score complete response rate vasculitis symptoms week 25 corticosteroid withdrawal prednisone 0 milligrams day week w 12 complete response defined remission affected organs involved baseline absence relapse skin articular remissions evaluated clinically disappearance purpura ulcers disappearance arthritis renal remission evaluated biologically proteinuria 0 5g 24h proteinuria creatininuria 50 milligrams mmol neurological remission evaluated clinically improvement pains paresthesia visual analogue scales stabilization improvement muscular testing case motor impairment baseline electrophysiologically stabilization improvement electromyogram abnormalities week 25 compared baseline digestive remission evaluated clinically improvement abdominal pain gastrointestinal symptoms endoscopy improvement potential gastrointestinal lesions seen baseline xray improvement abnormalities found baseline imaging complete remission baseline abnormalities required define digestive remission cardiac remission evaluated clinically improvement chest pains cardiac events electrically disappearance abnormalities indicating acute myocardial suffering ekg biologically normalization muscular enzymes complete remission baseline abnormalities required define cardiac remission central nervous system remission evaluated clinically stabilization improvement central nervous system manifestation magnetic resonance imaging stabilization disappearance vasculitis sign pulmonary remission evaluated clinically improvement dyspnea disappearance hemoptysis chest scan improvement vasculitis sign response week 5 defined early failure failure principal judgment criteria unblinded optimal performed physician charge relapse defined de novo appearance recurrence manifestation due cryoglobulinemia vasculitis week 5 week 25 considered failure according primary endpoint severe relapses unblinded optimal performed physician charge therapeutic management discretion investigator according standard care moderate mild relapse treated increase corticosteroids without breaking double blind severe flare defined appearance reappearance one following signs extensive skin necrosis loss substance specific cardiac involvement vasculitis documented ekg troponin magnetic resonance imaging specific digestive impairment vasculitis documented imaging endoscopy affection central nervous system specific vasculitis documented cerebral magnetic resonance imaging multiple mononeuropathy clinically defined asymmetrical motor impairment 2 nerve trunks documented electromyogram severe renal impairment defined doubling creatinine levels usual value glomerular filtration rate according mdrd less 30 ml min 1 73m2 absence prior history creatinine levels excluding causes renal impairment flare appearance reappearance purpura arthritis sensory neuropathy documented electromyogram glomerulonephritis proteinuria 1g 24h excluding causes proteinuria defined moderate mild discretion investigator safety tolerability treatments assessed frequency severity adverse events baseline week 25 week 48 complete partial non response rate week 13 week 25 week 48 complete renal response rate week 13 week 25 week 48 defined proteinuria 0 5g 24h proteinuria creatininuria 50 milligrams mmol disappearance hematuria glomerular filtration rate mdrd 60 ml min 1 73 month 2 rate cryoglobulinemia clearance negativation rheumatoid factor activity normalization c4 complement level week 13 week 25 week 48 rate early failures non response week 5 relapse rate defined de novo appearance recurrence manifestation attributable cryoglobulinemia vasculitis 48 weeks follow rate time relapse baseline week 48 cumulative dose prednisone week 25 week 48 evolution gammaglobulin cd19 b levels baseline week 48 quality life score sf 36 baseline week 25 week 48 rate infections severe complications 48 weeks follow bvas activity score baseline week 13 week 25 week 48 group belimumab benlysta administered subcutaneously 200mg weekly week 1 week 24 group ii placebo belimumab administered subcutaneously weekly week 1 week 24 experimental design multicentric randomized controlled stratified previous history naive versus relapsing severity cryoglobulinemia vasculitis e extensive skins necrosis glomerulonephritis multiple mononeuropathy myocarditis digestive central nervous system specific involvement 1 1 ratio groups evaluation primary assessment criteria week 25 primary assessment criteria final measures corticosteroid sparing reviewed endpoint adjudication committee blinded randomization committee role validating blind conditions following assignments complete remission failure relapse disease rct use adaptive bayesian design phase ii randomized national multicentre aims comparing new reference based binary endpoint e complete response week 25 offers greater flexibility simplicity inference monitoring safety evidence efficacy small randomized trials week 0 day inclusion randomization 1 1 ratio group belimumab administered subcutaneously 200mg weekly week 1 week 24 group ii placebo belimumab administered subcutaneously weekly week 1 week 24 groups corticosteroid tapering scheme initial dose 30 milligrams day following schedule reduction prednisone apply groups long disease inactive 30 milligrams day week w 0 week 2 20 milligrams day week 2 week 4 15 milligrams day week 4 week 6 10 milligrams day week 6 week 8 5 milligrams day week 8 week 10 week 10 week 12 strategy stopping glucocorticoids left investigator discretion stopping glucocorticoid therapy week 12 step prednisone dose reduced absence signs vasculitis activity case minimal moderate relapse dose prednisone increased previous level new dose maintained 4 weeks resuming regimen corticosteroid decay first administration belimumab placebo satisfy entry criteria including informed consent done within 7 days 2 days visit week 1 inclusion randomisation week 5 evaluation response week 25 evaluation primary assessment criteria week 13 25 48 evaluation secondary assessment criteria figure 1 scheme due pharmaceutic deliverance belimumab placebo fisrt injection occur within 7 days 2 days randomization multicentre national including 20 centres investigating doctor may request unblinding reason considers essential contacting emergency cases poison control centre fernand widal hospital telephone 33 0 1 40 05 48 48 apart emergency situation délégation à la recherche clinique et à l’innovation research innovation department délégation à la recherche clinique et à l’innovation project advisor whose contact information listed protocol cover page project manager elodie soler tel 01 44 84 17 35 french national reference center rare systemic autoimmune diseases located pitie salpetriere hospital paris leading center field cryoglobulinemia vasculitis cohort 500 french cryoglobulinemia vasculitis network recently conducted management noninfectious mixed cryoglobulinemia vasculitis recruited 242 working close collaboration french neurologist nephrologist dermatologist rheumatologist including pitie salpetriere hospital paris several situations possible temporary suspension investigator must document reason suspending resuming participants source file case report form case report form premature discontinuation participant remains enrolled end participation premature discontinuation withdrawal investigator must document reason collect assessment criteria time ending participation participant agrees schedule follow participant particularly case serious adverse event participants may exit time reason investigator temporarily permanently withdraw subject safety reason subject best interests participants lost follow participant cannot located investigator must make every effort reconnect participant document attempts source file least determine whether participant alive dead participant exits prematurely withdraws consent data collected prior date premature exit may still used participant exits prematurely participant agrees state procedure schedule collecting data required protocol primary endpoint secondary endpoints safety assessment nb must stated information consent form state premature exit affect participant ongoing care state exactly participant offered case serious adverse events see corresponding section vigilance case report form must list various reasons participant discontinued lack efficacy adverse reaction another medical issue personal reasons participant explicit withdrawal consent lost follow case withdrawal replaced initial notification severe adverse event must provided written report signed investigator using severe adverse event notification form specific intended purpose case report form item form must completed investigator sponsor carry appropriate analysis initial notification sponsor serious adverse event must quickly followed additional detailed written report reports case outcome may monitored safety department provide information whenever possible investigator provide sponsor documents may useful medical reports laboratory test results results additional examinations etc documents must non identifying addition documents must include following acronym number participants initials adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even participant left initial notification severe adverse event follow reports documents must sent sponsor safety department email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction noted possible send severe adverse event reports safety department fax 33 0 1 44 84 17 99 event failed attempt send severe adverse event report email order avoid duplication use e crfs investigator completes severe adverse event notification form e case report form validates prints signs form sending email possible connect e case report form investigator complete sign send severe adverse event notification form safety department soon connection restored severe adverse event notification form e case report form must duly completed investigator must respond requests sponsor additional information questions relating notification adverse event safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction cases utero exposure investigator complete notification follow form pregnancy occurring participation investigator must monitor pregnant woman throughout pregnancy pregnancy terminated must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage pregnancy termination foetal death congenital abnormality etc investigator must follow procedure reporting saes initial pregnancy notification severe adverse event follow reports documents sent sponsor according procedures specified herein father exposed investigator must obtain pregnant woman permission collecting information pregnancy special rules trials involving administration radioactive product e g pet scan subject develops secondary cancer cancer develops hereditary deficiency following exposure ionising radiation investigator shall complete special form reporting cancer investigator permit sponsors representatives monitor frequency defined contract depending enrolment center case report forms crfs related source documents reviewed detail monitoring visit completeness adherence guidelines accuracy compared source documents sponsors representative also review regulatory documents drug storage accountability investigator must maintain comprehensive centralized filing system related documentation suitable inspection sponsors monitors representatives regulatory agencies computer file used research implemented accordance french amended informatique et libertes law governing data protection european general data protection regulation gdpr regulations research governed commission nationale informatique et libertés french data protection agency reference methodology processing personal data used within scope health research amended medium risk 001 ap hp sponsor research signed declaration compliance reference methodology eligibility criteria checked inclusion randomization visit meeting following criteria may included age 18 years written inform consent active cryoglobulinemia vasculitis initiation rituximab define clinically active vasculitis skin joint renal peripheral nerve central neurological digestive pulmonary cardiac involvement history positive cryoglobulinemia affiliated national french social security system received rituximab induction therapy within 6 weeks 1 4 infusions dose discretion investigator female subjects childbearing potential must negative serum urinary pregnancy test inclusion visit confirmed monthly least 92 days 5 half lives post last dose subjects reproductive potential male female willingness use contraceptive measures adequate prevent subject subjects partner becoming pregnant 2 weeks prior administration 1st dose agent 92 days last dose agent therefore subjects agree 1 following complete abstinence intercourse 2 weeks prior administration 1st dose agent 92 days last dose agent sexual inactivity abstinence must consistent preferred usual lifestyle subject periodic abstinence e g calendar ovulation symptothermal post ovulation methods withdrawal acceptable methods contraception consistent correct use 1 following acceptable methods birth control 1 month prior start agent 92 days last dose agent oral contraceptive either combined progestogen alone injectable progestogen implants levonorgestrel etonogestrel estrogenic vaginal ring percutaneous contraceptive patches intrauterine device intrauterine device intrauterine system ius 1 failure rate stated product label male partner sterilization vasectomy documentation azoospermia prior female subject entry male sole partner subject definition documented refers outcome investigator designees medical examination subject review subject medical history eligibility obtained via verbal interview subject subjects medical records double barrier method condom occlusive cap diaphragm cervical vault caps plus spermicidal agent foam gel film cream suppository allowed methods contraception effective used consistently correctly accordance product label investigator responsible ensuring subjects understand properly use methods contraception human immunodeficiency virus negative serology negative hbs ag test hbc ab test hcv negative serology negative hcv rna positive hcv serology within 3 months inclusion neutrophils absolute neutrophil count 1x109 l subjects included meet following criteria vasculitis unrelated cryoglobulinemia non active cryoglobulinemia vasculitis initiation rituximab inactive vasculitis following rituximab administration may included excluded concomitant medications 365 days prior investigational medicinal product belimumab placebo biologic investigational agent e g abetimus sodium anti cd40l antibody bg9588 idec 131 investigational agent applies drug approved sale country used 180 days prior investigational medicinal product belimumab placebo intravenous cyclophosphamide 30 days prior investigational medicinal product belimumab placebo 5 half lives whichever greater non biologic investigational agent investigational agent applies drug approved sale country use live vaccines within 30 days prior baseline concurrently investigational medicinal product belimumab placebo history malignant neoplasm within last 5 years carcinoma situ cervix excised basal cell squamous cell carcinoma skin low grade hemopathy indication specific evidence serious suicide risk including history suicidal behaviour last 6 months suicidal ideation last 2 months investigator judgment pose significant suicide risk progressive multifocal leukoencephalopathy history primary immunodeficiency significant igg deficiency igg level 400 milligrams deciliter significant iga deficiency iga level 10 milligrams deciliter according results obtained within 1 month prior inclusion visit history major organ transplant hematopoietic stem cell marrow transplant renal transplant infection history currently suppressive therapy chronic infection tuberculosis pneumocystis cytomegalovirus infection requiring hospitalization use parenteral intravenous infusion intramuscular antibiotics antibacterials antivirals anti fungals anti parasitic agents within 60 days inclusion visit current drug alcohol abuse dependence history drug alcohol abuse dependence within 365 days prior inclusion visit historically positive human immunodeficiency virus test according results obtained within 3 months prior inclusion visit hepatitis status according results obtained within 3 month prior inclusion visit serologic evidence current past hepatitis b hb infection based results testing hbsag hbcab follows positive hbsag hbcab excluded positive test hepatitis c rna history hypersensitivity anaphylactic reaction parenteral administration belimumab corticosteroids excipients treatments administered women child bearing potential wcbp included please see special instructions inclusion criteria pregnant breast feeding women intercurrent significant medical psychiatric illness investigator considers would make candidate unsuitable legal protection unable consent participation another interventional persons responsible quality control article l 1121 3 code de la sante publique french public health code take necessary precautions ensure confidentiality information relating investigational medicinal products participants particular identity results obtained persons well investigators bound professional secrecy accordance conditions set articles 226 13 226 14 code penal french criminal code research involving human participants data collected concerning participants sent sponsor investigators specialised collaborators rendered non identifying circumstances shall names addresses participants involved shown participants initials recorded accompanied encoded number specific indicating order enrolment sponsor ensure participant given written permission personal information strictly necessary quality control accessed data entry carried electronic media via web browser bayesian phase ii randomized aims evaluating strategy non infectious cryoglobulinemia vasculitis based difference response rate measured week 25 randomization randomized phase ii trials still poorly used still large use single arm phase ii results interpreted relative historical control subjects introducing selection bias confounding may limit validity conclusions thus planning phase ii randomized appears worthy investment considering finite financial resources sharma 2011 moreover chose design bayesian three main reasons first allows incorporating information outside results decrease required sample size due fictive observations secondly bayes designs particularly well suited adaptive designs given inference based accumulated data along allowing interim sequential analyses without inflation type error biased estimation wang 2016 third design adapted binary outcomes observed end fixed follow period analyzed using absolute difference proportions shown greatly reduce sample size requirements use bayesian inference framework denotes probability response arm k k 1 2 using beta prior k posterior probability k still beta distribution given due natural conjugate property beta family binomial sampling setting inefficacy drug first assessed comparison historical minimal value interest sometimes called minimum required response rate set 0 70 thus compute arm 1 note true response rate belimumab arm 0 85 0 05 however randomized phase ii settings selection new drug mostly based evaluating potential benefits experimental control arm whitehead 2014 thus one may consider dropping new drug rather low posterior probability drug beneficial control targeted minimal level done computing value posterior probability difference response rates experimental arm control xie 2012 probability placebo arm 0 7 0 85 probability 0 90 calculations based using ak 0 5 bk 0 5 arms sensitivity analyses performed using ak 0 7 bk 0 3 placebo arm using ak 0 85 bk 0 25 belimumab arm,"week, uveitis, bd, vasculitis, cd, adalimumab, disease, 16, remission, tocilizumab"
Kapvec_protocole_V3_16.10.2020,0,19.809,23.891697,full title phase ii multicenter talimogene laherparepvec classic endemic kaposi sarcoma acronym kapvec coordinating investigator pr celeste lebbe oncodermatologie hopital saint louis sponsor assistance publique hopitaux de paris scientific justification kaposi sarcoma ks lymphangioproliferation associated human herpes virus 8 hhv8 promoted immunosuppression human immunodeficiency virus related ks iatrogenic posttransplantation ks treated immune restoration association local systemic therapies chemotherapies required conversely classic endemic ks underlying relative immunosuppression cannot directly targeted poorly codified mostly based surgery radiotherapy localized ks aggressive forms visceral involvement treated chemotherapies interferon give best 30 60 transient responses may well tolerated elderly talimogene laherparepvec first oncolytic immunotherapy approved fda metastatic unresectable melanoma injectable nodal cutaneous lesions designed induce tumor regression injected lesions direct lytic effects uninjected lesions induction systemic antitumor immunity merkel cell carcinoma mcc another virus induced tumor pharmacodynamic 1 pharmacodynamic l1 axis inhibitors proven efficacy thus providing proof principle immunotherapy could effective virus induced tumors two cases metastatic mcc succesfully treated talimogene laherparepvec recently reported suggesting talimogene laherparepvec may also effective therapeutic option considering high immunogenicity viral epitopes ks tumors role immune evasion development ks cutaneous manifestations 90 easily injected classic endemic ks good tumor model targeted talimogene laherparepvec main objective primary endpoint main objective assess whether talimogene laherparepvec clinically inactive partial complete response probability 0 10 truly active partial complete response probability 1 40 classic endemic kaposi sarcoma primary endpoint best overall response rate borr defined occurrence complete response partial response injected lesions following pga criteria pga 0 4 recorded start 6 months beginning specific therapy kaposi sarcoma occurs 6 months secondary objectives endpoints secondary objectives safety profile talimogene laherparepvec classic endemic kaposi sarcoma parameters efficacy best response response rate duration response efficacy injected uninjected lesions quality life exploratory objectives characterize efficacy talimogene laherparepvec related immunologic viral assessment tumor biopsies blood samples secondary endpoints adverse events following common terminology criteria for adverse events v5 0 borr according actg criteria response rate month 3 6 response rate lymphedema time response duration response response injected uninjected target lesions deaths cause ks adapted dlqi score exploratory endpoints characterize immune tumor infiltrate immune cells quantification viral infiltrate tumor necrosis hhv8 viral load blood tumor cells hhv8 sequencing design phase ii multicentre single arm open label population subjects adult inclusion criteria classic endemic histologically confirmed kaposi sarcoma ks progressive require systemic therapy injectable measurable disease defined least 2 cutaneous lesion 10mm largest diameter previously irradiated field least 2 cutaneous lesion 10mm largest diameter available repeated cutaneous biopsies previously irradiated field nb cutaneous lesion replaced cluster small lesions edge edge distance 2 millimeter biggest diameter cluster meet previous criteria willing provide tissue cutaneous biopsy least 4 weeks washout ks specific therapies including topical chemotherapy radiotherapy immunotherapy including interferon provide written informed consent prior performance specific procedures 18 years age day signing informed consent performance status 0 1 eastern cooperative oncology group (= performans status (= ecog)) performance scale demonstrate adequate organ function haematological absolute neutrophil count absolute neutrophil count 1500 cubic millimeter platelets 100 000 cubic millimeter haemoglobin 8 g deciliter renal serum creatinine 1 5 x upper limit normal upper limit of normal calculated creatinine clearance 40ml min using mdrd formula subject creatinine levels 1 5 x upper limit of normal hepatic aspartate amino transferase serum glutamic oxaloacetictransferase alanine amino transferase serum glutamopyruvatetransferase 2 5xuln serum total bilirubin 1 5xuln direct bilirubin upper limit of normal subjects total bilirubin levels 1 5xuln pt1 5 ptt tca 1 5 female subject childbearing potential negative serum pregnancy within 72 hours prior receiving first dose medication health insurance exclusion criteria known history organ transplantation including allogeneic stem cell transplantation human immunodeficiency virus human immunodeficiency virus 1 2 antibodies detected selection symptomatic visceral involvement ks including brain metastases active autoimmune disease requires systemic required systemic past 2 years e use disease modifying agents corticosteroids immunosuppressive drugs replacement therapy eg thyroxine insulin physiologic corticosteroid replacement therapy adrenal pituitary insufficiency etc considered form systemic vitiligo type diabetes mellitus hypothyroidism psoriasis non requiring systemic permitted enrol evidence clinically significant immunosuppression following primary immunodeficiency state severe combined immunodeficiency disease concurrent opportunistic infection receiving systemic immunosuppressive therapy including oral steroid doses 10 milligrams day prednisone equivalent within 7 days prior enrolment clinically significant cardiac dysfunction symptomatic heart failure clinically significant arrhythmia conduction disorders active herpetic skin lesions prior complications hsv 1 infection eg herpetic keratitis encephalitis intermittent chronic systemic intravenous oral antiherpetic drug eg acyclovir intermittent topical use previous talimogene laherparepvec oncolytic virus prior radiotherapy fields overlap injection sites prior immunosuppressive chemotherapy radiotherapy biological cancer therapy major surgery within 28 days prior enrollment recovered common terminology criteria for adverse events grade 1 better adverse event due ks therapy administered 28 days prior enrollment prior therapy tumor vaccine received live vaccine within 28 days prior enrolment currently another investigational device drug less 28 days since ending another investigational device drug acute chronic active hepatitis b hbs ag detected c infection hcv rna detected inclusion active tuberculosis bacillus tuberculosis known additional malignancy currently progressing requires active within last 3 years exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer sensitivity products components administered psychiatric substance abuse disorders would interfere cooperation requirements pregnant breastfeeding expecting conceive father children within projected duration 3 months last dose talimogene laherparepvec subjects unwilling minimize exposure blood body fluids individuals higher risks hsv 1 induced complications immunosuppressed individuals individuals known human immunodeficiency virus infection pregnant women infants age 3 months talimogene laherparepvec 30 days last dose talimogene laherparepvec pregnant breastfeeding expecting conceive father children within projected duration female subject childbearing potential unwilling use acceptable method effective contraception 3 months last dose talimogene laherparepvec sexually active subjects partners unwilling use male female latex condom avoid potential viral transmission sexual contact within 30 days talimogene laherparepvec addition male participants donate sperm 3 months last dose vulnerable subjects prisoners incarcerated following administrative court decision subjects psychiatric disorders involuntary hospitalized subjects legal protection measure subjects cannot express consent investigational medicinal product talimogene laherparepvec dose 10 6 pfu ml week 1 10 8 ml week 4 every 2 weeks 4ml injection route intralesional injection duration 6 months 12 cycles comparator interventions added immunovirologic evaluations based tumor tissue collection cutaneous biopsy correlative blood sampling risks added risk scope kaposi sarcoma number subjects included 9 enrolled first part another 11 second part total 20 implies screen maximum 40 number sites national multicenter 2 sites duration inclusion period 18 months participation period follow 1 month screening 12 cycles 6 months 1 month follow total duration 26 months number enrolments expected per site per month saint louis 0 2 cochin 0 1 statistical analysis simons 2 stage optimal design interim analysis planned 9 sources funding amgen data monitoring committee yes preclinical demonstrated talimogene laherparepvec demonstrated strong lytic activity variety human tumor cell lines vitro including colorectal cancer breast cancer glioblastoma astrocytoma prostate adenocarcinoma melanoma 1 murine models demonstrated tumor infiltration cd8 cells injected noninjected metastases melanoma treated talimogene laherparepvec demonstrated accumulation melanoma antigen specific cd8 cells within injected lesions associated reduction cd4 foxp3 regulatory cells cd14 myeloid derived suppressor cells 14 collectively observations demonstrate ability talimogene laherparepvec lyse human tumor cells induce antigen specific cd8 adaptive immune responses injected uninjected tumors talimogene laherparepvec studied melanoma phase iii injectable melanoma treated intralesional talimogene laherparepvec subcutaneous gm cerebro spinal fluid showed orr 26 4 vs 5 7 overall survival 23 3 vs 18 9 months 15 talimogene laherparepvec first approved oncolytic virus overall adverse events reported treated talimogene laherparepvec included flu like symptoms injection site reactions fatal adverse events related talimogene laherparepvec reported provide overview efficacy safety talimogene laherparepvec classic endemic ks benefit risk ratio seems favourable since talimogene laherparepvec previously tested several phase 2 3 diseases melanoma showed acceptable safety profile immunomodulator agent approved ks interferon poorly tolerated positive effects benefit drug evaluated larger series detailed description risks imposed research included safety assessment section oncolytic viruses represent novel drug class native modified viruses used cancer oncolytic viruses mediate tumor regression virus induced lytic effect tumor cells activation innate immune system virus coupled antigen release dying tumor cells creates favorable microenvironment adaptive systemic antitumor immunity thus able regressing tumor distant uninjected sites talimogene laherparepvec attenuated herpes simplex virus type 1 hsv 1 derived functional deletion 2 genes icp34 5 icp47 insertion coding sequence human granulocyte macrophage colony stimulating factor gm cerebro spinal fluid deletion icp34 5 allows selective replication talimogene laherparepvec tumor tissue normal cells able protect talimogene laherparepvec infection contain intact anti viral defense mechanisms deletion icp47 prevents regulation antigen presentation molecules increases expression hsv us11 gene enhances viral replication tumor cells gm cerebro spinal fluid recruits activates antigen presenting cells process present tumor derived antigens promote effector cell response 1 virus induced tumors kaposi sarcoma growing evidence immunotherapy could effective usual treatments chemotherapy merkel cell carcinoma mcc another virus induced tumor immune checkpoint inhibitors pharmacodynamic 1 pharmacodynamic l1 axis inhibitors proven efficacy phase ii trials 2 3 two cases metastatic mcc successfully treated talimogene laherparepvec recently reported suggesting talimogene laherparepvec may also effective therapeutic option 4 ks team others reported cases successfully treated pd1 blockade 5 6 currently ongoing considering high immunogenicity viral epitopes ks tumors role immune evasion development ks cutaneous manifestations 90 easily injected classic endemic ks appears good tumor model targeted talimogene laherparepvec main objective assess whether talimogene laherparepvec clinically inactive partial complete response probability 0 10 truly active partial complete response probability 1 40 classic endemic kaposi sarcoma secondary objectives assess safety profile talimogene laherparepvec classic endemic kaposi sarcoma assess parameters efficacy injected uninjected lesions best response response rate duration response assess disease related quality life collateral research performed characterize efficacy talimogene laherparepvec related immunologic virologic assessment tumor biopsies blood samples order characterize immune tumor infiltrate immune cells quantification viral infiltrate tumor necrosis hhv8 viral load monitored blood tumor cells hhv8 sequenced hsv1 quantified primary endpoint best overall response rate borr defined occurrence complete response partial response injected lesions following pga criteria pga 0 4 recorded start 6 months beginning specific therapy kaposi sarcoma occurs 6 months secondary endpoints 1 safety endpoints safety assessed terms drug toxicity evaluated clinic changes laboratory parameters scored according common terminology criteria adverse events common terminology criteria for adverse events version 5 0 https ctep cancer gov protocoldevelopment electronic_applications ctc htm ctc_50 2 efficacy endpoints best overall response rate borr injected uninjected target lesions according actg criteria best overall response rate borr uninjected target lesions according pga criteria response rate injected uninjected target lesions month 3 month 6 according pga actg criteria response rate lymphedema month 3 month 6 best response defined primary endpoint time response defined time first response pga criteria recorded start duration response defined time first response pga criteria progression deaths cause ks adapted dlqi dermatology life quality index talimogene laherparepvec given intralesionnal injection dose 10 6 pfu ml 4 ml week 1 10 8 pfu ml 4 ml week 4 every 2 weeks ks cutaneous lesions 6 months complete regression injected lesions clinically significant progression unacceptable toxicity see section 7 information administration product multicenter single arm open label phase ii design phase ii optimum simons two stage design test null hypothesis best overall response rate borr complete remission pr pga 0 4 p 0 100 versus alternative p 0 400 two stage design testing drug 9 first stage terminated 1 fewer respond continue 2 respond goes second stage total 20 studied total number responding less equal 4 drug rejected 2 stages inclusions could suspended observation borr 6 months last included first stage nevertheless 2 complete remission pr observed 9 stopping inclusions required multicenter french national including 2 participating centres members groupe de cancerologie cutanee recruited hospital dermatologist experts ks management examination intervention may carried investigator must obtain free informed written consent subject participating legal representative applicable subjects participating described article l 1121 1 1 paragraph code de la sante publique eligible prior medical examination appropriate screening follow end visits performed basis hospitalisation upon investigator choice performed investigator qualified designee different situations temporary suspension investigator must document reason suspending resuming subject source file case report form case report form premature termination subject remains enrolled end subject participation investigator must document reason premature termination exit planned termination subject exits prematurely withdraws consent data collected prior date premature exit may still used case report form must list various reasons subject exited withdrawn lack efficacy adverse reaction medical problem subject personal reasons explicit withdrawal consent lost follow consent withdrawn excluded analysis except allows investigators use already collected data primary endpoint new included order able apply simons optimal design included analyzed intention treat analysis immunologic viral evaluations performed sequential samples peripheral blood collected 3 time points baseline first dose week 6 cycle 3 eot one heparinate sample 20 ml one edta tube skin biopsy collected 2 time points first dose uninjected lesion week 6 cycle 3 one uninjected lesions one injected lesions kaposi lesion two 3mm punch biopsy samples one 6 millimeter biopsy cut half performed one flash frozen liquid nitrogen stored 80c fixed formalin afa follow biopsy performed residual disease possible kaposi lesion another lesion contiguous first lesion please refer table 5 annexe 18 5 distinction target lesion biopsy lesion injected uninjected lesions investigator initially complete severe adverse event reporting form contained case report form report must signed investigator investigator must complete every section severe adverse event form sponsor carry appropriate assessment initial report sent sponsor must rapidly followed one additional written reports describing course event complementary information whenever possible investigator provide sponsor documents may useful medical assessment case medical reports laboratory test results results additional exams etc documents must anonymized addition investigator must state acronym number initials participant paper adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even subject terminated participation initial report severe adverse event follow reports documents must sent sponsor safety department mail événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction noted possible send severe adverse event reports safety department fax 33 0 1 44 84 17 99 event failed attempt send severe adverse event report email order avoid duplication investigator completes severe adverse event report form e case report form validates prints signs form sending mail case failure connect e case report form investigator complete sign send severe adverse event report form safety department soon connection restored investigator must complete severe adverse event report form e case report form investigator must comply requests additional information sponsor questions relating adverse event report safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction cases utero exposure investigator complete initial notification follow report forms pregnancy exposure participation investigator must monitor pregnant woman throughout pregnancy pregnancy ends must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage termination foetal death congenital abnormality etc investigator must follow procedure reporting saes initial pregnancy report form severe adverse event follow forms documents sent sponsor using modalities described father exposed investigator must obtain mother permission collecting information pregnancy classic endemic histologically confirmed kaposi sarcoma ks progressive require systemic therapy injectable measurable disease defined least 2 cutaneous lesion 10mm largest diameter previously irradiated field least 2 cutaneous lesion 10mm largest diameter available repeated cutaneous biopsies previously irradiated field nb cutaneous lesion replaced cluster small lesions edge edge distance 2 millimeter biggest diameter cluster meet previous criteria willing provide tissue cutaneous biopsy least 4 weeks washout ks specific therapies including topical chemotherapy radiotherapy immunotherapy including interferon provide written informed consent prior performance specific procedures 18 years age day signing informed consent performance status 0 1 eastern cooperative oncology group (= performans status (= ecog)) performance scale demonstrate adequate organ function haematological absolute neutrophil count absolute neutrophil count 1500 cubic millimeter platelets 100 000 cubic millimeter haemoglobin 8 g deciliter renal serum creatinine 1 5 x upper limit normal upper limit of normal calculated creatinine clearance 40ml min using mdrd formula subject creatinine levels 1 5 x upper limit of normal hepatic aspartate amino transferase serum glutamic oxaloacetictransferase alanine amino transferase serum glutamopyruvatetransferase 2 5xuln serum total bilirubin 1 5xuln direct bilirubin upper limit of normal subjects total bilirubin levels 1 5xuln pt1 5 ptt tca 1 5 female subject childbearing potential negative serum pregnancy within 72 hours prior receiving first dose medication health insurance known history organ transplantation including allogeneic stem cell transplantation human immunodeficiency virus human immunodeficiency virus 1 2 antibodies detected selection symptomatic visceral involvement ks including brain metastases active autoimmune disease requires systemic required systemic past 2 years e use disease modifying agents corticosteroids immunosuppressive drugs replacement therapy eg thyroxine insulin physiologic corticosteroid replacement therapy adrenal pituitary insufficiency etc considered form systemic vitiligo type diabetes mellitus hypothyroidism psoriasis non requiring systemic permitted enrol evidence clinically significant immunosuppression following primary immunodeficiency state severe combined immunodeficiency disease concurrent opportunistic infection receiving systemic immunosuppressive therapy including oral steroid doses 10 milligrams day prednisone equivalent within 7 days prior enrolment clinically significant cardiac dysfunction symptomatic heart failure clinically significant arrhythmia conduction disorders active herpetic skin lesions prior complications hsv 1 infection eg herpetic keratitis encephalitis intermittent chronic systemic intravenous oral antiherpetic drug eg acyclovir intermittent topical use previous talimogene laherparepvec oncolytic virus prior radiotherapy fields overlap injection sites prior immunosuppressive chemotherapy radiotherapy biological cancer therapy major surgery within 28 days prior enrollment recovered common terminology criteria for adverse events grade 1 better adverse event due ks therapy administered 28 days prior enrollment prior therapy tumor vaccine received live vaccine within 28 days prior enrolment currently another investigational device drug less 28 days since ending another investigational device drug acute chronic active hepatitis b hbs ag detected c infection hcv rna detected inclusion active tuberculosis bacillus tuberculosis known additional malignancy currently progressing requires active within last 3 years exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer sensitivity products components administered psychiatric substance abuse disorders would interfere cooperation requirements pregnant breastfeeding expecting conceive father children within projected duration female subject childbearing potential unwilling use acceptable method effective contraception 3 months last dose talimogene laherparepvec sexually active subjects partners unwilling use male female latex condom avoid potential viral transmission sexual contact within 30 days talimogene laherparepvec addition male participants donate sperm 3 months last dose subjects unwilling minimize exposure blood body fluids individuals higher risks hsv 1 induced complications immunosuppressed individuals individuals known human immunodeficiency virus infection pregnant women infants age 3 months talimogene laherparepvec 30 days last dose talimogene laherparepvec vulnerable subjects prisoners incarcerated following administrative court decision subjects psychiatric disorders involuntary hospitalized subjects legal protection measure subjects cannot express consent persons responsible quality control article l 1121 3 french public health code take necessary precautions ensure confidentiality information relating investigational medicinal product participants particular identity participants results obtained persons well investigators bound professional secrecy accordance conditions set articles 226 13 226 14 french criminal code data collected participants sent sponsor investigators specialised collaborators anonymized circumstances names addresses subjects shown subject initials recorded along identification code specific indicating order enrolment sponsor ensure subject agreed writing personal information strictly necessary quality control accessed data entered electronically via web browser multicenter non randomized phase ii based 2 stage phase ii simons optimal design main endpoint best overall response rate borr defined occurrence complete response partial response following pga criteria pga 0 4 recorded start 6 months beginning specific systemic therapy ks occurs 6 months design developed test null hypothesis borr complete remission pr p 0 100 versus alternative p 0 400 two stage design testing drug 9 first stage terminated 1 fewer respond continue 2 respond goes second stage total 20 studied total number responding less equal 4 drug rejected 2 stages inclusions could suspended observation borr 6 months last included first stage nevertheless 2 complete remission pr observed 9 stopping inclusions required description general strategy continuous efficacy safety endpoints summarized using summary measures median interquartile range frequency distributions counts percentages used describe categorical endpoints similarly characteristics presented using summary measures median interquartile range quantitative characteristics counts percentages categoriel characteristics interim analysis interim analysis based first successively included 9 response recorded 6 months inclusion according design exposed interim analysis efficacy based observation best overall response see sample size 12 2 based hypotheses computed 9 would accrued stage 1 necessary inclusion stopped 6 months 9th inclusion waiting primary endpoint stop conclusion inactivity 0 1 response observed stage otherwise 11 additional recruited total sample size 20 least 5 responses indicate drug effective enough total number responding less equal 4 drug rejected case two observed responses end stage 1 stage 2 directly begin without stop terminal analysis based intent treat principle analysed whatever administered unless consent withdrawal primary endpoint terminal analysis done included end follow data quality checked point estimates 95 exact confidence intervals 95 ci computed borr secondary endpoint 1 safety endpoints adverse event fully described safety assessed terms drug toxicity evaluated clinic changes laboratory parameters scored according common terminology criteria adverse events common terminology criteria for adverse events version 5 0 https ctep cancer gov protocoldevelopment electronic_applications ctc htm ctc_50 2 efficacy endpoints best overall response rate borr injected uninjected target lesions according actg criteria described count percentage 95 exact confidence intervals 95 ci best overall response rate borr uninjected target lesions according pga criteria described count percentage 95 exact confidence intervals 95 ci response rate injected uninjected target lesions month 3 month 6 according pga actg criteria described count percentage 95 exact confidence intervals 95 ci response rate lymphedema month 3 month 6 best response defined primary endpoint described count percentage 95 exact confidence intervals 95 ci time response defined time first response following primary endpoint recorded start estimated kaplan median 95ci given case death consider competing events death precluding occurrence response latter case cumulative incidence considered grays estimator used duration response estimated date first response disease progression death end follow deaths cause censored end follow median 95ci given using kaplan meier estimator analyses performed sas sas inc cary nc r http www r project org software packages described targeted alpha risk 0 05 0 035 according 2 stage simons design targeted power 0 90 0 902 concerning primary endpoint missing data allowed given chosen design case loss follow locf approach applied concerning secondary endpoints characteristics complete case analyses performed additionally multiple imputation chained equation considered,"response, ks, tumor, stage, pharmacodynamic, met, pembrolizumab, simons, endemic, l1"
2021-001401-67_protocole v4.2_20220608_Metimgast-signe,0,23.241846,12.939242,immunotherapy anti pharmacodynamic 1 antibody pembrolizumab gives comparable results paclitaxel tumor response rate 16 vs 14 better safety profile second line 4 sub group high expression pharmacodynamic l1 combined positive score cps 10 tumor microsatellite instability effect pembrolizumab enhanced fda gave approval pembrolizumab monotherapy recurrent locally advanced metastatic gastric gastroesophageal junction adenocarcinoma whose tumors express pharmacodynamic l1 cps1 disease progression prior chemotherapy including fluoropyrimidine platinum appropriate her2 targeted therapy nevertheless anti pharmacodynamic l1 nivolumab showed activity advanced gastric adenocarcinoma irrespective pharmacodynamic l1 status 15 mismatch repair mmr deficiency microsatellite instability epstein barr virus ebv tumor positivity also shown mutually exclusive strong predictors pembrolizumab activity 16 mutation load analysis adds little predictive value mmr ebv determination met amplification present around 5 6 oesogastric adenocarcinoma represents oncogenic driver therapeutic target 17 targeting c met receptor monoclonal antibody disappointing use small molecule multitarget inhibitor crizotinib revealed response rate 3 9 met amplified oesogastric gene copie number 6 evaluate fish 100 nuclei adenocarcinoma treated french acse program 5 another reported 18 tumor response met amplified oesogastric adenocarcinoma treated amg 337 specific met inhibitor 18 fish ihc testing provides information regarding met amplification protein expression cannot identify met pathway alterations comprehensive next generation sequencing based tumor profiling added benefit interrogating types alteration met substitutions deletions insertions copy number changes chromosomal rearrangements probably define optimal met directed therapy spartalizumab risk spartalizumab comparable anti pd1 monoclonal antibody already extensively evaluated oesogastric adenocarcinoma mains toxicity spartalizumab observed previous consistent characteristic agents inhibit pharmacodynamic 1 receptor advanced cancer population investigated respective trials severe immune related adverse events iraes infrequent typically manageable dose interruption use immunosuppressive supportive therapy clinically indicated discontinuations due iraes rare treated single agent spartalizumab across different regimens 400 milligrams every 4 weeks n 427 300 milligrams q3w n 59 1 10 milligrams kilograms q2w every 4 weeks n 76 various advanced solid tumors types e mainly non small cell lung cancer nsclc melanoma triple negative breast cancer tnbc anaplastic thyroid carcinoma anatomical-therapeutic-chemical classification neuroendocrine tumors net nasopharyngeal carcinoma common aes 10 grades regardless relationship included fatigue 26 7 decreased appetite 23 7 anaemia 23 5 dyspnea 22 4 nausea 21 2 pyrexia 20 6 cough 20 3 constipation diarrhea 18 0 vomiting 15 8 asthenia 14 8 back pain abdominal pain 12 3 pruritus 11 4 weight decreased 11 2 aspartate amino transferase increased 10 7 oedema peripheral 10 3 rash 10 0 common aes 3 grades suspected drug related included fatigue 13 3 decreased appetite pruritus 7 1 hypothyroidism 6 8 diarrhea 6 6 nausea rash 6 0 asthenia 5 5 pyrexia 5 2 anaemia 4 8 aspartate amino transferase increased 4 6 alanine amino transferase increased 4 1 arthralgia 3 4 pneumonitis 3 2 rash maculo papular 3 0 common saes 1 grades regardless relationship dyspnoea 4 8 pneumonia 3 6 abdominal pain 2 8 pleural effusion 2 7 pyrexia 2 7 sepsis pneumonitis 2 1 hypercalcaemia 2 0 anaemia 1 6 back pain respiratory failure 1 4 cellulitis vomiting hyponatraemia 1 2 fatigue diarrhoea cardiac arrest spinal cord compression pneumonia aspiration 1 1 aes special interest aesi spartalizumab include endocrinopathies colitis skin reactions hepatitis nephritis pneumonitis iraes infusion reaction capmatinib cut date 28 sep 2020 800 participants solid tumors treated capmatinib single agent 720 participants received capmatinib combination therapies recommended phase ii dose rp2d capmatinib single agent determined 400 milligrams twice a day frequent aes suspected related capmatinib grade reported cinc280a2201 remains reference safety profile inc280 monotherapy oedema peripheral 42 9 nausea 34 3 vomiting 18 7 blood creatinine increased 18 4 fatigue 13 7 decreased appetite 12 6 diarrhea 12 4 majority grade 1 2 grade 3 4 aes suspected related capmatinib cinc280a2201 included oedema peripheral 7 6 alanine aminotransferase increased 5 5 lipase increased 5 2 amylase increased 3 0 fatigue 2 7 aspartate aminotransferase increased 2 5 vomiting 1 9 nausea 1 6 decreased appetite 0 8 constipation 0 5 diarrhea 0 3 combination spartalizumab capmatinib cinc280x2108 assessed combination spartalizumab capmatinib 59 treated hcc fifty eight 98 3 experienced aes grade regardless causality common aes peripherial oedema 31 52 5 nausea 24 40 7 pyrexia 21 35 6 decreased appetite 20 33 9 diarrhoea 18 30 5 asthenia 17 28 8 hypoalbuminemia 16 27 1 increased aspartate aminotransferase increased blood bilirubin vomiting 15 25 4 increased alanine aminotransferase 14 23 7 pruritus fatigue 13 22 ascites increased blood creatinine 12 20 3 abdominal pain 11 18 6 rash 10 16 9 majority aes grade 1 2 fifty two 88 experienced aes grade suspected related frequent aes suspected related nausea peripherial oedema 18 30 5 vomiting 14 23 7 decreased appetite diarrhoea 12 20 3 asthenia pyrexia 11 18 6 increased alanine aminotransferase fatigue pruritus 10 16 9 increased aspartate aminotransferase 9 15 2 increased blood creatinine rash 8 13 6 majority aes grade 1 2 forty five 76 3 experienced grade 3 4 aes regardless causality thirty two 54 2 grade 3 4 aes suspected related asthenia increased lipase 6 10 2 increased aspartate aminotransferase 4 6 8 increased alanine aminotransferase increased amylase cellulitis diarrhoea nausea neutropenia decreased platelet count 2 3 4 abscess acute myocardial infarction anaemia unstable angina increased blood bilirubin decreased blood corticotrophin cardiac arrest chronic kidney disease decreased appetite dehydration fatigue hyperlipasaemia hypertransaminasaemia hypotension immune mediated hepatitis lichen planus liver injury lymphocyte count decreased peripherial oedema pain pyrexia rash maculo papular rash skin ulcer stomatitis systemic inflammatory response syndrome 1 1 7 another cinc280j12201 evaluated combination spartalizumab capmatinib first line lung cancer increased risk hepatotoxicity observed lead novartis edict new recommendation inclusion criteria follow hepatotoxicity dose adaptation capmatinib spartalizumab new safety rules applied present protocol immunomodulatory role capmatinib recently suggested concomitant met inhibition promoted adoptive cell transfer checkpoint immunotherapies murine cancer models increasing effector cell infiltration tumors therapeutic effect independent tumor cell intrinsic met dependence absence met inhibition neutrophils recruited cell inflamed microenvironments rapidly acquired immunosuppressive properties restraining cell expansion effector functions cancer high serum levels met ligand hgf correlated increasing neutrophil counts poor responses checkpoint blockade therapies 1 another pre reported combination capmatinib pharmacodynamic 1 antibody efficient capmatinib alone pharmacodynamic 1 antibody alone model hepatocellular carcinoma moreover combination met inhibitor pharmacodynamic 1 antibody increased activated tumor infiltrating cd8 cell 2 phase ib ii capmatinib combination spartalizumab advanced hepatocellular carcinoma currently recruiting nct02795429 combination ongoing oesogastric cancer purpose proposal evaluate efficacy safety combination capmatinib spartalizumab pre treated oesogastric adenocarcinoma moreover efficacy assessed according met expression amplification level pharmacodynamic l1 expression order obtain data identify potential sub group benefit combination evaluate tumor response regimen 6 months inclusion evaluate safety regimen first second cycles administration day 42 day 42 evaluate safety tolerability regimen whole course kind toxicities 2 years immunotherapy related toxicity characterize tumor response regimen duration time response estimate progression free survival 2 years inclusion estimate overall survival 2 years inclusion according results interim analysis evaluate tolerance efficacy spartalizumab monotherapy non amplified met tumor evaluate pharmacokinetics capmatinib according presence gastrectomy concurrent proton pump inhibitor evaluate tumor response specific subgroups according residual level capmatinib cycle 2 day1 c2d1 b according met amplification level fish archival tumor sample c according baseline c2d1 neutrophil count circulating hgf level primary endpoint overall response rate orr defined proportion least one objective tumor response complete partial according recist v1 1 criteria within 6 months 8 cycles inclusion response evaluated thoraco abdomino pelvic ct scan abdominal magnetic resonance imaging thoracic ct scan without injection contraindication ct scan every 9 weeks independent centralized reading discontinue without tumor evaluation consider response intent treat analysis unacceptable toxicity within first second cycle occurrence event day 1 day 42 included defined using national cancer institute common terminology criteria for adverse events v5 criteria follows adverse event considered toxicity grade 3 least possibly related adverse event grade 3 unrelated disease disease progression intercurrent illness concomitant medications following events non hematological toxicity grade 3 except nausea vomiting fatigue recurring grade 2 pneumonitis myocarditis grade 2 autoimmune hemolytic anemia hemolytic uremic syndrome acquired hemophilia grade 3 guillain barre severe peripheral autonomic neuropathy transverse myelitis encephalitis aseptic meningitis laboratory abnormality grade 3 lasting 7 consecutive days except nephritis grade 3 4 creatinine 3x upper limit of normal combined elevations aspartate amino transferase alanine amino transferase total bilirubin see details section 7 1 2 criteria dose reduction interruption hyperglycaemia changes serum electrolytes enzymes without impact hematological toxicities defined febrile neutropenia absolute neutrophil count absolute neutrophil count 1 0 x109 l fever 38 5c documented infection absolute neutrophil count 1 0 x 109 l grade 3 neutropenia lasting 7 consecutive days grade 4 neutropenia grade 4 thrombocytopenia bleeding requiring platelet transfusion adverse event requiring permanent discontinuation 21 days drug related toxicity considered significant enough qualified unacceptable toxicity opinion investigators discussion sponsor unacceptable toxicity whole course occurrence event day 1 discontinuation defined using national cancer institute common terminology criteria for adverse events v5 criteria see adverse events whole course graded according national cancer institute common terminology criteria for adverse events v5 criteria cycle duration overall response dor defined time first occurrence tumor objective response partial complete defined primary endpoint using recist 1 1 first radiological progression response assessment every 9 weeks 24 months time response ttr defined time inclusion first occurrence tumor objective response complete partial defined primary endpoint according recist 1 1 end response assessment every 9 weeks 24 months progression free survival 24 months inclusion defined time inclusion date first radiological progression according recist 1 1 death cause last follow max 24 months whichever occurs first overall survival overall survival 24 months inclusion defined time inclusion death cause last follow max 24 months whichever occurs first alive censored date last record exploratory endpoints following pharmacokinetics parameters capmatinib gastrectomy determined using non compartmental analysis maximum plasma concentration cmax maximum plasma concentration time tmax area plasma concentration time curve area under the curve clearance cl mean residence time mrt distribution volume vd f pre defined subgroups analyses orr defined primary endpoint progression-free survival assessed according residual level capmatinib day 1 cycle 2 c2d1 baseline met amplification level fish baseline c2d1 neutrophil count circulating hgf level dosage capmatinib recommended previous phase ii trials 400 milligrams twice daily either monotherapy association tyrosine kinase inhibitors dosage spartalizumab recommended previous phase ib trials either 300 milligrams q3w 400 milligrams every 4 weeks schedule combination used ongoing nct02795429 hepatocellular carcinoma spartalizumab 300 milligrams q3w capmatinib 400 milligrams twice per day present dosage spartalizumab 300 milligrams q3w capmatinib 400 milligrams twice per day used nct02795429 resulting cycles 3 week duration multicenter single arm adaptive phase ii receiving investigational combination regimen progression refusal unacceptable toxicity maximum 12 months capmatinib 400 milligrams twice a day 16 spartalizumab cycles 3 weeks primary efficacy endpoint assessed 6 months initiation see next section detailed definition toxicity monitored sequentially allowing toxicity stopping rule case high probability unacceptable toxicity risk ivanova clin invest 2015 associated translational researches pharmacokinetics capmatinib solubility capmatinib poor bcs class ii compound hydrogen ion concentration dependent capmatinib absorption 37 5 decrease cmax 25 2 decrease area under the curve inf proton pump inhibitor ppi healthy subjects pharmacokinetics partial total gastrectomy never assessed pharmacokinetic profiling conducted first 20 included 10 total gastrectomy 10 partial gastrectomy gastrectomy treated ppi order assess impact gastrectomy drug drug interaction ppi pharmacokinetics capmatinib investigated phase ii cycle 2 day 1 steady state following pharmacokinetic parameters capmatinib determined using noncompartmental analysis winnonlin pharsight corporation maximum plasma concentration cmax maximum plasma concentration time tmax area plasma concentration time curve area under the curve clearance cl mean residence time mrt distribution volume vd f second pharmacokinetics trough peak plasma levels conducted 90 included concentrations capmatinib investigated cycle 2 day 1 70 cycle 3 day 1 blood sampling schedule pharmacokinetic profiles blood sampling taken according schedule provided following table trough peak plasma levels second pharmacokinetics performed 90 included c2d1 c3d1 alerted take capmatinib morning sampling days intake occur hospital sampling blood samples 5 0 ml collected heparinized tubes morning intake capmatinib perfusion spartalizumab immediately collection tubes inverted several times kept approximately 4 c centrifugation tubes centrifuged 10 min 1500g 4 c within 60 min collection separate plasma plasma separated 2 aliquots polypropylene screw cap tubes placed 80c analysis samples labeled identification identification sample number actual date time sample collected blood samples shipped end pr mourah laboratoire de pharmacologie biologique hopital saint louis 1 avenue claude vellefaux 75475 paris cedex 10 0142494325 0142499336 420 blood collections 5 0 ml heparinized tubes moreover orr progression-free survival analyzed according mean trough plasma concentrations mean peak plasma concentrations capmatinib follow met expression amplification previous shown met inhibitors direct action met driven tumors independent immunomodulatory action met inhibitor orr progression-free survival analyzed according baseline expression met amplification level fish archival diagnosis tumor sample met amplification determined previous enrollment participating center enrolled cohort 1 tumor present 6 met gene copies cohort 2 tumor present 6 met gene copies cohorts pooled analyzed primary endpoint evaluate different threshold met gene copies number ancillary pharmacodynamic l1 mmr msi ebv expression determination pharmacodynamic l1 expression mmr msi status ebv status routinely performed different investigational site local tumor phenotyping data investigational site collected allow pooled analysis without perform supplementary sample processing contradictory findings reported predictive value pharmacodynamic l1 level expression efficacy immune checkpoint inhibitors gastric adenocarcinoma data reported spartalizumab combined positive score cps assessed archival diagnosis tumor sample consistent data suggest mismatch repair deficiency dmmr strong predictor efficacy immune checkpoint inhibitors gastric colorectal adenocarcinoma dmmr assessed ihc mmr protein microsatellite status pcr analysis archival diagnosis tumor sample extracted dna may analyzed ngs ebv status reported predictive factor immune checkpoint inhibitors situ hybridization performed determine ebv tumor status archival diagnosis tumor sample orr progression-free survival analyzed according candidate predictive factors pharmacodynamic l1 expression mmr ebv status determination status performed investigational site archival tumor bloc collected end stored centre de ressource biologique saint louis hospital pr philippe bertheau jihene benlagha order allow planned ancillary ihc pdl 1 mmr fish ebv performed anatomo pathologic team saint louis hospital pr p bertheau msi status determination pcr performed molecular oncology unit saint louis hospital paris pr j lehmann che predictive value neutrophil count circulating hepatocyte growth factor hgf level suggested high serum levels met ligand hgf correlated increasing neutrophil counts poor responses checkpoint blockade therapies explore baseline neutrophil count circulating hgf level also evolution parameters 3 weeks combination capmatinib spartalizumab orr progression-free survival analyzed according baseline neutrophil count circulating hgf evolution parameters one month blood samples 5 0 ml collected dry tubes separator heparin plasma recommended use hgf immunoassay beginning capmatinib inclusion c2d1 dosage hgf performed using human hgf quantikine elisa kit rnd laboratory pharmacogenomic saint louis hospital pr mourah multicentric french national number centers 10 centers 7 public hospitals institute located france recruitment centres saint louis hospital assistance publique hôpitaux de paris paris gastroenterology digestive oncology department clipp cic centre leon berard lyon medical oncology clipp centre georges francois leclerc dijon medical oncology clipp unite de phase precoce gustave roussy villejuif digestive oncology clipp institut universitaire du cancer de toulouse toulouse medical oncology clipp hopital haut leveque bordeaux hepato gastroenterology unite de recherche clinique centre hospitalier regional universitaire jean minjoz de besancon medical oncology recruitment came directly gastroenterology oncology departments participating center also network participating center referred chemorefractory several situations possible temporary suspension investigator must document reason suspending resuming participants source file case report form case report form premature discontinuation participant remains enrolled end participation premature discontinuation withdrawal investigator must document reason collect assessment criteria time ending participation participant agrees schedule follow participant particularly case serious adverse event case severe adverse events investigator must notify sponsor follow participant 12 months following premature discontinuation notification serious adverse event must sent email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction sponsor serious adverse event monitored resolved data safety monitoring board created committee specify validate follow methods participants may exit time reason investigator temporarily permanently withdraw participant safety reason participants best interests participant lost follow participant cannot located investigator must make every effort reconnect participant document attempts source file least determine whether participant alive dead participant exits prematurely withdraws consent data collected prior date premature exit may still used participant exits prematurely participant agrees state procedure schedule collecting data required protocol primary endpoint secondary endpoints safety assessment nb must stated information consent form state premature exit affect participant ongoing care state exactly participant offered case serious adverse events see corresponding section vigilance case report form must list various reasons participant discontinued lack efficacy adverse reaction another medical issue personal reasons participant explicit withdrawal consent lost follow replace receive initial notification severe adverse event must provided written report signed investigator using severe adverse event notification form specific intended purpose case report form item form must completed investigator sponsor carry appropriate analysis initial notification sponsor serious adverse event must quickly followed additional detailed written report reports case outcome may monitored safety department provide information whenever possible investigator provide sponsor documents may useful medical reports laboratory test results results additional examinations etc documents must non identifying addition documents must include following acronym number participants initials adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even participant left initial notification severe adverse event follow reports documents must sent sponsor safety department email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction noted possible send severe adverse event reports safety department fax 33 0 1 44 84 17 99 event failed attempt send severe adverse event report email order avoid duplication use e crfs investigator completes severe adverse event notification form e case report form validates prints signs form sending email possible connect e case report form investigator complete sign send severe adverse event notification form safety department soon connection restored severe adverse event notification form e case report form must duly completed investigator must respond requests sponsor additional information questions relating notification adverse event safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction cases utero exposure investigator complete notification follow form pregnancy occurring participation investigator must monitor pregnant woman throughout pregnancy pregnancy terminated must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage pregnancy termination foetal death congenital abnormality etc investigator must follow procedure reporting saes initial pregnancy notification severe adverse event follow reports documents sent sponsor according procedures specified herein father exposed investigator must obtain pregnant woman permission collecting information pregnancy data collected prospectively electronic case report forms e case report form via cleanweb internet browser investigator permit sponsors representatives monitor frequency defined contract depending enrolment centre case report forms crfs related source documents reviewed detail monitoring visit completeness adherence guidelines accuracy compared source documents sponsors representative also review regulatory documents drug storage accountability investigator must maintain comprehensive centralized filing system related documentation suitable inspection sponsors monitors representatives regulatory agencies computer file used research implemented accordance french amended informatique et libertes law governing data protection european general data protection regulation gdpr regulations commitment comply reference methodology medium risk 001 research governed commission nationale informatique et libertés french data protection agency reference methodology processing personal data used within scope health research amended medium risk 001 ap hp sponsor research signed declaration compliance reference methodology histologically cytologically documented locally advanced metastatic oesogastric adenocarcinoma unresectable tumor must received least one prior systemic chemotherapy based platinium salt fluoropyrimidine documented progression chemotherapy must received trastuzumab case her2 positive tumor her2 her2 fish sish determination tumor met amplification fish available eastern cooperative oncology group (= performans status (= ecog)) performance status 1 measurable tumoral disease according recist 1 1 criteria must willing able swallow retain oral medication age 18 years women childbearing potential males sexually active must agree follow instructions method contraception duration treatments capmatinib spartalizumab 7 days last dose capmatinib 150 days last dose spartalizumab consent participate information affiliated social security system previous immunotherapy met inhibitor impossibility take oral medication persistent toxicities related prior grade greater 1 except alopecia grade grade 2 neuropathy related previous platinium salt presence history another malignant disease diagnosed required therapy within past 3 years exceptions exclusion include completely resected basal cell squamous cell skin cancers completely resected carcinoma situ type use live vaccines within 4 weeks initiation history severe hypersensitivity reactions monoclonal antibodies mabs history current interstitial lung disease non infectious pneumonitis active autoimmune disease documented history autoimmune disease vitiligo controlled type diabetes mellitus stable insulin dose residual autoimmune related hypothyroidism requiring hormone replacement psoriasis requiring systemic permitted allogenic bone marrow solid organ transplant uncontrolled active infection human immunodeficiency virus human immunodeficiency virus infection untreated active hepatitis b infection hbsag positive active hepatitis b hbsag positive may enrolled provided viral load hbv dna screening 100 ui ml may receive antiviral lamivudine tenofovir entecavir antiviral agents initiation suppress viral replication untreated active hepatitis c hcv rna positive achieved sustained virological response antiviral show absence detectable hcv rna 6 months cessation antiviral eligible untreated symptomatic central nervous system central nervous system lesion however eligible known central nervous system lesions treated radiotherapy surgery b remained without evidence central nervous system disease progression 4 weeks c must corticosteroid therapy 2 weeks clinically significant uncontrolled heart diseases recent acute coronary syndrome unstable ischemic heart disease congestive heart failure class iii intravenous infusion defined new york heart association long qt syndrome 480 ms women 470 ms men family history idiopathic sudden death congenital long qt syndrome uncontrolled hypertension defined systolic blood pressure sbp 150 millimeter hg diastolic blood pressure dbp 100 millimeter hg without antihypertensive medication initiation adjustment antihypertensive medication allowed prior screening surgery less 4 weeks radiotherapy less 2 weeks pregnancy breastfeeding women child bearing potential unless using highly effective methods contraception sexually active males unless use condom intercourse taking capmatinib 7 days stopping father child period participants receiving strong inducers cyp3a could discontinued 1 week prior start systemic chronic steroid therapy 10 milligrams day prednisone equivalent immunosuppressive therapy 7 days prior planned date first dose range laboratory values defined total bilirubin 1 5 x upper limit normal upper limit of normal alkaline phosphatase alp 5 x upper limit of normal alanine aminotransferase alanine amino transferase 3 x upper limit of normal aspartate aminotransferase aspartate amino transferase 3 x upper limit of normal coagulation prothrombin time pt 4 seconds upper limit of normal international normalized ratio inr 1 7 absolute neutrophil count absolute neutrophil count 1 5 x 109 l platelet count 75 x 109 l hemoglobin 9 g deciliter creatinine clearance calculated using cockcroft gault formula measured 45 ml min serum lipase 2 upper limit of normal cardiac troponin ctni elevation 2 x upper limit of normal potassium magnesium phosphorus total calcium corrected serum albumin outside normal limits may enrolled corrected within normal limits supplements screening legal protection participation another interventional whith persons responsible quality control article l 1121 3 code de la sante publique french public health code take necessary precautions ensure confidentiality information relating investigational medicinal products participants particular identity results obtained persons well investigators bound professional secrecy accordance conditions set articles 226 13 226 14 code penal french criminal code research involving human participants data collected concerning participants sent sponsor investigators specialised collaborators rendered non identifying circumstances shall names addresses participants involved shown participants initials recorded accompanied encoded number specific indicating order enrolment sponsor ensure participant given written permission personal information strictly necessary quality control accessed data entry performed specially trained staff non identifying e case report forms non identifying data entered electronically via web browser summary two cohorts constituted cohort 1 enroll met amplification cohort 1 primarily follow time event bayesian optimal phase 2 top design lin coleman yuan 2018 zhou lee yuan 2017 efficacy assessment combination spartalizumab capmatinib specifically maximum total 81 ensure 90 power 5 type error rate detect 30 response rate compared reference 15 including interim analysis 30 included futility stopping rule combination interim futility stooping boundary crossed combination inclusion 51 additional treated spartalizumab monotherapy ensure 80 power detect desirable 20 response rate 51 treated spartalizumab monotherapy 8 unacceptable 5 type error rate one sided using exact binomial comparison cohort 2 enroll met amplification exploratory purpose enrollment cohort 2 ongoing cohort 1 completed around 9 expected enrolled cohort 2 proportion response primary endpoint estimated using bayesian inference across cohort additional close toxicity monitoring performed jointly across cohorts ivanova others clin invest 2015 design cohort 1 primarily monitor efficacy endpoint using time event bayesian optimal phase 2 top design lin coleman yuan 2018 zhou lee yuan 2017 specifically let n denote interim sample size N denote maximum sample size let peff denote probability efficacy response rate evaluated combination spartalizumab capmatinib define null hypothesis H0 peff0 15 representing combination inefficacious stop enrolling claim promising peff 0 15 data n N 0 92 1 design parameters optimized maximize power alternative hypothesis H1 peff 0 3 controlling type error rate 0 05 e controlling chance incorrectly claiming inefficacious promising 5 assuming beta 0 15 0 85 prior distribution peff decision rule corresponds following go go rules yields maximum statistical power 0 9476 H1 table 1 go go efficacy rules cohort 1 ess effective sample size number complete observations total duration incomplete observations duration observation window 6 months reported table 1 perform interim efficacy analysis number enrolled treated combination therapy reaches 30 cohort 1 decide early stopping rule according table 1 rules reject null hypothesis conclude combination promising number responses becomes 18 otherwise combination stopped early conclude combination promising observe 17 less responses among total sample size n 81 table 2 shows operating characteristics top design assumption pt 0 risk unacceptable toxicity based 10000 simulations using top web application available http www trialdesign org simulation assessment window 6 months arrival uniformly distributed accrual rate 5 per month time response simulated uniform distribution controlling 50 responses occurring latter half response assessment window table 2 operating characteristics design assumption 0 e g risk unacceptable toxicity n 30 51 case combination stopped early futility resume enrolment cohort 1 51 treated spartalizumab monotherapy total sample size n 81 cohort 1 monotherapy sample 51 exact binomial design allow conclude promising monotherapy 80 power 5 one sided type error rate assuming response rate 20 promising 8 response rate undesirable specifically spartalizumab monotherapy claimed promising 8 responses observed among 51 receiving monotherapy cohort 2 enroll met amplification exploratory purpose enrollment cohort 2 ongoing cohort 1 completed around 9 expected enrolled cohort 2 proportion response primary endpoint estimated using bayesian inference additionally perform close toxicity monitoring based available information across cohorts ivanova others clin invest 2015 posterior probability unacceptable toxicity evaluated based beta binomial model pt binomial pt prior pt uniform 0 1 number experienced unacceptable toxicity plan scheduled safety analyses every 5 completed observations cohort 1 2 5 either completed two first cycles c1 c2 experienced unacceptable toxicity c1 c2 20 first approximately every 10 observations interim safety analyses posterior probability pt 0 25 becomes greater 0 95 prob pt 0 25 data 0 95 terminated table 3 presents safety stopping rules different analyses impact additional safety monitoring operating characteristics design terms efficacy conclusions evaluated simulation n 10000 limited probability unacceptable toxicity low true probability toxicity pt 0 20 probability concluding efficacy using top design defined table 1 close 0 05 H0 peff 0 15 greater 0 90 H1 peff 0 3 nevertheless probability unacceptable toxicity higher e g pt 0 30 stopped approximately 49 95 pt 0 40 endpoints described count percentage categorical endpoints toxicity aes mean median 95 confidence interval 95 credibility interval appropriate interquartile range continuous endpoints time event endpoints progression-free survival overall survival estimated using non parametric kaplan meier estimator obtain survival estimates 24 months inclusion analyses performed using r statistical platform along data management analyses conducted department biostatistics medical information hopital saint louis paris pr sylvie chevret labelled centre de traitement des donnees inca primary analysis cohort 1 design rely bayesian methods evaluation spartalizumab capmatinib combination exact binomial comparison evaluation spartalizumab monotherapy case combination found unpromising operating characteristics bayesian top design evaluated simulation design parameters calibrated ensure 5 risk erroneously concluding efficacy binomial exact comparison also one sided 5 type error risk test primary endpoint performed cohort 2 cohort 1 early termination rules implemented efficacy toxicity efficacy interim analysis performed 30 included stopping criteria detailed table 1 section 13 1 safety sequential monitoring analyses performed accounting cohorts every 5 completed observations cohort 1 2 5 either completed two first cycles c1 c2 experienced unacceptable toxicity c1 c2 20 first approximately every 10 observations interim safety analyses posterior probability pt 0 25 becomes greater 0 95 prob pt 0 25 data 0 95 terminated table 3 presents safety stopping rules different analyses table 3 safety stopping rules,"response, ks, tumor, stage, pharmacodynamic, met, pembrolizumab, simons, endemic, l1"
MAC-HAPLO-MUD_Protocole_HAO_02062017_,1,19.01659,-44.3864,full title randomized prospective phase iii comparing human leukocyte antigen 10 10 matched unrelated donor haploidentical allogeneic hematopoietic stem cell transplantation myeloablative conditioning regimen abbreviated title myelo ablative conditioning haplo mud coordinating investigator pr regis peffault de latour sponsor assistance publique hopitaux de paris scientific justification unrelated adult donor human leukocyte antigen matched recipient allele level human leukocyte antigen b c dqb1 drb1 considered best choice absence human leukocyte antigen matched sibling needing hematopoietic stem cell transplantation sct however using matched unrelated donors mud limited 1 prolonged time identify schedule donation mud allowing relapse transplantation performed 2 limited availability fully human leukocyte antigen mud non caucasian population alternative donors single human leukocyte antigen mismatched unrelated donor unrelated umbilical cord blood grafts haploidentical related donors still associated higher non relapse mortality delayed immune reconstitution recent strategy haploidentical haplo related donor sct haplo sct improved dramatically outcomes using cell replete grafts administration post transplantation cyclophosphamide ptcy targets alloreactive cells generated early human leukocyte antigen mismatched transplant sparing regulatory cells leaving unaffected non dividing hematopoietic stem cells standard post transplant immune suppression calcineurin inhibitor cni mycophenolate mofetil retrospective haplo sct ptcy associated similar overall progression free survivals mud stem cell transplantation mud sct lower rates toxicity graft versus host disease graft versus host disease thus potentially better results mud sct reduced intensity conditioning regimen phase iii randomized currently addressing question france elderly using reduced intensity conditioning regimen haplomudelederly 01 programme hospitalier de recherche clinique k 14 045 principal investigator blaise institut paoli calmettes randomized prospective phase iii comparing human leukocyte antigen 10 10 mud haplo sct myeloablative conditioning regimen urgently needed answer question main objective primary endpoint main objective improve 1 year progression free survival without acute grade ii intravenous infusion graft versus host disease without moderate severe chronic graft versus host disease using haplo donor compared 10 10 human leukocyte antigen mud myeloablative sct primary endpoint 1 year progression free survival without grade ii intravenous infusion acute graft versus host disease without moderate severe chronic graft versus host disease 65 haplo sct versus 50 10 10 human leukocyte antigen mud secondary objectives endpoints secondary objectives 1 compare two arms terms biological outcomes kinetic haematopoietic reconstitution graft failure graft versus host disease progression free survival relapse non relapse mortality overall survival interval inclusion transplant rehospitalizations related morbidity quality life chimerism immune reconstitution 2 search prognostic factors main outcome globally arm 3 search covariate interactions main outcome secondary endpoints interval inclusion transplant absolue numbers neutrophils platelets month 1 month 2 month 3 month 6 month 12 chimerism month 1 month 3 month 6 month 12 month 24 acute graft versus host disease incidence grading chronic graft versus host disease incidence grading relapse incidence progression free survival severe infections ctc adverse event grade 3 4 incidence veino occlusive disease incidence cardiac toxicities non relapse mortality overall survival quality life questionnaire ebmt number new days hospitalization hospitalization transplantation immune reconstitution month 1 month 3 month 6 month 12 month 24 lymphocytes cd4 cd8 b nk lymphocytes gammaglobulines design randomized prospective phase iii comparing human leukocyte antigen 10 10 matched unrelated donor haploidentical allogeneic hematopoietic stem cell transplantation myeloablative conditioning regimen population subjects 15 year age older high risk hematological malignancies indication allogeneic hematopoietic stem cell transplantation inclusion criteria aged 15 55 years old aml smd smp requiring allogeneic stem cell transplantation least partial response malignant disease without human leukocyte antigen matched related donor strong probability related haplo donor human leukocyte antigen 10 10 matched donor available needs least 5 mud identified outside book bmdw bone marrow donors worldwide using easy match software included usual criteria hematopoietic stem cell transplantation eastern cooperative oncology group (= performans status (= ecog)) 2 severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function aspartate amino transferase alanine-aminotransferase 2 5n total bilirubin 2n creatinine 150 mol l except abnormalities linked hematological disease health insurance coverage understand informed consent optimal follow prescription two effective contraception methods must prescribed duration signed written informed consent 2 parents aged less 18 exclusion criteria cancer last 2 years except basal cell carcinoma skin situ carcinoma cervix uncontrolled infection seropositivity human immunodeficiency virus htlv 1 active hepatitis b c yellow fever vaccine heart failure according “new york heart association” ii bile duct obstruction preexisting acute hemorrhagic cystitis renal failure creatinine clearance 30ml min pregnancy hcg positive breast feeding debilitating medical psychiatric illness preclude realization sct understanding protocol protection law tutorship curatorship unwilling unable comply protocol experimental group haplo donor myeloablative sct use cyclophosphamide 50 milligrams kilograms day intravenous route 3 4 stem cell transplantation control group human leukocyte antigen mud 10 10 myeloablative sct transplant modalities 1 conditioning regimen myeloid malignancies haploidentical sct thiotepa 5mg kilograms day day 7 6 fludarabine 40mg month 2 day day 5 2 intravenous infusion busulfan 3 2mg kilograms day day 5 3 b human leukocyte antigen matched unrelated donor sct fludarabine 30mg month 2 day day 6 2 intravenous infusion busulfan 3 2mg kilograms day 6 3 fludarabine 30 milligrams month 2 day days 7 5 total body irradiation 200 cgy twice daily days 4 2 total dose 1200 cgy 2 stem cell source bone marrow haploidentical sct peripheral blood stem cell pbsc human leukocyte antigen matched unrelated transplantation 3 graft versus host disease prophylaxis haploidentical sct cyclophosphamide 50 milligrams kilograms day 3 4 ciclosporine mycophenolate mycophenolate mofetil 5 human leukocyte antigen matched unrelated donor sct anti thymocyte globuline thymogobuline 5 milligrams kilograms total dose 2 5mg kilograms day 3 2 cyclosporine day 1 mycophenolate mofetil day 1 absence graft versus host disease mycophenolate mofetil stopped 35 arms interventions added randomization donor haplo 10 10 mud blood sample biobanking month 1 risks added risks related sct randomization haplo mud arm risk difference arms scope goal show superiority haplo sct primary endpoint even similar results arms obtained might revolutionize strategy sct since haplo donors used priority compared mud quick procedure cheaper available almost number subjects included 344 number sites 36 centres duration inclusion period 36 months participation period 24 months total duration 60 months number enrolments expected per site per month 0 4 month centre statistical analysis justification sample size hypothesize 1 year progression free survival without grade ii intravenous infusion acute graft versus host disease without moderate severe chronic graft versus host disease 65 haplo sct versus 50 10 10 human leukocyte antigen mud 172 arms n 344 overall required demonstrate difference based two sided logrank test 0 05 power 0 80 high risk 0 62 required total number events 146 bayesian interim analysis inflate interim analysis mid inclusion based bayesian computation stopping rules based modeling log hazard ratio high risk main endpoint spiegelhalter 1994 non informative prior loghr considered terminal analysis observation required number events sources funding industrial associations funding data monitoring committee yes benefits evaluated terms efficacy progression free survival 1 year without acute grade ii intravenous infusion graft versus host disease without moderate severe chronic graft versus host disease risks related sct randomization haplo mud arm essentially risk engraftment due reduced intensity conditioning infectious complications due immune deficiency post transplant events obviously studied carefully engraftment graft versus host infectious complications relapse survival pt hdcy also strictly followed myelo ablative conditioning haplo mud due known cardiac toxicity cyclophosphamide hemorrhagic cystits related use situation unrelated adult donor human leukocyte antigen matched recipient allele level human leukocyte antigen b c dqb1 drb1 considered best choice absence human leukocyte antigen matched sibling needing hematopoietic stem cell transplantation sct however using matched unrelated donors mud limited 1 prolonged time identify schedule donation mud allowing relapse transplantation performed 2 limited availability fully human leukocyte antigen mud non caucasian population alternative donors used transplantation without fully mud including single human leukocyte antigen mismatched unrelated donor unrelated umbilical cord blood grafts haploidentical related donors associated higher non relapse mortality delayed immune reconstitution recent strategy haploidentical haplo related donor sct haplo sct improved dramatically outcomes using cell replete grafts administration post transplantation cyclophosphamide ptcy targets alloreactive cells generated early human leukocyte antigen mismatched transplant sparing regulatory cells leaving unaffected non dividing hematopoietic stem cells standard post transplant immune suppression calcineurin inhibitor cni mycophenolate mofetil retrospective haplo sct ptcy associated similar overall progression free survivals mud stem cell transplantation mud sct lower rates toxicity graft versus host disease graft versus host disease thus potentially better results mud sct reduced intensity conditioning regimen haplo sct ptcy thus highly discussed nowadays motivating prospective trials confirm benefit procedure ref 1 et ref 2 phase iii randomized currently addressing question france elderly haplomudelederly 01 programme hospitalier de recherche clinique k 14 045 principal investigator blaise institut paoli calmettes nct 02623309 retrospective non controlled registry recently suggest outcomes haplo sct using ptcy approach might also superior terms graft versus host disease free survival mud sct setting myeloablative conditioning regimen adults high risk hematological malignancies randomized prospective phase iii comparing human leukocyte antigen 10 10 mud haplo sct myeloablative conditioning regimen thus urgently needed answer question main objective assess benefit terms 1 year progression free survival without acute grade ii intravenous infusion graft versus host disease without moderate severe chronic graft versus host disease haplo donor myeloablative transplantation compared 10 10 human leukocyte antigen mud 3 2 secondary objectives compare two arms terms biological outcomes kinetic haematopoietic reconstitution graft failure graft versus host disease progression free survival relapse non relapse mortality overall survival interval inclusion transplant rehospitalizations related morbidity quality life chimerism immune reconstitution search prognostic factors main outcome arm search covariate interactions main outcome one year progression free survival without acute grade ii intravenous infusion graft versus host disease without moderate severe chronic graft versus host disease myeloid malignancies relapse defined reappearance leukemic cells sct relapse defined reappearance leukemic cells sct increase least 50 smallest measure lymphnode considered abnormal partial response non responder pre transplant appearance new lesion compared pre transplantation evaluation interval inclusion transplant absolue numbers neutrophils platelets month 1 month 2 month 3 month 6 month 12 chimerism month 1 month 3 month 6 month 12 month 24 acute graft versus host disease incidence grading chronic graft versus host disease incidence grading relapse incidence progression free survival severe infections ctae grade 3 4 incidence veino occlusive disease incidence cardiac toxicities non relapse mortality overall survival quality life questionnaire ebmt inclusion month 3 month 12 month 24 number new days hospitalization hospitalization transplantation immune reconstitution month 1 month 3 month 6 month 12 month 24 lymphocytes cd4 cd8 b nk lymphocytes gammaglobulines developed section 2 2 haplo sct using replete graft reduced intensity conditioning regimen associated adequate immunosuppression part 2 baltimore group developed pt hdcy using haploidentical related donors intra venous injection day 3 day 4 using replete bone marrow advanced hematological malignancies 9 high dose post transplantation cy administered early fixed time point bone marrow infusion shown eradicate alloreactive donor host cells activated respective antigens thereby reducing incidence graft versus host disease reaction 10 approach used many french centres using ric protocols sfgm tc report 500 haploidentical related donors hematopoietic stem cell transplantation pt hdcy mostly done day 3 day 4 acceptable expected toxicity profile report accessible demand reasons decided used pt hdcy day 3 day 4 intravenously phase iii multicenter randomized open two parallel arms based two types transplantation haplo donor myeloablative transplantation experimental group human leukocyte antigen mud myeloablative transplantation 172 included group ie 344 whole national multi center including adult paediatric transplant centres sfgm tc 36 centres recruited hematology units referred transplant team pre transplant assessment screening visit takes place 60 30 transplant investigator checks eligibility criteria proposes information protocol delivered transplant physician charge additional test specific examinations performed research assessment performed usual care allogeneic transplant visit consent collect latest 15 transplantation information sheet consent form given investigator original conserved investigator third copy sponsor randomized receiving transplant human leukocyte antigen mud haplo donor physical examination reports disease history eastern cooperative oncology group (= performans status (= ecog)) assessment sorror score comorbidities complete physical examination evaluation tumor localization electrocardiogram echocardiogram evaluation left ventricular ejection evaluation cardiovascular risk factors dyslipidemia hbp obesity smoking pulmonary function tests including least forced expiratory volume 1 second fev1 forced vital capacity forced vital capacity liver ultrasound doppler echography baseline values biological test complete blood count prothrombin time pt partial thromboplastin time ptt abo rh typing blood cell chemistry panel serum electrolytes creatinine calcium glucose uric acid magnesium levels ferritin c reactive protein liver function tests transaminases alkaline phosphatase gamma gt bilirubine circulating protein electrophoresis pregnancy test women childbearing age human leukocyte antigen compatibility check recipient donor search anti human leukocyte antigen antibodies luminex technology dsa chimerism markers identification dental radiography infectious assessment urine culture viral serologies serology hepatitis b c aspergillus antigen ebv igg cmv igg hsv igg human immunodeficiency virus 2 elisa tests htlv 1 2 toxoplasmosis igg tpha vdrl sinus thorax ct scan tumor assessment pre transplant disease evaluation assessment performed according practice investigator quality life temporary suspension procedure investigator must document reason suspending resuming subject source file case report form case report form premature termination procedure subject remains enrolled end subject participation investigator must document reason investigator must document reason schedule follow visits especially case serious adverse event subjects may exit time reason investigator temporarily permanently withdraw subject safety reason subject best interests investigator must make every effort contact subjects lost follow attempts contact subjects must documented subjects records e g times dates attempted telephone contact receipt sending registered letter subject exits prematurely withdraws consent data collected prior date premature exit may still used case report form must list various reasons subject exited withdrawn investigator initially complete severe adverse event reporting form appendix 2 contained case report form report must signed investigator investigator must complete every section severe adverse event form sponsor carry appropriate assessment initial report sent sponsor must rapidly followed one additional written reports describing course event complementary information whenever possible investigator provide sponsor documents may useful medical assessment case medical reports laboratory test results results additional exams etc documents must anonymized addition investigator must state acronym number initials participant paper adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even subject terminated participation initial report severe adverse event follow reports documents must sent sponsor safety department fax fax 33 0 1 44 84 17 99 trials use e case report form investigator completes severe adverse event report form e case report form validates prints signs form sending fax case failure connect e case report form investigator complete sign send severe adverse event report form safety department soon connection restored investigator must complete severe adverse event report form e case report form investigator must comply requests additional information sponsor questions relating adverse event report safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction cases utero exposure investigator complete initial notification follow report forms pregnancy exposure participation investigator must monitor pregnant woman throughout pregnancy pregnancy ends must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage termination foetal death congenital abnormality etc investigator must follow procedure reporting saes initial pregnancy report form severe adverse event follow forms documents sent sponsor using modalities described father exposed investigator must obtain mother permission collecting information pregnancy aged 15 55 years old aml smd smp requiring allogeneic stem cell transplantation least partial response malignant hemopathy without human leukocyte antigen matched related donor strong probability related haplo donor human leukocyte antigen 10 10 matched donor available needs least 5 mud identified outside book bmdw bone marrow donors worldwide using easy match software included usual criteria hematopoietic stem cell transplantation eastern cooperative oncology group (= performans status (= ecog)) 2 severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function aspartate amino transferase alanine-aminotransferase 2 5n total bilirubin 2n creatinine 150 mol l except abnormalities linked hematological disease health insurance coverage beneficiaire ou ayant droit understand informed consent optimal follow prescription two effective contraception methods must prescribed duration signed written informed consent 2 parents aged less 18 cancer last 2 years except basal cell carcinoma skin situ carcinoma cervix uncontrolled infection seropositivity human immunodeficiency virus htlv 1 active hepatitis b c yellow fever vaccine heart failure according “new york heart association” ii bile duct obstruction preexisting acute hemorrhagic cystitis renal failure creatinine clearance 30ml min pregnancy hcg positive breast feeding debilitating medical psychiatric illness would preclude realization sct understanding protocol tutorship curatorship unwilling unable comply protocol persons responsible quality control article l 1121 3 french public health code take necessary precautions ensure confidentiality information relating medicinal products participants particular identity participants results obtained persons well investigators bound professional secrecy accordance conditions set articles 226 13 226 14 french criminal code data collected participants sent sponsor investigators specialised collaborators anonymised circumstances names addresses subjects shown subject initials recorded along identification code specific indicating order enrolment sponsor ensure subject agreed writing personal information strictly necessary quality control accessed analysis based intent treat basis including randomized whatever administered consent withdrawls positive report using data excluded one interim analysis performed mid inclusion terminal analysis done required number events n 146 observed baseline summary statistics namely percentages median interquartile range iqr computed randomized arm without statistical test comparison right censored endpoint estimated using nonparametric methods kaplan meier curves cumulative incidence curves considered case non informative informative censoring comparison across randomized arms based log rank test gray test respectively adjustment potential confounders used cox proportional hazards models statistical analyses performed sas sas inc cary nc r https www r project org software packages type error fixed 0 05 interim analysis performed mid inclusion based bayesian computation stopping rules based modeling log hazard ratio high risk denoted main endpoint spiegelhalter 1994 based posterior probability conditional data accumulated time interim analysis evaluate two following criteria _0 p loghr_0data 0 95 _1 p loghr_1data 0 95 hr_0 1 hr_1 0 62 denote value hazard ratio postulated null alternate hypotheses respectively posterior densities loghr computed using mcmc methods non informative prior loghr considered,"graft, transplantation, host, versus, stem, cell, disease, haplo, transplant, donor"
2024-A00262-45_Protocole_v1.4_20240624_APARR (clean),1,16.943441,-32.497368,full title evaluation optimized allogeneic hematopoietic stem cell transplantation protocol post transplant cyclophosphamide aged 40 60 years old acquired aplastic anemia refractory relapse immunosuppression acronym reference aparr coordinating investigator regis peffault de latour sponsor assistance publique hopitaux de paris scientific justification hematopoietic stem cell transplantation hematopoietic stem cell transplantation major therapeutic option acquired aplastic anemia aa improved survival achieved younger 40 years old thanks better donor selection conditioning regimens graft versus host disease prophylaxis together improved supportive care however never case age 40 overall survival hematopoietic stem cell transplantation never exceeded 60 5 years using available sibling unrelated donor ref 3 thus standard immunosuppressive therapy ist associating cisclosporine horse anti thymocyte globuline together addition eltrombopag epag considered standard care adult older 40 years aa ref 1 indeed outcomes refractory first line ist remain poor lack non transplant poor results transplantation age ref 2 37 past 2 decades significant decrease infection related mortality population initial ist risk hemorrhage long term fatigue still present moreover clonal evolution including paroxysmal nocturnal hemoglobinuria pnh myelodysplastic syndrome mds acute myeloid leukemia aml still occur long term grim prognosis mds aml ref 2 overall survival adult acquired aa refractory relapse ist outside hematopoietic stem cell transplantation thus 60 2 years ref 2 recently new strategies prevent acute chronic graft versus host disease including cell replete grafts administration post transplantation cyclophosphamide ptcy revolutionized field changes extended option hematopoietic stem cell transplantation primary refractory relapse aa lack human leukocyte antigen matched donor ref 4 recently optimized baltimore protocol using ptcy strategy also appears improve engraftment reduce graft versus host disease graft versus host disease classical setting sibling matched unrelated hematopoietic stem cell transplantation outside aa ref 5 one first cause death hematopoietic stem cell transplantation older 40 years age refractory relapse aa graft versus host disease use optimized baltimore protocol type donors haplo also sibling matched unrelated transplantation within field aa rapidly appears promising ref 6 7 using optimized hematopoietic stem cell transplantation procedure marrow source stem cells ptcy strategy haplo identical donor setting also case available matched sibling unrelated donor might prevent drastically graft versus host disease eventually practice changing evaluating new transplant protocol new strategy main objective aparr main objective primary endpoint main objective demonstrate benefit terms 2 year grfs graft versus host disease graft versus host disease primary secondary graft failure free survival 50 historical rates refractory relapse aa undergoing hematopoietic stem cell transplantation ref 8 70 using optimized hematopoietic stem cell transplantation procedure marrow source stem cells ptcy strategy 40 years old haplo identical donor setting primary endpoint 2 year grfs following hcst primary composite endpoint measured time hematopoietic stem cell transplantation first following events primary secondary graft failures grade 3 4 acute graft versus host disease severe chronic graft versus host disease death secondary objectives endpoints secondary objectives demonstrate benefit terms biological outcomes primary secondary graft failure mortality overall survival quality life related morbidity notably severe infections cardiac toxicities chimerism immune reconstitution secondary endpoints 100 day engraftment 3 consecutive days neutrophiles 0 5 g l 7 consecutive days platelets 20 g l donor chimerism 85 total blood absolute numbers neutrophils platelets month 1 month 3 month 6 month 12 month 24 day last platelet red blood cell transfusions acute graft versus host disease incidence grade 2 4 month 3 chronic graft versus host disease incidence month 24 severe chronic graft versus host disease month 24 secondary graft failure month 12 month 24 severe infections common terminology criteria for adverse events grade 3 4 month 1 month 3 month 6 month 12 month 24 incidence cardiac toxicities month 12 incidence cmv ebv infection month 12 mortality month 12 month 24 overall survival 12 months 24 months quality life questionnaire pre transplant month 6 month 12 month 24 chimerism month 1 month 3 month 6 month 12 month 24 immune reconstitution month 1 month 3 month 6 month 12 month 24 lymphocytes cd4 cd8 b nk lymphocytes gammaglobulines design phase ii multicenter national prospective single arm population participants aged 40 60 years refractory relapse aa ist eligible hematopoietic stem cell transplantation inclusion criteria aged 40 60 years old suffering acquired refractory severe idiopathic aplastic anemia least 6 months anti thymocyte globulin cyclosporine eltrombopag relapse allograft validated national multidisciplinary expertise meetings french reference centre aplastic anemia available geno identical donor 10 10 matched donor haploidentical donor absence donor specific antibody detected mfi 1500 antibodies distinct haplotype donor recipient usual criteria hematopoietic stem cell transplantation eastern cooperative oncology group (= performans status (= ecog)) 2 severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function aspartate amino transferase alanine-aminotransferase 3n conjugated bilirubin 2n total bilirubin 2n available clearance creatinine 50ml min health insurance coverage women childbearing potential men must use contraceptive methods participation research 12 months 6 months last dose cyclophosphamide respectively signed written informed consent nb authorized contraceptive methods women childbearing potential absence permanent sterilization oral intravaginal transdermal combined hormonal contraception oral injectable transdermal progestogen hormonal contraception intrauterine hormonal releasing system ius sexual abstinence need evaluated relation duration preferred usual lifestyle participants men absence permanent sterilization sexual abstinence condoms individuals must meet inclusion criteria verified screening inclusion visit eligible participate exclusion criteria morphologic evidence clonal evolution isolated bone marrow cytogenetic abnormalities also eligible excepted chromosome 7 abnormalities complex karyotype seropositivity human immunodeficiency virus htlv 1 2 active hepatitis b c associated hepatic cytolysis cancer last 5 years except basal cell carcinoma skin situ carcinoma cervix pregnant hcg positive breast feeding yellow fever vaccine others live virus vaccines within 2 months transplantation research uncontrolled coronary insufficiency recent myocardial infarction 6 month current manifestations heart failure according “new york heart association” ii ventricular ejection fraction 50 renal failure creatinine clearance 50ml min contraindication mentioned smpc investigators brochure medicinal products planned used including conditioning regimen graft versus host disease prophylaxis prevention ebv reactivation infection prophylaxis known allergy intolerance medicinal products excipients planned used including conditioning regimen graft versus host disease prophylaxis prevention ebv reactivation infection prophylaxis according investigators brochure smpc debilitating medical psychiatric illness precludes understanding inform consent well optimal follow legal protection tutorship curatorship state medical aid participation another interventional medicinal product cell therapy individuals meeting exclusion criteria verified screening inclusion visit ineligible participate transplants modalities 1 conditioning regimen thymoglobulin 0 5 milligrams kilograms 9 2 milligrams kilograms 8 2 5 milligrams kilograms 7 fludarabine 30mg month 2 day v day 6 day 2 pre transplant cyclophosphamide 14 5 milligrams kilograms day v day 6 day 5 total body irradiation 2 gray day 1 2 stem cell source bone marrow target 4 108 nucleated cells kilograms recipient body weight granulocyte colony stimulating factor given subcutaneously starting day 5 5 milligrams kilograms day absolute neutrophil count greater 1 5 109 l 3 days 3 graft versus host disease prophylaxis cyclophosphamide 50 milligrams kilograms day 3 4 tacrolimus 0 2 0 3 milligrams kilograms day per overall survival divided 2 doses 0 05 0 1 milligrams kilograms ivse mycophenolate mycophenolate mofetil begin 5 absence graft versus host disease mycophenolate mofetil stopped day 35 day 45 tacrolimus day 365 4 prevention ebv reactivation rituximab 150mg month 2 intravenously day 5 post hematopoietic stem cell transplantation except donor ebv serology ebv pcr negative infusion rituximab preceded administration anti pyretic antihistaminic e g paracetamol diphenhydramine nb however permissible delay administration rituximab 24 hours 5 occurs sunday greater safety discretion investigator interventions added additional test specific examinations except quality life questionnaire rituximab considered added research provided sponsor expected benefits participants society outcomes adult refractory relapse aa older 40 years remain poor hematopoietic stem cell transplantation sole therapeutically valid option results always disappointing transplantation currently rarely possible optimized hematopoietic stem cell transplantation protocol haplo identical donor setting also case available matched sibling unrelated donor might prevent graft versus host disease eventually drastically improve outcome hematopoietic stem cell transplantation older 40 years refractory relapse aa direct benefits since curative safe options available far absence transplantation aged 40 years refractory relapse aa ist thus exposed infections risk hemorrhage prolonged fatigue also long term clonal evolution including paroxysmal nocturnal hemoglobinuria pnh well myelodysplastic syndrome mds acute myeloid leukemia aml grim prognosis global health care benefit also possible since wont need medical support including hospitalization also daily hospital care antibiotics need transfusions risks burdens added rituximab injection risk level practical implementation indication hematopoietic stem cell transplantation refractory relapse aa aged 40 years refractory relapse first line ist number participants included 52 number centres 28 centers affiliated sfgm tc france duration inclusion period 36 months participation period bmt follow 24 months total duration 60 months number enrolments expected per site per month 0 05 centre month statistical analysis sample size calculation two sided one sample log rank test calculated sample 52 subjects achieves 80 power 0 05 significance level detect 2 years grfs 70 new group 2 years grfs historic control group 50 followed 2 years analysis primary endpoint several interim analyses primary outcome measure planned every 12 months unless less 20 enrolled based bayesian approach end accrual follow grfs estimated using kaplan meier method corresponding 95 confidence interval compared historical rate using one sample two sided log rank test additional terminal analysis use external observational cohort propensity score weighting ensure unbiased comparison enhance level evidence effect funding sources programme hospitalier de recherche clinique n 2022 data safety monitoring board yes unmet need unacceptable toxicity hematopoietic stem cell transplantation refractory relapse saa 40 years age since decades age known strong negative predictor survival undergoing hematopoietic stem cell transplantation acquired aa higher mortality 40 years age ref 9 constantly confirmed several large ref 10 11 12 13 14 multivariate analysis recently confirmed lack improvement term overall survival 2010 2015 compared 2001 2009 high risk 0 95 95 ci 0 73 1 24 p 7 ref 15 overall using classical hematopoietic stem cell transplantation procedure hematopoietic stem cell transplantation age 40 years continues carry significant risk mortality reduced current era reason current guidelines firmly recommend use first line immunosuppression age 40 hand tremendous progress done recently regarding ist acquired aa addition eltrombopag epag standard ist associating cisclosporine horse anti thymocyte globuline lead almost 80 response rate considered standard care older ref 1 however 20 remain refractory immunosuppression 30 40 relapse options today outside supportive care antibiotics transfusion support thus urgent need improve hematopoietic stem cell transplantation outcomes older able propose acceptable option case refractoriness relapse ist successful haplo identical transplantation using ptcy aplastic anemia recent strategy haploidentical haplo related donor sct haplo sct improved drastically outcomes using cell replete grafts administration post transplantation cyclophosphamide ptcy targets alloreactive cells generated early human leukocyte antigen mismatched transplant sparing regulatory cells leaving unaffected non dividing hematopoietic stem cells standard post transplant immune suppression calcineurin inhibitor cni mycophenolate mofetil preliminary results little number refractory saa kings college london uk john hopkins baltimore usa promising ref 16 17 also showed behalf severe aplastic anemia working party european blood marrow transplantation group promising results 36 median age 42 years transplanted 2010 2017 1 year overall survival 78 low rate graft versus host disease suggesting approach might valid option particular poor situation ref 18 since baltimore group published last year confirmatory clear messages use ptcy aplastic anemia context haplo identical donor ref 19 1 despite human leukocyte antigen barriers cure rates acquired aa following human leukocyte antigen haploidentical bmt using non myeloablative conditioning regimen ptcy exceed 80 overall survival low rates graft versus host disease eventually trm 2 results drastically improved added anti thymocyte globuline 2 5 milligrams kilograms total dose classical baltimore protocol ref 20 3 recommended source stem cells bone marrow peripheral blood stem cells due low incidence graft versus host disease bone marrow grafts bone marrow grafts aim collect 4 108 mononuclear cells per kilograms ideal body weight recipient since grafts containing 2 5 108 mononuclear cells per kilograms ideal body weight inferior engraftment ref 21 results good colleagues united states proposing approach upfront first line young ref 19 france prospective phase 2 open confirm good results young refractory aplastic anemia haploidentical allogeneic hematopoietic stem cell transplantation post transplant cyclophosphamide acquired refractory aplastic anemia nationwide phase ii haplo empty funded programme hospitalier de recherche clinique n 2019 nct05126849 successful performance haploidentical transplants ptcy transformative advance field alternative haplo identical hematopoietic stem cell transplantation saa expansion ptcy graft versus host disease prophylaxis matched unrelated donor hematopoietic stem cell transplantation diseases aplastic anemia success ptcy enabling successful transplantation across human leukocyte antigen barriers low rates acute chronic graft versus host disease led next inevitable question would work well better human leukocyte antigen matched setting question burning topic research recent years explore bmt ctn 1203 progress launched goal identifying promising graft versus host disease prophylaxis regimen could challenge existing paradigm calcineurin inhibitor methotrexate human leukocyte antigen matched unrelated transplantation randomly assigned one three experimental arms namely ptcy tac mycophenolate mofetil ptcy based tac methotrexate bortezomib bort based tac methotrexate maraviroc mvc based primary end point graft versus host disease free relapse free survival gfrs measured time transplant first four events onset grade iii intravenous infusion agvhd cgvhd requiring systemic immunosuppression disease relapse death intent treat analysis best results obtained ptcy based cohort ref 22 promising results ptcy arm led development bmt ctn 1703 large multi center randomized n 428 comparing ptcy tac mycophenolate mofetil tac methotrexate reduced intensity setting using peripheral blood stem cells pbsc myeloid lymphoid malignancies nct03959241 practice changing completed accrual year ahead schedule despite covid pandemic results presented 2022 american society hematology meeting ref 23 primary end point 1 year grfs met primary end point grfs favoring ptcy tac mycophenolate mofetil 52 7 compared tac methotrexate 34 9 high risk 0 641 p 001 thus defining standard graft versus host disease prophylaxis ric human leukocyte antigen matched unrelated transplantation secondary lower rates acute chronic graft versus host disease meantime similar smaller randomized conducted hovon group europe hovon 96 final results recently published favor ptcy ref 24 ptcy becoming standard graft versus host disease prophylaxis hematopoietic stem cell transplantation unrelated donor outside aplastic anemia use ptcy graft versus host disease prophylaxis matched sibling unrelated donor hematopoietic stem cell transplantation aplastic anemia ptcy also reported used aa undergoing hematopoietic stem cell transplantation first report small case series baltimore group including old high risk graft failure graft versus host disease due massive transfusions alloimmunization demonstrated feasibility ref 25 research also investigated possibility use ptcy sole graft versus host disease prophylaxis compared cyclosporine a methotrexate receiving pbsc owing lower rates grade ii intravenous infusion acute graft versus host disease 22 2 vs 37 1 p 0 56 chronic graft versus host disease 22 7 vs 63 6 p 0 013 ref 26 combination ptcy standard immunosuppression cyclosporine a methotrexate proven superiority cyclosporine a methotrexate alone receiving pbsc known higher rates graft failure graft versus host disease lower grade ii intravenous infusion acute graft versus host disease 22 6 vs 52 2 p 0 0015 similar chronic graft versus host disease 16 7 vs 26 p 0 306 ref 27 promising results using marrow source stem cells ptcy strategy reported baltimore 2020 3 receiving matched sibling 7 receiving unrelated 6 matched 1 1 antigen mismatched donor allografts reported alive fully engrafted graft versus host disease ist time publication two reactivated cmv none ebv moreover 9 evidence pnh clone presence hematopoietic stem cell transplantation negative tested posttransplant one female bmt performed 200 cgy total body irradiation become pregnant naturally 4 5 years post hematopoietic stem cell transplantation spontaneous loss 14 weeks placental insufficiency natural pregnancy occurred 5 years post bmt currently third trimester uncomplicated pregnancy ref 28 several expert international centers experimenting approach hematopoietic stem cell transplantation using ptcy aa sibling matched unrelated donor ref 6 saint louis hospital used approach 4 refractory aa transplanted unrelated donors high risk acute chronic graft versus host disease using bone marrow source stem cells ptcy according baltimore protocol ref 19 results promising reason would like assess strategy aparr actual proposal ptcy used hematopoietic stem cell transplantation sibling unrelated donor refractory relapse aa promising results grfs new endpoint hematopoietic stem cell transplantation saa contrast hematopoietic stem cell transplantation hematological malignancies challenges hematopoietic stem cell transplantation aplastic anemia remains achievement sustained engraftment without significant alloreactivity graft versus tumor effect needed achieve long term survival long term follow repeatedly reported graft versus host disease strongly impairs quality life plays pivotal role occurrence late complications including secondary cancers thus avoiding graft versus host disease particularly important aim hematopoietic stem cell transplantation saa ref 29 30 31 beyond high overall survival rate saa adapted composite endpoint graft versus host disease rejection free survival grfs may thus accurate assess outcomes may meaningful endpoint recently assess grfs large cohort aplastic anemia ref 8 behalf saawp ebmt analyzed grfs 479 idiopathic saa underwent hematopoietic stem cell transplantation 2 conventional situations upfront hematopoietic stem cell transplantation matched related donor minimal residual disease upfront cohort 209 ii hematopoietic stem cell transplantation relapsed refractory saa rel ref cohort 270 relevant events grfs calculation included graft failure grade 3 4 acute graft versus host disease severe chronic graft versus host disease death relapse refractory cohort n 270 subject aparr 5 year grfs 61 age one main factors significantly increasing risk death high risk 1 04 95 ci 1 02 1 06 p 0 001 well acute graft versus host disease high risk 1 03 95 ci 1 00 1 07 p 0 041 chronic graft versus host disease high risk 1 04 95 ci 1 01 1 08 p 0 032 sub analysis cohort aged 40 60 years 2 year grfs 50 thus represents standard rate results described previous section use bone marrow source stem cells aplastic anemia baltimore protocol believed reach 2 year grfs 70 experimental approach see section 13 2 hypotheses justification saa adapted composite endpoint graft versus host disease primary secondary graft failure free survival grfs accurate assess outcomes endpoint outcomes adult aa aged 40 years refractory relapse first line ist remain poor hematopoietic stem cell transplantation sole therapeutically valid option results always disappointing far hematopoietic stem cell transplantation rarely possible using marrow source stem cells ptcy strategy haplo identical donor setting also case available matched sibling unrelated donor might prevent graft versus host disease eventually drastically improve outcome hematopoietic stem cell transplantation setting direct benefits since curative safe options available far absence transplantation aged 40 years saa refractory relapse ist thus exposed infections risk hemorrhage prolonged fatigue also clonal evolution including paroxysmal nocturnal hemoglobinuria pnh myelodysplastic syndrome mds acute myeloid leukemia aml might also occur long term grim prognosis global health care benefit also possible since wont need medical support anymore including hospitalization also daily hospital care antibiotics need transfusions risks associated hematopoietic stem cell transplantation purpose described follows primary non engraftment secondary rejection graft failures acute graft versus host disease grades chronic graft versus host disease severe infectious complications bacterial fungal viral parasites toxicity might also associated digestive disorders mucositis asthenia skin rash additionally high dose cyclophosphamide may also exhibit cardiac toxicity also exposed long term complications osteonecrosis cataract fatigue kidney dysfunction liver dysfunction lung dysfunction graft versus host disease related due age range population might exposed complications related hematopoietic stem cell transplantation also age moreover types complications similar ones presented younger ages number complications usually higher aged 40 years undergoing hematopoietic stem cell transplantation outcomes adult aplastic anemia aa aged 40 years refractory relapse first line ist remain poor hematopoietic stem cell transplantation hematopoietic stem cell transplantation sole therapeutically valid option results always disappointing transplantation rarely possible unacceptable toxicity using optimized hematopoietic stem cell transplantation protocol marrow source stem cells ptcy strategy haplo identical donor setting also case available matched sibling unrelated donor might prevent graft versus host disease eventually drastically improve outcome hematopoietic stem cell transplantation refractory relapse aa ist overall survival reflecting anymore main goal older undergoing hematopoietic stem cell transplantation considering beyond simple overall survival use grfs graft versus host disease graft versus host disease relapse rejection free survival may thus meaningful endpoint allowing greater accuracy assessing outcomes thus benefits experimental approach main hypothesis aged 40 years refractory relapsed aa applying new hematopoietic stem cell transplantation strategy based marrow stem cells whichever donor type haplo identical related unrelated donor together haplo identical conditioning platform ptcy may beneficial terms 2 year grfs increase 50 historical controls ref 8 70 primary composite endpoint measured time hematopoietic stem cell transplantation first four events primary secondary graft failures grade 3 4 acute graft versus host disease severe chronic graft versus host disease death main objective demonstrate benefit terms 2 year grfs graft versus host disease graft versus host disease primary secondary graft failure free survival 50 historical rates refractory relapse aa undergoing standard hematopoietic stem cell transplantation using bone marrow related unrelated donor ref 8 70 using optimized hematopoietic stem cell transplantation protocol bone marrow source stem cells haplo identical conditioning platform including ptcy 40 years old haplo identical donor setting secondary objectives evaluate following biological outcomes primary secondary graft failure mortality overall survival quality life related morbidity notably severe infections cardiac toxicities chimerism immune reconstitution 2 year grfs grfs composite right censored endpoint defined time hematopoietic stem cell transplantation first following events primary graft failure defined absence engraftment aplasia day 60 graft day 0 e persistence neutrophils 500 platelets 20 giga l secondary graft failure defined reoccurrence aplasia engraftment defined occurrence neutrophils 500 3 days platelets 20 giga l 7 consecutive days grade 3 4 acute graft versus host disease according magic consortium 2016 severe chronic graft versus host disease according nih classification death whatever cause 100 day engraftment 3 consecutive days neutrophils 0 5 g l 7 consecutive days platelets 20 g l donor chimerism 85 total blood absolute numbers neutrophils platelets month 1 month 3 month 6 month 12 month 24 day last platelet red blood cell transfusions acute graft versus host disease incidence grade 2 4 month 3 chronic graft versus host disease incidence month 24 severe chronic graft versus host disease month 24 secondary graft failure month 12 month 24 severe infections common terminology criteria for adverse events grade 3 4 month 1 month 3 month 6 month 12 month 24 incidence cardiac toxicities month 12 incidence cmv ebv infection month 12 mortality month 12 month 24 overall survival 12 months 24 months quality life questionnaire pre transplant month 6 month 12 month 24 chimerism month 1 month 3 month 6 month 12 month 24 immune reconstitution month 1 month 3 month 6 month 12 month 24 lymphocytes cd4 cd8 b nk lymphocytes gammaglobulines phase ii multicenter french single arm national multi center including adult transplant centers sfgm tc 28 centres recruitment centres recruited hematology units referred transplant team pre transplant assessment visit consent collected latest 10 transplant information sheet consent form given investigator original conserved investigator third copy sponsor signing written informed consent included investigators electronic case report form cleanwebtm physician receive confirmation inclusion email assessment performed usual care allogeneic transplant data collected research physical examination reports disease history including biology diagnosis specific aa treatments weight height eastern cooperative oncology group (= performans status (= ecog)) performans status assessment sorror score comorbidities complete physical examination human leukocyte antigen compatibility check recipient donor pre transplant bone marrow aspiration smear cytogenetics done inclusion within 6 8 weeks electrocardiogram done screening visit less 2 months inclusion echocardiogram evaluation left ventricular ejection done screening visit less 2 months inclusion evaluation cardiovascular risk factors dyslipidemia hbp obesity diabetes smoking done screening visit pulmonary function tests including least forced expiratory volume 1 second fev1 forced vital capacity forced vital capacity done screening visit less 2 months inclusion respiratory function tests done screening visit less 2 months inclusion liver ultrasound doppler echography baseline values biological test complete blood count neutrophil monocyte lymphocyte haemoglobin platelet screening inclusion visit abo rh typing blood cell chemistry panel serum electrolytes creatinine calcium glucose uric acid magnesium levels ferritin c reactive protein liver function tests transaminases alkaline phosphatase gamma gt bilirubine circulating protein electrophoresis four pregnancy test women childbearing potential starting search anti human leukocyte antigen antibodies luminex technology dsa chimerism markers identification marrow aspiration karyotype analysis within 6 8 weeks hematopoietic stem cell transplantation serum urine pregnancy test sensitivity least 25 miu ml women childbearing potential used indifferently infectious assessment viral serologies serology hepatitis b antigen hbs ig antihbc c aspergillus antigen ebv igg cmv igg hsv igg human immunodeficiency virus 2 elisa tests htlv 1 2 igg toxoplasmosis igg tpha vdrl pcr human immunodeficiency virus b c hepatitis imaging dental radiography total body ct scan assessment performed according practice investigator quality life eortc qlq c30 v3 preservation fertility women may proposed stimulation collection follicles secondary ovocytes order realize either gamete vitrification vitro fertilisation followed embryo preservation technique reserved couples cryopreservation gonadal tissue stimulation transvaginal punctures required techniques may contraindicated thrombocytopenia neutropenia woman stable partner embryo freezing theoretically possible rarely compatible emergency management b men essential propose consultation cecos centre conservation sperm collection cryopreservation sperm protocol carried french aplastic anemia reference centre societe francophone de greffe de moelle et de therapie cellulaire sfgm tc members sfgm tc participate research french biomedicine agency association also support proposal refractory aplastic anemia population concerns 30 150 new per year 60 aged 40 years receiving immunosuppression anti thymocyte globulin cyclosporine eltrombopag disease french reference sfgm tc network illustrates feasibility transplant procedure started cannot interrupted unless dies particular disposition procedure case prematurely terminating transplant procedure case occurrence adverse reaction physicians opinion requiring discontinuation described smpc tacrolimus mycophenolate mofetil medical management care mycophenolate mofetil stopped decreased faster case unexpected prolonged cytopenias case digestive disorders diarrhea tacrolimus stopped case severe hepatic renal insufficiency replaced corticosteroides 0 5mg kilograms day 7 14 1mg kilograms day 15 29 0 5mg kilograms day 30 45 0 25mg kilograms day 46 60 taper zero day 61 84 ref 39 hepatic renal function improve tacrolimus reintroduced half dose discussed multidisciplinary meetings participants may exit time reason followed case part classic care follow procedure graft investigator temporarily permanently withdraw participant safety reason participants best interests transplant procedure initiated discharged participant lost follow participant cannot located investigator must make every effort reconnect participant document attempts source file least determine whether participant alive dead participant exits prematurely withdrawing consent data collected prior date premature exit may still used case report form must list various reasons participant discontinued another medical issue explicit withdrawal consent lost follow death initial notification severe adverse event must provided written report signed investigator using severe adverse event notification form specific intended purpose case report form item form must completed investigator sponsor carry appropriate analysis initial notification sponsor serious adverse event must quickly followed additional detailed written report reports case outcome may monitored safety department provide information whenever possible investigator provide sponsor documents may useful medical reports laboratory test results results additional examinations etc documents must non identifying addition documents must include following acronym number participants initials adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even participant left initial notification severe adverse event follow reports documents must sent sponsor safety department email événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction noted possible send severe adverse event reports safety department fax 33 0 1 44 84 17 99 event failed attempt send severe adverse event report email order avoid duplication use e crfs investigator completes severe adverse event notification form e case report form validates prints signs form sending email possible connect e case report form investigator complete sign send severe adverse event notification form safety department soon connection restored severe adverse event notification form e case report form must duly completed investigator must respond requests sponsor additional information questions relating notification adverse event safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction cases utero exposure investigator complete notification follow form pregnancy occurring participation investigator must monitor pregnant woman throughout pregnancy pregnancy terminated must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage pregnancy termination foetal death congenital abnormality etc investigator must follow procedure reporting saes initial pregnancy notification severe adverse event follow reports documents sent sponsor according procedures specified herein father exposed investigator must obtain pregnant woman permission collecting information pregnancy data entry performed centre authorized persons computer file used research implemented accordance french amended informatique et libertes law governing data protection european general data protection regulation gdpr regulations commitment comply reference methodology medium risk 001 research governed commission nationale informatique et libertés french data protection agency reference methodology processing personal data used within scope health research amended medium risk 001 ap hp sponsor research signed declaration compliance reference methodology aged 40 60 years old suffering acquired refractory severe idiopathic aplastic anemia least 6 months anti thymocyte globulin cyclosporine eltrombopag relapse allograft validated national multidisciplinary expertise meetings french reference centre aplastic anemia available geno identical donor 10 10 matched donor haploidentical donor absence donor specific antibody detected mfi 1500 antibodies distinct haplotype donor recipient usual criteria hematopoietic stem cell transplantation eastern cooperative oncology group (= performans status (= ecog)) 2 severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function aspartate amino transferase alanine-aminotransferase 3n conjugated bilirubin 2n total bilirubin 2n available clearance creatinine 50ml min health insurance coverage women childbearing potential men must use contraceptive methods participation research 12 months 6 months last dose cyclophosphamide respectively signed written informed consent nb authorized contraceptive methods women childbearing age absence permanent sterilization oral intravaginal transdermal combined hormonal contraception oral injectable transdermal progestogen hormonal contraception intrauterine hormonal releasing system ius sexual abstinence need evaluated relation duration preferred usual lifestyle participants men absence permanent sterilization sexual abstinence condoms https www hma eu fileadmin dateien human_medicines 01 about_hma working_groups ctfg 2020_09_hma_ctfg_contraception_guidance_version_1 1_updated pdf individuals must meet inclusion criteria verified screening inclusion visit eligible participate morphologic evidence clonal evolution isolated bone marrow cytogenetic abnormalities also eligible excepted chromosome 7 abnormalities complex karyotype seropositivity human immunodeficiency virus htlv 1 2 active hepatitis b c associated hepatic cytolysis cancer last 5 years except basal cell carcinoma skin situ carcinoma cervix pregnant hcg positive breast feeding yellow fever vaccine others live virus vaccines within 2 months transplantation research uncontrolled coronary insufficiency recent myocardial infarction 6 month current manifestations heart failure according “new york heart association” ii ventricular ejection fraction 50 renal failure creatinine clearance 50ml min contraindication mentioned smpc investigators brochure medicinal products planned used including conditioning regimen graft versus host disease prophylaxis prevention ebv reactivation infection prophylaxis known allergy intolerance medicinal products excipients planned used including conditioning regimen graft versus host disease prophylaxis prevention ebv reactivation infection prophylaxis according investigators brochure smpc debilitating medical psychiatric illness precludes understanding inform consent well optimal follow legal protection tutorship curatorship state medical aid participation another interventional medicinal product cell therapy individuals meeting exclusion criteria verified screening inclusion visit ineligible participate selection follow jacie standard first choice sibling donor available unrelated matched donor used second choice case human leukocyte antigen matched donor available eligible excellent general status might benefit within protocol haplo identical transplantation donor unable tolerate bone marrow harvest receive general anesthesia psychological medical reasons donor refusing bone marrow harvest pregnancy donor haplo identical donor presence donor specific antibody dsa mfi 1500 detected persons responsible quality control article l 1121 3 code de la sante publique french public health code take necessary precautions ensure confidentiality information relating investigational medicinal products participants particular identity results obtained persons well investigators bound professional secrecy accordance conditions set articles 226 13 226 14 code penal french criminal code research involving human participants data collected concerning participants sent sponsor investigators specialised collaborators rendered non identifying circumstances shall names addresses participants involved shown participants initials recorded accompanied encoded number specific indicating order enrolment sponsor ensure participant given written permission personal information strictly necessary quality control accessed non identifying data entered electronically via web browser several interim analyses planned see interim primary analyses performed intent to treat population secondary analysis performed per protocol population descriptive statistics present median interquartile range mean standard deviation quantitative variables count percentages qualitative variables interim analyses interim analyses take place every 12 months unless less 20 enrolled use bayesian inference frawework compute posterior mean credible band grf survival function well posterior mean hazard event piecewise exponential prior gamma distributed independent heights castillo van der pas 2020 multiscale bayesian survival analysis arxiv 2005 02889 assuming exponential grfs distribution compute posterior probability hazard event 0 03 corresponding expected survival 50 month 24 results provide data safety monitoring board toll decision making r package bayessurvival used primary endpoint analysis primary endpoint grfs estimated plotted using kaplan meier estimator along 95 confidence interval using greenwoods formula 2 year grf rate estimation compared historical rate using one sample two sided log rank test secondary endpoints time event endpoints competing risks assuming non informative censoring analysed similarly grfs time event endpoints competing risk setting cumulative incidence endpoint estimated competing risks setting plotted corresponding 95 ci binary endpoints proportion calculated corresponding exact binomial 95 ci quantitative endpoints summary statistics median iqr mean sd presented subgroup analyses two subgroups interest defined based type hematopoietic stem cell transplantation donor 1 haplo identical hematopoietic stem cell transplantation donors 2 sibling matched unrelated donors analysis primary secondary endpoints additional performans status (= ecog) based analysis see repeated specifically 2 subgroups interaction tests gail simon used performans status (= ecog) based analysis enhance level evidence single arm add comparison external controls ref 34 35 access individual data observational cohort ref 8 perform causal inference analysis propensity score performans status (= ecog) weighting analysis ref 36 primary endpoint secondary endpoints compared cohort using ipw methods att weights propensity score include already known prognostic factors among time diagnosis bmt age type donor disease type time bmt observed prognostic factors effect grfs compared using cox proportional hazard weighted model secondary time event endpoints either cox cox cause specific weighted models used depending presence competing risks binary endpoints weighted logistic model used,"graft, transplantation, host, versus, stem, cell, disease, haplo, transplant, donor"
HAPLO-EMPTY_Protocole en vigueur signé V1.1 du 20210816,1,23.641912,-29.302996,full title haploidentical allogeneic hematopoietic stem cell transplantation post transplant cyclophosphamide acquired refractory aplastic anemia nationwide phase ii acronym reference haplo empty coordinating investigator pr regis peffault de latour sponsor assistance publique hopitaux de paris scientific justification outcomes severe aplastic anemia saa refractory first line immunosuppressive therapy ist lack matched unrelated donor mud remain poor recently use eltrombopag elt shown blood count improvements 40 1 however refractory respond elt second line therefore exposed life threatening infections bleeding past 2 decades significant decrease infection related mortality saa unresponsive initial ist clonal evolution including paroxysmal nocturnal hemoglobinuria pnh myelodysplastic syndrome mds acute myeloid leukemia aml still occur long term grim prognosis overall overall survival acquired refractory saa elt 60 70 2 years 2 hematopoietic stem cell transplantation hematopoietic stem cell transplantation using alternative donor sources e mismatched unrelated donors cord blood cbt haplo identical family donors may curative refractory saa despite carrying much higher rates complications transplantations matched related unrelated donors recently group showed cbt valuable curative option young adults refractory saa 3 however available cb cbt related mortality high adult haploidentical haplo related donor stem cell transplantation haplo sct improved dramatically outcomes using cell replete grafts administration post transplantation cyclophosphamide ptcy preliminary results little number refractory saa kings college london uk john hopkins baltimore usa seem promising 4 5 retrospectively analyzed data 36 median age 42 years transplanted 2010 2017 europe behalf saa working party european blood marrow transplantation group 1 year overall survival 80 suggesting approach might valid option particular poor situation 6 main objective primary endpoint main objective demonstrate benefit term 2 year overall survival rate 60 historical rates acquired refractory idiopathic aplastic anemia 80 using haplo sct ptcy primary endpoint 2 year overall survival rate 80 secondary objectives endpoints secondary objectives biological outcomes graft failure graft versus host disease graft versus host disease progression free survival relapse non relapse mortality overall survival quality life chimerism immune reconstitution secondary endpoints graft failure incidence neutrophils platelets engraftment day 100 3 consecutive days neutrophiles 0 5 g l 7 consecutive days platelets 20 g l absolute numbers neutrophils platelets month 1 month 2 month 3 month 6 month 12 day last platelet red blood cell transfusions incidence use growth factors poor hematopoietic reconstitution acute graft versus host disease incidence month 3 month 3 date maximum grading first line response steroids courses case steroid refractory graft versus host disease chronic graft versus host disease incidence date grading month 24 relapse incidence month 12 month 24 progression free survival month 12 month 24 incidence cmv ebv infection month 12 severe infections ctae grade 3 4 month 3 month 6 month 12 month 24 non relapse mortality month 24 incidence cardiac toxicities month 12 overall survival month 12 quality life questionnaire inclusion post transplantation month 3 month 6 month 12 month 24 chimerism month 1 month 3 month 6 month 12 month 24 immune reconstitution analyzing b nk regulatory cell levels peripheral blood month 3 month 6 month 12 month 24 post transplantation ferritin levels month 3 month 6 month 12 month 24 design phase ii multicenter national prospective cohort population participants aged 3 35 years acquired refractory idiopathic aplastic anemia indication haploidentical allogeneic hematopoietic stem cell transplantation inclusion criteria aged 3 35 years old suffering refractory acquired idiopathic aplastic anemia least one course immunosuppression anti thymocyte globulin absence geno identical donor 10 10 matched donor identification haploidentical donor brother sister parents adult children cousin absence donor specific antibody detected mfi 1500 antibodies directed towards distinct haplotype donor recipient usual criteria hematopoietic stem cell transplantation eastern cooperative oncology group (= performans status (= ecog)) 2 severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function aspartate amino transferase alanine-aminotransferase 2 5n total bilirubin 2n creatinine 150 mol l health insurance coverage contraception methods must prescribed duration research women men childbearing age must use contraceptive methods within 12 months 6 months last dose cyclophosphamide respectively signed written informed consent 2 parents aged less 18 nb authorized contraceptive methods women childbearing age absence permanent sterilization oral intravaginal transdermal combined hormonal contraception oral injectable transdermal progestogen hormonal contraception intrauterine hormonal releasing system ius sexual abstinence need evaluated relation duration preferred usual lifestyle participants man absence permanent sterilization sexual abstinence condoms exclusion criteria morphologic evidence clonal evolution isolated bone marrow cytogenetic abnormalities also eligible uncontrolled infection seropositivity human immunodeficiency virus htlv 1 active hepatitis b c defined positive pcr hbv hcv associated hepatic cytolysis cancer last 5 years except basal cell carcinoma skin situ carcinoma cervix pregnant hcg positive breast feeding received attenuated vaccine within 2 months transplantation uncontrolled coronary insufficiency recent myocardial infarction 6 month current manifestations heart failure uncontrolled cardiac rhythm disorders ventricular ejection fraction 50 heart failure according “new york heart association” ii preexisting acute hemorrhagic cystitis renal failure creatinine clearance 30ml min urinary tract obstruction contraindications treatments used research debilitating medical psychiatric illness preclude understanding inform consent well optimal follow tutorship curatorship transplant modalities 1 conditioning regimen fludarabine 30mg month 2 day v day 6 day 2 pre transplant cyclophosphamide 14 5 milligrams kilograms day v day 6 day 5 total body irradiation 2 gray day 1 2 stem cell source bone marrow 3 graft versus host disease prophylaxis rabbit anti thymoglobulin dosed 0 5 milligrams kilograms day 9 2 milligrams kilograms days 8 7 cyclophosphamide 50 milligrams kilograms day 3 4 tacrolimus residual 8 12 microg l mycophenolate mycophenolate mofetil 5 absence graft versus host disease mycophenolate mofetil stopped day 35 tacrolimus day 365 4 prevention ebv reactivation rituximab 150mg month 2 intravenously day 5 post hematopoietic stem cell transplantation infusion rituximab preceded administration anti pyretic antihistaminic e g paracetamol diphenhydramine interventions added additional test specific examinations expected benefits participants society outcomes saa refractory first line ist lack mud remain poor transplantation sole therapeutically valid option cbt valuable curative option young adults mortality using approach high adult cb always available haplo sct ptcy recently showed promising results situation nearly available haplo donor biologic parents children haplo sibling 50 chance haplo moreover haplo sct ptcy available almost also quick cheap procedure might thus demonstrate haplo sct ptcy curative option adult refractory aplastic anemia children young cbt available risks burdens added risks related sct cardiac toxicities hemorrhagic cystitis particularly monitored practical implementation indication allograft context acquired refractory aplastic anemia number participants included objective 31 allo grafted anticipate 35 include number centres 36 centres france duration inclusion period 36 months participation period post transplant 24 months total duration 60 months number enrolments expected per site per month 0 3 year centre 0 02 month centre statistical analysis justification sample size hypothesize 2 year overall survival overall survival 80 versus 60 historical controls two sided one sample logrank test calculated sample 31 subjects achieves 80 7 power 0 050 significance level detect proportion overall survival 80 new group proportion overall survival historic control group 60 2 years terminal analysis realized observation required number events funding sources ministry health programme hospitalier de recherche clinique n 2019 data safety monitoring board yes haplo sct ptcy refractory saa prospective haplo empty justified following reason 1 outcome refractory aplastic anemia ist generally poor outside transplantation refractory use eltrombopag elt alone within second course ist shown blood count improvements 40 60 1 13 however refractory respond elt second line therefore exposed life threatening infections bleeding moreover refractory higher risk clonal evolution mds lam also exposed pnh evolution overall overall survival acquired refractory saa elt 60 70 2 years 2 conclusion 1 refractory aplastic anemia exposed long term complications absence mud available eligible alternative hematopoietic stem cell transplantation haplo sct might offer real chance cure eligible 2 results haplo sct ptcy retrospective refractory saa promising clay co authors published first report 8 refractory saa failed previous hematopoietic stem cell transplantation 4 received haplo sct ptcy using uniform reduced intensity conditioning regimen median age 32 years range 19 57 six 8 engrafted graft failure associated donor directed human leukocyte antigen antibodies despite intensive pre hematopoietic stem cell transplantation desensitization plasma exchange rituximab 1 case grade ii skin graft versus host disease first proof evidence haplo sct successfully rescue refractory saa group baltimore employed post transplantation high dose cyclophosphamide ptcy effort safely expand donor pool 16 consecutive refractory saa matched sibling donor july 2011 august 2016 16 underwent allogeneic allo bmt refractory saa 13 haploidentical donors three transplanted using conditioning regimen ptcy unrelated donors haplo identical donor non myeloablative conditioning regimen used like first including also antithymocyte globulin median age time transplantation 30 years range 11 69 graft failure primary secondary seen 16 alive transfusion independent without evidence clonality median follow 21 months range 3 64 two grade 1 2 skin acute graft versus host disease 2 also mild chronic graft versus host disease skin mouth requiring systemic steroids one graft versus host disease able come ist 15 months 17 months stopped ist 1 year approach led 100 engraftment low risk graft versus host disease 5 severe aplastic anemia working party european group blood marrow transplantation ebmt recently conducted retrospective analysis 36 72 male received haplo ptcy aplastic anemia 22 ebmt centers june 2010 march 2017 haplo ptcy first transplantation 81 second 11 third 8 received non myeloablative preparatory regimen cyclophosphamide 50mg kilograms day intravenous infusion days 3 4 post transplant median age 19 4 years range 2 5 45 4 years 58 adults cumulative incidence ci neutrophil recovery day 60 78 64 91 median time 21 days 18 26 cumulative incidence ci platelet recovery day 60 60 44 76 median time 31 days 22 185 ci grade ii intravenous infusion acute graft versus host disease 26 12 41 grade ii 19 7 32 grade iii 6 0 13 grade intravenous infusion ci chronic graft versus host disease 17 5 30 1 year 6 0 13 extensive ci 22 7 37 2 years limited new case extensive cgvhd one year median follow 24 6 months 15 9 38 2 estimated probability overall survival overall survival 78 64 91 1 year 74 60 89 2 years 6 several case reports shown interest procedure kids publications already presented submission process contain pediatric however main publication regarding category using haplo identical donors published bbmt 2020 brazilian group 87 underwent haplo ptcy 2010 2019 reported median age 14 years heavily transfused received previous immunosuppression received ptcy based graft versus host disease graft versus host disease prophylaxis grafts 93 bone marrow bone marrow median duration follow 2 years 2 months median time neutrophil recovery 17 days primary graft failure occurred 15 secondary poor graft function occurred 5 incidences grade ii intravenous infusion acute graft versus host disease 14 chronic graft versus host disease 9 two year overall survival event free survival event-free survival 79 70 respectively thus highlights feasibility overall benefit approach kids justifying prospective confirm results e haplo emtpy conclusion 2 population refractory saa therapeutic options retrospective suggest haplo sct ptcy feasible option encouraging results outcomes saa refractory first line ist lack mud remain poor transplantation sole therapeutically valid option cbt valuable curative option young adults mortality using approach high adult cb always available haplo sct ptcy recently showed promising results situation nearly available haplo donor biologic parents children haplo sibling 50 chance haplo retrospective non controlled recently suggest outcomes haplo sct using ptcy approach might superior actual standard care outside cbt moreover haplo sct ptcy available almost also quick cheap procedure might thus curative option adult refractory aplastic anemia children young cbt available outcomes saa refractory first line ist lack matched unrelated donor mud remain poor recently use eltrombopag elt shown blood count improvements 40 1 however refractory respond elt second line therefore exposed life threatening infections bleeding moreover refractory higher risk clonal evolution mds lam also exposed pnh evolution overall overall survival acquired refractory saa elt 60 70 2 years 2 hematopoietic stem cell transplantation hematopoietic stem cell transplantation using alternative donor sources e mismatched unrelated donors cord blood cbt haplo identical family donors may curative refractory saa despite carrying much higher rates complications transplantations matched related unrelated donors 3 recently group showed cbt valuable curative option young adults refractory saa 7 however available cb cbt related mortality high adult haploidentical haplo related donor stem cell transplantation haplo sct improved dramatically outcomes using cell replete grafts administration post transplantation cyclophosphamide ptcy preliminary results little number 3 retrospective shown encouraging results 4 5 6 hypothesis presented aim demonstrate benefit term 2 year overall survival rate 60 historical rates acquired refractory idiopathic aplastic anemia 80 using haplo sct ptcy main objective demonstrate benefit term 2 year overall survival compared historical controls secondary objectives evaluate following biological outcomes graft failure graft versus host disease graft versus host disease progression free survival relapse non relapse mortality overall survival quality life chimerism immune reconstitution demonstrate benefit term 2 year overall survival rate 60 historical rates acquired refractory idiopathic aplastic anemia 80 using haplo sct ptcy graft failure incidence neutrophils platelets engraftment day 100 3 consecutive days neutrophiles 0 5 g l 7 consecutive days platelets 20 g l absolute numbers neutrophils platelets month 1 month 2 month 3 month 6 month 12 day last platelet red blood cell transfusions incidence use growth factors poor hematopoietic reconstitution acute graft versus host disease incidence month 3 month 3 date maximum grading first line response steroids courses case steroid refractory graft versus host disease chronic graft versus host disease incidence date grading month 24 relapse incidence month 12 month 24 progression free survival month 12 month 24 incidence cmv ebv infection month 12 severe infections ctae grade 3 4 month 3 month 6 month 12 month 24 non relapse mortality month 24 incidence cardiac toxicities month 12 overall survival month 12 quality life questionnaire eortc qlq c30 v3 adult qql ped minor inclusion post transplantation month 3 month 6 month 12 month 24 chimerism month 1 month 3 month 6 month 12 month 24 immune reconstitution analyzing b nk regulatory cell levels peripheral blood month 3 month 6 month 12 month 24 post transplantation ferritin levels month 3 month 6 month 12 month 24 phase ii multicenter national prospective cohort national multi center including adult pediatric transplant centres sfgm tc 36 centres recruited hematology units referred transplant team pre transplant assessment visit consent collected latest 10 haplo sct information sheet consent form given investigator original conserved investigator third copy sponsor signing written informed consent included investigators electronic case report form cleanwebtm physician receive confirmation inclusion email physical examination reports disease history eastern cooperative oncology group (= performans status (= ecog)) assessment sorror score comorbidities complete physical examination electrocardiogram echocardiogram evaluation left ventricular ejection evaluation cardiovascular risk factors dyslipidemia hbp obesity smoking pulmonary function tests including least forced expiratory volume 1 second fev1 forced vital capacity forced vital capacity liver ultrasound doppler echography baseline values biological test complete blood count prothrombin time pt partial thromboplastin time ptt abo rh typing blood cell chemistry panel serum electrolytes creatinine calcium glucose uric acid magnesium levels ferritin c reactive protein liver function tests transaminases alkaline phosphatase gamma gt bilirubine circulating protein electrophoresis two pregnancy tests women childbearing age starting search anti human leukocyte antigen antibodies luminex technology dsa chimerism markers identification marrow aspiration karyotype analysis 6 weeks hematopoietic stem cell transplantation young girl considerate women childbearing age following menarche pregnancy tests performed menarche serum urine pregnancy test sensitivity least 25 miu ml women childbearing age used indifferently young girl infectious assessment urine culture viral serologies serology hepatitis b c aspergillus antigen ebv igg cmv igg hsv igg human immunodeficiency virus 2 elisa tests htlv 1 2 toxoplasmosis igg tpha vdrl imaging dental radiography total body ct scan assessment performed according practice investigator quality life eortc qlq c30 v3 qql ped minor preservation fertility 1 fertility preservation girls boys puberty dalle jh others 2017 menarche girl age 12 13 years tanner stage p3 t3 possible consider preserving gametes cryopreservation gonadal tissue considered may feasible cases profound thrombocytopenia neutropenia due high risk bleeding infection prepubertal girl cryopreservation ovarian cortex area containing oocytes proposed 20 years pregnancies reported hetero orthotopic reimplantation frozen tissue allograft non malignant pathologybut still experimental b prepubertal boys possible propose testicular pulp cryopreservation contains spermatogonia spermatozoa pubertal period onwards experimental technique practical application date 2 preservation fertility pubertal subject women may proposed stimulation collection follicles secondary ovocytes order realize either gamete vitrification vitro fertilisation followed embryo preservation technique reserved couples cryopreservation gonadal tissue stimulation transvaginal punctures required techniques may contraindicated thrombocytopenia neutropenia woman stable partner embryo freezing theoretically possible rarely compatible emergency management b men essential propose consultation cecos centre conservation sperm collection cryopreservation sperm protocol carried french aplastic anemia reference centre societe francophone de greffe de moelle et de therapie cellulaire sfgm tc adult pediatric centres members sfgm tc participate research french biomedicine agency association also support proposal refractory aplastic anemia concerns 30 150 new per year receiving immunosuppression disease french reference sfgm tc network illustrates feasibility transplant procedure started cannot interrupted unless dies investigator must document reason collect assessment criteria time ending participation participant agrees schedule follow participant particularly case serious adverse event participants may exit time reason investigator temporarily permanently withdraws participant safety reason participants best interests participant lost follow participant cannot located investigator must make every effort reconnect participant document attempts source file least determine whether participant alive dead participant exits prematurely withdraws consent data collected prior date premature exit may still used participant exits prematurely participant agrees state procedure schedule collecting data required protocol primary endpoint secondary endpoints safety assessment nb must stated information consent form state premature exit affect participant ongoing care state exactly participant offered case report form must list various reasons participant discontinued lack efficacy death another medical issue personal reasons participant explicit withdrawal consent lost follow initial notification severe adverse event must provided written report signed investigator using severe adverse event notification form specific intended purpose case report form item form must completed investigator sponsor carry appropriate analysis initial notification sponsor serious adverse event must quickly followed additional detailed written report reports case outcome may monitored safety department provide information whenever possible investigator provide sponsor documents may useful medical reports laboratory test results results additional examinations etc documents must de identified addition documents must include following acronym number participants initials adverse event monitored fully resolved stabilisation level considered acceptable investigator return previous state even participant left initial report severe adverse event follow reports documents must sent sponsor safety department e mail événement indésirable grave (see severe adverse event) vigilance drc assistance publique hôpitaux de paris shortening fraction sponsors safety department possible send severe adverse event safety department fax sponsors safety department fax 33 0 1 44 84 17 99 case unsuccessful attempt send severe adverse event e mail order avoid duplicates use e case report form investigator completes severe adverse event notification form e case report form validates prints signs form sending email possible connect e case report form investigator complete sign send severe adverse event notification form safety department soon connection restored severe adverse event notification form e case report form must duly completed investigator must respond requests sponsor additional information questions relating notification adverse event safety department contacted via email vigilance drc assistance publique hôpitaux de paris shortening fraction cases utero exposure investigator complete notification follow form pregnancy occurring participation investigator must monitor pregnant woman throughout pregnancy pregnancy terminated must notify sponsor outcome pregnancy using form outcome pregnancy falls within definition serious adverse event miscarriage pregnancy termination foetal death congenital abnormality etc investigator must follow procedure reporting saes initial pregnancy notification severe adverse event follow reports documents sent sponsor according procedures specified herein father exposed investigator must obtain pregnant woman permission collecting information pregnancy computer file used research implemented accordance french amended informatique et libertes law governing data protection european general data protection regulation gdpr regulations choose one two options proposed b pre drafted text delete option retained completed relative reasons exclusion medium risk reference methodology commitment comply reference methodology medium risk 001 research governed commission nationale informatique et libertés french data protection agency reference methodology processing personal data used within scope health research amended medium risk 001 ap hp sponsor research signed declaration compliance reference methodology aged 3 35 years old suffering refractory acquired idiopathic aplastic anemia least one course immunosuppression anti thymocyte globulin absence geno identical donor 10 10 matched donor absence donor specific antibody detected mfi 1500 antibodies directed towards distinct haplotype donor recipient identification haploidentical donor brother sister parents adult children cousin usual criteria hematopoietic stem cell transplantation eastern cooperative oncology group (= performans status (= ecog)) 2 severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function aspartate amino transferase alanine-aminotransferase 2 5n total bilirubin 2n creatinine 150 mol l health insurance coverage contraception methods must prescribed duration research using effective contraceptive methods within 12 months women childbearing age 6 months men childbearing age last dose cyclophosphamide signed written informed consent 2 parents aged less 18 authorized contraceptive methods women childbearing age absence permanent sterilization oral intravaginal transdermal combined hormonal contraception oral injectable transdermal progestogen hormonal contraception intrauterine hormonal releasing system ius sexual abstinence need evaluated relation duration preferred usual lifestyle participants man absence permanent sterilization sexual abstinence condoms morphologic evidence clonal evolution isolated bone marrow cytogenetic abnormalities also eligible uncontrolled infection seropositivity human immunodeficiency virus htlv 1 active hepatitis b c defined positive pcr hbv hcv associated hepatic cytolysis cancer last 5 years except basal cell carcinoma skin situ carcinoma cervix pregnant hcg positive breast feeding received attenuated vaccine within 2 months transplantation uncontrolled coronary insufficiency recent myocardial infarction 6 month current manifestations heart failure uncontrolled cardiac rhythm disorders ventricular ejection fraction 50 heart failure according “new york heart association” ii urinary tract obstruction preexisting acute hemorrhagic cystitis renal failure creatinine clearance 30ml min debilitating medical psychiatric illness preclude understanding inform consent well optimal follow tutorship curatorship contraindications treatments used research see smpc available base de donnees publique des medicaments website http base donnees publique medicaments gouv shortening fraction algorithm selection haploidentical donor defined french society stem cell transplantation 16 17 18 intrafamilial donor 1 human leukocyte antigen haplotype common recipient aged 18 70 years old adult fulfills inclusion criteria minor donor may chosen case management minor donors 18 years old done pediatrician including bone marrow harvest minor donors give assessment donors legally authorized representative accordance applicable laws regulations shall documented presence usual biological criteria eligibility donors hematopoietic stem including particular serological assessment authorizing transplant physician charge recipient manage donor procedure follow donors includes routine management management collection associated adverse events presence donor specific antibody dsa mfi 1500 detected donor unable tolerate bone marrow harvest receive general anesthesia psychological medical reasons donor refusing bone marrow harvest pregnancy donor persons responsible quality control article l 1121 3 code de la sante publique french public health code take necessary precautions ensure confidentiality information relating investigational medicinal products participants particular identity results obtained persons well investigators bound professional secrecy accordance conditions set articles 226 13 226 14 code penal french criminal code research involving human participants data collected concerning participants sent sponsor investigators specialised collaborators rendered non identifying circumstances shall names addresses participants involved shown sponsor ensure participant given written permission personal information strictly necessary quality control accessed non identifying data entered electronically via web browser analysis populations following analysis sets considered intent treat includes included subjects refer primary analyses statistical methods general strategy characteristics presented using summary measures median interquartile range quantitative characteristics counts percentages categoriel characteristics disposition subjects disposition subjects described number subjects enrolled number subjects treated number subjects permanently discontinued including reasons discontinuation analysis primary efficacy endpoint overall survival estimated using kaplan maiers estimator 95 confidences intervals ci comparaison historical controls 60 2 year performed using one sample log rank test proposed standardization of uveitis nomenclature x others 2011 21 analysis secondary endpoints graft failure incidence estimated 95 ci neutrophils platelets engraftment day 100 3 consecutive days neutrophiles 0 5 g l 7 consecutive days platelets 20 g l estimated 95 ci using grays estimator considering death without neutrophils platelets engraftment respectively competing risks absolute numbers neutrophils platelets month 1 month 2 month 3 month 6 month 12 day last platelet red blood cell transfusions described using median interquartile range incidence use growth factors poor hematopoietic reconstitution estimated 95 ci acute graft versus host disease incidence month 3 month 3 date maximum grading first line response steroids courses case steroid refractory graft versus host disease estimated 95 ci using grays estimator considering death without acute graft versus host disease competing risks chronic graft versus host disease incidence date grading month 24 estimated 95 ci using grays estimator considering death without chronic graft versus host disease competing risks relapse incidence month 12 month 24 using grays estimator considering death without relapse competing risks progression free survival month 12 month 24 estimated using kaplan maiers estimator 95 ci incidence cmv ebv infection month 12 estimated using kaplan maiers estimator 95 ci severe infections incidence ctae grade 3 4 month 3 month 6 month 12 month 24 estimated 95 ci non relapse mortality month 24 estimated 95 ci using grays estimator considering relapse competing risks incidence cardiac toxicities month 12 estimated 95 ci quality life questionnaire eortc qlq c30 v3 inclusion post transplantation month 3 month 6 month 12 month 24 described using median interquartile range chimerism month 1 month 3 month 6 month 12 month 24 estimated 95 ci immune reconstitution analyzing b nk regulatory cell levels peripheral blood month 3 month 6 month 12 month 24 post transplantation described using median interquartile range ferritin levels month 3 month 6 month 12 month 24 described using median interquartile range,"graft, transplantation, host, versus, stem, cell, disease, haplo, transplant, donor"
